

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (A-19)

Report of Reference Committee on Amendments to Constitution and Bylaws

William C. Reha, MD, MBA, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

2
3 **RECOMMENDED FOR ADOPTION**

- 4
- 5 1. Board of Trustees Report 2 – New Specialty Organizations Representation in the
 - 6 House of Delegates
 - 7 2. Board of Trustees Report 33 – Specialty Society Representation in the House of
 - 8 Delegates - Five-Year Review
 - 9 3. Council on Ethical and Judicial Affairs Report 1 – Competence, Self-Assessment
 - 10 and Self-Awareness
 - 11 4. Council on Ethical and Judicial Affairs Report 2 – Physician Assisted Suicide
 - 12 5. Council on Ethical and Judicial Affairs Report 3 – CEJA's Sunset Review of 2009
 - 13 House Policies
 - 14 6. Resolution 003 – Conforming Sex and Gender Designation in Government IDs
 - 15 and Other Documents
 - 16 7. Resolution 006 – Use of Person-Centered Language
 - 17 8. Resolution 009 – References to Terms and Language in Policies Adopted to
 - 18 Protect Populations from Discrimination and Harassment
 - 19 9. Resolution 014 – Disclosure of Funding Sources and Industry Ties of
 - 20 Professional Medical Associations and Patient Advocacy Organizations
 - 21 10. Resolution 018 – Support for Requiring Investigations into Deaths of Children in
 - 22 Foster Care
 - 23 11. Resolution 021 – Health, In All Its Dimensions, Is A Basic Human Right
 - 24 12. Resolution 023 – Distribution and Display of Human Trafficking Aid Information in
 - 25 Public Places
 - 26 13. Resolution 024 – Eliminating Use of the Term “Mental Retardation” by Physicians
 - 27 in Clinical Settings
 - 28 14. Resolution 025 – Gender Equity in Hospital Medical Staff Bylaws
 - 29 15. Resolution 026 – Restrictive Covenants of Large Health Care Systems
 - 30 16. Resolution 027 – Model Legislation for “Mature Minor” Consent to Vaccinations

31
32 **RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED**

- 33
- 34 17. Resolution 004 – Reimbursement for Care of Practice Partner Relatives
 - 35 18. Resolution 005 – Right for Gamete Preservation Therapies
 - 36 19. Resolution 007 – Delegation of Informed Consent
 - 37 20. Resolution 008 – Preventing Anti-Transgender Violence
 - 38 21. Resolution 011 – Mature Minor Consent to Vaccinations
 - 39 22. Resolution 012 – Improving Body Donation Regulation
 - 40 23. Resolution 013 – Opposing Office of Refugee Resettlement's Use of Medical and
 - 41 Psychiatric Records for Evidence in Immigration Court
 - 42 24. Resolution 015 – Opposing Mandated Reporting of People Who Question Their
 - 43 Gender Identity

1 25. Resolution 016 – Sexual and Gender Minority Populations in Medical Research
2

3 **RECOMMENDED FOR REFERRAL**
4

- 5 26. Board of Trustees Report 26 – Research Handling of De-Identified Patient
6 Information
7 27. Council on Constitution & Bylaws Report 1 – Clarification to the Bylaws: Delegate
8 Representation, Registration and Credentialing
9 28. Resolution 001 – Opposing Attorney Presence at and/or Recording of
10 Independent Medical Examinations
11 29. Resolution 010 – Covenants not to Compete
12 30. Resolution 017 – National Guidelines for Guardianship
13 31. Resolution 019 – Opposition to Requirements for Gender-Based Medical
14 Treatments for Athletes
15 32. Resolution 022 – Opposition to Involuntary Civil Commitment for Substance Use
16 Disorder
17

18 **RECOMMENDED FOR NOT ADOPTION**
19

- 20 33. Resolution 002 – Addressing Existential Suffering in End-of-Life Care
21 34. Resolution 020 – CEJA Opinion E-5.7

1 (1) BOARD OF TRUSTEES REPORT 2 – NEW SPECIALTY
2 ORGANIZATIONS REPRESENTATION IN THE HOUSE
3 OF DELEGATES
4

5 RECOMMENDATION:
6

7 Madam Speaker, your Reference Committee recommends
8 that the recommendations in Board of Trustees Report 2 be
9 adopted and the remainder of the report be filed.

10
11 Board of Trustees Report 2 recommends that our AMA grant representation in the House
12 of Delegates to the American Academy of Sleep Medicine and the American Society of
13 Cytopathology. The report outlines the criteria National Medical Specialty Societies must
14 meet to be granted representation to the House, and confirms that these societies have
15 met these criteria.
16

17 The only testimony heard on Board of Trustees Report 02 was given by the authors. Your
18 Reference Committee recommends that Board of Trustees Report 2 be adopted.
19

20 (2) BOARD OF TRUSTEES REPORT 33 – SPECIALTY
21 SOCIETY REPRESENTATION IN THE HOUSE OF
22 DELEGATES - FIVE-YEAR REVIEW
23

24 RECOMMENDATION:
25

26 Madam Speaker, your Reference Committee recommends
27 that the recommendations in Board of Trustees Report 33
28 be adopted and the remainder of the report be filed.
29

30 Board of Trustees Report 33 recommends that the American Association of Gynecologic
31 Laparoscopists, American Academy of Cosmetic Surgery, American Association for
32 Thoracic Surgery, American Association of Plastic Surgeons, American Association of
33 Public Health Physicians, American College of Allergy, Asthma and Immunology,
34 American Society for Metabolic and Bariatric Surgery, and the Society of
35 Laparoendoscopic Surgeons retain representation in the American Medical Association
36 House of Delegates. The report also recommends that, having failed to meet the
37 requirements for continued representation in the AMA House of Delegates as set forth in
38 AMA Bylaw B-8.50, the American Society for Aesthetic Plastic Surgery, American Society
39 of Interventional Pain Physicians, Association of University Radiologists, Infectious
40 Diseases Society of America and the International Society for the Advancement of Spine
41 Surgery be placed on probation and be given one year to work with AMA membership
42 staff to increase their AMA membership.
43

44 The only testimony heard on Board of Trustees Report 33 was given by the authors. Your
45 Reference Committee recommends that Board of Trustees Report 2 be adopted.

1 (3) COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS
2 REPORT 1 – COMPETENCE, SELF-ASSESSMENT AND
3 SELF-AWARENESS
4

5 RECOMMENDATION:
6

7 Madam Speaker, your Reference Committee recommends
8 that the recommendations in Council on Ethical and Judicial
9 Affairs Report 1 be adopted and the remainder of the report
10 be filed.
11

12 Council on Ethical and Judicial Affairs Report 1 examines physicians' ethical responsibility
13 of commitment to competence as one that encompasses more than knowledge and skill.
14 This responsibility requires that physicians understand that as a practical matter in the
15 care of actual patients, competence is fluid and dependent on context, and that they need
16 to recognize when they are and when they are not able to provide appropriate care for the
17 patient in front of them. Hence, it is important for physicians to practice informed self-
18 assessment that leads to self-awareness of their own ability to practice safely "in the
19 moment." The report proposes guidance to this end.
20

21 Your Reference Committee heard concerns regarding circumstances in which physicians
22 no longer possess the self-awareness to accurately assess their own competence, such
23 as in the case of impairment (e.g. in the case of dementia). Testimony argued that
24 impaired physicians should not be considered to be acting unethically. Other testimony
25 suggested that the recommendations as written in the current version of this report
26 successfully address that concern. While your Reference Committee is sensitive to these
27 concerns, its judgment is that these issues are duly addressed both by section (f) in the
28 recommendations of this report and Opinion E-9.3.2 "Physician Responsibilities to
29 Impaired Colleagues". Therefore, your Reference Committee recommends that Council
30 on Ethical and Judicial Affairs Report 01 be adopted as written.
31

32 (4) COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS
33 REPORT 2 – PHYSICIAN ASSISTED SUICIDE
34

35 RECOMMENDATION:
36

37 Madam Speaker, your Reference Committee recommends
38 that the recommendations in Council on Ethical and Judicial
39 Affairs Report 2 be adopted and the remainder of the report
40 be filed.
41

42 Council on Ethical and Judicial Affairs Report 2 responds to Resolution 15-A-15, "Study
43 Aid-in-Dying as End-of-Life Option," and Resolution 14- A-17, "The Need to Distinguish
44 between 'Physician-Assisted Suicide' and 'Aid in Dying'." Resolution 15-A-15 asks that
45 CEJA study medical aid-in-dying and make a recommendation regarding the AMA taking
46 a neutral stance; Resolution 14-A-17 asks that the AMA define and clearly distinguish
47 "physician assisted suicide" and "aid in dying" for use in all AMA policy and position
48 statements. This report holds that the terms 'aid in dying' and 'physician-assisted suicide'
49 reflect different ethical perspectives. The Council finds "physician assisted suicide" to be
50 the most precise term and urges that it be used by the AMA. Importantly, the report

1 explains that there are irreducible differences in moral perspectives regarding the issue of
2 physician-assisted suicide, such that both sides share common commitment to
3 “compassion and respect for human dignity and rights,” (see Principle I of the AMA
4 Principles of Medical Ethics) but draw different moral conclusions from these shared
5 commitments. The report considers the risks of unintended consequences of physician-
6 assisted suicide, noting that there is debate about the available data. The report argues
7 that where physician-assisted suicide is legal, safeguards can and should be improved to
8 mitigate risk. The report further notes that too often physicians and patients do not have
9 the conversations they should about death and dying and that physicians should be skillful
10 in engaging in these difficult conversations and knowledgeable about the options available
11 to terminally ill patients. The report concludes that in existing opinions on physician-
12 assisted suicide and the exercise of conscience, the *Code of Medical Ethics* offers
13 sufficient guidance to support physicians and the patients they serve in making well-
14 considered, mutually respectful decisions about legally available options for care at the
15 end of life while respecting the intimacy of a patient-physician relationship. Thus, the report
16 recommends that the *Code* not be amended, and that Resolutions 15-A-16 and 14-A-17
17 not be adopted.

18
19 Your Reference Committee heard extensive testimony regarding Council on Ethical and
20 Judicial Affairs Report 2. Your Reference Committee heard concerns that maintaining the
21 AMA’s current opposition to physician-assisted suicide would not be a true reflection of
22 the analysis contained in the report. However, testimony offered a great deal of support
23 for the acceptance of CEJA’s report and keeping the current *Code* unchanged. Your
24 Reference Committee recommends that Council on Ethical and Judicial Affairs Report 02
25 be adopted.

26
27 (5) COUNCIL ON ETHICAL AND JUDICIAL AFFAIRS
28 REPORT 3 – CEJA’S SUNSET REVIEW OF 2009 HOUSE
29 POLICIES

30
31 RECOMMENDATION:

32
33 Madam Speaker, your Reference Committee recommends
34 that the recommendations in Council on Ethical and Judicial
35 Affairs Report 3 be adopted and the remainder of the report
36 be filed.

37
38 Council on Ethical and Judicial Affairs Report 3 presents the annual sunset report of House
39 policies. This report reviewed House policies from 2009 and recommends that the policies
40 listed in the Appendix of this report be acted upon in the manner indicated.

41
42 Testimony was offered against the reaffirmation of H-140.952, “Physician Assisted
43 Suicide” in light of the fact that Council on Ethical and Judicial Affairs Report 02 on the
44 same topic has not yet been adopted by the House. However, your Reference Committee
45 believes that not reaffirming the existing policy would constitute a significant change in
46 policy, and therefore agrees with the Council’s recommendation to reaffirm H-140.952,
47 “Physician Assisted Suicide”. Other speakers noted that multiple reaffirmed, consolidated,
48 or otherwise maintained policies reviewed in this sunset report use only male pronouns.
49 Your Reference Committee urges that the language in these policies be editorially updated

1 by AMA staff since CEJA reports cannot be amended, and recommends that CEJA Report
2 03 be adopted.

3
4 (6) RESOLUTION 003 – CONFORMING SEX AND GENDER
5 DESIGNATION IN GOVERNMENT IDS AND OTHER
6 DOCUMENTS

7
8 RECOMMENDATION:

9
10 Madam Speaker, your Reference Committee recommends
11 that Resolution 008 be adopted.

12
13 Resolution 003 asks that our AMA modify Policy H-65.967, “Conforming Birth Certificate
14 Policies to Current Medical Standards for Transgender Patients,” to address change of
15 sex designation on government documents and other forms of government identification.
16 Currently, policy H-65.967 advocates for the removal of barriers to change the sex
17 designation on an individual’s birth certificate. This resolution asks our AMA to modify the
18 policy to support every individual’s right to determine their gender identity and sex
19 designation on other government documents and forms of government identification.
20 Additionally, Resolution 003 asks our AMA to support policies that allow a sex designation
21 or change of designation on all government IDs to reflect an individual’s gender identity,
22 as reported by the individual and without need for verification by a medical professional,
23 and policies that include an undesignated or nonbinary gender option for government
24 records and forms of government-issued identification in addition to “male” and “female.”
25 The resolution also asks that our AMA support efforts to ensure that the sex designation
26 on an individual’s government-issued documents and IDs does not hinder access to
27 medically appropriate care or other social services in accordance with that individual’s
28 needs.

29
30 Your Reference Committee heard testimony in almost unanimous support of the
31 resolution. Limited testimony was offered for referral, suggesting that there may be
32 unintended security issues if government identification reflected something other than the
33 gender identified at birth. However, significant testimony noted that individuals in the
34 transgender community face harassment due to inappropriate gender markers on various
35 forms of identification, and this resolution would be in line with laws passed in several
36 states. It was also noted that the World Health Organization has recently moved forward
37 changes that being transgender or gender non-binary is not a disorder. Your Reference
38 Committee recommends that Resolution 003 be adopted.

39
40 (7) RESOLUTION 006 – USE OF PERSON-CENTERED
41 LANGUAGE

42
43 RECOMMENDATION:

44
45 Madam Speaker, your Reference Committee recommends
46 that Resolution 006 be adopted.

47
48 Resolution 006 asks that our AMA encourage the use of person-centered language, a
49 style of communication in which the person is listed first followed by descriptive terms such
50 as a disease state (e.g., “a person with schizophrenia” rather than “a schizophrenic”).

1 Your Reference Committee heard testimony that unanimously supported the resolution.
2 Speakers noted that no person should be described by their disease state, and that
3 stigmatizing language should be avoided. Speakers suggested that the use of person-
4 centered language could be effective in eliminating biases that may impact patient care.
5 Your Reference Committee therefore recommends that Resolution 006 be adopted.
6
7

8 (8) RESOLUTION 009 – REFERENCES TO TERMS AND
9 LANGUAGE IN POLICIES ADOPTED TO PROTECT
10 POPULATIONS FROM DISCRIMINATION AND
11 HARASSMENT
12

13 RECOMMENDATION:
14

15 Madam Speaker, your Reference Committee recommends
16 that Resolution 009 be adopted.
17

18 Resolution 009 asks that our AMA undertake a study to identify all discrimination and
19 harassment references in AMA policies and the code of ethics, noting when the language
20 is consistent and when it is not, and research language and terms used by other national
21 organizations and the federal government in their policies on discrimination and
22 harassment. The resolution asks that the preliminary study results be presented to the
23 Minority Affairs Section, the Women’s Physician Section, and the Advisory Committee on
24 LGBTQ Issues to reach consensus on optimal language to protect vulnerable populations
25 including racial and ethnic minorities, sexual and gender minorities, and women, from
26 discrimination and harassment. The resolution asks for a report with the study results and
27 recommendations within 18 months.
28

29 Limited testimony was offered in support of the resolution, and your Reference Committee
30 recommends that Resolution 009 be adopted.
31

32 (9) RESOLUTION 014 – DISCLOSURE OF FUNDING
33 SOURCES AND INDUSTRY TIES OF PROFESSIONAL
34 MEDICAL ASSOCIATIONS AND PATIENT ADVOCACY
35 ORGANIZATIONS
36

37 RECOMMENDATION:
38

39 Madam Speaker, your Reference Committee recommends
40 that Resolution 014 be adopted.
41

42 Resolution 014 asks that our AMA support guidelines for members of the Federation of
43 Medicine and patient advocacy organizations to disclose donations, sponsorships, and
44 other financial transactions by industry and commercial stakeholders.
45

46 Your Reference Committee heard general positive testimony regarding Resolution 014.
47 Your Reference Committee recommends that Resolution 014 be adopted.

1 (10) RESOLUTION 018 – SUPPORT FOR REQUIRING
2 INVESTIGATIONS INTO DEATHS OF CHILDREN IN
3 FOSTER CARE

4
5 RECOMMENDATION:

6
7 Madam Speaker, your Reference Committee recommends
8 that Resolution 018 be adopted.

9
10 Resolution 018 asks our AMA to support legislation requiring investigations into the deaths
11 of children in the foster care system that occur while the child is in the foster care system.

12
13 Your Reference Committee heard testimony in unanimous support of Resolution 018. An
14 amendment was offered to stipulate that autopsies should be performed after
15 investigations, as abuse is sometimes not visible externally, however your Reference
16 Committee believes that the medical examiner or coroner should make this determination
17 in order to avoid autopsies on children whose cause of death is known. Your Reference
18 Committee recommends that Resolution 018 be adopted.

19
20 (11) RESOLUTION 021 – HEALTH, IN ALL ITS DIMENSIONS,
21 IS A BASIC HUMAN RIGHT

22
23 RECOMMENDATION:

24
25 Madam Speaker, your Reference Committee recommends
26 that Resolution 021 be adopted.

27
28 Resolution 021 asks that our AMA acknowledge that enjoyment of the highest attainable
29 standard of health, in all its dimensions, including health care, is a basic human right, and
30 that the provision of health care services, as well as optimizing the social determinants of
31 health, is an ethical obligation of a civil society.

32
33 Your Reference Committee heard testimony in strong support of Resolution 021.
34 Speakers suggested that this issue is timely and may be the most important resolution to
35 pass at this session, as this a statement of the AMA's values. Speakers noted that other
36 organizations, including the World Health Organization, define health care as a basic
37 human right, and that the AMA cannot address health care without acknowledging that it
38 is a right. Limited testimony was offered in opposition, expressing concern about the use
39 of the term "right", as such a term creates an obligation. Testimony was also offered
40 suggesting that other organizations define health care as a "good," but not a "right." Your
41 Reference Committee recommends that Resolution 021 be adopted.

42

1 (12) RESOLUTION 023 – DISTRIBUTION AND DISPLAY OF
2 HUMAN TRAFFICKING AID INFORMATION IN PUBLIC
3 PLACES

4
5 RECOMMENDATION:

6
7 Madam Speaker, your Reference Committee recommends
8 that Resolution 023 be adopted.

9
10 Resolution 023 asks that our AMA adopt as policy that readily available signs, notices,
11 posters, placards and other readily available educational materials providing information
12 about reporting human trafficking activities or aiding victims and survivors must be
13 permitted in local clinics, emergency departments and other medical settings. The
14 resolution also asks our AMA to utilize its website or internet presence to provide
15 downloadable materials displaying the National Human Trafficking Hotline Number to aid
16 in displaying such information in the aforementioned settings, and advocate that other
17 recognized medical professional organizations do the same. Additionally, the resolution
18 asks our AMA to urge the federal government to make changes in laws to advocate for
19 the broad posting of the National Human Trafficking Hotline number in areas such as local
20 clinics, emergency departments, and other medical settings.

21
22 Limited testimony was heard that was generally supportive of the resolution. Testimony
23 was offered that some victims of human trafficking are not aware that they are being
24 exploited, and that visible public signage would be quite helpful when caring for these
25 patients. Testimony was also offered for referral, as there are multiple phone numbers that
26 can be utilized for this purpose, in addition to posted information advising victims and
27 survivors to call 9-1-1, and that this resolution has the potential to confuse individuals
28 regarding proper cause of action. However, your Reference Committee believes that
29 publicly posting this information is ultimately beneficial, and recommends that Resolution
30 023 be adopted.

31
32 (13) RESOLUTION 024 – ELIMINATING USE OF THE TERM
33 “MENTAL RETARDATION” BY PHYSICIANS IN CLINICAL
34 SETTINGS

35
36 RECOMMENDATION:

37
38 Madam Speaker, your Reference Committee recommends
39 that Resolution 024 be adopted.

40
41 Resolution 024 asks that our AMA recommend that physicians adopt the term “intellectual
42 disability” rather than “mental retardation” in clinical settings.

43
44 Your Reference Committee heard testimony that unanimously supported Resolution 024.
45 Speakers noted that words matter, and the term “retardation” is both outdated and used
46 to demean individuals. Your Reference Committee recommends that Resolution 024 be
47 adopted.

1 (14) RESOLUTION 025 – GENDER EQUITY IN HOSPITAL
2 MEDICAL STAFF BYLAWS

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 025 be adopted.

8
9 Resolution 025 asks that our AMA affirm that hospital medical staff bylaws should
10 promote, and not impede, gender equity in their implementation. The resolution also asks
11 that our AMA study existing hospital medical staff bylaws as to how they impact on issues
12 of gender equity, directly or indirectly, and suggest any addition(s) to its model bylaws to
13 assure this issue is properly addressed, and gender equity affirmed.

14
15 Your Reference Committee heard unanimous support for Resolution 025. Speakers
16 testified to the importance of gender equity in professional medicine and how the
17 documented inequities and gender bias that exist within the profession must be
18 recognized and addressed. It is appropriate that our AMA should play a critical role in
19 taking measures in helping to address this problem, which includes examination of
20 hospital bylaws and their impact on the problem. Your Reference Committee recommends
21 that Resolution 025 be adopted.

22
23 (15) RESOLUTION 026 – RESTRICTIVE COVENANTS OF
24 LARGE HEALTH CARE SYSTEMS

25
26 RECOMMENDATION:

27
28 Madam Speaker, your Reference Committee recommends
29 that Resolution 026 be adopted.

30
31 Resolution 026 asks that our AMA, through its Organized Medical Staff Section, educate
32 medical students, physicians-in-training, and physicians entering into employment
33 contracts with large health care system employers on the dangers of aggressive restrictive
34 covenants, including, but not limited to, the impact on patient choice and access to care.
35 The resolution also asks that our AMA study the impact that restrictive covenants have
36 across all practice settings, including, but not limited to, the effect on patient access to
37 health care, the patient-physician relationship, and physician autonomy, with report back
38 at I-19.

39
40 Your Reference Committee heard testimony largely supportive of Resolution 026, with
41 speakers noting that this is a significant issue that is rarely looked at, that physicians often
42 are not given a choice but to sign a covenant, and that students are rarely educated on
43 the practice before entering the workforce. Speakers also noted that the practice has
44 negative ramifications for rural medicine, and that physicians can be limited from even
45 volunteering to practice in retirement due to restrictive covenants. Your Reference
46 Committee recommends that Resolution 026 be adopted.

1 (16) RESOLUTION 027 – MODEL LEGISLATION FOR
2 “MATURE MINOR” CONSENT TO VACCINATIONS
3

4 RECOMMENDATION:
5

6 Madam Speaker, your Reference Committee recommends
7 that Resolution 027 be adopted.
8

9 Resolution 027 asks that our AMA support physicians in assessing whether a minor has
10 met maturity and medical decision-making capacity requirements when providing consent
11 for vaccinations and in developing protocols for appropriate documentation. The resolution
12 also asks our AMA to develop model legislation to aid states in developing their own
13 policies to allow “mature minors”, defined as “certain older minors who have the capacity
14 to give informed consent to do so for care that is within the mainstream of medical practice,
15 not high risk, and provided in a nonnegligent manner,” to self-consent for vaccinations.
16

17 Limited testimony was offered in unanimous support of Resolution 027. Your Reference
18 Committee recommends that Resolution 027 be adopted.
19

20 (17) RESOLUTION 004 – REIMBURSEMENT FOR CARE OF
21 PRACTICE PARTNER RELATIVES
22

23 RECOMMENDATION A:
24

25 Madam Speaker, your Reference Committee recommends
26 that Resolution 001 be amended by addition and deletion to
27 read as follows:
28

29 RESOLVED, That our American Medical Association
30 support changes in the Medicare guidelines to allow a
31 physician, ~~who is a partner in the practice,~~ to care for and
32 receive appropriate reimbursement for immediate relatives
33 of one of the ~~other partners~~ colleagues in their practice.
34 (Directive to Take Action)
35

36 RECOMMENDATION B:
37

38 Madam Speaker, your Reference Committee recommends
39 that Resolution 004 be adopted as amended.
40

41 Resolution 004 asks that our AMA support changes in the Medicare guidelines to allow a
42 physician who is a partner in a practice to care for and receive appropriate reimbursement
43 for immediate relatives of other partners in their practice.
44

45 Limited testimony was heard in support of Resolution 004. Testimony suggested that this
46 issue is particularly relevant in rural areas and smaller communities, in which physicians
47 often refer family members to their colleagues by necessity, and that is unfair to expect
48 the resulting work to be done for free due to Medicare guidelines. An amendment was
49 offered that the word “partner” be changed, as it is often used colloquially, and may have

1 unintended consequences as it is also used a legal term. Thus, your Reference Committee
2 recommends that Resolution 004 be adopted as amended.

3
4 (18) RESOLUTION 005 – RIGHT FOR GAMETE
5 PRESERVATION THERAPIES

6
7 RECOMMENDATION A:

8
9 Madam Speaker, your Reference Committee recommends
10 that Resolution 005 be amended by addition and deletion to
11 read as follows:

12
13 RESOLVED, That fertility preservation services be ~~officially~~
14 recognized by our American Medical Association as an
15 option for the members of the transgender and non-binary
16 community who wish to preserve future fertility through
17 gamete preservation prior to undergoing gender affirming
18 medical or surgical therapies (New HOD Policy); and be it
19 further

20
21 RESOLVED, That our AMA ~~officially~~ support the right of
22 transgender or non-binary individuals to seek gamete
23 preservation therapies. (New HOD Policy); and be it further

24
25 RESOLVED, That our American Medical Association
26 supports insurance coverage for gamete preservation in any
27 individual for whom a medical diagnosis or treatment
28 modality is expected to result in the loss of fertility (New
29 HOD Policy).

30
31 RECOMMENDATION B:

32
33 Madam Speaker, your Reference Committee recommends
34 that Resolution 005 be adopted as amended.

35
36 Resolution 005 asks that fertility preservation services be officially recognized by our AMA
37 as an option for members of the transgender and non-binary communities who wish to
38 preserve future fertility through gamete preservation prior to undergoing gender affirming
39 medical or surgical therapies, and asks that our AMA officially support the right of
40 transgender or non-binary individuals to seek gamete preservation therapies.

41
42 Your Reference Committee heard testimony that unanimously supported Resolution 005.
43 Speakers discussed the barriers that transgender and non-binary individuals often face
44 when seeking fertility preservation services. Testimony agreed that our AMA should
45 address these barriers by recognizing that transgender and non-binary individuals have
46 the right to seek gamete preservation therapies. Testimony reflected the need for two
47 minor amendments. The first amendment adds a third resolve clause reflecting testimony
48 that the AMA should also support insurance coverage with regards to gamete
49 preservation. The second amendment reflects testimony that the word “officially” be struck
50 from the resolved clauses, as such word is redundant and implied, as all actions that the

1 AMA takes are “official.” Your Reference Committee recommends that Resolution 005 be
2 adopted as amended.

3
4 (19) RESOLUTION 007 – DELEGATION OF INFORMED
5 CONSENT

6
7 RECOMMENDATION A:

8
9 Madam Speaker, your Reference Committee recommends
10 that first Resolved clause in Resolution 007 be amended by
11 addition and deletion to read as follows:

12
13 RESOLVED, That our American Medical Association in
14 cooperation with other relevant stakeholders advocate that
15 a qualified physician, while retaining the ultimate
16 responsibility for all aspects of the informed consent
17 process, be able to delegate tasks associated with the
18 process to other qualified members of the health care team
19 ~~or her duty to obtain informed consent to another provider~~
20 ~~that who has have~~ knowledge of the patient, the patient’s
21 condition, and the procedures to be performed on the
22 patient (Directive to Take Action);

23
24 RECOMMENDATION B:

25
26 Madam Speaker, your Reference Committee recommends
27 that Resolution 007 be adopted as amended.

28
29 Resolution 007 asks that our AMA, in cooperation with other relevant stakeholders,
30 advocate that a qualified physician be able to delegate his or her duty to obtain informed
31 consent to another provider that has knowledge of the patient, the patient’s condition and
32 the procedures to be performed on the patient. The resolution also asks that our AMA
33 study the implication of the *Shinal v. Toms* ruling and its potential effects on the informed
34 consent process. *Shinal v. Toms* was a 2017 Pennsylvania Supreme Court Ruling that
35 mandated that a physician may not delegate to others his or her obligation to provide
36 sufficient information to obtain a patient’s informed consent, and that the duty of informed
37 consent is a non-delegable duty owed by the physician conducting the surgery or
38 treatment.

39
40 Your Reference Committee heard testimony largely supportive of Resolution 007. A
41 number of amendments were offered to the resolution, suggesting the addition of
42 language indicating that the physician retain the ultimate responsibility of the informed
43 consent process. The original authors of the resolution as well as other speakers offered
44 support for the proposed amendments. Other speakers expressed concern about the use
45 of the term “provider,” and suggested that it should be changed to “physician.” Limited
46 testimony was offered in support of referral, suggesting that the issue may require further
47 study, however the second Resolved clause satisfies this concern. Your Reference
48 Committee recommends that Resolution 007 be adopted as amended.

1 (20) RESOLUTION 008 – PREVENTING ANTI-
2 TRANSGENDER VIOLENCE

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 the sixth Resolved clause in Resolution 008 be deleted:

8
9 ~~RESOLVED, That our AMA issue a press release following~~
10 ~~the conclusion of the annual House of Delegates meeting~~
11 ~~with updates to be published in both scientific and~~
12 ~~mainstream publications regarding the prevalence of~~
13 ~~physical and mental health conditions and barriers faced by~~
14 ~~the LGBTQ community. (Directive to Take Action)~~

15
16 RECOMMENDATION B:

17
18 Madam Speaker, your Reference Committee recommends
19 that Resolution 008 be adopted as amended.

20
21 Resolution 008 asks that our AMA partner with other medical organizations and
22 stakeholders to immediately increase efforts to educate the public, legislators, and
23 members of law enforcement using verified data related to the hate crimes against
24 transgender individuals highlighting the disproportionate number of Black transgender
25 women who have succumbed to violent deaths. The resolution also asks that our AMA
26 advocate for federal, state, and local law enforcement agencies to consistently collect and
27 report data on hate crimes, including victim demographics, to the FBI; for the federal
28 government to provide incentives for such reporting; for demographic data on an
29 individual's birth sex and gender identity to be incorporated into the National Crime
30 Victimization Survey and the National Violent Death Reporting System; for a central law
31 enforcement database to collect data about reported hate crimes that correctly identifies
32 an individual's birth sex and gender identity; for stronger law enforcement policies
33 regarding interactions with transgender individuals; and for local, state, and federal efforts
34 that will increase access to mental health treatment and that will develop models designed
35 to address the health disparities that LGBTQ individuals experience. Resolution 008 also
36 asks our AMA to issue a press release following the conclusion of the Annual Meeting with
37 updates to be published in both scientific and mainstream publications regarding the
38 prevalence of physical and mental health conditions and barriers faced by the LGBTQ
39 community.

40
41 Testimony was offered in unanimous support of the first five resolved clauses of
42 Resolution 008. Speakers noted that the issue is critical and in line with current AMA policy
43 on hate crimes and access to health care. A number of speakers expressed reservations
44 about the sixth resolved clause, which asks our AMA to issue a press release at the
45 conclusion of the Annual Meeting and publishing updates in both scientific and
46 mainstream publications regarding the prevalence of physical and mental health
47 conditions and barriers faced by the LGBTQ community. However, your Reference
48 Committee recognizes that the AMA media team routinely develops press releases
49 regarding adopted policy, and cannot control publication in outside media. Therefore, your
50 Reference Committee recommends that Resolution 008 be adopted as amended.

1 (21) RESOLUTION 011 – MATURE MINOR CONSENT TO
2 VACCINATIONS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 011 be amended by addition and deletion to
8 read as follows:

9
10 Our AMA (a) encourages the development and
11 dissemination of evidence-based public awareness
12 campaigns aimed at increasing vaccination rates; (b)
13 encourages the development of educational materials that
14 can be distributed to patients and their families clearly
15 articulating the benefits of immunizations and highlighting
16 the exemplary safety record of vaccines; (c) supports the
17 development and evaluation, in collaboration with health
18 care providers, of evidence-based educational resources to
19 assist parents in educating and encouraging other parents
20 who may be reluctant to vaccinate their children; (d)
21 encourages physicians and state and local medical
22 associations to work with public health officials to inform
23 those who object to immunizations about the benefits of
24 vaccinations and the risks to their own health and that of the
25 general public if they refuse to accept them; (e) will promote
26 the safety and efficacy of vaccines while rejecting claims
27 that have no foundation in science; and (f) supports state
28 policies allowing minors ~~adolescents~~ to override their
29 parent's refusal and provide consent for vaccinations;
30 ~~provide their own consent for vaccination~~ and encourages
31 state legislatures to establish comprehensive vaccine and
32 minor consent policies; and (g) will continue its ongoing
33 efforts with other immunization advocacy organizations to
34 assist physicians and other health care professionals in
35 effectively communicating to patients, parents, policy
36 makers, and the media that vaccines do not cause autism
37 and that decreasing immunization rates have resulted in a
38 resurgence of vaccine-preventable diseases and deaths.
39 (Modify Current HOD Policy)

40
41 RECOMMENDATION B:

42
43 Madam Speaker, your Reference Committee recommends
44 that Resolution 011 be adopted as amended.

45
46 Resolution 011 asks that our AMA amend policy H-440.830, "Education and Public
47 Awareness on Vaccine Safety and Efficacy," by adding language to support state policies
48 that allow adolescents to provide their own consent for vaccination, as well as encouraging
49 state legislatures to establish comprehensive vaccine and minor consent policies.
50

1 Your Reference Committee heard testimony largely in support of the sentiment of
2 Resolution 011. Some concern was heard about a lack of clarity in regards to the scope
3 of vaccine consent and refusal by mature minors, as well as the term “mature minor” itself.
4 Amendments were offered to clarify the appropriate scope of the decisions a mature minor
5 should be able to make in these situations. Your Reference Committee also recognizes
6 that mature minor doctrines are established clearly on a state level and thus do not need
7 further clarification in this instance. Your Reference Committee therefore recommends
8 that Resolution 011 be adopted as amended.

9
10 (22) RESOLUTION 012 – IMPROVING BODY DONATION
11 REGULATION

12
13 RECOMMENDATION A:

14
15 Madam Speaker, your Reference Committee recommends
16 that Resolution 012 be amended by addition to read as
17 follows:

18
19 RESOLVED, That our American Medical Association
20 recognize the need for ethical, transparent, and consistent
21 body and body part donation regulations. (New HOD Policy)

22
23 RECOMMENDATION B:

24
25 Madam Speaker, your Reference Committee recommends
26 that Resolution 012 be adopted as amended.

27
28 Resolution 012 asks that our AMA recognize the need for ethical, transparent, and
29 consistent body donation regulations.

30
31 Your Reference Committee heard limited testimony in general support of Resolution 012.
32 A proposed amendment suggested that the resolution also address body parts and not
33 only the whole body. Your Reference Committee recommends that Resolution 012 be
34 adopted as amended.

35
36 (23) RESOLUTION 013 – OPPOSING OFFICE OF REFUGEE
37 RESETTLEMENT'S USE OF MEDICAL AND
38 PSYCHIATRIC RECORDS FOR EVIDENCE IN
39 IMMIGRATION COURT

40
41 RECOMMENDATION A:

42
43 Madam Speaker, your Reference Committee recommends
44 that the first Resolved clause in Resolution 013 be amended
45 by addition to read as follows.

46
47 RESOLVED, That our American Medical Association
48 advocate that healthcare services provided to minors in
49 immigrant detention and border patrol stations focus solely

1 on the health and well-being of the children (Directive to
2 Take Action);

3
4 RECOMMENDATION B:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 013 be adopted as amended.

8
9 Resolution 013 asks that our AMA advocate that health care services provided to minors
10 in immigrant detention focus solely on the health and well-being of the children. The
11 resolution also asks that our AMA condemn the use of confidential medical and
12 psychological records and social work case files as evidence in immigration courts without
13 patient consent.

14
15 Your Reference Committee heard testimony in unanimous support of Resolution 013. An
16 amendment was offered to include the mention of border patrol stations in addition to
17 immigrant detention in the first resolved clause, and subsequent testimony supported the
18 amendment. Therefore, your Reference Committee recommends that Resolution 013 be
19 adopted as amended.

20
21 (24) RESOLUTION 015 – OPPOSING MANDATED
22 REPORTING OF PEOPLE WHO QUESTION THEIR
23 GENDER IDENTITY

24
25 RECOMMENDATION A:

26
27 Madam Speaker, your Reference Committee recommends
28 that Resolution 015 be amended by addition and deletion to
29 read as follows:

30
31 RESOLVED, That our American Medical Association
32 oppose mandated reporting of ~~youth~~ individuals who
33 question or express interest in exploring their gender
34 identity. (New HOD Policy)

35
36 RECOMMENDATION B:

37
38 Madam Speaker, your Reference Committee recommends
39 that Resolution 015 be adopted as amended.

40
41 Resolution 015 asks that our AMA oppose mandated reporting of youth who question or
42 express interest in exploring their gender identity.

43
44 Your Reference Committee heard testimony in unanimous support of the spirit of the
45 resolution. Speakers noted that it is inappropriate to ask patients to share personal
46 information and then report what they have been told; confidentiality is essential. Other
47 speakers noted that this resolution is in line with AMA policy. An amendment was offered
48 to change the word “youth” to “individuals.” Your Reference Committee recommends that
49 Resolution 015 be adopted as amended.

1 (25) RESOLUTION 016 – SEXUAL AND GENDER MINORITY
2 POPULATIONS IN MEDICAL RESEARCH

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 016 be amended by deletion to read as
8 follows:

9
10 RESOLVED, That our American Medical Association
11 amend policy H-315.967, “Promoting Inclusive Gender,
12 Sex, and Sexual Orientation Options on Medical
13 Documentation,” by addition and deletion as follows:

14
15 Promoting Inclusive Gender, Sex, and Sexual Orientation
16 Options on Medical Documentation Our AMA: (1) supports
17 the voluntary inclusion of a patient's biological sex, current
18 gender identity, sexual orientation, and preferred gender
19 pronoun(s) in medical documentation and related forms,
20 including in electronic health records, in a culturally sensitive
21 and voluntary manner; and (2) will advocate for collection of
22 patient data in medical documentation and in medical
23 research studies, according to current best practices, that is
24 inclusive of ~~sexual orientation/gender identity sexual~~
25 ~~orientation, gender identity, and other sexual and gender~~
26 ~~minority traits such as differences/disorders of sex~~
27 ~~development~~ for the purposes of research into patient and
28 population health. (Modify Current HOD Policy)

29
30 RECOMMENDATION B:

31
32 Madam Speaker, your Reference Committee recommends
33 that Resolution 016 be adopted as amended.

34
35 Resolution 016 asks that our AMA amend policy H-315.967, “Promoting Inclusive Gender,
36 Sex, and Sexual Orientation Options on Medical Documentation.” The amended language
37 would stipulate that our AMA advocate for the collection of patient data in medical
38 documentation and medical research studies, according to current best practices, that is
39 inclusive of sexual orientation, gender identity, and other sexual and gender minority traits
40 such as differences and disorders of sex development.

41
42 Your Reference Committee heard testimony that unanimously supported Resolution 016.
43 There was clear support for the importance of collecting data of sexual and gender minority
44 populations for research and that that modification of H-315.967, “Promoting Inclusive
45 Gender, Sex, and Sexual Orientation Options on Medical Documentation” should be
46 modified to make it inclusive of the important of collecting this data with regards to the
47 medical research. Testimony reflected the need for one minor amendment by deletion be
48 made with regards to the language “such as differences/disorders of sex development”.
49 Such language was deemed to be problematic, as “differences of sex development” is an
50 umbrella term that encompasses many different conditions, and there is not uniform

1 agreement of what constitutes “differences of sex development”, rendering the
2 terminology imprecise and both under-and over-inclusive. Your Reference Committee
3 recommends that Resolution 016 be adopted as amended.

4
5 (26) BOARD OF TRUSTEES REPORT 26 – RESEARCH
6 HANDLING OF DE-IDENTIFIED PATIENT INFORMATION

7
8 RECOMMENDATION:

9
10 Madam Speaker, your Reference Committee recommends
11 that the recommendations in Board of Trustees Report 26
12 be referred.

13
14 Board of Trustees Report 26 responds to Policy D-315.975, “Research Handling of De-
15 Identified Patient Information,” adopted A-18. This policy directs the AMA to study handling
16 of de-identified patient data. This report outlines appropriate and inappropriate use of de-
17 identified patient data, perspectives from stakeholders in organized medicine, potential
18 ethical concerns of the commercial use of such data, regulatory implications, and the
19 future use of de-identified patient data. BOT 26 recommends that our AMA reaffirm
20 Policies H-315.974, “Guiding Principles Collection and Warehousing of Electronic Medical
21 Record Information,” H-315.983, “Patient Privacy and Confidentiality,” H-315.975, “Policy,
22 Payer, and Government Access to Patient Health Information,” H-315.978, “Privacy and
23 Confidentiality,” and H-315.987, “Limiting Access to Medical Records.” The report further
24 recommends that our AMA support state-based efforts to protect patient privacy including
25 a patient’s right to know whether information is being disclosed or sold and to whom, as
26 well as the right to opt out of the sale of their data. The report also recommends that our
27 Council on Ethical and Judicial Affairs consider re-examining existing guidance relevant
28 to the confidentiality of patient information in light of new practices regarding de-identified
29 patient data, including the use of exclusive de-identified data licensing agreements in
30 health care. Finally, the report recommends that Policy D-315.975, “Research Handling of
31 De-Identified Patient Information,” be rescinded, as it was fulfilled by this report.

32
33 Significant testimony was offered in favor of referral. Concerns raised included the impact
34 on patient registries, inconsistency of laws across state lines, and the necessity to
35 consider underserved populations. The report authors agreed that referral was
36 acceptable. Your Reference Committee therefore recommends that Board of Trustees
37 Report 26 be referred.

38
39 (27) COUNCIL ON CONSTITUTION AND BYLAWS REPORT
40 1 – CLARIFICATION TO THE BYLAWS: DELEGATE
41 REPRESENTATION, REGISTRATION AND
42 CREDENTIALING

43
44 RECOMMENDATION:

45
46 Madam Speaker, your Reference Committee recommends
47 that the recommendations in Council on Constitution and
48 Bylaws Report 1 be referred.

49

1 Council on Constitution and Bylaws Report 1 recommends amended bylaw language for
2 consideration of the House of Delegates to eliminate ambiguity/inconsistencies related to
3 representation, registration and credentialing of AMA delegates and alternate delegates.
4 Several proposed changes clarify to delegates, alternate delegates and those responsible
5 for certifying them that AMA membership and membership in the organization being
6 represented is mandatory. Recommended bylaw amendments also address the
7 individuals responsible for certifying organization's delegations, the formal recredentialing
8 process and the timing of such, and parity for specialty society presidents to allow the
9 specialties, like the states, to credential their president as an extra alternate delegate.

10
11 Your Reference Committee heard testimony largely in favor of referral. A number of
12 speakers noted that the unique challenges for medical students and trainees—whose
13 schedules are often out of their control—make it necessary to utilize everyone present in
14 order to fill their allotted seats. Other speakers also noted that the proposed changes may
15 similarly make it difficult for smaller delegations to fill their seats. Speakers noted that our
16 AMA's goal should be inclusivity, and barriers to an inclusive democratic process should
17 be removed, not added. Your Reference Committee therefore recommends that Council
18 on Constitution and Bylaws report 01 be referred.

19
20 (28) RESOLUTION 001 – OPPOSING ATTORNEY
21 PRESENCE AT AND/OR RECORDING OF
22 INDEPENDENT MEDICAL EXAMINATIONS

23
24 RECOMMENDATION:

25
26 Madam Speaker, your Reference Committee recommends
27 that Resolution 001 be referred.

28
29 Resolution 001 asks that Policy H-365.981, "Workers' Compensation," be amended by
30 addition to include language that opposes the ability of courts to compel recording and
31 videotaping of, or allow a court reporter or opposing attorney to be present during, the
32 independent medical examination, as a condition for the physician's medical opinion to be
33 allowed in court.

34
35 Your Reference Committee heard testimony largely in opposition to Resolution 001.
36 Speakers noted that states have different laws regarding the recording of independent
37 medical examinations (IME) regarding workers' compensation; the state-by-state nature
38 of the laws preclude the prescribing of workers' compensation guidelines. Supportive
39 testimony noted that third parties should not be present for a private medical exam, and
40 that the resolution is consistent with the ethical guidelines of other organizations.

41
42 (29) RESOLUTION 010 – COVENANTS NOT TO COMPETE

43
44 RECOMMENDATION:

45
46 Madam Speaker, your Reference Committee recommends
47 that Resolution 010 be referred.

48
49 Resolution 010 asks that our AMA consider as the basis for model legislation the New
50 Mexico statute allowing a requirement that liquidated damages be paid when a physician

1 partner who is a part owner in practice is lured away by a competing hospital system. The
2 resolution also asks our AMA to ask our Council on Ethical and Judicial Affairs to
3 reconsider their blanket opposition to covenants not to compete in the case of a physician
4 partner who is a part owner of a practice, in light of the protection that liquidated damages
5 can confer to independent physician owned partnerships, and because a requirement to
6 pay liquidated damages does not preclude a physician from continuing to practice in his
7 or her community.

8
9 Your Reference Committee heard mixed testimony on Resolution 010. A number of
10 speakers suggested that more information is necessary and that the item should be
11 referred to the Board for further study. Testimony was offered suggesting that the Board
12 of Trustees, and not CEJA, is the appropriate entity to study this issue. Speakers also
13 expressed hesitation in basing model legislation on the New Mexico statute, as well as
14 hesitation to basing AMA policy on state law. Your Reference Committee recommends
15 that Resolution 010 be referred.

16
17 (30) RESOLUTION 017 – NATIONAL GUIDELINES FOR
18 GUARDIANSHIP

19
20 RECOMMENDATION:

21
22 Madam Speaker, your Reference Committee recommends
23 that Resolution 017 be referred.

24
25 Resolution 017 asks that our AMA collaborate with relevant stakeholders to advocate for
26 federal creation and adoption of national standards for guardianship programs,
27 appropriate program funding measures, and quality control measures.

28
29 Your Reference Committee heard limited testimony in opposition of the resolution as
30 written, with some speakers lauding the intent but expressing concern that the issue of
31 guardianship is a complex one, relating to both the individual and the property in question,
32 and requires further study. Testimony was also heard suggesting that the ask in the
33 resolution is not specific enough. Your Reference Committee therefore recommends that
34 Resolution 017 be referred.

35
36
37 (31) RESOLUTION 019 – OPPOSITION TO REQUIREMENTS
38 FOR GENDER-BASED MEDICAL TREATMENTS FOR
39 ATHLETES

40
41 RECOMMENDATION:

42
43 Madam Speaker, your Reference Committee recommends
44 that Resolution 019 be referred.

45
46 Resolution 019 asks that our AMA oppose any regulations requiring mandatory medical
47 treatment or surgery for athletes with Differences of Sex Development (DSD) to be allowed
48 to compete in alignment with their identity. The resolution also asks our AMA to oppose
49 the creation of distinct hormonal guidelines to determine gender classification for athletic
50 competitions.

1 Your Reference Committee heard testimony largely in favor of referral, with speakers
2 noting that the topic is complex and that data can be interpreted differently. Speakers
3 noted that further study may broaden the issue beyond what is explicitly addressed in the
4 resolution. Testimony was also offered suggesting that the AMA should reach out to other
5 organizations with expertise on the issues. Therefore, your Reference Committee
6 recommends that Resolution 019 be referred.

7
8 (32) RESOLUTION 022 – OPPOSITION TO INVOLUNTARY
9 CIVIL COMMITMENT FOR SUBSTANCE USE
10 DISORDER

11
12 RECOMMENDATION:

13
14 Madam Speaker, your Reference Committee recommends
15 Resolution 022 be referred.

16
17 Resolution 022 asks that our AMA oppose involuntary civil commitment without judicial
18 involvement of persons for reasons solely related to substance use disorder. The
19 resolution also asks that our AMA work to advance policy and programmatic efforts to
20 address gaps in voluntary substance-use treatment services.

21
22 Your Reference Committee heard mixed testimony on Resolution 022, with some
23 speakers supporting the resolution and others in support of referral. Testimony was
24 offered suggesting that involuntary commitment can be performed for laudable reasons,
25 and that patients coerced into commitment have better outcomes than patients who are
26 committed voluntarily. Other speakers suggested that the decision on commitment should
27 be made by a physician, and that judicial oversight is essential. An amendment was
28 offered suggesting that criminalization of substance use disorder during pregnancy should
29 be treated as though the patient is not pregnant.

30
31 (33) RESOLUTION 002 – ADDRESSING EXISTENTIAL
32 SUFFERING IN END-OF-LIFE CARE

33
34 RECOMMENDATION:

35
36 Madam Speaker, your Reference Committee recommends
37 that Resolution 002 not be adopted.

38
39 Resolution 002 asks that our AMA ask the Council on Ethical and Judicial Affairs (CEJA)
40 to review Ethical Opinion 5.6, “Sedation to Unconsciousness in End-of-Life Care,” to
41 address (1) appropriate treatments beyond social, psychological or spiritual support to
42 treat existential suffering, and (2) the recognition of a patient’s previously expressed
43 wishes with end of life care.

44
45 Your Reference Committee heard testimony in general opposition to Resolution 002.
46 Testimony suggested that current CEJA ethical opinions are adequate on the issue, and
47 that to adopt this resolution while other related, controversial issues are still on the table
48 will serve to complicate the issues. Testimony also suggested that the public’s trust in
49 physicians is based on the confidence that physicians will not cause them harm. Your
50 Reference Committee recommends that Resolution 002 not be adopted.

1 (34) RESOLUTION 020 – CEJA OPINION E-5.7

2

3

RECOMMENDATION:

4

5

Madam Speaker, your Reference Committee recommends

6

that Resolution 020 be not be adopted.

7

8

Resolution 020 asks that our AMA's Council on Judicial and Ethical Affairs (CEJA) be strongly encouraged to modify Opinion E-5.7, "Physician-Assisted Suicide," to adopt the ethical position of "Engaged Neutrality," defined as neither in favor of nor in opposition to Physician Assisted Dying (PAD), while providing reassurance that our AMA will be a resource to lawmakers, physicians and the public to ensure compliance with standards of lawful medical practice, and to protect physicians' freedom to participate or not participate in PAD in accordance with their personal beliefs and our AMA's Opinion E-1.1.7, "Physician Exercise of Conscience."

9

10

11

12

13

14

15

16

17

Your Reference Committee heard mixed testimony on Resolution 020. Speakers suggested that elements of the Code of Medical Ethics, particularly Opinions E-5.7 and E-1.1.7 are inconsistent. Speakers suggested that resolution adds ambiguity to the issue by using unclear terminology, and that engaged neutrality is not neutral and implies acceptance to physician assisted suicide. Testimony argued against the use of the term "suicide" in addressing this issue due to the associated stigma. Testimony was also offered suggesting that this resolution is attempting to tell CEJA how to write their report. Your Reference Committee recommends that Resolution 020 not be adopted.

18

19

20

21

22

23

24

Madam Speaker, this concludes the report of Reference Committee on Amendments to Constitution and Bylaws. I would like to thank Robert Gibbs, MD, Bassam Nasr, MD, MBA, Jill Owens, MD, Scott Pasichow, MD, MPH, Abdul Rehman, MD, Richard Wilbur, MD, JD, and all those who testified before the Committee.

Robert Gibbs, MD
Kansas

Scott Pasichow, MD, MPH
Resident & Fellow Section

Bassam Nasr, MD, MBA
Michigan

Abdul Rehman, MD (Alternate)
New York

Jill Owens, MD
Pennsylvania

Richard Wilbur, MD, JD
American College of Legal Medicine

William C. Reha, MD, MBA
Virginia
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (A-19)

Report of Reference Committee A

John Montgomery, MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:
2

3 **RECOMMENDED FOR ADOPTION**

- 4
- 5 1. Council on Medical Service Report 2 - Covering the Uninsured under the AMA
6 Proposal for Reform
7 in lieu of
8 Resolution 116 - Medicare for All
 - 9 2. Council on Medical Service Report 3 - Medicare Coverage for Dental Services
 - 10 3. Council on Medical Service Report 5 - The Impact of Pharmacy Benefit
11 Managers on Patients and Physicians
 - 12 4. Council on Medical Service Report 6 - Preventive Prostate Cancer Screening
 - 13 5. Resolution 102 - Use of HSAs for Direct Primary Care
14

15 **RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED**

- 16
- 17 6. Council on Medical Service Report 4 - Reclassification of Complex Rehabilitation
18 Technology
 - 19 7. Resolution 105 - Payment for Brand Medications When the Generic Medication is
20 Recalled
 - 21 8. Resolution 107 - Investigate Medicare Part D – Insurance Company Upcharge
 - 22 9. Resolution 113 - Ensuring Access to Statewide Commercial Health Plans
23 Resolution 114 - Ensuring Access to Nationwide Commercial Health Plans
 - 24 10. Resolution 115 - Safety of Drugs Approved by Other Countries
25 Resolution 129 - The Benefits of Importation of International Pharmaceutical
26 Medications
 - 27 11. Resolution 117 - Support for Medicare Disability Coverage of Contraception for
28 Non-Contraceptive Use
 - 29 12. Resolution 119 - Returning Liquid Oxygen to Fee Schedule Payment
 - 30 13. Resolution 122 - Reimbursement for Telemedicine Visits
 - 31 14. Resolution 124 - Increased Affordability and Access to Hearing Aids and Related
32 Care
33 in lieu of
34 Resolution 120 - Medicare Coverage of Hearing Aids
 - 35 15. Resolution 126 - Ensuring Prescription Drug Price Transparency from Retail
36 Pharmacies
37

38 **RECOMMENDED FOR REFERRAL FOR DECISION**

- 39
- 40 16. Resolution 131 - Update Practice Expense Component of Relative Value Units
41

1 RECOMMENDED FOR REAFFIRMATION IN LIEU OF

- 2
- 3 17. Resolution 101 - Health Hazards of High Deductible Insurance
- 4 Resolution 125 - Mitigating the Negative Effects of High-Deductible Health Plans
- 5 18. Resolution 109 - Part A Medicare Payment to Physicians
- 6 19. Resolution 111 - Practice Overhead Expense and the Site-of-Service Differential
- 7 Resolution 132 (Late Resolution 1003) – Site of Service Differential
- 8 20. Resolution 112 - Health Care Fee Transparency
- 9 21. Resolution 123 - Standardizing Coverage of Applied Behavioral Analysis Therapy
- 10 for Persons with Autism Spectrum Disorder
- 11 22. Resolution 127 - Eliminating the CMS Observation Status

Existing policy was reaffirmed in lieu of the following resolutions via the Reaffirmation Consent Calendar:

- Resolution 103 - Health System Improvement Standards
- Resolution 104 - Adverse Impacts of Single Specialty Independent Practice Associations
- Resolution 106 - Raising Medicare Rates for Physicians
- Resolution 108 - Congressional Healthcare Proposals
- Resolution 110 - Establishing Fair Medicare Payer Rates
- Resolution 118 - Pharmaceutical Pricing Transparency
- Resolution 121 - Maintenance Hemodialysis for Undocumented Persons
- Resolution 128 - Elimination of CMS Hospital Readmission Penalties
- Resolution 130 - Notification of Generic Drug Manufacturing Changes

1 (1) COUNCIL ON MEDICAL SERVICE REPORT 2 -
2 COVERING THE UNINSURED UNDER THE AMA
3 PROPOSAL FOR REFORM
4 RESOLUTION 116 - MEDICARE FOR ALL

5
6 RECOMMENDATION:

7
8 Madam Speaker, your Reference Committee recommends
9 that the recommendations in Council on Medical Service
10 Report 2 be adopted in lieu of Resolution 116 and the
11 remainder of the report be filed.

12
13 Council on Medical Service Report 2 recommends that our AMA support eliminating the
14 subsidy “cliff”, thereby expanding eligibility for premium tax credits beyond 400 percent
15 of the federal poverty level (FPL); support increasing the generosity of premium tax
16 credits; support expanding eligibility for cost-sharing reductions; support increasing the
17 size of cost-sharing reductions; and reaffirm Policies H-165.828, H-165.842, H-165.824,
18 D-290.979, H-290.965, H-290.976, H-290.971, H-290.982, D-290.982 and D-165.942.

19
20 Resolution 116 asks that our AMA gather current, accurate data on the reimbursement
21 from Medicare for private practice physicians, medical clinics, hospital outpatient
22 services, hospitals including rural hospitals and critical access hospitals, and healthcare
23 systems along with accurate data as to how the reimbursement compares to the cost for
24 providing the medical care for these services; evaluate what would happen to the
25 healthcare economics of the United States and the ability to continue outpatient medical
26 practice if the current Medicare reimbursement, compared to the cost of providing that
27 care, became the major financing resource for medical care and predict what effect this
28 would have on the access to medical care in the U.S.; evaluate how the current
29 differential payments in Medicare to various entities for the same service would change
30 in a “Medicare for all” scenario; after analysis of the data, provide to the patients and
31 physicians of our country the relevant questions that we can ask of political candidates
32 advocating “Medicare for all”; and provide a better understanding of the impact of
33 “Medicare for all” in terms of healthcare financing, workforce, ability to continue private
34 practice medical care, incentives for physicians to join hospital systems, availability of
35 care, and help understand how this might change the provision of healthcare in the
36 United States.

37
38 Your Reference Committee heard predominantly supportive testimony on Council on
39 Medical Service Report 2. In introducing the report, a member of the Council on Medical
40 Service underscored that by putting forward strong recommendations to improve the
41 Affordable Care Act (ACA), the Council report appropriately targets providing coverage
42 to the uninsured population, as well as making coverage more affordable for millions of
43 Americans. At the same time, the report recommendations recognize that almost 60
44 percent of nonelderly Americans (more than 156 million) are enrolled in employer-
45 sponsored insurance, and are generally satisfied with their coverage.

46
47 Testimony on Resolution 116 was mixed. Notably, many speakers stressed that
48 adopting Resolution 116 would have unintended consequences. Importantly, a member
49 of the Council on Medical Service noted that Council on Medical Service Report 2
50 addressed the intent of Resolution 116, and should be adopted in lieu of the resolution.

1 The President of the AMA urged support for Council on Medical Service Report 2. In her
2 testimony, she noted that the recommendations of Council on Medical Service Report 2
3 build upon the AMA's extensive policy foundation—supporting individually owned health
4 insurance with tax credits inversely related to income—that was established in 1998.
5 She continued that the Council's recommendations respond to policy gaps to ensure that
6 the AMA proposal for reform has the potential to cover millions more Americans.
7 Important to those in our House who are disappointed that the Council on Medical
8 Service did not recommend removing AMA's opposition to single payer proposals, she
9 stressed that the AMA will be at the table as health reform proposals are introduced and
10 debated—just as we were from when our “Voice for the Uninsured” campaign launched
11 in 2007 up to the passage of the ACA.

12
13 A member of the Council on Legislation also testified in strong support of the report,
14 noting that since the enactment of the ACA in 2010, the AMA has been highly engaged
15 on the legislative, regulatory and judicial fronts regarding the law's implementation,
16 guided by policy. Notably, the member of the Council on Legislation noted that the
17 recommendations of CMS Report 2 to eliminate the “subsidy cliff”, make premium tax
18 credits more generous, and expand eligibility for and increase the size of cost-sharing
19 reductions are in line with recent federal legislation that has been introduced to improve
20 the ACA. The Council member stated that having policy specifically on point for these
21 provisions would be incredibly meaningful to AMA advocacy efforts, and lead to millions
22 more Americans to get covered. Finally, the member of the Council on Legislation stated
23 that it looked forward to continuing to review legislation that is introduced, ranging from
24 ACA improvement legislation to other bills that may not be in clear alignment with AMA
25 policy. Importantly, it was stressed that having policy in opposition to single payer
26 proposals would not prevent the Council on Legislation from evaluating proposals as
27 they are introduced, that will vary greatly in substance and scope.

28
29 An amendment was offered for our AMA to support public choice options that would
30 allow individuals and families a choice of publicly-financed or private insurance as long
31 as payments to physicians are appropriate, sufficient, fair, and sustainable (not limited to
32 Medicare rates) to ensure access to care. The amendment received strong support. A
33 member of the Council on Medical Service welcomed study of the coverage options
34 outlined in the amendment. Your Reference Committee agrees with need for study, and
35 believes that the impacts of the options outlined in the amendment on coverage rates,
36 affordability, health plan choice, the Medicare Trust Fund, and crowd-out from private to
37 public coverage must be comprehensively analyzed before enacting any change to AMA
38 policy. Accordingly, your Reference Committee is proposing such a study alongside
39 Resolutions 113 and 114 (see item 9). Your Reference Committee also notes that our
40 AMA already has policy addressing a public option. Policy H-165.838 states that
41 insurance coverage options offered in a health insurance exchange be self-supporting;
42 have uniform solvency requirements; not receive special advantages from government
43 subsidies; include payment rates established through meaningful negotiations and
44 contracts; not require provider participation; and not restrict enrollees' access to out-of-
45 network physicians.

46
47 An amendment was also offered to remove AMA policy opposition to single-payer
48 proposals – which is the focus of the referred resolution to which Council on Medical
49 Service Report 2 responded. Your Reference Committee agrees with the Council on
50 Medical Service that our AMA proposal for reform provides a strong policy foundation to

1 use in evaluating health reform proposals as they get introduced in the coming years,
2 regardless of whether they are tied to the ACA. Your Reference Committee heard
3 testimony from members of the Board of Trustees and the Council on Legislation that
4 even with policy opposition to single-payer proposals, our AMA will continue to
5 thoughtfully engage in discussions of health reform proposals, which will vary greatly in
6 their structure and scope.

7
8 Your Reference Committee thanks the Council on Medical Service for a comprehensive
9 report. Your Reference Committee agrees that our AMA proposal for reform, including
10 the report recommendations, outlines a strong strategy to cover the remaining
11 uninsured, with specific, targeted policy proposals for the uninsured subpopulations.
12 Importantly, your Reference Committee notes that the Council report recommendations
13 promote physician practice viability by maintaining the variety in the potential payer mix
14 for physician practices that is essential to cover practice expenses, as well as support
15 payment and delivery reforms. As such, your Reference Committee recommends that
16 the recommendations of Council on Medical Service Report 2 be adopted in lieu of
17 Resolution 116, and the remainder of the report be filed.

18
19 (2) COUNCIL ON MEDICAL SERVICE REPORT 3 -
20 MEDICARE COVERAGE FOR DENTAL SERVICES

21
22 RECOMMENDATION:

23
24 Madam Speaker, your Reference Committee recommends
25 that the recommendations in Council on Medical Service
26 Report 3 be adopted and the remainder of the report be
27 filed.

28
29 Council on Medical Service Report 3 recommends that our AMA reaffirm Policy D-
30 160.925; support continued opportunities to work with the American Dental Association
31 and other interested national organizations to improve access to dental care for
32 Medicare beneficiaries; and support initiatives to expand health services research on the
33 effectiveness of expanded dental coverage in improving health and preventing disease
34 in the Medicare population, the optimal dental benefit plan designs to cost-effectively
35 improve health and prevent disease in the Medicare population, and the impact of
36 expanded dental coverage on health care costs and utilization.

37
38 Testimony on Council on Medical Service Report 3 was unanimously supportive. In
39 introducing the report, a member of the Council on Medical Service underscored the fact
40 that the ADA is currently engaged in their own study of a potential Medicare dental
41 benefit so that they can make an informed recommendation for their profession. The
42 Surgeon General testified supporting oral health and efforts to cover oral health care.
43 The Surgeon General explained that while he is not permitted to express an advocacy
44 opinion on the matter, he applauded Council on Medical Service Report 3, and thanked
45 the AMA for taking on this issue. Your Reference Committee believes that the
46 recommendations of the report constitute important steps to improve dental care for
47 Medicare beneficiaries, and recommends that the recommendations of Council on
48 Medical Service Report 3 be adopted and the remainder of the report be filed.

1 (3) COUNCIL ON MEDICAL SERVICE REPORT 5 - THE
2 IMPACT OF PHARMACY BENEFIT MANAGERS ON
3 PATIENTS AND PHYSICIANS
4

5 RECOMMENDATION:
6

7 Madam Speaker, your Reference Committee recommends
8 that the recommendations in Council on Medical Service
9 Report 5 be adopted and the remainder of the report be
10 filed.
11

12 Council on Medical Service Report 5 recommends that our AMA support the active
13 regulation of pharmacy benefit managers (PBMs) under state departments of insurance;
14 develop model state legislation addressing the state regulation of PBMs, which shall
15 include provisions to maximize the number of PBMs under state regulatory oversight;
16 support requiring the application of manufacturer rebates and pharmacy price
17 concessions, including direct and indirect remuneration (DIR) fees, to drug prices at the
18 point-of-sale; support efforts to ensure that PBMs are subject to state and federal laws
19 that prevent discrimination against patients, including those related to discriminatory
20 benefit design and mental health and substance use disorder parity; support outlined
21 principles to improve transparency of PBM operations; encourage increased
22 transparency in how DIR fees are determined and calculated; and reaffirm Policies H-
23 125.979, H-320.939, H-285.965, D-330.910 and H-320.958.
24

25 Your Reference Committee heard highly supportive testimony on Council on Medical
26 Service Report 5. In introducing the report, a member of the Council on Medical Service
27 underscored that the recommendations of the report aim to increase transparency in
28 PBM operations, while taking steps to increase state and federal regulation of PBMs in
29 response to their role in managing drug benefits, which now resembles the typical role of
30 insurers.
31

32 There was an amendment offered to advocate for stronger PBM reform at the federal
33 level, including advocating for the elimination of rebates. A member of the Council on
34 Medical Service raised concerns with the amendment, noting that the elimination of
35 rebates would have unintended consequences, including higher premiums and cost-
36 sharing. Further, a member of the Council on Legislation testified in support of Council
37 on Medical Service Report 5, noting that the AMA has been highly engaged in
38 advocating for PBM transparency and improved regulation of PBMs, from testifying
39 before congressional committees, to submitting regulatory comments, to supporting
40 federal legislation, to leveraging model state legislation. For example, in his statement to
41 the U.S. House of Representatives Energy and Commerce Committee Health
42 Subcommittee for the hearing "Lowering Prescription Drug Prices: Deconstructing the
43 Drug Supply Chain," Dr. Jack Resneck, Chair, AMA Board of Trustees, testified in
44 support of increased PBM transparency. In its statement for the record to the US House
45 of Representatives Committee on Oversight and Reform on examining the actions of
46 drug companies in raising prescription drug prices in January 2019, the AMA called for
47 improved regulation and transparency of PBMs, priorities that were also echoed in the
48 comments of the AMA submitted in response to American Patients First, The Trump
49 Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
50 (Blueprint) in July 2018.

1 Your Reference Committee believes that Council on Medical Service Report 5 is highly
2 consistent with AMA advocacy efforts in support of increased transparency and
3 regulation of PBMs. As such, your Reference Committee recommends that the
4 recommendations of Council on Medical Service Report 5 be adopted and the remainder
5 of the report be filed.

6
7 (4) COUNCIL ON MEDICAL SERVICE REPORT 6 -
8 PREVENTIVE PROSTATE CANCER SCREENING

9
10 RECOMMENDATION:

11
12 Madam Speaker, your Reference Committee recommends
13 that the recommendations in Council on Medical Service
14 Report 6 be adopted and the remainder of the report be
15 filed.

16
17 Council on Medical Service Report 6 recommends that our AMA encourage public and
18 private payers to ensure coverage for prostate cancer screening when the service is
19 deemed appropriate following informed physician-patient shared decision-making;
20 encourage national medical specialty societies to promote public education around the
21 importance of informed physician-patient shared decision-making regarding medical
22 services that are particularly sensitive to patient values and circumstances, such as
23 prostate cancer screening; amend Policy D-450.957 to change the title to read, "Clinical
24 Guidelines and Evidence Regarding Benefits of Prostate Cancer Screening and Other
25 Preventive Services," and to add a new subsection, "(3) encouraging scientific research
26 to address the evidence gaps highlighted by organizations making evidence-based
27 recommendations about clinical preventive services"; and reaffirm Policies D-185.979,
28 H-185.939, H-373.997, H-450.938, D-185.980 and H-425.997.

29
30 Testimony on Council on Medical Service Report 6 was unanimously and strongly
31 supportive. In introducing the report, a member of the Council on Medical Service
32 explained how medical services currently qualify for insurance coverage without patient
33 cost-sharing and placed prostate cancer screening in the context of other cancer
34 screening services that do not currently meet the evidentiary threshold required to
35 qualify for coverage without cost-sharing. In addition, the co-authors of the original
36 resolution testified in strong support of Council on Medical Service Report 6 and thanked
37 the Council for its report. Your Reference Committee believes that the recommendations
38 of the report build off of existing policy guiding the coverage of preventive services, and
39 recommends that the recommendations of Council on Medical Service Report 6 be
40 adopted and the remainder of the report be filed.

41
42 (5) RESOLUTION 102 - USE OF HSAs FOR DIRECT
43 PRIMARY CARE

44
45 RECOMMENDATION:

46
47 Madam Speaker, your Reference Committee recommends
48 that Resolution 102 be adopted.

1 Resolution 102 asks that our AMA adopt policy that the use of a health savings account
2 (HSA) to access direct primary care providers and/or to receive care from a direct
3 primary care medical home constitutes a bona fide medical expense, and that particular
4 sections of the IRS code related to qualified medical expenses should be amended to
5 recognize the use of HSA funds for direct primary care and direct primary care medical
6 home models as a qualified medical expense; and seek federal legislation or regulation,
7 as necessary, to amend appropriate sections of the IRS code to specify that direct
8 primary care access or direct primary care medical homes are not health “plans” and
9 that the use of HSA funds to pay for direct primary care provider services in such
10 settings constitutes a qualified medical expense, enabling patients to HSAs to help pay
11 for Direct Primary Care and to enter DPC periodic-fee agreements without IRS
12 interference or penalty.

13
14 Your Reference Committee heard testimony supportive of the intent of Resolution 102.
15 Your Reference Committee believes that Resolution 102 is consistent with existing
16 policy and advocacy efforts, and as such recommends its adoption.

17
18 (6) COUNCIL ON MEDICAL SERVICE REPORT 4 -
19 RECLASSIFICATION OF COMPLEX REHABILITATION
20 TECHNOLOGY

21
22 RECOMMENDATION A:

23
24 Madam Speaker, your Reference Committee recommends
25 that Recommendation 3 of Council on Medical Service
26 Report 4 be amended by addition and deletion to read as
27 follows:

28
29 3. That our AMA support, upon reclassification of CRT as
30 a distinct category, the development by the Centers for
31 Medicare & Medicaid Services, with the advice of
32 physicians with appropriate training and expertise, of
33 appropriate, simplified and streamlined ~~of additional~~
34 ~~requirements and/or regulations~~ specific to CRT that
35 reduce the administrative burden on physicians, ~~beyond~~
36 ~~those that exist under the broad category of durable~~
37 ~~medical equipment.~~ (New HOD Policy)

38
39 RECOMMENDATION B

40
41 Madam Speaker, your Reference Committee recommends
42 that the recommendations in Council on Medical Service
43 Report 4 be adopted as amended and the remainder of the
44 report be filed.

45
46 Council on Medical Service Report 4 recommends that our AMA support the
47 reclassification of complex rehabilitation technology (CRT) as a separate, distinct, and
48 adequately funded payment category to improve access to the most appropriate and
49 necessary equipment to allow individuals with significant disabilities and chronic medical
50 conditions to increase their independence, reduce their overall health care expenses and

1 appropriately manage their medical needs; support state medical association and
2 national medical specialty society efforts to accomplish adequately funded
3 reclassification of CRT; and support, upon reclassification of CRT as a distinct category,
4 the development by the Centers for Medicare & Medicaid Services of additional
5 requirements and/or regulations specific to CRT, beyond those that exist under the
6 broad category of durable medical equipment.

7
8 Testimony on Council on Medical Service Report 4 was supportive. In introducing the
9 report, a member of the Council on Medical Service noted that the Council specifically
10 considered the potential impacts of reclassifying CRT as a separate and adequately
11 funded payment category, and concluded that the reclassification was warranted. An
12 amendment was offered to Recommendation 3 to strengthen and clarify the
13 recommendation. A member of the Council on Medical Service testified in support of
14 this amendment. Your Reference Committee accordingly recommends adoption of
15 Council on Medical Service Report 4 as amended.

16
17 (7) RESOLUTION 105 - PAYMENT FOR BRAND
18 MEDICATIONS WHEN THE GENERIC MEDICATION IS
19 RECALLED

20
21 RECOMMENDATION:

22
23 Madam Speaker, your Reference Committee recommends
24 that the following alternate resolution be adopted in lieu of
25 Resolution 105:

26
27 RESOLVED, That our AMA support health plans and
28 pharmacy benefit managers providing a process for
29 expedited formulary exceptions in the event of a recall of a
30 generic medication, to ensure patient access to the brand
31 medication or more affordable, alternative treatment
32 options (New HOD Policy); and be it further

33
34 RESOLVED, That our AMA reaffirm Policy H-110.987,
35 which supports the expedited review of generic drug
36 applications and prioritizing review of such applications
37 when there is a drug shortage or no available comparable
38 generic drug (Reaffirm HOD Policy); and be further

39
40 RESOLVED, That our AMA reaffirm Policy H-100.956,
41 which outlines policy priorities to respond to national drug
42 shortages (Reaffirm HOD Policy).

43
44 Resolution 105 asks that our AMA petition the Centers for Medicare and Medicaid
45 Services as well as third party payers to allow reimbursement for brand medications at
46 the lowest copayment tier so that patients can be effectively treated until the medication
47 manufacturing crisis is resolved.

48
49 There was no testimony on Resolution 105. Your Reference Committee notes that in the
50 case of a generic medication recall, the physician should be able to request an

1 expedited formulary exception request for coverage of the brand if the patient needs to
2 stay on the same drug product. Your Reference Committee also notes that recalls of
3 generic medications can lead to other generic manufacturers of the same product to
4 significantly increase their prices. As such, your Reference Committee has crafted an
5 alternate resolution that addresses the intent of Resolution 105, and responds to the
6 potential impacts of generic medication recalls.

7
8 H-100.956 National Drug Shortages

9 1. Our AMA considers drug shortages to be an urgent public health crisis, and
10 recent shortages have had a dramatic and negative impact on the delivery and
11 safety of appropriate health care to patients. 2. Our AMA supports
12 recommendations that have been developed by multiple stakeholders to improve
13 manufacturing quality systems, identify efficiencies in regulatory review that can
14 mitigate drug shortages, and explore measures designed to drive greater
15 investment in production capacity for products that are in short supply, and will
16 work in a collaborative fashion with these and other stakeholders to implement
17 these recommendations in an urgent fashion. 3. Our AMA supports authorizing
18 the Secretary of the U.S. Department of Health and Human Services (DHHS) to
19 expedite facility inspections and the review of manufacturing changes, drug
20 applications and supplements that would help mitigate or prevent a drug
21 shortage. 4. Our AMA will advocate that the US Food and Drug Administration
22 (FDA) and/or Congress require drug manufacturers to establish a plan for
23 continuity of supply of vital and life-sustaining medications and vaccines to avoid
24 production shortages whenever possible. This plan should include establishing
25 the necessary resiliency and redundancy in manufacturing capability to minimize
26 disruptions of supplies in foreseeable circumstances including the possibility of a
27 disaster affecting a plant. 5. The Council on Science and Public Health shall
28 continue to evaluate the drug shortage issue, including the impact of group
29 purchasing organizations on drug shortages, and report back at least annually to
30 the House of Delegates on progress made in addressing drug shortages. 6. Our
31 AMA urges the development of a comprehensive independent report on the root
32 causes of drug shortages. Such an analysis should consider federal actions, the
33 number of manufacturers, economic factors including federal reimbursement
34 practices, as well as contracting practices by market participants on competition,
35 access to drugs, and pricing. In particular, further transparent analysis of
36 economic drivers is warranted. The federal Centers for Medicare & Medicaid
37 Services (CMS) should review and evaluate its 2003 Medicare reimbursement
38 formula of average sales price plus 6% for unintended consequences including
39 serving as a root cause of drug shortages. 7. Our AMA urges regulatory relief
40 designed to improve the availability of prescription drugs by ensuring that such
41 products are not removed from the market due to compliance issues unless such
42 removal is clearly required for significant and obvious safety reasons. 8. Our
43 AMA supports the view that wholesalers should routinely institute an allocation
44 system that attempts to fairly distribute drugs in short supply based on remaining
45 inventory and considering the customer's purchase history. 9. Our AMA will
46 collaborate with medical specialty society partners and other stakeholders in
47 identifying and supporting legislative remedies to allow for more reasonable and
48 sustainable payment rates for prescription drugs. 10. Our AMA urges that during
49 the evaluation of potential mergers and acquisitions involving pharmaceutical
50 manufacturers, the Federal Trade Commission consult with the FDA to determine

1 whether such an activity has the potential to worsen drug shortages. 11. Our
2 AMA urges the FDA to require manufacturers to provide greater transparency
3 regarding production locations of drugs and provide more detailed information
4 regarding the causes and anticipated duration of drug shortages. 12. Our AMA
5 encourages electronic health records (EHR) vendors to make changes to their
6 systems to ease the burden of making drug product changes. 13. Our AMA urges
7 the FDA to evaluate and provide current information regarding the quality of
8 outsourcer compounding facilities. 14. Our AMA urges DHHS and the U.S.
9 Department of Homeland Security (DHS) to examine and consider drug
10 shortages as a national security initiative and include vital drug production sites
11 in the critical infrastructure plan. (CSAPH Rep. 2, I-11; Modified: CSAPH Rep. 7,
12 A-12; Modified: CSAPH Rep. 2, I-12; Modified: CSAPH Rep. 8, A-13; Modified in
13 lieu of Res. 912, I-13; Modified: CSAPH Rep. 3, A-14; Modified: CSAPH Rep. 2,
14 I-15; Appended: CSAPH Rep. 04, I-17; Modified: CSAPH Rep. 02, A-18)

15 H-110.987 Pharmaceutical Costs

16 1. Our AMA encourages Federal Trade Commission (FTC) actions to limit
17 anticompetitive behavior by pharmaceutical companies attempting to reduce
18 competition from generic manufacturers through manipulation of patent
19 protections and abuse of regulatory exclusivity incentives. 2. Our AMA
20 encourages Congress, the FTC and the Department of Health and Human
21 Services to monitor and evaluate the utilization and impact of controlled
22 distribution channels for prescription pharmaceuticals on patient access and
23 market competition. 3. Our AMA will monitor the impact of mergers and
24 acquisitions in the pharmaceutical industry. 4. Our AMA will continue to monitor
25 and support an appropriate balance between incentives based on appropriate
26 safeguards for innovation on the one hand and efforts to reduce regulatory and
27 statutory barriers to competition as part of the patent system. 5. Our AMA
28 encourages prescription drug price and cost transparency among pharmaceutical
29 companies, pharmacy benefit managers and health insurance companies. 6. Our
30 AMA supports legislation to require generic drug manufacturers to pay an
31 additional rebate to state Medicaid programs if the price of a generic drug rises
32 faster than inflation. 7. Our AMA supports legislation to shorten the exclusivity
33 period for biologics. 8. Our AMA will convene a task force of appropriate AMA
34 Councils, state medical societies and national medical specialty societies to
35 develop principles to guide advocacy and grassroots efforts aimed at addressing
36 pharmaceutical costs and improving patient access and adherence to medically
37 necessary prescription drug regimens. 9. Our AMA will generate an advocacy
38 campaign to engage physicians and patients in local and national advocacy
39 initiatives that bring attention to the rising price of prescription drugs and help to
40 put forward solutions to make prescription drugs more affordable for all patients.
41 10. Our AMA supports: (a) drug price transparency legislation that requires
42 pharmaceutical manufacturers to provide public notice before increasing the
43 price of any drug (generic, brand, or specialty) by 10% or more each year or per
44 course of treatment and provide justification for the price increase; (b) legislation
45 that authorizes the Attorney General and/or the Federal Trade Commission to
46 take legal action to address price gouging by pharmaceutical manufacturers and
47 increase access to affordable drugs for patients; and (c) the expedited review of
48 generic drug applications and prioritizing review of such applications when there
49 is a drug shortage, no available comparable generic drug, or a price increase of
50

1 10% or more each year or per course of treatment. 11. Our AMA advocates for
2 policies that prohibit price gouging on prescription medications when there are no
3 justifiable factors or data to support the price increase. 12. Our AMA will provide
4 assistance upon request to state medical associations in support of state
5 legislative and regulatory efforts addressing drug price and cost transparency.
6 (CMS Rep. 2, I-15; Reaffirmed in lieu of: Res. 817, I-16; Appended: Res. 201, A-
7 17; Reaffirmed in lieu of: Res. 207, A-17; Modified: Speakers Rep. 01, A-17;
8 Appended: Alt. Res. 806, I-17; Reaffirmed: BOT Rep. 14, A-18; Appended: CMS
9 Rep. 07, A-18)

10
11 (8) RESOLUTION 107 - INVESTIGATE MEDICARE PART D
12 – INSURANCE COMPANY UPCHARGE

13
14 RECOMMENDATION A:

15
16 Madam Speaker, your Reference Committee recommends
17 that Resolution 107 be amended by addition and deletion
18 to read as follows:

19
20 ~~RESOLVED, That our American Medical Association~~
21 ~~investigate Medicare Part D rules which allow providers to~~
22 ~~keep up to 5% more than their actual cost of providing~~
23 ~~pharmacy prescription services while at the same time they~~
24 ~~are eligible to get paid by Centers for Medicare and~~
25 ~~Medicaid Services reinsurance rules for certain losses.~~
26 ~~(Directive to Take Action)~~

27
28 RESOLVED, That our AMA support a US Government
29 Accountability Office (GAO) study of Medicare Part D plan
30 risk assessment behaviors and strategies, and their impact
31 on direct subsidy, reinsurance subsidy and risk corridor
32 payments. (Directive to Take Action)

33
34 RECOMMENDATION B:

35
36 Madam Speaker, your Reference Committee recommends
37 that Resolution 107 be adopted as amended.

38
39 Resolution 107 asks that our AMA investigate Medicare Part D rules which allow
40 providers to keep up to 5% more than their actual cost of providing pharmacy
41 prescription services while at the same time they are eligible to get paid by Centers for
42 Medicare and Medicaid Services reinsurance rules for certain losses.

43
44 Your Reference Committee heard mixed testimony on Resolution 107. A speaker raised
45 concerns about whether the AMA would be the appropriate entity to conduct the
46 investigation called for in Resolution 107. As such, your Reference Committee is offering
47 an amendment to bring the study under the auspices of the US Government
48 Accountability Office. Accordingly, your Reference Committee recommends that
49 Resolution 107 be adopted as amended.

- 1 (9) RESOLUTION 113 - ENSURING ACCESS TO
2 STATEWIDE COMMERCIAL HEALTH PLANS
3 RESOLUTION 114 - ENSURING ACCESS TO
4 NATIONWIDE COMMERCIAL HEALTH PLANS
5

6 RECOMMENDATION:
7

8 Madam Speaker, your Reference Committee recommends
9 that the following alternate resolution be adopted in lieu of
10 Resolutions 113 and 114:
11

12 RESOLVED, That our AMA study the impacts of various
13 approaches that offer a public option in addition to current
14 sources of coverage, private or public, including but not
15 limited to a Medicare buy-in; a public option offered on
16 health insurance exchanges; and buying into either the
17 Federal Employees Health Benefits Program or a state
18 employee health plan (Directive to Take Action); and be it
19 further

20
21 RESOLVED, That our AMA reaffirm Policy H-165.838
22 addressing a public option, which states that insurance
23 coverage options offered in a health insurance exchange
24 be self-supporting; have uniform solvency requirements;
25 not receive special advantages from government
26 subsidies; include payment rates established through
27 meaningful negotiations and contracts; not require provider
28 participation; and not restrict enrollees' access to out-of-
29 network physicians (Reaffirm HOD Policy).
30

31 Resolution 113 asks that our AMA study the concept of offering state employee health
32 plans to every state resident, including exchange participants qualifying for federal
33 subsidies, and report back to the House of Delegates this year; and advocate that State
34 Employees Health Benefits Program health insurance plans be subject to all fully insured
35 state law requirements on prompt payment, fairness in contracting, network adequacy,
36 limitations or restrictions against high deductible health plans, retrospective audits and
37 reviews, and medical necessity.
38

39 Resolution 114 asks that our AMA advocate that Federal Employees Health Benefits
40 Program health insurance plans should become available to everyone to purchase at
41 actuarially appropriate premiums as well as be eligible for federal premium tax credits;
42 and advocate that Federal Employees Health Benefits Program health insurance plans
43 be subject to all fully insured state law requirements on prompt payment, fairness in
44 contracting, network adequacy, limitations or restrictions against high deductible health
45 plans, retrospective audits and reviews, and medical necessity.
46

47 Your Reference Committee heard generally supportive testimony on Resolution 113,
48 and calls for referral for Resolution 114. A member of Council on Medical Service
49 welcomed referral of both resolutions for study, and suggested broadening the study to
50 incorporate other approaches to a public option as outlined in the amendment offered by

1 the American College of Physicians (ACP) during discussion of Council on Medical
2 Service Report 2. Your Reference Committee agrees, and believes that the impacts of
3 the various options outlined in Resolutions 113 and 114, and outlined in the ACP
4 amendment, must be assessed. Such a study can analyze the impacts of various public
5 option proposals on coverage rates, affordability, health plan choice, the Medicare Trust
6 Fund, and crowd-out from private to public coverage. Your Reference Committee
7 believes that such a comprehensive study will be helpful in guiding future AMA policy
8 development pertaining to health system reform. Accordingly, your Reference
9 Committee recommends adoption of an alternate resolution in lieu of Resolutions 113
10 and 114.

11 H-165.838 Health System Reform Legislation

12 1. Our American Medical Association is committed to working with Congress, the
13 Administration, and other stakeholders to achieve enactment of health system
14 reforms that include the following seven critical components of AMA policy: a.
15 Health insurance coverage for all Americans b. Insurance market reforms that
16 expand choice of affordable coverage and eliminate denials for pre-existing
17 conditions or due to arbitrary caps c. Assurance that health care decisions will
18 remain in the hands of patients and their physicians, not insurance companies or
19 government officials d. Investments and incentives for quality improvement and
20 prevention and wellness initiatives e. Repeal of the Medicare physician payment
21 formula that triggers steep cuts and threaten seniors' access to care f.
22 Implementation of medical liability reforms to reduce the cost of defensive
23 medicine g. Streamline and standardize insurance claims processing
24 requirements to eliminate unnecessary costs and administrative burdens 2. Our
25 American Medical Association advocates that elimination of denials due to pre-
26 existing conditions is understood to include rescission of insurance coverage for
27 reasons not related to fraudulent representation. 3. Our American Medical
28 Association House of Delegates supports AMA leadership in their unwavering
29 and bold efforts to promote AMA policies for health system reform in the United
30 States. 4. Our American Medical Association supports health system reform
31 alternatives that are consistent with AMA policies concerning pluralism, freedom
32 of choice, freedom of practice, and universal access for patients. 5. AMA policy is
33 that insurance coverage options offered in a health insurance exchange be self-
34 supporting, have uniform solvency requirements; not receive special advantages
35 from government subsidies; include payment rates established through
36 meaningful negotiations and contracts; not require provider participation; and not
37 restrict enrollees' access to out-of-network physicians. 6. Our AMA will actively
38 and publicly support the inclusion in health system reform legislation the right of
39 patients and physicians to privately contract, without penalty to patient or
40 physician. 7. Our AMA will actively and publicly oppose the Independent
41 Medicare Commission (or other similar construct), which would take Medicare
42 payment policy out of the hands of Congress and place it under the control of a
43 group of unelected individuals. 8. Our AMA will actively and publicly oppose, in
44 accordance with AMA policy, inclusion of the following provisions in health
45 system reform legislation: a. Reduced payments to physicians for failing to report
46 quality data when there is evidence that widespread operational problems still
47 have not been corrected by the Centers for Medicare and Medicaid Services b.
48 Medicare payment rate cuts mandated by a commission that would create a
49 double-jeopardy situation for physicians who are already subject to an
50

1 expenditure target and potential payment reductions under the Medicare
2 physician payment system c. Medicare payments cuts for higher utilization with
3 no operational mechanism to assure that the Centers for Medicare and Medicaid
4 Services can report accurate information that is properly attributed and risk-
5 adjusted d. Redistributed Medicare payments among providers based on
6 outcomes, quality, and risk-adjustment measurements that are not scientifically
7 valid, verifiable and accurate e. Medicare payment cuts for all physician services
8 to partially offset bonuses from one specialty to another f. Arbitrary restrictions on
9 physicians who refer Medicare patients to high quality facilities in which they
10 have an ownership interest 9. Our AMA will continue to actively engage
11 grassroots physicians and physicians in training in collaboration with the state
12 medical and national specialty societies to contact their Members of Congress,
13 and that the grassroots message communicate our AMA's position based on
14 AMA policy. 10. Our AMA will use the most effective media event or campaign to
15 outline what physicians and patients need from health system reform. 11. AMA
16 policy is that national health system reform must include replacing the
17 sustainable growth rate (SGR) with a Medicare physician payment system that
18 automatically keeps pace with the cost of running a practice and is backed by a
19 fair, stable funding formula, and that the AMA initiate a "call to action" with the
20 Federation to advance this goal. 12. AMA policy is that creation of a new single
21 payer, government-run health care system is not in the best interest of the
22 country and must not be part of national health system reform. 13. AMA policy is
23 that effective medical liability reform that will significantly lower health care costs
24 by reducing defensive medicine and eliminating unnecessary litigation from the
25 system should be part of any national health system reform. (Sub. Res. 203, I-09;
26 Reaffirmation A-10; Reaffirmed in lieu of Res. 102, A-10; Reaffirmed in lieu of
27 Res. 228, A-10; Reaffirmed: CMS Rep. 2, I-10; Reaffirmed: Sub. Res. 222, I-10;
28 Reaffirmed: CMS Rep. 9, A-11; Reaffirmation A-11; Reaffirmed: CMS Rep. 6, I-
29 11; Reaffirmed in lieu of Res. 817, I-11; Reaffirmation I-11; Reaffirmation A-12;
30 Reaffirmed in lieu of Res. 108, A-12; Reaffirmed: Res. 239, A-12; Reaffirmed:
31 Sub. Res. 813, I-13; Reaffirmed: CMS Rep. 9, A-14; Reaffirmation A-15;
32 Reaffirmed in lieu of Res. 215, A-15; Reaffirmation: A-17; Reaffirmed in lieu of:
33 Res. 712, A-17; Reaffirmed in lieu of: Res. 805, I-17; Reaffirmed: CMS Rep. 03,
34 A-18)

35

36 (10) RESOLUTION 115 - SAFETY OF DRUGS APPROVED
37 BY OTHER COUNTRIES
38 RESOLUTION 129 - THE BENEFITS OF IMPORTATION
39 OF INTERNATIONAL PHARMACEUTICAL
40 MEDICATIONS

41

42 RECOMMENDATION:

43

44 Madam Speaker, your Reference Committee recommends
45 that the following alternate resolution be adopted in lieu of
46 Resolutions 115 and 129:

1 RESOLVED, That our AMA support the personal
2 importation of prescription drugs only if:

- 3 a. patient safety can be assured;
- 4 b. product quality, authenticity and integrity can be
5 assured;
- 6 c. prescription drug products are subject to reliable,
7 “electronic” track and trace technology; and
- 8 d. prescription drug products are obtained directly
9 from a licensed foreign pharmacy, located in a
10 country that has statutory and/or regulatory
11 standards for the approval and sale of prescription
12 drugs that are comparable to the standards in the
13 United States (New HOD Policy); and be it further
14

15 RESOLVED, That our AMA reaffirm Policy D-100.983,
16 which guides AMA advocacy with respect to the
17 prescription drug importation by wholesalers and
18 pharmacies (Reaffirm HOD Policy); and be it further
19

20 RESOLVED, That our AMA reaffirm D-100.985, which
21 states that our AMA will continue to actively oppose illegal
22 drug diversion, illegal Internet sales of drugs, illegal
23 importation of drugs, and drug counterfeiting (Reaffirm
24 HOD Policy).
25

26 Resolution 115 asks that our AMA compare the results of our US Food and Drug
27 Administration (FDA) and the European Medicines Agency (EMA) approval processes in
28 terms of determining the safety and efficacy of pharmaceuticals using whatever data is
29 available in order to determine whether the health of the citizens of the United States
30 would be at risk if drugs approved by the EMA were imported and used as compared to
31 the FDA; and estimate what the reduction in the cost of medications would be for our
32 patients if they were allowed to import EMA certified medications for use in the United
33 States and thereby increasing competition for some of our current expensive
34 pharmaceuticals.
35

36 Resolution 129 asks that our AMA study the implications of prescription drug importation
37 for personal use and wholesale prescription drug purchase across our southern and
38 northern borders.
39

40 Your Reference Committee heard generally supportive testimony on the intent of
41 Resolutions 115 and 129. A representative from the US Food and Drug Administration
42 raised significant concerns with Resolution 115 pertaining to patient safety, drug quality
43 and integrity, and innovation and drug development. A member of the Council on
44 Legislation offered an amendment that would establish AMA policy on the personal
45 importation of prescription drugs that would apply to potential legislation addressing
46 importation from Canada, Mexico, European countries and other countries. The member
47 of the Council on Legislation noted that existing Policy D-100.983 blanketly addresses
48 importation by wholesalers and pharmacies. The Council on Medical Service strongly
49 supported the COL amendment. Your Reference Committee agrees that the COL
50 amendment builds off of existing AMA policy with respect to prescription drug

1 importation, and ensures that our policy is able to be used to evaluate state and federal
2 proposals on importation as they are introduced, regardless of countries included in the
3 proposals. Accordingly, your Reference Committee recommends adoption of an
4 alternate resolution in lieu of Resolutions 115 and 129.

5

6

D-100.983 Prescription Drug Importation and Patient Safety

7 Our AMA will: (1) support the legalized importation of prescription drug products
8 by wholesalers and pharmacies only if: (a) all drug products are Food and Drug
9 Administration (FDA)-approved and meet all other FDA regulatory requirements,
10 pursuant to United States laws and regulations; (b) the drug distribution chain is
11 "closed," and all drug products are subject to reliable, "electronic" track and trace
12 technology; and (c) the Congress grants necessary additional authority and
13 resources to the FDA to ensure the authenticity and integrity of prescription drugs
14 that are imported; (2) oppose personal importation of prescription drugs via the
15 Internet until patient safety can be assured; (3) review the recommendations of
16 the forthcoming report of the Department of Health and Human Services (HHS)
17 Task Force on Drug Importation and, as appropriate, revise its position on
18 whether or how patient safety can be assured under legalized drug importation;
19 (4) educate its members regarding the risks and benefits associated with drug
20 importation and reimportation efforts; (5) support the in-person purchase and
21 importation of Health Canada-approved prescription drugs obtained directly from
22 a licensed Canadian pharmacy when product integrity can be assured, provided
23 such drugs are for personal use and of a limited quantity; and (6) advocate for an
24 increase in funding for the US Food and Drug Administration to administer and
25 enforce a program that allows the in-person purchase and importation of
26 prescription drugs from Canada, if the integrity of prescription drug products
27 imported for personal use can be assured. (BOT Rep. 3, I-04; Reaffirmation A-
28 09; Reaffirmed in lieu of: Res. 817, I-16; Appended: CMS Rep. 01, I-18)

29

30

D-100.985 Federal Regulation and Computerized Tracking of Pharmaceuticals 31 During Shipping and Handling from Manufacture Until Ultimately Received by 32 Patient

33

34

35

36

37

38

39

Our AMA will: (1) continue to actively oppose illegal drug diversion, illegal
Internet sales of drugs, illegal importation of drugs, and drug counterfeiting; and
(2) work with the Congress, the Food and Drug Administration, the Drug
Enforcement Administration, and other federal agencies, the pharmaceutical
industry, and other stakeholders to ensure that these illegal activities are
minimized. (Res. 501, A-04; Reaffirmation I-06; Reaffirmed: BOT Rep. 06, A-16;
Reaffirmed: CMS Rep. 01, I-18)

1 (11) RESOLUTION 117 - SUPPORT FOR MEDICARE
2 DISABILITY COVERAGE OF CONTRACEPTION FOR
3 NON-CONTRACEPTIVE USE
4

5 RECOMMENDATION A:
6

7 Madam Speaker, your Reference Committee recommends
8 that Resolution 117 be amended by addition and deletion
9 to read as follows:

10
11 RESOLVED, That our American Medical Association work
12 with the Centers for Medicare and Medicaid Services and
13 other stakeholders to include coverage for all US Food and
14 Drug Administration-approved ~~contraception~~ contraceptive
15 methods for contraceptive and non-contraceptive use for
16 all patients covered by Medicare, regardless of eligibility
17 pathway (age or disability). (Directive to Take Action)
18

19 RECOMMENDATION B:
20

21 Madam Speaker, your Reference Committee recommends
22 that Resolution 117 be adopted as amended.
23

24 RECOMMENDATION C:
25

26 Madam Speaker, your Reference Committee recommends
27 that the title of Resolution 117 be changed to read as
28 follows:
29

30 SUPPORT FOR MEDICARE COVERAGE OF
31 CONTRACEPTIVE METHODS
32

33 Resolution 117 asks that our AMA work with the Centers for Medicare and Medicaid
34 Services and other stakeholders to include coverage for all US Food and Drug
35 Administration-approved contraception for non-contraceptive use for patients covered by
36 Medicare.
37

38 Your Reference Committee heard generally supportive testimony on Resolution 117. A
39 member of the Council on Medical Service testified that AMA policy already addresses
40 the intent of Resolution 117. Several speakers testified in support of Resolution 117,
41 emphasizing the importance of AMA action on this issue. An amendment was offered to
42 broaden the scope of Resolution 117. Your Reference Committee accepts the
43 amendment and recommends Resolution 117 be adopted as amended.

1 (12) RESOLUTION 119 - RETURNING LIQUID OXYGEN TO
2 FEE SCHEDULE PAYMENT

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 119 be amended by deletion to read as
8 follows:

9
10 RESOLVED, That our American Medical Association
11 support policy to remove liquid oxygen from the
12 competitive bidding system and return payments for liquid
13 oxygen to a Medicare fee schedule basis. (New HOD
14 Policy); ~~and be it further~~

15
16 ~~RESOLVED, That our AMA convey its patient quality and~~
17 ~~access concerns for Medicare beneficiaries obtaining~~
18 ~~insurance coverage for liquid oxygen in comments to the~~
19 ~~Centers for Medicare and Medicaid Services, including the~~
20 ~~forthcoming proposed rule, Durable Medical Equipment,~~
21 ~~Prosthetics, Orthotics and Supplies (DMEPOS)~~
22 ~~Competitive Bidding Program (CBP) for Calendar Year~~
23 ~~2020. (Directive to Take Action)~~

24
25 RECOMMENDATION B:

26
27 Madam Speaker, your Reference Committee recommends
28 that Resolution 119 be adopted as amended.

29
30 Resolution 119 asks that our AMA support policy to remove liquid oxygen from the
31 competitive bidding system and return payments for liquid oxygen to a Medicare fee
32 schedule basis; and convey its patient quality and access concerns for Medicare
33 beneficiaries obtaining insurance coverage for liquid oxygen in comments to the Centers
34 for Medicare and Medicaid Services (CMS), including the forthcoming proposed rule,
35 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) Competitive
36 Bidding Program (CBP) for Calendar Year 2020.

37
38 Testimony on Resolution 119 was supportive. The sponsor of Resolution 119 testified,
39 emphasizing the importance of returning liquid oxygen to a Fee For Service schedule.
40 Consistent with this testimony, your Reference Committee suggests an amendment to
41 delete reference to specific advocacy efforts to allow the AMA to advocate for any
42 avenues as appropriate. Accordingly, your Reference Committee recommends that
43 Resolution 119 be adopted as amended.

1 (13) RESOLUTION 122 - REIMBURSEMENT FOR
2 TELEMEDICINE VISITS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 122 be amended by addition and deletion
8 to read as follows:

9
10 RESOLVED, That our American Medical Association work
11 with third-party payers, ~~and~~ the Centers for Medicare and
12 Medicaid Services, Congress and interested state medical
13 associations to provide coverage and reimbursement ~~for~~
14 ~~both synchronous and asynchronous telemedicine services~~
15 for telehealth to ensure ~~encourage~~ increased access and
16 use of these services by patients and physicians.

17
18 RECOMMENDATION B:

19
20 Madam Speaker, your Reference Committee recommends
21 that Resolution 122 be adopted as amended.

22
23 RECOMMENDATION C:

24
25 Madam Speaker, your Reference Committee recommends
26 that the title of Resolution 122 be changed to read as
27 follows:

28
29 REIMBURSEMENT FOR TELEHEALTH

30
31 Resolution 122 asks that our AMA work with third-party payers and the Centers for
32 Medicare and Medicaid Services at the national level to provide reimbursement for both
33 synchronous and asynchronous telemedicine services to encourage increased access
34 and use of these services by patients and physicians.

35
36 Your Reference Committee heard highly supportive testimony on Resolution 122. A
37 member of the Council on Legislation testified that while the AMA has overarching policy
38 guiding the coverage for and payment of telemedicine adopted by the House in 2014,
39 the AMA does need to advocate that commercial payers provide payment parity for
40 physicians who offer in-person and virtual services. The member of the Council on
41 Legislation also noted that the impediment to synchronous telehealth is not the Centers
42 for Medicare and Medicaid Services – it is the Social Security Act. As such, the Council
43 member offered an amendment to include Congress and state medical associations, as
44 well as use the term “telehealth” to be all-encompassing of synchronous and
45 asynchronous telemedicine as well as digital health services, and remove confusion in
46 the terms used.

1 (14) RESOLUTION 124 - INCREASED AFFORDABILITY AND
2 ACCESS TO HEARING AIDS AND RELATED CARE
3 RESOLUTION 120 - MEDICARE COVERAGE OF
4 HEARING AIDS
5

6 RECOMMENDATION A:
7

8 Madam Speaker, your Reference Committee recommends
9 that the third Resolve of Resolution 124 be amended by
10 deletion to read as follows:
11

12 RESOLVED, That our AMA support the availability of over-
13 the-counter hearing aids for the treatment of ~~age-related~~
14 mild-to-moderate hearing loss. (New HOD Policy)
15

16 RECOMMENDATION B:
17

18 Madam Speaker, your Reference Committee recommends
19 that Resolution 124 be adopted as amended in lieu of
20 Resolution 120.
21

22 Resolution 120 asks that our AMA urge Medicare to cover some or all of the costs of a
23 "reasonable" device for both ears if a patient has had an audiological exam that
24 identifies the need, and for Medicare to identify a vendor, or vendors, of hearing devices
25 that produce a quality product without an exorbitant retail price.
26

27 Resolution 124 asks that our AMA support policies that increase access to hearing aids
28 and other technologies and services that alleviate hearing loss and its consequences for
29 the elderly; encourage increased transparency and access for hearing aid technologies
30 through itemization of audiologic service costs for hearing aids; and support the
31 availability of over-the-counter hearing aids for the treatment of age-related mild-to-
32 moderate hearing loss.
33

34 Testimony on Resolution 124 was supportive, and testimony on Resolution 120 was
35 mixed. A member of the Council on Medical Service testified in support of adopting
36 Resolution 124 in lieu of Resolution 120, explaining that the Council recently issued a
37 report on hearing aid coverage that specifically addressed the intent of Resolution 120
38 and is consistent with the intent of Resolution 124. The member from the Council on
39 Medical Service explained that in their report, the Council explicitly considered and
40 decided not to recommend that the AMA support Medicare coverage of hearing aids.
41 Other speakers testified that Resolution 124 offers a novel approach to the issue
42 highlighted by both Resolutions 120 and 124.
43

44 Your Reference Committee believes that Resolution 124 is consistent with existing AMA
45 policy regarding improving coverage of and access to hearing aids, and suggests an
46 amendment to broaden the impact of Resolution 124. Moreover, your Reference
47 Committee believes that Resolution 124 accomplishes the purpose of Resolution 120.
48 Accordingly, your Reference Committee recommends that Resolution 124 be adopted as
49 amended, and that amended Resolution 124 be adopted in lieu of Resolution 120.

1 (15) RESOLUTION 126 - ENSURING PRESCRIPTION DRUG
2 PRICE TRANSPARENCY FROM RETAIL PHARMACIES
3

4 RECOMMENDATION A:
5

6 Madam Speaker, your Reference Committee recommends
7 that Resolution 126 be amended by addition and deletion
8 to read as follows:
9

10 RESOLVED, That our American Medical Association
11 amend policy H-110.991, "Price of Medicine," by addition
12 and deletion as follows:
13

14 Our AMA: ~~(1) work with relevant organizations to advocate~~
15 ~~for increased transparency through access to meaningful~~
16 ~~and relevant information about medication price and out-~~
17 ~~of-pocket costs for prescription medications sold at both~~
18 ~~retail and mail order/online pharmacies, including but not~~
19 ~~limited to Medicare's drug-pricing dashboard; (1)~~
20 ~~advocates that pharmacies be required to list the full retail~~
21 ~~price of the prescription on the receipt along with the co-~~
22 ~~pay that is required in order to better inform our patients of~~
23 ~~the price of their medications; (2) will pursue legislation~~
24 ~~requiring pharmacies, pharmacy benefit managers and~~
25 ~~health plans to inform patients of the actual cash price as~~
26 ~~well as the formulary price of any medication prior to the~~
27 ~~purchase of the medication; (3) opposes provisions in~~
28 ~~pharmacies' contracts with pharmacy benefit managers~~
29 ~~that prohibit pharmacists from disclosing that a patient's~~
30 ~~co-pay is higher than the drug's cash price; (4) will~~
31 ~~disseminate model state legislation to promote drug price~~
32 ~~and cost transparency and to prohibit "clawbacks" and~~
33 ~~standard gag clauses in contracts between pharmacies~~
34 ~~and pharmacy benefit managers (PBMs) that bar~~
35 ~~pharmacists from telling consumers about less-expensive~~
36 ~~options for purchasing their medication; and (5) supports~~
37 ~~physician education regarding drug price and cost~~
38 ~~transparency, manufacturers' pricing practices, and~~
39 ~~challenges patients may encounter at the pharmacy point-~~
40 ~~of-sale. (6) work with relevant organizations to advocate for~~
41 ~~increased transparency through access to meaningful and~~
42 ~~relevant information about medication price and out-of-~~
43 ~~pocket costs for prescription medications sold at both retail~~
44 ~~and mail order/online pharmacies, including but not limited~~
45 ~~to Medicare's drug-pricing dashboard. (Modify Current~~
46 HOD Policy)

1 RECOMMENDATION B:
2

3 Madam Speaker, your Reference Committee recommends
4 that Resolution 126 be adopted as amended.
5

6 Resolution 126 asks that our AMA amend Policy H-110.991 as follows: Our AMA: (1)
7 work with relevant organizations to advocate for increased transparency through access
8 to meaningful and relevant information about medication price and out-of-pocket costs
9 for prescription medications sold at both retail and mail order/online pharmacies,
10 including but not limited to Medicare's drug-pricing dashboard; ~~(1) advocates that~~
11 pharmacies be required to list the full retail price of the prescription on the receipt along
12 with the co-pay that is required in order to better inform our patients of the price of their
13 medications;(2) will pursue legislation requiring pharmacies, pharmacy benefit managers
14 and health plans to inform patients of the actual cash price as well as the formulary price
15 of any medication prior to the purchase of the medication; (3) opposes provisions in
16 pharmacies' contracts with pharmacy benefit managers that prohibit pharmacists from
17 disclosing that a patient's co-pay is higher than the drug's cash price; (4) will
18 disseminate model state legislation to promote drug price and cost transparency and to
19 prohibit "clawbacks" and standard gag clauses in contracts between pharmacies and
20 pharmacy benefit managers (PBMs) that bar pharmacists from telling consumers about
21 less-expensive options for purchasing their medication; and (5) supports physician
22 education regarding drug price and cost transparency, manufacturers' pricing practices,
23 and challenges patients may encounter at the pharmacy point-of-sale.
24

25 Your Reference Committee heard highly supportive testimony on Resolution 126. An
26 amendment was offered to reinstate language that our AMA will disseminate model state
27 legislation to prohibit "clawbacks." Your Reference Committee accepts the amendment.
28 Your Reference Committee also is offering an amendment to retain the original first
29 clause of Policy H-110.991, while also accepting the new language proffered in
30 Resolution 126. Accordingly, your Reference Committee recommends that Resolution
31 126 be adopted as amended.
32

33 (16) RESOLUTION 131 - UPDATE PRACTICE EXPENSE
34 COMPONENT OF RELATIVE VALUE UNITS
35

36 RECOMMENDATION:
37

38 Madam Speaker, your Reference Committee recommends
39 that that Resolution 131 be referred for decision.
40

41 Resolution 131 asks that our AMA pursue efforts to update resource-based relative
42 value unit practice expense methodology so it accurately reflects current physician
43 practice costs, with a report back at the AMA House of Delegates 2019 Interim Meeting.
44

45 Your Reference Committee heard mixed testimony on Resolution 131. A member of the
46 Council on Medical Service recommended reaffirmation of existing Policy D-330.902 in
47 lieu of the resolution. This policy directive specifically calls for our AMA to "urge CMS to
48 update the data used to calculate the practice expense component of the Medicare
49 physician fee schedule by administering a physician practice survey (similar to the
50 Physician Practice Information Survey administered in 2007-2008) every five years, and

1 that this survey collect data to ensure that all physician practice costs are captured.”
2 Further, the policy calls for our AMA to “collect data and conduct research to facilitate
3 adjustments to the portion of the Medicare budget allocated to physician services that
4 more accurately reflects practice costs and changes in health care delivery.” The CMS
5 attested that this study is currently underway.
6

7 The authors provided ardent testimony that the AMA should conduct a new study of
8 current physician practice costs for its members, since hospitals do so annually and
9 have seen increases in payments. Further, physicians have borne the entire burden of
10 budget neutrality while all stakeholders should be accountable. Compelling testimony
11 was provided by the AMA’s representative to the RVS Update Committee (RUC) which
12 acknowledged the inequitableness in a conversion factor that is not increasing while
13 costs are, but explained that a new survey would only lead to redistribution of funds
14 within the payment schedule. As the Medicare physician payment schedule is a budget
15 neutral system, a survey to update the practice expense relative values would lead only
16 to redistribution and not to an overall increase in physician payment.
17

18 Your Reference Committee acknowledges the importance and complexity of this issue.
19 Moreover, the \$5 million fiscal note deserves consideration by the AMA Board of
20 Trustees. For these reasons, your Reference Committee recommends that Resolution
21 131 be referred for decision.
22

- 23 (17) RESOLUTION 101 - HEALTH HAZARDS OF HIGH
24 DEDUCTIBLE INSURANCE
25 RESOLUTION 125 - MITIGATING THE NEGATIVE
26 EFFECTS OF HIGH-DEDUCTIBLE HEALTH PLANS
27

28 RECOMMENDATION:
29

30 Madam Speaker, your Reference Committee recommends
31 that the Policies H-165.846, D-185.979 and H-165.828 be
32 reaffirmed in lieu of Resolutions 101 and 125.
33

34 Resolution 101 asks that our AMA support health insurance deductibles of not more than
35 \$1,000 for an individual per year, especially to patients with significant chronic disease.
36 Resolution 125 asks that our AMA advocate for legislation or regulation specifying that
37 codes for outpatient evaluation and management services, including initial and
38 established patient office visits, be exempt from deductible payments.
39

40 Resolution 125 asks that our AMA advocate for legislation or regulation specifying that
41 codes for outpatient evaluation and management services, including initial and
42 established patient office visits, be exempt from deductible payments.
43

44 Your Reference Committee heard mixed testimony on Resolutions 101 and 125.
45 Testimony stressed that high deductibles and cost-sharing requirements can serve as
46 barriers to patients accessing the care they need. A member of the Council on Medical
47 Service testified that the approaches put forward in Resolutions 101 and 125 would have
48 the unintended consequence of increasing premiums, potentially making health
49 insurance coverage unaffordable for many. Furthermore, the Council member stated that
50 both resolutions would severely limit patient choice of health plan, and Resolution 101 in

1 particular would hamper patient use of health savings accounts. Your Reference
2 Committee notes that, in addition, Resolution 125 could cause cost-sharing
3 requirements for benefits not included in the resolution to increase, in order to maintain a
4 plan's actuarial value (the percentage of total average costs for covered benefits that a
5 plan will cover).
6

7 The Council member continued that existing policy addresses the spirit of Resolutions
8 101 and 125. In addition, the recommendations of Council on Medical Service Report 2
9 being considered at this meeting also call for more people to be eligible for cost-sharing
10 reductions for ACA exchange coverage, and for such reductions to be more generous in
11 size. Policy H-165.846 states that provisions must be made to assist individuals with
12 low-incomes or unusually high medical costs in obtaining health insurance coverage and
13 meeting cost-sharing obligations. Policy D-185.979 supports innovations that expand
14 access to affordable care, including changes needed to allow high-deductible health
15 plans paired with health savings accounts to provide pre-deductible coverage for
16 preventive and chronic care management services. In addition, for low-income
17 individuals who qualify for cost-sharing reductions who instead enroll in a bronze plan
18 with higher out-of-pocket costs, Policy H-165.828 encourages the development of
19 demonstration projects to allow individuals eligible for cost-sharing subsidies, who forego
20 these subsidies by enrolling in a bronze plan, to have access to a health savings
21 account partially funded by an amount determined to be equivalent to the cost-sharing
22 subsidy. This change would help affected individuals meet the deductibles and other
23 cost-sharing obligations of their bronze plan.
24

25 Your Reference Committee agrees that existing policy addresses the intent of
26 Resolutions 101 and 125. As such, your Reference Committee recommends the
27 reaffirmation of Policies H-165.846, D-185.979 and H-165.828 in lieu of Resolutions 101
28 and 125.
29

30 H-165.828 Health Insurance Affordability

31 1. Our AMA supports modifying the eligibility criteria for premium credits and
32 cost-sharing subsidies for those offered employer-sponsored coverage by
33 lowering the threshold that determines whether an employee's premium
34 contribution is affordable to that which applies to the exemption from the
35 individual mandate of the Affordable Care Act (ACA). 2. Our AMA supports
36 legislation or regulation, whichever is relevant, to fix the ACA's "family glitch,"
37 thus determining the affordability of employer-sponsored coverage with respect
38 to the cost of family-based or employee-only coverage. 3. Our AMA encourages
39 the development of demonstration projects to allow individuals eligible for cost-
40 sharing subsidies, who forego these subsidies by enrolling in a bronze plan, to
41 have access to a health savings account (HSA) partially funded by an amount
42 determined to be equivalent to the cost-sharing subsidy. 4. Our AMA supports
43 capping the tax exclusion for employment-based health insurance as a funding
44 stream to improve health insurance affordability, including for individuals
45 impacted by the inconsistency in affordability definitions, individuals impacted by
46 the "family glitch," and individuals who forego cost-sharing subsidies despite
47 being eligible. 5. Our AMA supports additional education regarding deductibles
48 and cost-sharing at the time of health plan enrollment, including through the use
49 of online prompts and the provision of examples of patient cost-sharing
50 responsibilities for common procedures and services. 6. Our AMA supports

1 efforts to ensure clear and meaningful differences between plans offered on
2 health insurance exchanges. 7. Our AMA supports clear labeling of exchange
3 plans that are eligible to be paired with a Health Savings Account (HSA) with
4 information on how to set up an HSA. (CMS Rep. 8, I-15; Reaffirmed in lieu of:
5 Res. 121, A-16; Reaffirmation: A-17)
6

7 H-165.846 Adequacy of Health Insurance Coverage Options

8 1. Our AMA supports the following principles to guide in the evaluation of the
9 adequacy of health insurance coverage options: A. Any insurance pool or similar
10 structure designed to enable access to age-appropriate health insurance
11 coverage must include a wide variety of coverage options from which to choose.
12 B. Existing federal guidelines regarding types of health insurance coverage (e.g.,
13 Title 26 of the US Tax Code and Federal Employees Health Benefits Program
14 [FEHBP] regulations) should be used as a reference when considering if a given
15 plan would provide meaningful coverage. C. Provisions must be made to assist
16 individuals with low-incomes or unusually high medical costs in obtaining health
17 insurance coverage and meeting cost-sharing obligations. D. Mechanisms must
18 be in place to educate patients and assist them in making informed choices,
19 including ensuring transparency among all health plans regarding covered
20 services, cost-sharing obligations, out-of-pocket limits and lifetime benefit caps,
21 and excluded services. 2. Our AMA advocates that the Early and Periodic
22 Screening, Diagnostic, and Treatment (EPSDT) program be used as the model
23 for any essential health benefits package for children. 3. Our AMA: (a) opposes
24 the removal of categories from the essential health benefits (EHB) package and
25 their associated protections against annual and lifetime limits, and out-of-pocket
26 expenses; and (b) opposes waivers of EHB requirements that lead to the
27 elimination of EHB categories and their associated protections against annual
28 and lifetime limits, and out-of-pocket expenses. (CMS Rep. 7, A-07;
29 Reaffirmation I-07; Reaffirmation A-09; Reaffirmed: Res. 103, A-09;
30 Reaffirmation I-09; Reaffirmed: CMS Rep. 3, I-09; Reaffirmed: CMS Rep. 2, A-
31 11; Appended: CMS Rep. 2, A-11; Reaffirmed in lieu of Res. 109, A-12;
32 Reaffirmed: CMS Rep. 1, I-12; Reaffirmed: CMS Rep. 3, A-13; Reaffirmed in lieu
33 of Res. 812, I-13; Reaffirmed: CMS Rep. 6, I-14; Reaffirmed: CMS Rep. 6, I-15;
34 Appended: CMS Rep. 04, I-17)
35

36 D-185.979 Aligning Clinical and Financial Incentives for High-Value Care

37 1. Our AMA supports Value-Based Insurance Design (VBID) plans designed in
38 accordance with the tenets of “clinical nuance,” recognizing that (a) medical
39 services may differ in the amount of health produced, and (b) the clinical benefit
40 derived from a specific service depends on the person receiving it, as well as
41 when, where, and by whom the service is provided. 2. Our AMA supports
42 initiatives that align provider-facing financial incentives created through payment
43 reform and patient-facing financial incentives created through benefit design
44 reform, to ensure that patient, provider, and payer incentives all promote the
45 same quality care. Such initiatives may include reducing patient cost-sharing for
46 the items and services that are tied to provider quality metrics. 3. Our AMA will
47 develop coding guidance tools to help providers appropriately bill for zero-dollar
48 preventive interventions and promote common understanding among health care
49 providers, payers, patients, and health care information technology vendors
50 regarding what will be covered at given cost-sharing levels. 4. Our AMA will

1 develop physician educational tools that prepare physicians for conversations
2 with their patients about the scope of preventive services provided without cost-
3 sharing and instances where and when preventive services may result in
4 financial obligations for the patient. 5. Our AMA will continue to support requiring
5 private health plans to provide coverage for evidence-based preventive services
6 without imposing cost-sharing (such as co-payments, deductibles, or
7 coinsurance) on patients. 6. Our AMA will continue to support implementing
8 innovative VBID programs in Medicare Advantage plans. 7. Our AMA supports
9 legislative and regulatory flexibility to accommodate VBID that (a) preserves
10 health plan coverage without patient cost-sharing for evidence-based preventive
11 services; and (b) allows innovations that expand access to affordable care,
12 including changes needed to allow High Deductible Health Plans paired with
13 Health Savings Accounts to provide pre-deductible coverage for preventive and
14 chronic care management services. 8. Our AMA encourages national medical
15 specialty societies to identify services that they consider to be high-value and
16 collaborate with payers to experiment with benefit plan designs that align patient
17 financial incentives with utilization of high-value services. (Joint CMS CSAPH
18 Rep. 01, I-18)

19
20 (18) RESOLUTION 109 - PART A MEDICARE PAYMENT TO
21 PHYSICIANS

22
23 RECOMMENDATION:

24
25 Madam Speaker, your Reference Committee recommends
26 that Policies D-390.969 and D-330.902 be reaffirmed in
27 lieu of Resolution 109.
28

29 Resolution 109 asks that our AMA work for enactment of legislation to direct cash
30 payments from Part A Medicare to physicians in direct proportion to demonstrated
31 savings that are made in Part A Medicare through the efforts of physicians.
32

33 Your Reference Committee heard testimony in favor of reaffirmation of Resolution 109.
34 Significant testimony from the Council on Medical Service highlighted that existing policy
35 addresses the intent of the resolution. The Council's report from the last meeting (D-
36 330.902) recommended a study to document the role that physicians have played in
37 reducing Medicare spending, as noted in the third Whereas clause, and existing policy
38 on parity in Medicare reimbursement directly aligns with the Resolved clause. The
39 authors expressed that existing policy should be made a top priority of the Association.
40 Your Reference Committee empathizes but agrees that existing policy is sufficient for
41 supporting continued AMA efforts in this important area. As such, your Reference
42 Committee recommends that Policies D-390.969 and D-330.902 be reaffirmed in lieu of
43 Resolution 109.
44

45 D-390.969 Parity in Medicare Reimbursement
46 Our AMA will continue its comprehensive advocacy campaign to: (1) repeal the
47 reductions in Medicare payment for imaging services furnished in physicians'
48 offices, as mandated by the Deficit Reduction Act of 2005; (2) pass legislation
49 allowing physicians to share in Medicare Part A savings that are achieved when
50 physicians provide medical care that results in fewer in-patient complications,

1 shorter lengths-of-stays, and fewer hospital readmissions; and (3) advocate for
2 other mechanisms to ensure adequate payments to physicians, such as balance
3 billing and gainsharing. (Referred for decision Res. 236, A-06; Reaffirmation I-08;
4 Modified: BOT Rep. 09, A-18; Reaffirmed in lieu of: Res. 823, I-18)
5

6 D-330.902 The Site-of-Service Differential

7 1. Our AMA supports Medicare payment policies for outpatient services that are
8 site-neutral without lowering total Medicare payments. 2. Our AMA supports
9 Medicare payments for the same service routinely and safely provided in multiple
10 outpatient settings (e.g., physician offices, HOPDs, and ASCs) that are based on
11 sufficient and accurate data regarding the actual costs of providing the service in
12 each setting. 3. Our AMA will urge CMS to update the data used to calculate the
13 practice expense component of the Medicare physician fee schedule by
14 administering a physician practice survey (similar to the Physician Practice
15 Information Survey administered in 2007-2008) every five years, and that this
16 survey collect data to ensure that all physician practice costs are captured. 4.
17 Our AMA encourages CMS to both: a) base disproportionate share hospital
18 payments and uncompensated care payments to hospitals on actual
19 uncompensated care data; and b) study the costs to independent physician
20 practices of providing uncompensated care. 5. Our AMA will collect data and
21 conduct research both: a) to document the role that physicians have played in
22 reducing Medicare spending; and b) to facilitate adjustments to the portion of the
23 Medicare budget allocated to physician services that more accurately reflects
24 practice costs and changes in health care delivery. (CMS Rep. 04, I-18)
25

- 26 (19) RESOLUTION 111 - PRACTICE OVERHEAD EXPENSE
27 AND THE SITE-OF-SERVICE DIFFERENTIAL
28 RESOLUTION 132 (LATE RESOLUTION 1003) - SITE OF
29 SERVICE DIFFERENTIAL
30

31 RECOMMENDATION:

32
33 Madam Speaker, your Reference Committee recommends
34 that Policies D-330.902, D-390.969, H-240.993 and H-
35 400.957 be reaffirmed in lieu of Resolution 111 and Late
36 Resolution 1003.
37

38 Resolution 111 asks that our AMA appeal to the US Congress for legislation to direct the
39 Centers for Medicare and Medicaid Services (CMS) to eliminate any site-of-service
40 differential payments to hospitals for the same service that can safely be performed in a
41 doctor's office; appeal to the US Congress for legislation to direct CMS in regards to any
42 savings to Part B Medicare, through elimination of the site-of-service differential
43 payments to hospitals, (for the same service that can safely be performed in a doctor's
44 office), be distributed to all physicians who participate in Part B Medicare, by means of
45 improved payments for office-based Evaluation and Management Codes, so as to
46 immediately redress underpayment to physicians in regards to overhead expense; and
47 appeal to the US Congress for legislation to direct CMS to make Medicare payments for
48 the same service routinely and safely provided in multiple outpatient settings (e.g.,
49 physician offices, HOPDs and ASCs) that are based on sufficient and accurate data
50 regarding the actual costs of providing the service in each setting.

1 Resolution 132 (Late Resolution 1003) asks that our American Medical Association
2 advocate for site of service payment equalization to be calculated in a manner that both
3 enhances physician reimbursement while maintaining hospital rates for physician
4 services at an objectively justifiable level, including but not limited to the filing of amicus
5 briefs in relevant lawsuits as determined appropriate by the Office of General Counsel.
6

7 Your Reference Committee heard mixed testimony on Resolution 111 and Resolution
8 132 which spoke to the historical inequality between payments for Medicare part A and
9 part B. The majority of testimony favored reaffirmation of existing policies, in particular
10 D-330.992 from CMS Report 4-I-18 "The Site-of-Service Differential." The third resolve
11 clause for Resolution 111 uses language verbatim from this report. Testimony from the
12 authors called for a serious legislative initiative and did not believe that the resolution
13 was redundant. The AMA's representative to the RVS Update Committee (RUC)
14 provided testimony stating that the AMA is already working with the Centers for Medicaid
15 and Medicare Services (CMS) and that the best course of action is reaffirmation.
16 Further, regarding the second resolve of Resolution 111, the CPT recently revised the
17 E/M office visits and the RUC made recommendations to CMS that would be applied
18 across the entire Medicare payment schedule, if adopted. In addition, the AMA
19 submitted an OPPS/ASC comment letter last year which states that savings should be
20 reinvested back into the physician fee schedule but did not specifically point to E/M
21 payments. Regarding Resolution 132, your Reference Committee concurs that current
22 policy is supportive of AMA action in this area including the filing of amicus briefs. For
23 these reasons, your Reference Committee recommends that Policies D-330.902, D-
24 390.969, H-240.993 and H-400.957 be reaffirmed in lieu of Resolution 111 and
25 Resolution 132.
26

27 D-330.902 The Site-of-Service Differential

28 1. Our AMA supports Medicare payment policies for outpatient services that are
29 site-neutral without lowering total Medicare payments. 2. Our AMA supports
30 Medicare payments for the same service routinely and safely provided in multiple
31 outpatient settings (e.g., physician offices, HOPDs, and ASCs) that are based on
32 sufficient and accurate data regarding the actual costs of providing the service in
33 each setting. 3. Our AMA will urge CMS to update the data used to calculate the
34 practice expense component of the Medicare physician fee schedule by
35 administering a physician practice survey (similar to the Physician Practice
36 Information Survey administered in 2007-2008) every five years, and that this
37 survey collect data to ensure that all physician practice costs are captured. 4.
38 Our AMA encourages CMS to both: a) base disproportionate share hospital
39 payments and uncompensated care payments to hospitals on actual
40 uncompensated care data; and b) study the costs to independent physician
41 practices of providing uncompensated care. 5. Our AMA will collect data and
42 conduct research both: a) to document the role that physicians have played in
43 reducing Medicare spending; and b) to facilitate adjustments to the portion of the
44 Medicare budget allocated to physician services that more accurately reflects
45 practice costs and changes in health care delivery. (CMS Rep. 04, I-18)
46

47 D-390.969 Parity in Medicare Reimbursement

48 Our AMA will continue its comprehensive advocacy campaign to: (1) repeal the
49 reductions in Medicare payment for imaging services furnished in physicians'

1 offices, as mandated by the Deficit Reduction Act of 2005; (2) pass legislation
2 allowing physicians to share in Medicare Part A savings that are achieved when
3 physicians provide medical care that results in fewer in-patient complications,
4 shorter lengths-of-stays, and fewer hospital readmissions; and (3) advocate for
5 other mechanisms to ensure adequate payments to physicians, such as balance
6 billing and gainsharing. (Referred for decision Res. 236, A-06 Reaffirmation I-08
7 Modified: BOT Rep. 09, A-18 Reaffirmed in lieu of: Res. 823, I-18)
8

9 H-240.993 Discontinuance of Federal Funding for Ambulatory Care Centers
10 The AMA strongly urges more aggressive implementation by HHS of existing
11 provisions in federal legislation calling for equity of reimbursement between
12 services provided by hospitals on an outpatient basis and similar services in
13 physicians' offices. (CMS Rep. B, A-83 Reaffirmed: CLRPD Rep. 1, I-93
14 Reaffirmation I-98 Reaffirmation I-03 Reaffirmation I-07 Reaffirmed: CMS Rep. 3,
15 A-13 Reaffirmation A-15 Reaffirmed: CMS Rep. 04, I-18)
16

17 H-400.957 Medicare Reimbursement of Office-Based Procedures
18 Our AMA will: (1) encourage CMS to expand the extent and amount of
19 reimbursement for procedures performed in the physician's office, to shift more
20 procedures from the hospital to the office setting, which is more cost effective; (2)
21 seek to have the RBRVS practice expense RVUs reflect the true cost of
22 performing office procedures; and (3) work with CMS to develop consistent
23 regulations to be followed by carriers that include reimbursement for the costs of
24 disposable supplies and surgical tray fees incurred with office-based procedures
25 and surgery. (Sub. Res. 103, I-93 Reaffirmed by Rules & Credentials Cmt., A-96
26 Reaffirmation A-04 Reaffirmation I-04 Reaffirmed: CMS Rep. 1, A-14
27 Reaffirmed: CMS Rep. 3, A-14 Reaffirmed in lieu of Res. 216, I-14
28 Reaffirmed: CMS Rep. 04, I-18)
29

30 (20) RESOLUTION 112 - HEALTH CARE FEE
31 TRANSPARENCY
32

33 RECOMMENDATION:
34

35 Madam Speaker, your Reference Committee recommends
36 that Policies H-105.988, D-155.987 and H-373.998 be
37 reaffirmed in lieu of Resolution 112.
38

39 Resolution 112 asks that our AMA advocate for federal legislation and/or regulation to
40 require disclosure of hospital prices negotiated with insurance companies in effort to
41 achieve third-party contract transparency; and advocate for federal legislation and/or
42 regulation to require pharmaceutical companies to disclose drug prices in their television
43 (TV) ads in order to provide consumers more choice and control over their healthcare.
44

45 There was mixed testimony on Resolution 112. In the introduction of the resolution, the
46 sponsor of Resolution 112 stated that the second resolve of the resolution is indeed a
47 reaffirmation of already existing policy. Further, members of the Council on Medical
48 Service and Council on Legislation called for reaffirmation of existing policy in lieu of
49 Resolution 112 in its entirety. The member of the Council on Medical Service stated that

1 existing policy enables the AMA to advocate in response to the provisions of the 21st
2 Century Cures Act (Cures Act) highlighted by the sponsor of Resolution 112.

3
4 In addition, the member of the Council on Legislation underscored that the AMA has
5 engaged in advocacy efforts directly addressing the intent of Resolution 112. For
6 example, the AMA submitted a letter to select U.S. Senators, which provided feedback
7 on Congressional efforts to increase health care price and information transparency to
8 empower patients, improve the quality of health care, and lower health care costs.
9 Furthermore, the AMA submitted a letter to CMS Administrator Seema Verma in
10 response to the proposed rule requiring the disclosure of prescription drug list prices in
11 direct-to-consumer advertisements on television.

12
13 Your Reference Committee believes that Resolution 112 is already addressed by
14 existing AMA policy and ongoing advocacy efforts. As such, your Reference Committee
15 recommends that Policies H-105.988, D-155.987 and H-373.998 be reaffirmed in lieu of
16 Resolution 112.

17
18 H-105.988 Direct-to-Consumer Advertising (DTCA) of Prescription Drugs and
19 Implantable Devices

20 1. To support a ban on direct-to-consumer advertising for prescription drugs and
21 implantable medical devices. 2. That until such a ban is in place, our AMA
22 opposes product-claim DTCA that does not satisfy the following guidelines: (a)
23 The advertisement should be indication-specific and enhance consumer
24 education about the drug or implantable medical device, and the disease,
25 disorder, or condition for which the drug or device is used. (b) In addition to
26 creating awareness about a drug or implantable medical device for the treatment
27 or prevention of a disease, disorder, or condition, the advertisement should
28 convey a clear, accurate and responsible health education message by providing
29 objective information about the benefits and risks of the drug or implantable
30 medical device for a given indication. Information about benefits should reflect
31 the true efficacy of the drug or implantable medical device as determined by
32 clinical trials that resulted in the drug's or device's approval for marketing. (c) The
33 advertisement should clearly indicate that the product is a prescription drug or
34 implantable medical device to distinguish such advertising from other advertising
35 for non-prescription products. (d) The advertisement should not encourage self-
36 diagnosis and self-treatment, but should refer patients to their physicians for
37 more information. A statement, such as "Your physician may recommend other
38 appropriate treatments," is recommended. (e) The advertisement should exhibit
39 fair balance between benefit and risk information when discussing the use of the
40 drug or implantable medical device product for the disease, disorder, or
41 condition. The amount of time or space devoted to benefit and risk information,
42 as well as its cognitive accessibility, should be comparable. (f) The advertisement
43 should present information about warnings, precautions, and potential adverse
44 reactions associated with the drug or implantable medical device product in a
45 manner (e.g., at a reading grade level) such that it will be understood by a
46 majority of consumers, without distraction of content, and will help facilitate
47 communication between physician and patient. (g) The advertisement should not
48 make comparative claims for the product versus other prescription drug or
49 implantable medical device products; however, the advertisement should include
50 information about the availability of alternative non-drug or non-operative

1 management options such as diet and lifestyle changes, where appropriate, for
2 the disease, disorder, or condition. (h) In general, product-claim DTCA should not
3 use an actor to portray a health care professional who promotes the drug or
4 implantable medical device product, because this portrayal may be misleading
5 and deceptive. If actors portray health care professionals in DTCA, a disclaimer
6 should be prominently displayed. (i) The use of actual health care professionals,
7 either practicing or retired, in DTCA to endorse a specific drug or implantable
8 medical device product is discouraged but if utilized, the advertisement must
9 include a clearly visible disclaimer that the health care professional is
10 compensated for the endorsement. (j) The advertisement should be targeted for
11 placement in print, broadcast, or other electronic media so as to avoid audiences
12 that are not age appropriate for the messages involved. (k) In addition to the
13 above, the advertisement must comply with all other applicable Food and Drug
14 Administration (FDA) regulations, policies and guidelines. 3. That the FDA review
15 and pre-approve all DTCA for prescription drugs or implantable medical device
16 products before pharmaceutical and medical device manufacturers (sponsors)
17 run the ads, both to ensure compliance with federal regulations and consistency
18 with FDA-approved labeling for the drug or implantable medical device product.
19 4. That the Congress provide sufficient funding to the FDA, either through direct
20 appropriations or through prescription drug or implantable medical device user
21 fees, to ensure effective regulation of DTCA. 5. That DTCA for newly approved
22 prescription drug or implantable medical device products not be run until
23 sufficient post-marketing experience has been obtained to determine product
24 risks in the general population and until physicians have been appropriately
25 educated about the drug or implantable medical device. The time interval for this
26 moratorium on DTCA for newly approved drugs or implantable medical devices
27 should be determined by the FDA, in negotiations with the drug or medical device
28 product's sponsor, at the time of drug or implantable medical device approval.
29 The length of the moratorium may vary from drug to drug and device to device
30 depending on various factors, such as: the innovative nature of the drug or
31 implantable medical device; the severity of the disease that the drug or
32 implantable medical device is intended to treat; the availability of alternative
33 therapies; and the intensity and timeliness of the education about the drug or
34 implantable medical device for physicians who are most likely to prescribe it. 6.
35 That our AMA opposes any manufacturer (drug or device sponsor) incentive
36 programs for physician prescribing and pharmacist dispensing that are run
37 concurrently with DTCA. 7. That our AMA encourages the FDA, other appropriate
38 federal agencies, and the pharmaceutical and medical device industries to
39 conduct or fund research on the effect of DTCA, focusing on its impact on the
40 patient-physician relationship as well as overall health outcomes and cost benefit
41 analyses; research results should be available to the public. 8. That our AMA
42 supports the concept that when companies engage in DTCA, they assume an
43 increased responsibility for the informational content and an increased duty to
44 warn consumers, and they may lose an element of protection normally accorded
45 under the learned intermediary doctrine. 9. That our AMA encourages physicians
46 to be familiar with the above AMA guidelines for product-claim DTCA and with
47 the Council on Ethical and Judicial Affairs Ethical Opinion E-9.6.7 and to adhere
48 to the ethical guidance provided in that Opinion. 10. That the Congress should
49 request the Agency for Healthcare Research and Quality or other appropriate
50 entity to perform periodic evidence-based reviews of DTCA in the United States

1 to determine the impact of DTCA on health outcomes and the public health. If
2 DTCA is found to have a negative impact on health outcomes and is detrimental
3 to the public health, the Congress should consider enacting legislation to
4 increase DTCA regulation or, if necessary, to prohibit DTCA in some or all media.
5 In such legislation, every effort should be made to not violate protections on
6 commercial speech, as provided by the First Amendment to the U.S.
7 Constitution. 11. That our AMA supports eliminating the costs for DTCA of
8 prescription drugs as a deductible business expense for tax purposes. 12. That
9 our AMA continues to monitor DTCA, including new research findings, and work
10 with the FDA and the pharmaceutical and medical device industries to make
11 policy changes regarding DTCA, as necessary. 13. That our AMA supports "help-
12 seeking" or "disease awareness" advertisements (i.e., advertisements that
13 discuss a disease, disorder, or condition and advise consumers to see their
14 physicians, but do not mention a drug or implantable medical device or other
15 medical product and are not regulated by the FDA). 14. Our AMA will advocate to
16 the applicable Federal agencies (including the Food and Drug Administration, the
17 Federal Trade Commission, and the Federal Communications Commission)
18 which regulate or influence direct-to-consumer advertising of prescription drugs
19 that such advertising should be required to state the manufacturer's suggested
20 retail price of those drugs. BOT Rep. 38 and Sub. Res. 513, A-99; Reaffirmed:
21 CMS Rep. 9, Amended: Res. 509, and Reaffirmation I-99; Appended &
22 Reaffirmed: Sub. Res. 503, A-01; Reaffirmed: Res. 522, A-02; Reaffirmed: Res.
23 914, I-02; Reaffirmed: Sub. Res. 504, A-03; Reaffirmation A-04; Reaffirmation A-
24 05; Modified: BOT Rep. 9, A-06; Reaffirmed in lieu of Res. 514, A-07; BOT
25 Action in response to referred for decision: Res. 927, I-15; Modified: BOT Rep.
26 09, I-16; Appended: Res. 236, A-17; Reaffirmed in lieu of: Res. 223, A-17)

27

28 D-155.987 Price Transparency

29 1. Our AMA encourages physicians to communicate information about the cost of
30 their professional services to individual patients, taking into consideration the
31 insurance status (e.g., self-pay, in-network insured, out-of-network insured) of the
32 patient or other relevant information where possible. 2. Our AMA advocates that
33 health plans provide plan enrollees or their designees with complete information
34 regarding plan benefits and real time cost-sharing information associated with
35 both in-network and out-of-network provider services or other plan designs that
36 may affect patient out-of-pocket costs. 3. Our AMA will actively engage with
37 health plans, public and private entities, and other stakeholder groups in their
38 efforts to facilitate price and quality transparency for patients and physicians, and
39 help ensure that entities promoting price transparency tools have processes in
40 place to ensure the accuracy and relevance of the information they provide. 4.
41 Our AMA will work with states to support and strengthen the development of all-
42 payer claims databases. 5. Our AMA encourages electronic health records
43 vendors to include features that assist in facilitating price transparency for
44 physicians and patients. 6. Our AMA encourages efforts to educate patients in
45 health economics literacy, including the development of resources that help
46 patients understand the complexities of health care pricing and encourage them
47 to seek information regarding the cost of health care services they receive or
48 anticipate receiving. 7. Our AMA will request that the Centers for Medicare and
49 Medicaid Services expand its Medicare Physician Fee Schedule Look-up Tool to
50 include hospital outpatient payments. (CMS Rep. 4, A-15; Reaffirmed in lieu of:

1 Res. 121, A-16; Reaffirmed in lieu of: Res. 213, I-17; Reaffirmed: BOT Rep. 14,
2 A-18)

3
4 H-373.998 Patient Information and Choice

5 Our AMA supports the following principles: 1. Greater reliance on market forces,
6 with patients empowered with understandable fee/price information and
7 incentives to make prudent choices, and with the medical profession empowered
8 to enforce ethical and clinical standards which continue to place patients'
9 interests first, is clearly a more effective and preferable approach to cost
10 containment than is a government-run, budget-driven, centrally controlled health
11 care system. 2. Individuals should have freedom of choice of physician and/or
12 system of health care delivery. Where the system of care places restrictions on
13 patient choice, such restrictions must be clearly identified to the individual prior to
14 their selection of that system. 3. In order to facilitate cost-conscious, informed
15 market-based decision-making in health care, physicians, hospitals, pharmacies,
16 durable medical equipment suppliers, and other health care providers should be
17 required to make information readily available to consumers on fees/prices
18 charged for frequently provided services, procedures, and products, prior to the
19 provision of such services, procedures, and products. There should be a similar
20 requirement that insurers make available in a standard format to enrollees and
21 prospective enrollees information on the amount of payment provided toward
22 each type of service identified as a covered benefit. 4. Federal and/or state
23 legislation should authorize medical societies to operate programs for the review
24 of patient complaints about fees, services, etc. Such programs would be
25 specifically authorized to arbitrate a fee or portion thereof as appropriate and to
26 mediate voluntary agreements, and could include the input of the state medical
27 society and the AMA Council on Ethical and Judicial Affairs. 5. Physicians are the
28 patient advocates in the current health system reform debate. Efforts should
29 continue to seek development of a plan that will effectively provide universal
30 access to an affordable and adequate spectrum of health care services, maintain
31 the quality of such services, and preserve patients' freedom to select physicians
32 and/or health plans of their choice. 6. Efforts should continue to vigorously
33 pursue with Congress and the Administration the strengthening of our health care
34 system for the benefit of all patients and physicians by advocating policies that
35 put patients, and the patient/physician relationships, at the forefront. BOT Rep.
36 QQ, I-91; Reaffirmed: BOT Rep. TT, I-92; Reaffirmed: Ref. Cmte. A, A-93;
37 Reaffirmed: BOT Rep. UU, A-93; Reaffirmed: CMS Rep. E, A-93; Reaffirmed:
38 CMS Rep. G, A-93; Reaffirmed: Sub. Res. 701, A-93; Sub. Res. 125, A-93;
39 Reaffirmation A-93; Reaffirmed: BOT Rep. 25, I-93; Reaffirmed: BOT Rep. 40, I-
40 93; Reaffirmed: CMS Rep. 5, I-93; Reaffirmed: CMS Rep. 10, I-93; Reaffirmed:
41 Sub. Res. 107, I-93; Reaffirmed: BOT Rep. 46, A-94; Reaffirmed: Sub. Res. 127,
42 A-94; Reaffirmed: Sub. Res. 132, A-94; Reaffirmed: BOT Rep. 16, I-94; BOT
43 Rep. 36 - I-94; Reaffirmed: CMS Rep. 8, A-95; Reaffirmed: Sub. Res. 109, A-95;
44 Reaffirmed: Sub. Res. 125, A-95; Reaffirmed by Sub. Res. 107, I-95; Reaffirmed:
45 Sub. Res. 109, I-95; Reaffirmed by Rules & Credentials Cmt., A-96;
46 Reaffirmation A-96; Reaffirmation I-96; Reaffirmation A-97; Reaffirmed: Rules
47 and Cred. Cmt., I-97; Reaffirmed: CMS Rep. 3, I-97; Reaffirmation I-98;
48 Reaffirmed: CMS Rep. 9, A-98; Reaffirmation A-99; Reaffirmation A-00;
49 Reaffirmation I-00; Reaffirmation A-04; Consolidated and Renumbered: CMS
50 Rep. 7, I-05; Reaffirmation A-07; Reaffirmation A-08; Reaffirmed: CMS Rep. 4,

1 A-09; Reaffirmed: CMS Rep. 3, I-09; Reaffirmation I-14; Reaffirmed: CMS Rep.
2 4, A-15; Reaffirmation: A-17; Reaffirmed: Res. 108, A-17)

3

4 (21) RESOLUTION 123 - STANDARDIZING COVERAGE OF
5 APPLIED BEHAVIORAL ANALYSIS THERAPY FOR
6 PERSONS WITH AUTISM SPECTRUM DISORDER

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

RECOMMENDATION:

Madam Speaker, your Reference Committee recommends that Policies H-90.968 and H-185.963 be reaffirmed in lieu of Resolution 123.

Resolution 123 asks that our AMA support the coverage and reimbursement for Applied Behavioral Analysis for the purpose of treating Autism Spectrum Disorder.

Your Reference Committee heard mixed testimony on Resolution 123. A member of the Council on Medical Service testified that existing policy addresses the intent of Resolution 123 by seeking public and private insurance coverage that reflects the true cost of health care for individuals with intellectual and developmental disabilities. In addition, the member of the Council on Medical Service testified that the AMA has engaged in advocacy efforts to advance access to care for individuals with developmental disabilities, such as autism. Finally, the Council member explained that AMA policy generally avoids mandating coverage of specific benefits, both to better allow markets to determine benefit packages and to avoid jeopardizing current coverage. Other testimony supported Resolution 123, specifically because it is seeking mandated coverage for a specific treatment.

Your Reference Committee believes that existing policy addresses the intent of Resolution 123. Accordingly, your Reference Committee recommends that Policies H-90.968 and H-185.963 be reaffirmed in lieu of Resolution 123.

H-90.968 Medical Care of Persons with Developmental Disabilities

1. Our AMA encourages: (a) clinicians to learn and appreciate variable presentations of complex functioning profiles in all persons with developmental disabilities; (b) medical schools and graduate medical education programs to acknowledge the benefits of education on how aspects in the social model of disability (e.g. ableism) can impact the physical and mental health of persons with Developmental Disabilities; (c) medical schools and graduate medical education programs to acknowledge the benefits of teaching about the nuances of uneven skill sets, often found in the functioning profiles of persons with developmental disabilities, to improve quality in clinical care; (d) the education of physicians on how to provide and/or advocate for quality, developmentally appropriate medical, social and living supports for patients with developmental disabilities so as to improve health outcomes; (e) medical schools and residency programs to encourage faculty and trainees to appreciate the opportunities for exploring diagnostic and therapeutic challenges while also accruing significant personal rewards when delivering care with professionalism to persons with profound developmental disabilities and multiple comorbid medical conditions in any setting; (f) medical schools and graduate medical education programs to

1 establish and encourage enrollment in elective rotations for medical students and
2 residents at health care facilities specializing in care for the developmentally
3 disabled; and (g) cooperation among physicians, health & human services
4 professionals, and a wide variety of adults with developmental disabilities to
5 implement priorities and quality improvements for the care of persons with
6 developmental disabilities. 2. Our AMA seeks: (a) legislation to increase the
7 funds available for training physicians in the care of individuals with intellectual
8 disabilities/developmentally disabled individuals, and to increase the
9 reimbursement for the health care of these individuals; and (b) insurance industry
10 and government reimbursement that reflects the true cost of health care of
11 individuals with intellectual disabilities/developmentally disabled individuals. 3.
12 Our AMA entreats health care professionals, parents and others participating in
13 decision-making to be guided by the following principles: (a) All people with
14 developmental disabilities, regardless of the degree of their disability, should
15 have access to appropriate and affordable medical and dental care throughout
16 their lives; and (b) An individual's medical condition and welfare must be the
17 basis of any medical decision. Our AMA advocates for the highest quality
18 medical care for persons with profound developmental disabilities; encourages
19 support for health care facilities whose primary mission is to meet the health care
20 needs of persons with profound developmental disabilities; and informs
21 physicians that when they are presented with an opportunity to care for patients
22 with profound developmental disabilities, that there are resources available to
23 them. 4. Our AMA will continue to work with medical schools and their
24 accrediting/licensing bodies to encourage disability related
25 competencies/objectives in medical school curricula so that medical
26 professionals are able to effectively communicate with patients and colleagues
27 with disabilities, and are able to provide the most clinically competent and
28 compassionate care for patients with disabilities. 5. Our AMA recognizes the
29 importance of managing the health of children and adults with developmental
30 disabilities as a part of overall patient care for the entire community. 6. Our AMA
31 supports efforts to educate physicians on health management of children and
32 adults with developmental disabilities, as well as the consequences of poor
33 health management on mental and physical health for people with developmental
34 disabilities. 7. Our AMA encourages the Liaison Committee on Medical
35 Education, Commission on Osteopathic College Accreditation, and allopathic and
36 osteopathic medical schools to develop and implement curriculum on the care
37 and treatment of people with developmental disabilities. 8. Our AMA encourages
38 the Accreditation Council for Graduate Medical Education and graduate medical
39 education programs to develop and implement curriculum on providing
40 appropriate and comprehensive health care to people with developmental
41 disabilities. 9. Our AMA encourages the Accreditation Council for Continuing
42 Medical Education, specialty boards, and other continuing medical education
43 providers to develop and implement continuing education programs that focus on
44 the care and treatment of people with developmental disabilities. 10. Our AMA
45 will advocate that the Health Resources and Services Administration include
46 persons with intellectual and developmental disabilities (IDD) as a medically
47 underserved population.

1 H-185.963 Insurance Coverage for Adults with Childhood Diseases
2 Our AMA: (1) urges public and private third party payers to increase access to
3 health insurance products for adults with congenital and/or childhood diseases
4 that are designed for the unique needs of this population; and
5 (2) emphasizes that any health insurance product designed for adults with
6 congenital and/or childhood diseases include the availability of specialized
7 treatment options, medical services, medical equipment and pharmaceuticals, as
8 well as the accessibility of an adequate number of physicians specializing in the
9 care of this unique population. (CMS Rep. 2, I-99 Modified and Reaffirmed: CMS
10 Rep. 5, A-09)

11
12 (22) RESOLUTION 127 - ELIMINATING THE CMS
13 OBSERVATION STATUS

14
15 RECOMMENDATION:

16
17 Madam Speaker, your Reference Committee recommends
18 that Policies D-160.932, D-280.988, D-280.989, and H-
19 185.941 be reaffirmed in lieu of Resolution 127.
20

21 Resolution 127 asks that our AMA request, for the benefit of our patients' financial,
22 physical and mental health, that the Centers for Medicare and Medicaid Services (CMS)
23 terminate the "48 hour observation period" and observation status in total.
24

25 Your Reference Committee heard mixed testimony on Resolution 127. A member of the
26 Council on Medical Service testified that AMA policy addresses the intent of Resolution
27 127 and that the AMA has already taken the advocacy action sought by Resolution 127.
28 The member of the Council on Medical Service also noted that the Council presented a
29 report in 2014 on the Place-of-Service Code for Observation Services that resulted in the
30 reaffirmation and adoption of policy that speaks to the resolution's request. In addition, a
31 member of the Council on Legislation called for reaffirmation, noting that the AMA has
32 already engaged in advocacy efforts that address the intent of Resolution 127.
33 Specifically, the AMA has written to CMS advocating repeal of the "two-midnight" policy
34 several times, including in 2018, 2017, and 2014. Other testimony consistently
35 requested action on this issue.
36

37 Your Reference Committee agrees that existing policy addresses the intent of
38 Resolution 127, and supports advocacy efforts to achieve the resolution's objective. The
39 policies recommended for reaffirmation include three directives to take action, and the
40 AMA has, in fact, undertaken significant advocacy action on this issue. As alluded to in
41 testimony by the member of the Council on Legislation, the AMA has repeatedly, over
42 many years, asked CMS resolve this problem. Key advocacy includes:
43

- 44 • In a June 2014 comment letter, the AMA stated, "The AMA has written to CMS
45 numerous times to communicate our serious concerns with CMS' two midnight
46 policy and the rise of observation care, and most recently submitted testimony on
47 this issue before the House Committee on Ways & Means . . . The AMA
48 opposes Medicare's two-midnight policy and believes it should be rescinded in its
49 entirety. Adding to the complexity of the two-midnight policy is the inconsistency
50 between when a hospital stay is considered to be inpatient for purposes of

1 hospital reimbursement versus when a patient is considered an inpatient for
2 purposes of coverage . . . This policy is having very real and negative impact on
3 patient safety. Emergency physicians are reporting patients coming to the
4 emergency department often ask whether they are being admitted as inpatients.
5 If these patients are not given assurances that they will be treated as an
6 inpatient, they leave—even when they clearly require medical attention.”

- 7 • In a June 2017 comment letter, the AMA stated, “The ‘2-Midnight’ rule has had
8 significant unintended negative consequences that burden Medicare
9 beneficiaries. It remains an artificial construct reflecting a flawed approach that
10 gets in the way of the physician-patient relationship and unnecessarily increases
11 the administrative burden of admitting physicians. . . CMS should rescind the 2-
12 midnight rule in favor of clinical judgement for determining a patient’s
13 inpatient/observation status.”
- 14 • The AMA restated its June 2017 comments in a November 2018 comment letter.

15
16 In recognition of existing policy calling for action on this issue and the AMA’s
17 longstanding, ongoing zealous advocacy, your Reference Committee believes that an
18 additional directive to take action is unnecessary and would not help the AMA achieve
19 this advocacy goal. Accordingly, your Reference Committee recommends that Policies
20 D-160.932, D-280.988, D-280.989, and H-185.941 be reaffirmed in lieu of Resolution
21 127.

22 23 D-160.932 Medicare's Two-Midnight Rule

24 Our AMA will petition the Centers for Medicare & Medicaid Services to repeal the
25 August 19 rules regarding Hospital Inpatient Admission Order and Certification.
26 (Res. 223, I-13 Reaffirmed: CMS Rep. 4, A-14 Reaffirmation A-14)

27 28 D-280.988 Observation Status and Medicare Part A Qualification

29 Our AMA will advocate for Medicare Part A coverage for a patient's direct
30 admission to a skilled facility if directed by their physician and if the patient's
31 condition meets skilled nursing criteria. (Res. 117, A-13 Reaffirmed: CMS Rep. 4,
32 A-14 Reaffirmation A-15)

33 34 D-280.989 Inclusion of Observation Status in Mandatory Three Day Inpatient 35 Stay

36 1. Our AMA will continue to monitor problems with patient readmissions to
37 hospitals and skilled nursing facilities and recoding of inpatient admissions as
38 observation care and advocate for appropriate regulatory and legislative action to
39 address these problems. 2. Our AMA will continue to advocate that the Centers
40 for Medicare & Medicaid Services explore payment solutions to reduce the
41 inappropriate use of hospital observation status. (BOT Rep. 32, A-09 Appended:
42 CMS Rep. 4, A-14)

43 44 H-185.941 Patient Cost-Sharing Requirements for Hospital Inpatient and 45 Observation Services

46 Our AMA will advocate that patients be subject to the same cost-sharing
47 requirements whether they are admitted to a hospital as an inpatient, or for
48 observation services. (Res. 117, A-12 Reaffirmed: CMS Rep. 4, A-14)

49

1 Madam Speaker, this concludes the report of Reference Committee A. I would like to
2 thank William Davison, MD, Gregory Fuller, MD, Russell Libby, MD, Loralie Ma, MD,
3 Kevin Nohner, MD, Laura Shea, MD, and all those who testified before the Committee. I
4 would also like to thank AMA staff: Courtney Perlino, MPP, Julie Marder JD, and
5 Rebecca Gierhahn, MS.

William Davison, MD, FAAN
American Academy of Neurology

Loralie Ma, MD
Maryland

Gregory Fuller, MD (Alternate)
Texas

Kevin Nohner, MD
Nebraska

Russell Libby, MD
Integrated Physician Practice Section

Laura Shea, MD
Illinois

John Montgomery, MD
Florida
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (A-19)

Report of Reference Committee B

Charles Rothberg, MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

2
3 **RECOMMENDED FOR ADOPTION**

- 4
5 1. Board of Trustees Report 14 — Reforming the Orphan Drug Act (Resolution 217-
6 A-18) An Optional National Prescription Drug Formulary (Resolution 227-A-18)
7 Reform of Pharmaceutical Pricing: Negotiated Payment Schedules (Resolution
8 238-A-18)
9 2. Board of Trustees Report 19 — FDA Conflict of Interest (Resolution 216-A-18)
10 3. Board of Trustees Report 23 — Prior Authorization Requirements for Post-
11 Operative Opioids (Resolution 208-A-18)
12 4. Board of Trustees Report 30 — Opioid Treatment Programs Reporting to
13 Prescription Monitoring Programs (Resolution 507-A-18)
14 5. Resolution 213 — Financial Penalties and Clinical Decision-Making
15 6. Resolution 223 — Simplification and Clarification of Smoking Status
16 Documentation in the Electronic Health Record
17 7. Resolution 242 — Improving Health Information Technology Products to Properly
18 Care for LGBTQ Patients
19 8. Resolution 244 — EHR-Integrated Prescription Drug Monitoring Program Rapid
20 Access
21

22 **RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED**

- 23
24 9. Board of Trustees Report 9 — Council on Legislation Sunset Report
25 10. Board of Trustees Report 17 — Ban on Medicare Advantage "No Cause"
26 Network Terminations
27 11. Board of Trustees Report 18 — Increased Use of Body-Worn Cameras by Law
28 Enforcement Officers (Resolution 208-I-17)
29 12. Board of Trustees Report 20 — Safe and Efficient e-Prescribing
30 13. Board of Trustees Report 21 — Augmented Intelligence in Health Care
31 14. Board of Trustees Report 22 — Inappropriate Use of CDC Guidelines for
32 Prescribing Opioids (Resolution 235-I-18)
33 Resolution 229 — Clarification of CDC Opioid Prescribing Guidelines
34 15. Resolution 201 — Assuring Patient Access to Kidney Transplantation
35 16. Resolution 204 — Holding the Pharmaceutical Industry Accountable for Opioid-
36 Related Costs
37 17. Resolution 208 — Repeal or Modification of the Sunshine Act
38 18. Resolution 211 — Use of Fair Health
39 19. Resolution 212 — Pharmacy Benefit Managers
40 20. Resolution 214 — The Term Physician
41 Resolution 216 — Eliminate the Word Provider from Healthcare Contracts
42 21. Resolution 217 — Medicare Vaccine Billing

- 1 22. Resolution 218 — Payment for Medications Used Off Label for Treatment of Pain
 2 Resolution 235 — Prescription Coverage of the Lidocaine Transdermal Patch
 3 23. Resolution 220 — Study of Confidentiality and Privacy Protection in the
 4 Treatment of Substance Disorders
 5 Resolution 231 — Alignment of Federal Privacy Law and Regulations Governing
 6 Substance Use Disorder Treatment (42 CFR Part 2) with the Health Insurance
 7 Portability and Accountability Act
 8
 9 24. Resolution 221 — Extending Medicaid Coverage to 12-Months Postpartum
 10 Resolution 224 — Extending Pregnancy Medicaid to One Year Postpartum
 11 25. Resolution 228 — Truth in Advertising
 12 26. Resolution 232 — COPD National Action Plan
 13 27. Resolution 233 — GME Cap Flexibility
 14 28. Resolution 237 — Opportunities in Blockchain for Healthcare
 15 29. Resolution 241 — Facilitation of Research with Medicare Claims Data
 16 30. Resolution 246 — Call for Transparency Regarding the Announcement of 17,000
 17 Cuts to Military Health Providers
 18

19 **RECOMMENDED FOR REFERRAL**

- 20
 21 31. Resolution 203 — Medicare Part B and Part D Drug Price Negotiation
 22 32. Resolution 207 — Direct-to-Consumer Genetic Tests
 23 33. Resolution 219 — Medical Marijuana License Safety
 24 34. Resolution 226 — Physician Access to Their Medical and Billing Records
 25 35. Resolution 243 — Improving the Quality Payment Program and Preserving
 26 Patient Access
 27 36. Resolution 245—Sensible Appropriate Use Criteria in Medicare
 28 Resolution 247—Sensible Appropriate Use Criteria in Medicare
 29

30 **RECOMMENDED FOR NOT ADOPTION**

- 31
 32 37. Resolution 227 — Controlled Substance Management
 33 38. Resolution 239 — Improving Access to Medical Care Through Tax Treatment of
 34 Physicians
 35

36 **RECOMMEND FOR REAFFIRMATION IN LIEU OF**

- 37
 38 39. Resolution 206 — Changing the Paradigm: Opposing Present and Obvious
 39 Restraint of Trade
 40 Resolution 240 — Formation of Collective Bargaining Workgroup
 41 40. Resolution 210 — Air Ambulances
 42 41. Resolution 236 — Support for Universal Basic Income Pilot Studies
 43

44 The alternate resolutions were included on the Reaffirmation Consent Calendar
 45 and were not addressed by the Reference Committee:
 46

- 47 Resolution 202 – Reducing the Hassle Factor in Quality Improvement Programs
 48 Resolution 205 – Use of Patient or Co-Worker Experience/Satisfaction Surveys Tied to
 49 Employed Physician Salary
 50 Resolution 209 – Mandates by ACOs Regarding Specific EMR Use
 51 Resolution 215 – Reimbursement for Health Information Technology

- 1 Resolution 222 – Protecting Patients from Misleading and Potentially Harmful "Bad
- 2 Drug" Ads
- 3 Resolution 225 – DACA in GME
- 4 Resolution 230 – State legislation mandating electrocardiogram (ECG) and/or
- 5 echocardiogram screening of scholastic athletes
- 6 Resolution 234 – Improved Access to Non-Opioid Therapies
- 7 Resolution 238 – Coverage Limitations and Non-Coverage of Interventional Pain
- 8 Procedures Correlating to the Worsening Opioid Epidemic and Public Health Crisis

1 (1) BOARD OF TRUSTEES REPORT 14 – REFORMING THE
2 ORPHAN DRUG ACT (RESOLUTION 217-A-18) AN
3 OPTIONAL NATIONAL PRESCRIPTION DRUG
4 FORMULARY (RESOLUTION 227-A-18) REFORM OF
5 PHARMACEUTICAL PRICING: NEGOTIATED PAYMENT
6 SCHEDULES (RESOLUTION 238-A-18)
7

8 RECOMMENDATION:
9

10 Madam Speaker, your Reference Committee recommends that
11 the recommendations of the Board of Trustees Report 14 be
12 adopted and the remainder of the report be filed.
13

14 The Board of Trustees recommends that the following be adopted in lieu of Resolutions 217-
15 A-18, 227-A-18, and 238-A-18, and the remainder of this report be filed. 1. That our AMA
16 reaffirm Policy H-110.987, “Pharmaceutical Costs,” which outlines a series of measures to
17 address anti-competitive actions by pharmaceutical manufacturers as well as policies to
18 promote increased transparency along the pharmaceutical supply chain including among
19 PBMs. (Reaffirm HOD Policy); 2. That our AMA support legislation to shorten the exclusivity
20 period for FDA pharmaceutical products where manufacturers engage in anti-competitive
21 behaviors or unwarranted price escalations. (New HOD Policy)
22

23 Your Reference Committee heard positive testimony on Board of Trustees Report 14. Your
24 Reference Committee heard testimony that the report highlights the need to focus on
25 increasing transparency and competition to improve access to affordable prescription
26 medication. Your Reference Committee heard testimony that both efforts to advance
27 transparency and competition are driving congressional and federal agency action. Your
28 Reference Committee also heard testimony that current policy that has been central to this
29 advocacy should be affirmed and additional policy to further combat anticompetitive practices
30 should be adopted. Accordingly, your Reference Committee recommends that Board of
31 Trustees Report 14 be adopted and the remainder of the report be filed.
32

33 (2) BOARD OF TRUSTEES REPORT 19 – FDA CONFLICT OF
34 INTEREST (RESOLUTION 216-A-18)
35

36 RECOMMENDATION:
37

38 Madam Speaker, your Reference Committee recommends that
39 the recommendations in Board of Trustees Report 19 be
40 adopted and the remainder of the report be filed.
41

42 The Board of Trustees recommends that the following be adopted in lieu of Resolution 216-
43 A-18 and the remainder of this report be filed: 1. That our AMA reaffirm Policy H-100.992,
44 “FDA,” which supports that FDA conflicts of interest should not overrule scientific evidence in
45 making policy decisions and the FDA should include clinical experts on advisory committees.
46 (Reaffirm HOD Policy); 2. That our AMA adopt the following new policy: It is the position of
47 the American Medical Association that decisions of the Food and Drug Administration (FDA)
48 must be trustworthy. Patients, the public, physicians, other health care professionals and
49 health administrators, and policymakers must have confidence that FDA decisions and the
50 recommendations of FDA advisory committees are ethically and scientifically credible and
51 derived through a process that is rigorous, independent, transparent, and accountable.

1 Rigorous policies and procedures should be in place to minimize the potential for financial or
2 other interests to influence the process at all key steps. These should include, but not
3 necessarily be limited to: a) required disclosure of all relevant actual or potential conflicts of
4 interest, both financial and personal; b) a mechanism to independently audit disclosures when
5 warranted; c) clearly defined criteria for identifying and assessing the magnitude and
6 materiality of conflicts of interest; and d) clearly defined processes for preventing or
7 terminating the participation of a conflicted member, and mitigating the influence of identified
8 conflicts of interest (such as prohibiting individuals from participating in deliberations, drafting,
9 or voting on recommendations on which they have conflicts) in those limited circumstances
10 when an individual's participation cannot be terminated due to the individual's unique or rare
11 skillset or background that is deemed highly valuable to the process. Further, clear statements
12 of COI policy and procedures, and disclosures of FDA advisory committee members' conflicts
13 of interest relating to specific recommendations, should be published or otherwise made
14 public. Finally, it is recognized that, to the extent feasible in accordance with the principles
15 stated above, participation on advisory committees should be facilitated through appropriate
16 balancing of the relative scarcity or uniqueness of an individual's expertise and ability to
17 contribute to the process, on the one hand, as compared to the feasibility and effectiveness
18 of mitigation measures including those noted above. (New HOD Policy); 3. That our AMA
19 adopt the following new policy: It is the position of the American Medical Association that the
20 FDA should undertake an evaluation of pay-later conflicts of interest (e.g., where a FDA
21 advisory committee member develops a financial conflict of interest only after his or her initial
22 appointment on the advisory committee has expired) to assess whether these undermine the
23 independence of advisory committee member recommendations and whether policies should
24 be adopted to address this issue. (New HOD Policy)
25

26 Your Reference Committee heard mixed testimony on Board of Trustees Report 19. Your
27 Reference Committee heard testimony that additional restrictions on Conflict of Interest
28 waivers will negatively impact the U.S. Food and Drug Administration's (FDA's) ability to
29 obtain expertise on regulated products, ultimately harming patient access and undermining
30 safety. Your Reference Committee further heard testimony that trust in the FDA's decision-
31 making is compromised when relying on advisory panels with individuals with conflicts and
32 the decisions skew against patient interests. Your Reference Committee also heard testimony
33 that our AMA Code of Medical Ethics has a section that governs conflicts of interest and
34 research and clinical practice guidelines, which can address concerns raised by the original
35 resolution. Accordingly, your Reference Committee recommends adoption of Board of
36 Trustees Report 19 and the remainder of the report be filed.
37

38 (3) BOARD OF TRUSTEES REPORT 23 – PRIOR
39 AUTHORIZATION REQUIREMENTS FOR POST-
40 OPERATIVE OPIOIDS (RESOLUTION 208-A-18)

41
42 RECOMMENDATION:

43
44 Madam Speaker, your Reference Committee recommends that
45 the recommendations in the Board of Trustees Report 23 be
46 adopted and the remainder of the report be filed.
47

48 The Board recommends that the following recommendation be adopted in lieu of Resolution
49 208-A-18, and that the remainder of the report be filed. 1. That our American Medical
50 Association (AMA) advocate for state legislatures and other policymakers, health insurance
51 companies and pharmaceutical benefit management companies to remove barriers, including

1 prior authorization, to non-opioid pain care; (New HOD Policy) 2. That our AMA support
2 amendments to opioid restriction policies to allow for exceptions that enable physicians, when
3 medically necessary in the physician's judgment, to exceed statutory, regulatory or other
4 thresholds for post-operative care and other medical procedures or conditions. (New HOD
5 Policy); 3. That our AMA oppose health insurance company and pharmacy benefit
6 management company utilization management policies, including prior authorization, that
7 restrict access to post-operative pain care, including opioid analgesics, if those policies are
8 not based upon sound clinical evidence, data and emerging research. (New HOD Policy)
9

10 Your Reference Committee heard positive testimony on Board of Trustees Report 23. Your
11 Reference Committee agrees with testimony that clinical decision making must remain the
12 purview of physicians rather than legislatures, health insurance companies, pharmacies, or
13 pharmacy benefit managers. Your Reference Committee agrees with our Board of Trustees
14 that physicians have been taking tangible steps to make more judicious prescribing decisions
15 before the advent of different national guidelines, arbitrary prescribing restrictions, and other
16 barriers to evidence-based patient care.

17
18 Your Reference Committee heard that there has been a 33 percent reduction in opioid
19 prescribing yet health insurance companies, pharmacy benefit management companies, and
20 other payers have not provided any substantive increase in non-opioid alternatives. Your
21 Reference Committee heard further testimony that patients with pain—whether post-surgery
22 or in other settings—have suffered because of multiple barriers to pain care, including prior
23 authorization requirements and blind adherence to arbitrary guidelines. Accordingly, your
24 Reference Committee recommends that the recommendations in Board of Trustees Report
25 23 be adopted and the remainder of the report be filed.

26
27 (4) BOARD OF TRUSTEES REPORT 30 – OPIOID TREATMENT
28 PROGRAMS REPORTING TO PRESCRIPTION
29 MONITORING PROGRAMS (RESOLUTION 507-A-18)

30
31 RECOMMENDATION:

32
33 Madam Speaker, your Reference Committee recommends that
34 the recommendations in the Board of Trustees Report 30 be
35 adopted and the remainder of the report be filed.

36
37 The Board of Trustees recommends that Resolution 507-A-18 not be adopted and the
38 remainder of this report be filed.

39
40 Your Reference Committee heard extensive and conflicting information on Board of Trustees
41 Report 30. Your Reference Committee notes that, at the outset, it is important to clarify that
42 the debate on BOT 30 should be focused squarely on whether our AMA should continue
43 support for state flexibility to determine whether state Opioid Treatment Programs should be
44 required to report to state prescription monitoring programs (PDMP). Understandably, issues
45 covered by the Board of Trustees in its report highlighted areas that included patient privacy,
46 care coordination, and concerns for inappropriate disclosure of a patient's personal health
47 information. Those issues were also extensively addressed by testimony surrounding
48 Resolutions 220 and 231. Your Reference Committee addresses those issues in more detail
49 in consideration of those resolutions.

1 Your Reference Committee heard testimony that state laws regarding access to a state PDMP
2 vary considerably and some states allow access to the PDMP by law enforcement with
3 minimal patient protections (e.g. California), and some have considerable patient protections
4 (e.g., Maryland)—although those do not always prevent disclosure of personal health
5 information to law enforcement and others outside the patient-physician relationship.
6 Testimony indicated that BOT 30 simply highlights the issues raised by including personal
7 health information from an Opioid Treatment Program into a state PDMP. Your Reference
8 Committee heard testimony that states are well-equipped to determine whether to take action
9 depending on what federal law may allow—issues that are covered by Resolutions 220 and
10 231.

11
12 Furthermore, your Reference Committee points out that support for state flexibility is
13 consistent with multiple different AMA policies (see, for example, Federal Preemption of State
14 Professional Liability Laws H-435.964; Any Willing Provider Provisions and Laws H-285.984;
15 Federal Preemption of State Professional Liability Laws H-435.964; Corporate Practice of
16 Medicine H-215.981; Medicare Balance Billing D-390.986 Balance Billing for All Physicians
17 D-380.996). Accordingly, your Reference Committee does not believe our AMA should dictate
18 how states approach this issue. Therefore, your Reference Committee recommends the
19 issues concerning HIPAA and 42 CFR Part 2 be focused in the discussion of Resolution 220
20 and 231, that BOT 30 be adopted and the remainder of the report be filed.

21
22 (5) RESOLUTION 213 – FINANCIAL PENALTIES AND
23 CLINICAL DECISION-MAKING

24
25 RECOMMENDATION:

26
27 Madam Speaker, your Reference Committee recommends that
28 Resolution 213 be adopted.

29
30 Resolution 213 asks that our American Medical Association oppose the practice of a payer
31 utilizing statistical targets alone (and not outcomes data) to determine ‘cost effectiveness’ of
32 a therapeutic choice (New HOD Policy); and be it further; that our AMA oppose the practice
33 of a payer imposing financial penalties upon physicians and/or associated physicians based
34 upon the use of statistical targets without first considering the clinical factors unique to each
35 patient’s claim. (New HOD Policy)

36
37 Your Reference Committee heard positive testimony on Resolution 213. Your Reference
38 Committee heard testimony that our AMA opposes the use of utilization reviews and penalties
39 against physicians that are based on statistical analysis alone. Your Reference Committee
40 heard strong opposition to insurer penalties given the clinical complexity of delivering care.
41 Your Reference Committee heard further testimony about concerns regarding limiting what
42 clinical information should be considered when assessing the cost effectiveness of a
43 therapeutic choice to patient outcomes. Your Reference Committee heard testimony seeking
44 to add language that would further oppose financial penalties for patients, in addition to
45 physicians and other associated physicians. However, financial penalties most often have
46 been exclusively applied to physicians and other health care professionals. Accordingly, your
47 Reference Committee recommends that Resolution 213 be adopted.

1 (6) RESOLUTION 223 – SIMPLIFICATION AND CLARIFICATION
2 OF SMOKING STATUS DOCUMENTATION IN THE
3 ELECTRONIC HEALTH RECORD
4

5 RECOMMENDATION:
6

7 Madam Speaker, your Reference Committee recommends that
8 Resolution 223 be adopted.
9

10 Resolution 223 asks that our American Medical Association support the streamlining of the
11 SNOMED categories for smoking status and passive smoking exposure documentation in the
12 electronic medical record so that the categories are discrete, non-overlapping, and better
13 understood per The Association for the Treatment of Tobacco Use and Dependence 2019
14 recommendations as follows: Smoking status categories: Current Every Day Smoker, Current
15 Some Day Smoker Former Smoker, Never Smoker, and Smoking Status Unknown and
16 Passive smoking exposure: Exposure to Second Hand Tobacco Smoke, Past Exposure to
17 Second Hand Tobacco Smoke, No Known Exposure to Second Hand Tobacco Smoke
18 (Directive to Take Action)
19

20 Your Reference Committee heard overall positive testimony on Resolution 223. Your
21 Reference Committee heard testimony that our AMA has already written to the Office of the
22 National Coordinator for Health Information Technology recommending the streamlining of
23 SNOMED categories for smoking status and passive smoking exposure documentation in the
24 electronic health record. Your Reference Committee heard singular testimony that considered
25 the SNOMED categories too limited. Your Reference Committee also heard testimony that
26 expanding reporting requirements could result in more administrative burden and yield less
27 viable data for clinical and research utilization. Accordingly, your Reference Committee
28 recommends that Resolution 223 be adopted.
29

30 (7) RESOLUTION 242 – IMPROVING HEALTH INFORMATION
31 TECHNOLOGY PRODUCTS TO PROPERLY CARE FOR
32 LGBTQ PATIENTS
33

34 RECOMMENDATION:
35

36 Madam Speaker, your Reference Committee recommends that
37 Resolution 242 be adopted.
38

39 Resolution 242 asks that our American Medical Association research the problems related to
40 the handling of sex and gender within health information technology (HIT) products and how
41 to best work with vendors so their HIT products treat patients equally and appropriately,
42 regardless of sexual or gender identity (Directive to Take Action); and be it further; that our
43 AMA investigate the use of personal health records to reduce physician burden in maintaining
44 accurate patient information instead of having to query each patient regarding sexual
45 orientation and gender identity at each encounter (Directive to Take Action); and be it further;
46 that our AMA advocate for the incorporation of recommended best practices into electronic
47 health records and other HIT products at no additional cost to physicians. (Directive to Take
48 Action)

1 Your Reference Committee heard limited but overwhelmingly positive testimony on Resolution
2 242. Accordingly, your Reference Committee recommends that Resolution 242 be adopted.

3
4 (8) RESOLUTION 244 – EHR-INTEGRATED PRESCRIPTION
5 DRUG MONITORING PROGRAM RAPID ACCESS

6
7 RECOMMENDATION:

8
9 Madam Speaker, your Reference Committee recommends that
10 Resolution 244 be adopted.

11
12 Resolution 244 asks that our American Medical Association advocate, at the state and
13 national levels, to promote Prescription Drug Monitoring Program (PDMP) integration/access
14 within Electronic Health Record workflows (of all developers/vendors) at no cost to the
15 physician or other authorized health care provider. (Directive to Take Action)

16
17 Your Reference Committee heard limited but supportive testimony for Resolution 244. Your
18 Reference Committee heard testimony that our AMA has existing policy that supports
19 initiatives to improve the functionality of state Prescription Drug Monitoring Programs (PDMP)
20 including directing state-based PDMPs to support improved integrated electronic health
21 records interfaces. Your Reference Committee heard further testimony that Resolution 244
22 would add to this existing policy. Accordingly, your Reference Committee recommends that
23 Resolution 244 be adopted.

24
25 (9) BOARD OF TRUSTEES REPORT 9 – COUNCIL ON
26 LEGISLATION SUNSET REPORT

27
28 RECOMMENDATION A:

29
30 Madam Speaker, your Reference Committee recommends that
31 the Recommendation of Board of Trustees Report 9 be
32 amended by addition to read as follows:

33
34 The Board of Trustees recommends that the House of
35 Delegates policies listed in Appendix 1 to this report be acted
36 upon in the manner indicated, except for Policy D-65.993, which
37 should be retained, and the remainder of this report be filed.

38
39 RECOMMENDATION B:

40
41 Madam Speaker, your Reference Committee recommends that
42 the Recommendation of Board of Trustees Report 9 be adopted
43 as amended and that the remainder of the report be filed.

44
45 RECOMMENDATION C:

46
47 Madam Speaker, your Reference Committee recommends that
48 Policy D-65.993 be amended by addition and deletion to read
49 as follows:

1 Our American Medical Association will ~~write to Secretary of~~
2 ~~State Hillary Rodham Clinton, the World Medical Association,~~
3 ~~and the World Health Organization in reference to the complex~~
4 ~~situations in Darfur and Sri Lanka, stating (1) our concerns~~
5 ~~related to the health~~ (1) implore all parties at all times to
6 understand and minimize the health costs of war on civilian
7 populations generally and the adverse effects of physician
8 persecution in particular, (2) ~~that we~~ support the efforts of
9 physicians around the world to practice medicine ethically in any
10 and all circumstances, including during wartime or episodes of
11 civil strife, and that we condemn the military targeting of health
12 care facilities and personnel and using denial of medical
13 services as a weapon of war, ~~as has occurred in Darfur and Sri~~
14 ~~Lanka, by any party, wherever and whenever it occurs,~~ and (3)
15 ~~that our AMA will~~ advocate for the protection of physicians'
16 rights to provide ethical care without fear of persecution.

17
18 RECOMMENDATION D:

19
20 Madam Speaker, your Reference Committee recommends that
21 the title of Policy D-65.993 be changed to read as follows:

22
23 WAR CRIMES AS A THREAT TO PHYSICIANS'
24 HUMANITARIAN RESPONSIBILITIES

25
26 The Board of Trustees recommends that the House of Delegates policies listed in the
27 Appendix to this report be acted upon in the manner indicated and the remainder of this report
28 be filed.

29
30 Your Reference Committee heard and agrees with testimony that D-65.993 includes policy
31 that remains important and relevant regarding the threat of war crimes on physicians'
32 humanitarian responsibilities. Your Reference Committee agrees with testimony that D-
33 65.993 should be amended to delete reference to AMA advocacy activities that have been
34 accomplished and retain the language that remains relevant. Your Reference Committee
35 therefore recommends that D-65.993 should be retained, amended, and that the title be
36 changed to reflect the substance of the amended language.

37
38 (10) BOARD OF TRUSTEES REPORT 17 – BAN ON MEDICARE
39 ADVANTAGE "NO CAUSE" NETWORK TERMINATIONS

40
41 RECOMMENDATION A:

42
43 Madam Speaker, your Reference Committee recommends that
44 BOT Report 17 be amended by addition as follows:

45
46 1. That our American Medical Association (AMA) urge Centers
47 for Medicare & Medicaid Services (CMS) to further enhance the
48 agency's efforts to ensure directory accuracy by:
49 a. Requiring Medicare Advantage (MA) plans to submit
50 accurate provider directories to CMS every year prior to the

- 1 Medicare open enrollment period and whenever there is a
2 significant change in the physicians included in the network
3 b. Conducting accuracy reviews on provider directories more
4 frequently for plans that have had deficiencies
5 c. Publicly reporting the most recent accuracy score for each
6 plan on Medicare Plan Finder,
7 d. Indicating to plans that failure to maintain complete and
8 accurate directories, as well as failure to have a sufficient
9 number of physician practices open and accepting new
10 patients, may subject the MA plans to one of the following: 1.
11 civil monetary penalties; 2. enrollment sanctions; or 3.
12 incorporating the accuracy score into the Stars rating for each
13 plan,
14 e. Offering plans the option of using AMA/Lexis-Nexis
15 VerifyHCP system to update provider directory information.
16 (Directive to Take Action),
17 f. Requiring MA plans immediately remove from provider
18 directories providers who no longer participate in their network.
19
20 2. That our AMA urge CMS to ensure that network adequacy
21 standards provide adequate access for beneficiaries and
22 support coordinated care delivery by:
23 a. Requiring plans to report the percentage of the physicians,
24 broken down by specialty and subspecialty, in the network who
25 actually provided services to plan members during the prior
26 year,
27 b. Publishing the research supporting the adequacy of the ratios
28 and distance requirements CMS currently uses to determine
29 network adequacy.
30 c. Conducting a study of the extent to which networks maintain
31 or disrupt teams of physicians and hospitals that work together,
32 e. Evaluating alternative/additional measures of adequacy.
33 (Directive to Take Action);
34
35 3. That our AMA urge CMS to ensure lists of contracted
36 physicians are made more easily accessible by:
37 a. Requiring that MA plans submit their contracted provider list
38 to CMS annually and whenever changes occur, and post the
39 lists on the Medicare Plan Finder website in both a web-friendly
40 and downloadable spreadsheet form. (Directive to Take Action);
41 b. Linking the provider lists to Physician Compare so that a
42 patient can first find a physician and then find which health plans
43 contract with that physician. That our AMA urge CMS to simplify
44 the process for beneficiaries to compare network size and
45 accessibility by expanding the information for each MA plan on
46 Medicare Plan Finder to include: A. the number of contracted
47 physicians in each specialty and county; B. the extent to which
48 a plan's network exceeds minimum standards in each specialty,
49 subspecialty, and county; and C. the percentage of the
50 physicians in each specialty and county participating in

1 Medicare who are included in the plan's network. (Directive to
2 Take Action);

3
4 4.That our AMA urge CMS to measure the stability of networks
5 by calculating the percentage change in the physicians in each
6 specialty and subspecialty in an MA plan's network compared
7 to the previous year and over several years and post that
8 information on Plan Finder. (Directive to Take Action);

9
10 5.That our AMA urge CMS to develop a
11 marketing/communication plan to effectively communicate with
12 patients about network access and any changes to the network
13 that may directly or indirectly impact patients; including updating
14 the Medicare Plan Finder website. (Directive to Take Action);

15
16 6.That our AMA urge CMS to develop process improvements
17 for recurring input from in-network physicians regarding network
18 policies by creating a network adequacy task force that includes
19 multiple stakeholders including patients. (Directive to Take
20 Action);

21
22 7.That our AMA rescind Policy D-285.961, which directed the
23 AMA to conduct the study herein. (Rescind AMA Policy)

24
25 RECOMMENDATION B:

26
27 Madam Speaker, your Reference Committee recommends that
28 the recommendations of the Board of Trustees Report 17 be
29 adopted as amended and the remainder of the report be filed.

30
31 The Board of Trustees recommends that the following recommendations be adopted and that
32 the remainder of the report be filed: 1.That our American Medical Association (AMA) urge
33 Centers for Medicare & Medicaid Services (CMS) to further enhance the agency's efforts to
34 ensure directory accuracy by: a. Requiring MA plans to submit provider directories to CMS
35 every year prior to the Medicare open enrollment period and whenever there is a significant
36 change in the physicians included in the network, b. Conducting accuracy reviews on provider
37 directories more frequently for plans that have had deficiencies, c. Publicly reporting the most
38 recent accuracy score for each plan on Medicare Plan Finder, d. Indicating to plans that failure
39 to maintain complete and accurate directories, as well as failure to have a sufficient number
40 of physician practices open and accepting new patients, may subject the MA plans to one of
41 the following: 1. civil monetary penalties; 2. enrollment sanctions; or 3. incorporating the
42 accuracy score into the Stars rating for each plan, e. Offering plans the option of using
43 AMA/Lexis-Nexis VerifyHCP system to update provider directory information. (Directive to
44 Take Action); 2.That our AMA urge CMS to ensure that network adequacy standards provide
45 adequate access for beneficiaries and support coordinated care delivery by: a. Requiring
46 plans to report the percentage of the physicians in the network who actually provided services
47 to plan members during the prior year, b. Publishing the research supporting the adequacy of
48 the ratios and distance requirements CMS currently uses to determine network adequacy.
49 c. Conducting a study of the extent to which networks maintain or disrupt teams of physicians
50 and hospitals that work together, d. Evaluating alternative/additional measures of adequacy.

1 (Directive to Take Action); 3. That our AMA urge CMS to ensure lists of contracted physicians
2 are made more easily accessible by: a. Requiring that MA plans submit their contracted
3 provider list to CMS annually and whenever changes occur, and post the lists on the Medicare
4 Plan Finder website in both a web-friendly and downloadable spreadsheet form. (Directive to
5 Take Action), b. Linking the provider lists to Physician Compare so that a patient can first find
6 a physician and then find which health plans contract with that physician. That our AMA urge
7 CMS to simplify the process for beneficiaries to compare network size and accessibility by
8 expanding the information for each MA plan on Medicare Plan Finder to include: A. the number
9 of contracted physicians in each specialty and county; B. the extent to which a plan's network
10 exceeds minimum standards in each specialty and county; and C. the percentage of the
11 physicians in each specialty and county participating in Medicare who are included in the
12 plan's network. (Directive to Take Action); 4. That our AMA urge CMS to measure the stability
13 of networks by calculating the percentage change in the physicians in each specialty in an MA
14 plan's network compared to the previous year and over several years and post that information
15 on Plan Finder. (Directive to Take Action); 5. That our AMA urge CMS to develop a
16 marketing/communication plan to effectively communicate with patients about network access
17 and any changes to the network that may directly or indirectly impact patients; including
18 updating the Medicare Plan Finder website. (Directive to Take Action); 6. That our AMA urge
19 CMS to develop process improvements for recurring input from in-network physicians
20 regarding network policies by creating a network adequacy task force. (Directive to Take
21 Action); 7. That our AMA rescind Policy D-285.961, which directed the AMA to conduct the
22 study herein. (Rescind AMA Policy)

23
24 Your Reference Committee heard positive testimony on Board of Trustees Report 17. Your
25 Reference Committee heard testimony that our AMA and other physician groups have raised
26 concerns that narrow physician networks create challenges for patients seeking care and
27 pose potential patient protection issues. Your Reference Committee heard testimony that
28 inaccurate information commonly found in Medicare Advantage (MA) provider directories
29 delays timely access to medical care for beneficiaries. Your Reference Committee heard
30 testimony that female physicians often receive lower quality ratings secondary to implicit bias,
31 which can negatively impact the long-term ability for those physicians to remain within a MA
32 network. Your Reference Committee heard testimony calling for additional network adequacy
33 measures including evaluation of changes related to gender ratios for participating network
34 physicians. Your Reference Committee determined that the inclusion of metrics specifically
35 related to gender may proffer criticism for the lack of inclusion of other metrics such as sexual
36 orientation, race, and ethnicity. Therefore, your Reference Committee recommends that the
37 recommended language not be included in the report recommendations. Your Reference
38 Committee heard testimony in support of including original language calling for outright bans
39 on "no cause" terminations of MA network physicians during the initial term or any subsequent
40 renewal of a physician's participation contract with that plan. Your Reference Committee
41 heard additional testimony that access to subspecialists is important as medicine becomes
42 increasingly specialized, and that MA plans should be required to ensure that a sufficient
43 amount of physicians who can provide this type of care are present within their networks. Your
44 Reference Committee heard testimony that to improve how MA plans develop and modify
45 their physician networks, Board of Trustees Report 17 offers several policy proposals focused
46 on network directory accuracy, network adequacy, network stability, communications with
47 patients, and establishment of an external advisory group to better inform the Centers for
48 Medicare and Medicaid Services regarding MA network issues. Accordingly, your Reference
49 Committee recommends that Board of Trustees Report 17 be adopted as amended and the
50 remainder of the report be filed.

1 (11) BOARD OF TRUSTEES REPORT 18 – INCREASED USE OF
2 BODY-WORN CAMERAS BY LAW ENFORCEMENT
3 OFFICERS (RESOLUTION 208-I-17)

4
5 RECOMMENDATION A:

6
7 Madam Speaker, your Reference Committee recommends that
8 recommendation three of Board of Trustees Report 18 be
9 amended by addition as follows:

10
11 3. That our AMA recommend that law enforcement policies
12 governing the use of body-worn cameras in health care settings
13 be developed and evaluated with input from physicians and
14 others in the medical community and not interfere with the
15 patient-physician relationship.

16
17 RECOMMENDATION B:

18
19 Madam Speaker, your Reference Committee recommends that
20 the recommendations of the Board of Trustees Report 18 be
21 adopted as amended and the remainder of the report be filed.

22
23 The Board of Trustees recommends that the following be adopted in lieu of Resolution 208-I-
24 17, and that the remainder of the report be filed: 1. That our American Medical Association
25 (AMA) work with interested state and national medical specialty societies to support state
26 legislation and/or regulation addressing implementation of body-worn camera programs for
27 law enforcement officers, including funding for the purchase body-worn cameras, training for
28 officers and technical assistance for law enforcement agencies. (Directive to Take Action); 2.
29 That our AMA continue to monitor privacy issues raised by body-worn cameras in health care
30 settings. (Directive to Take Action); and 3. That our AMA recommend that law enforcement
31 policies governing the use of body-worn cameras in health care settings be developed and
32 evaluated with input from the medical community and not interfere with the patient-physician
33 relationship. (Directive to Take Action)

34
35 Your Reference Committee heard testimony unanimously in support of Board of Trustees
36 Report 18. Your Reference Committee commends the Board of Trustees for their
37 comprehensive report. To ensure that physicians have input into the development of law
38 enforcement policies governing the use of body-worn cameras in health care settings, your
39 Reference Committee recommends that Recommendation 3 be amended and the remainder
40 of Board of Trustees Report 18 be filed.

41
42 (12) BOARD OF TRUSTEES REPORT 20 – SAFE AND EFFICIENT
43 E-PRESCRIBING

44
45 RECOMMENDATION A:

46
47 Madam Speaker, your Reference Committee recommends that
48 recommendation one of Board of Trustees Report 20 be
49 amended by addition as follows:

- 1 1. That our American Medical Association (AMA) reaffirm the
- 2 following policies:
- 3 a. H-125.979, "Private Health Insurance Formulary
- 4 Transparency"
- 5 b. D-120.956, "Electronic Prescribing and Conflicting Federal
- 6 Guidelines"
- 7 c. H-120.941, "e-Prescribing of Scheduled Medications"
- 8 d. D-120.958, "Federal Roadblocks to E-Prescribing"
- 9 e. D-120.945. "Completing the Electronic Prescription Loop for
- 10 Controlled Substances"
- 11 f. H-478.983, "Electronic Prescription Cancellation" (Reaffirm
- 12 HOD Policy)

13
14 RECOMMENDATION B:

15
16 Madam Speaker, your Reference Committee recommends that

17 recommendation three of Board of Trustees Report 20 be

18 amended by addition as follows:

19
20 3. That our AMA encourage health care stakeholders to improve

21 electronic prescribing practices in meaningful ways that will

22 result in increased patient safety, reduced medication error,

23 improved care quality, and reduced administrative burden

24 associated with e-prescribing processes and requirements.

25 Specifically, the AMA encourages:

26
27 a. E-prescribing system implementation teams to conduct an

28 annual audit to evaluate the number, frequency and user

29 acknowledgment/dismissal patterns of e-prescribing system

30 alerts and provide an audit report to the software vendors for

31 their consideration in future releases.

32 b. Health care organizations and implementation teams to

33 improve prescriber end-user training and on-going education.

34 c. Implementation teams to prioritize the adoption of features

35 like structured and codified Sig formats that can help address

36 quality issues, allowing for free text when necessary.

37 d. Implementation teams to enable functionality of pharmacy

38 directories and preferred pharmacy options.

39 e. Organizational leadership to encourage the practice of

40 inputting a patient's preferred pharmacy at registration, and re-

41 confirming it upon check-in at all subsequent visits.

42 f. Implementation teams to establish interoperability between

43 the e-prescribing system and the EHR to allow prescribers to

44 easily confirm continued need for e-prescription refills and to

45 allow for ready access to pharmacy choice and selection during

46 the refill process.

47 g. Implementation teams to enhance EHR and e-prescribing

48 system functions to require residents assign an authorizing

49 attending physician when required by state law.

50 h. Organizational leadership to implement e-prescribing

51 systems that feature more robust clinical decision support, and

1 ensure prescriber preferences are tested and seriously
2 considered in implementation decisions.

3 i. Organizational leadership to designate e-prescribing as the
4 default prescription method.

5 j. The DEA to allow for lower-cost, high-performing biometric
6 devices (e.g., fingerprint readers on laptop computers and
7 mobile phones) to be leveraged in two-factor authentication.

8 k. States to allow integration of PDMP data into EHR systems.

9 l. Health insurers, pharmacies and e-prescribing software
10 vendors to enable real-time benefit check applications that
11 enable more up to date prescription coverage information and
12 allow notification when a patient changes health plans or a
13 health insurer has changed a pharmacy's network status.

14 m. Functionality supporting the electronic transfer and
15 cancellation of prescriptions. (New HOD Policy)

16
17 **RECOMMENDATION C:**

18
19 Madam Speaker, your Reference Committee recommends that
20 the recommendations in Board of Trustees Report 20 be
21 adopted as amended and the remainder of the report be filed.

22
23 The Board of Trustees recommends that the following be adopted in lieu of Resolution 237-
24 A-18 and that the remainder of this report be filed: 1. That our American Medical Association
25 (AMA) reaffirm the following policies: a.H-125.979, "Private Health Insurance Formulary
26 Transparency", b. D-120.956, "Electronic Prescribing and Conflicting Federal Guidelines," c.
27 H-120.941, "e-Prescribing of Scheduled Medications," d. D-120.958, "Federal Roadblocks to
28 E-Prescribing," e.D-120.945. "Completing the Electronic Prescription Loop for Controlled
29 Substances" (Reaffirm HOD Policy); 2. That the second paragraph of AMA Policy D-120.972,
30 "Electronic Prescribing," be rescinded as having been fulfilled by this report. (Rescind HOD
31 Policy); 3. That our AMA encourage health care stakeholders to improve electronic prescribing
32 practices in meaningful ways that will result in increased patient safety, reduced medication
33 error, improved care quality, and reduced administrative burden associated with e-prescribing
34 processes and requirements. Specifically, the AMA encourages: E-prescribing system
35 implementation teams to conduct an annual audit to evaluate the number, frequency and user
36 acknowledgment/dismissal patterns of e-prescribing system alerts and provide an audit report
37 to the software vendors for their consideration in future releases; Health care organizations
38 and implementation teams to improve prescriber end-user training and on-going education;
39 Implementation teams to prioritize the adoption of features like structured and codified Sig
40 formats that can help address quality issues; Implementation teams to enable functionality of
41 pharmacy directories and preferred pharmacy options; Organizational leadership to
42 encourage the practice of inputting a patient's preferred pharmacy at registration, and re-
43 confirming it upon check-in at all subsequent visits. Implementation teams to establish
44 interoperability between the e-prescribing system and the EHR to allow prescribers to easily
45 confirm continued need for e-prescription refills and to allow for ready access to pharmacy
46 choice and selection during the refill process; Implementation teams to enhance EHR and e-
47 prescribing system functions to require residents assign an authorizing attending physician;
48 Organizational leadership to implement e-prescribing systems that feature more robust clinical
49 decision support, and ensure prescriber preferences are tested and seriously considered in
50 implementation decisions; Organizational leadership to designate e-prescribing as the default
51 prescription method; The DEA to allow for lower-cost, high-performing biometric devices (e.g.,

1 fingerprint readers on laptop computers and mobile phones) to be leveraged in two-factor
2 authentication; States to allow integration of PDMP data into EHR systems; Health insurers,
3 pharmacies and e-prescribing software vendors to enable real-time benefit check applications
4 that enable more up to date prescription coverage information and allow notification when a
5 patient changes health plans or a health insurer has changed a pharmacy's network status.
6 (New HOD Policy)
7

8 Your Reference Committee heard positive testimony on Board of Trustees Report 20. Your
9 Reference Committee heard testimony that while e-prescribing has many benefits, barriers to
10 adoption exist such as system errors, network challenges, and the process of prescribing
11 controlled substances. Your Reference Committee heard testimony that our AMA supports e-
12 prescribing for both controlled and non-controlled substances and has numerous policies
13 expressing its commitment to advocating for better regulations and better systems. Your
14 Reference Committee heard testimony that this report builds upon existing policy by
15 encouraging health care stakeholders to improve electronic prescribing practices in
16 meaningful ways that will result in increased patient safety, reduced medication error,
17 improved care quality, and reduced administrative burden associated with e-prescribing
18 processes and requirements.
19

20 Your Reference Committee heard that additional existing policy should be reaffirmed
21 regarding electronic prescription cancellations. Your Reference Committee heard testimony
22 that prioritizing the adoption of features like structured formats should also take into account
23 allowing for free text when necessary. Testimony also indicated that our AMA should support
24 the functionality that supports both the electronic transfer and cancellation of prescriptions.
25 Your Reference Committee agrees with the intent of the testimony to strike the language
26 regarding having an attending physician authorization for resident physicians who are
27 prescribing and believes that this issue can be solved by including such functionality when
28 required by state law. Accordingly, your Reference Committee recommends that Board of
29 Trustees Report 20 be adopted with amendments and the remainder of the report be filed.
30

31 (13) BOARD OF TRUSTEES REPORT 21 – AUGMENTED
32 INTELLIGENCE IN HEALTH CARE
33

34 RECOMMENDATION A:
35

36 Madam Speaker, your Reference Committee recommends that
37 recommendation three of Board of Trustees Report 21 be
38 amended by addition as follows:
39

40 3. Payment and coverage for health care AI systems intended
41 for clinical care must be conditioned on (a) clinical validation; (b)
42 alignment with clinical decision-making that is familiar to
43 physicians; and (c) high quality clinical evidence.
44

45 RECOMMENDATION B:
46

47 Madam Speaker, your Reference Committee recommends that
48 recommendation Board of Trustees Report 21 be amended by
49 addition as follows:

1 10. AI is designed to enhance human intelligence and the
2 patient-physician relationship rather than replace it.

3
4 RECOMMENDATION C:

5
6 Madam Speaker, your Reference Committee recommends that
7 the recommendations in the Board of Trustees Report 21 be
8 adopted as amended and the remainder of the report be filed.

9
10 The Board of Trustees recommends that the following be adopted in lieu of the
11 recommendation and the remainder of this report be filed: Our AMA supports the use and
12 payment of augmented intelligence (AI) systems that advance the quadruple aim. AI systems
13 should enhance the patient experience of care and outcomes, improve population health,
14 reduce overall costs for the health care system while increasing value, and support the
15 professional satisfaction of physicians and the health care team. To that end our AMA will
16 advocate that: 1. Oversight and regulation of health care AI systems must be based on risk of
17 harm and benefit accounting for a host of factors, including but not limited to: intended and
18 reasonably expected use(s); evidence of safety, efficacy, and equity including addressing
19 bias; AI system methods; level of automation; transparency; and, conditions of deployment;
20 2. Payment and coverage for all health care AI systems must be conditioned on complying
21 with all appropriate federal and state laws and regulations, including, but not limited to those
22 governing patient safety, efficacy, equity, truthful claims, privacy, and security as well as state
23 medical practice and licensure laws; 3. Payment and coverage for health care AI systems
24 intended for clinical care must be conditioned on (a) clinical validation; (b) alignment with
25 clinical decision-making that is familiar to physicians; and (c) clinical evidence; 4. Payment
26 and coverage for health care AI systems must (a) be informed by real world workflow and
27 human-centered design principles; (b) enable physicians to prepare for and transition to new
28 care delivery models; (c) support effective communication and engagement between patients,
29 physicians, and the health care team; (d) seamlessly integrate clinical, administrative, and
30 population health management functions into workflow; and (e) seek end-user feedback to
31 support iterative product improvement; 5. Payment and coverage policies must advance
32 affordability and access to AI systems that are designed for small physician practices and
33 patients and not limited to large practices and institutions. Government-conferred exclusivities
34 and intellectual property laws are meant to foster innovation, but constitute interventions into
35 the free market, and therefore, should be appropriately balanced with the need for
36 competition, access, and affordability; 6. Physicians should not be penalized if they do not
37 use AI systems while regulatory oversight, standards, clinical validation, clinical usefulness,
38 and standards of care are in flux. Furthermore, our AMA opposes: a. Policies by payers,
39 hospitals, health systems, or governmental entities that mandate use of health care AI
40 systems as a condition of licensure, participation, payment, or coverage, b. The imposition of
41 costs associated with acquisition, implementation, and maintenance of healthcare AI systems
42 on physicians without sufficient payment; 7. Liability and incentives should be aligned so that
43 the individual(s) or entity(ies) best positioned to know the AI system risks and best positioned
44 to avert or mitigate harm do so through design, development, validation, and implementation.
45 Our AMA will further advocate: a. Where a mandated use of AI systems prevents mitigation
46 of risk and harm, the individual or entity issuing the mandate must be assigned all applicable
47 liability, b. Developers of autonomous AI systems with clinical applications (screening,
48 diagnosis, treatment) are in the best position to manage issues of liability arising directly from
49 system failure or misdiagnosis and must accept this liability with measures such as
50 maintaining appropriate medical liability insurance and in their agreements with users, c.
51 Health care AI systems that are subject to non-disclosure agreements concerning flaws,

1 malfunctions, or patient harm (referred to as gag clauses) must not be covered or paid and
2 the party initiating or enforcing the gag clause assumes liability for any harm; 8. Our AMA,
3 national medical specialty societies, and state medical associations—a. Identify areas of
4 medical practice where AI systems would advance the quadruple aim, b. Leverage existing
5 expertise to ensure clinical validation and clinical assessment of clinical applications of AI
6 systems by medical experts, c. Outline new professional roles and capacities required to aid
7 and guide health care AI systems; and d. Develop practice guidelines for clinical applications
8 of AI systems; 9. There should be federal and state interagency collaboration with participation
9 of the physician community and other stakeholders in order to advance the broader
10 infrastructural capabilities and requirements necessary for AI solutions in health care to be
11 sufficiently inclusive to benefit all patients, physicians, and other health care stakeholders.
12 (New HOD Policy)
13

14 Your Reference Committee heard positive testimony on Board of Trustees Report 21. Your
15 Reference Committee heard testimony that physicians must be involved in rapidly evolving
16 public policy discussions related to liability, payment, and regulation of Augmented
17 Intelligence (AI) systems in health care. Your Reference Committee further heard testimony
18 that Congress, federal agencies, and standards organizations along with other stakeholders
19 are building the foundation for AI policy, and that our AMA is playing a key role in these
20 discussions and expanded policy addresses key issues with greater specificity. Your
21 Reference Committee heard testimony on the importance of high-quality clinical evidence.
22 Further testimony indicated that AI should be designed to enhance human intelligence and
23 the patient-physician relationship rather than replace it. Accordingly, your Reference
24 Committee recommends adoption of Board of Trustees Report 21 and the remainder of the
25 report be filed.
26

27 (14) BOARD OF TRUSTEES REPORT 22 – INAPPROPRIATE
28 USE OF CDC GUIDELINES FOR PRESCRIBING OPIOIDS
29 (RESOLUTION 235-I-18)
30 RESOLUTION 229 – CLARIFICATION OF CDC OPIOID PRESCRIBING
31 GUIDELINES
32

33 RECOMMENDATION A:

34
35 Madam Speaker, your Reference Committee recommends that
36 Board of Trustees Report 22 be amended by addition as
37 follows:
38

39 3. That our American Medical Association reaffirm Policy D-
40 120.932, “Inappropriate Use of Centers for Disease Control and
41 Prevention Guidelines for Prescribing Opioids”; (Reaffirm HOD
42 Policy) and be it further
43

44 4. That our AMA incorporate into their advocacy that clinical
45 practice guidelines specific to cancer treatment, palliative care,
46 and end of life be utilized in lieu of the CDC’s Guideline for
47 Prescribing Opioids for Chronic Pain as per the CDC’s clarifying
48 recommendation. (Directive to Take Action)
49

50 RECOMMENDATION B:
51

1 Madam Speaker, your Reference Committee recommends that
2 the recommendations of the Board of Trustees Report 22 be
3 adopted as amended in lieu of Resolution 229 and the
4 remainder of the report be filed.

5
6 The Board of Trustees recommends that the following recommendations be adopted in lieu
7 of the second resolve of alternate Resolution 235-I-18, and that the remainder of the report
8 be filed: 1. That our American Medical Association (AMA) support balanced opioid-sparing
9 policies that are not based on hard thresholds, but on patient individuality, and help ensure
10 safe prescribing practices, minimize workflow disruption, and ensure patients have access to
11 their medications in a timely manner, without additional, cumbersome documentation
12 requirements. (New HOD Policy); 2. That our AMA oppose the use of “high prescriber” lists
13 used by national pharmacy chains, pharmacy benefit management companies or health
14 insurance companies when those lists do not provide due process and are used to blacklist
15 physicians from writing prescriptions for controlled substances and preventing patients from
16 having the prescription filled at their pharmacy of choice. (New HOD Policy) Resolution 229
17 asks that our American Medical Association reaffirm Policy D-120.932, “Inappropriate Use of
18 Centers for Disease Control and Prevention Guidelines for Prescribing Opioids”; (Reaffirm
19 HOD Policy) and be it further; that our AMA incorporate into their advocacy that clinical
20 practice guidelines specific to cancer treatment, palliative care, and end of life be utilized in
21 lieu of the CDC’s Guideline for Prescribing Opioids for Chronic Pain as per the CDC’s clarifying
22 recommendation. (Directive to Take Action)

23
24 Your Reference Committee heard overwhelmingly positive testimony in support of Board of
25 Trustees Report 22. Your Reference Committee also heard testimony in support of Resolution
26 229. Testimony indicated that BOT 22 and Resolution 229 each highlight the considerable
27 frustration physicians and patients have experienced because of arbitrary thresholds on opioid
28 prescribing. Your Reference Committee heard testimony that some of these frustrations have
29 been the result of the misapplication of the CDC’s Guideline for Prescribing Opioids for
30 Chronic Pain, which has been used by health insurance companies, national pharmacy
31 chains, pharmacy benefit management companies, and state legislatures to restrict opioid
32 prescribing to arbitrary thresholds—limits that have been inappropriately used on many
33 different patient populations, including those undergoing cancer treatment, palliative care, and
34 end-of-life care. Your Reference Committee heard testimony that our Board of Trustees called
35 for renewed balance between efforts to encourage judicious prescribing and protecting
36 patients’ access to opioid therapy when appropriate. Your Reference Committee heard
37 testimony that the actions that have harmed patients were emphasized by U.S. Surgeon
38 General Jerome A. Adams, MD, who testified to the Reference Committee that the CDC and
39 others in the Administration know that the balance is not there, and patients are being harmed
40 by the misapplication of the guidelines.

41
42 Dr. Adams called attention to the recent “Perspective” piece in the *New England Journal of*
43 *Medicine* authored by the CDC, which noted that “Unfortunately, some policies and
44 practices purportedly derived from the guideline have in fact been inconsistent with, and often
45 go beyond, its recommendations.... Such misapplication has been reported for patients with
46 pain associated with cancer, surgical procedures, or acute sickle cell crises. There have also
47 been reports of misapplication of the guideline’s dosage thresholds to opioid agonists for
48 treatment of opioid use disorder. Such actions are likely to result in harm to patients.”
49 (Available at <https://www.nejm.org/doi/full/10.1056/NEJMp1904190>).

50

1 Your Reference Committee heard, at the same time, that the reduction in the nation’s opioid
2 supply—33 percent between 2013 and 2018, according to the company IQVIA—was
3 generally a positive development, but state laws, pharmacy policies, and health insurance
4 restrictions have not led to improvements in pain care. Your Reference Committee heard
5 testimony that the recommendations in Board of Trustees Report 22 provide a strong measure
6 of support for individualized patient care while also providing our AMA with the necessary
7 guidance to further advocate for the removal of policies that have harmed patients. Your
8 Reference Committee also heard that it is important to help protect vulnerable populations,
9 including those with cancer or receiving hospice or palliative care. Accordingly, your
10 Reference Committee recommends adoption of the recommendations in Board of Trustees
11 Report 22 with the addition of the recommendations in Resolution 229 and the remainder of
12 the report be filed.

13
14 (15) RESOLUTION 201 – ASSURING PATIENT ACCESS TO
15 KIDNEY TRANSPLANTATION

16
17 RECOMMENDATION A:

18
19 Madam Speaker, your Reference Committee recommends that
20 the third Resolve of Resolution 201 be amended by addition and
21 deletion as follows:

22
23 RESOLVED, That our AMA actively oppose any legislative or
24 regulatory effort that would create financial incentives that
25 would curtail the access to ~~organ~~ kidney transplantation
26 (Directive to Take Action); and be it further

27
28 RECOMMENDATION B:

29
30 Madam Speaker, your Reference Committee recommends that
31 Resolution 201 be adopted as amended.

32
33 Resolution 201 asks that our American Medical Association work with professional and
34 patient-centered organizations to advance patient and physician-directed coordinated care for
35 End Stage Renal Disease (ESRD) patients (Directive to Take Action); and be it further; that
36 our AMA actively oppose any legislative or regulatory efforts to remove patient choice and
37 physician involvement in ESRD care decisions (Directive to Take Action); and be it further;
38 that our AMA actively oppose any legislative or regulatory effort that would create financial
39 incentives that would curtail the access to organ transplantation (Directive to Take Action);
40 and be it further; that our AMA House of Delegates be advised in a timely fashion regarding
41 any legislative or regulatory efforts to abrogate patient and physician-advised decision-making
42 regarding modality of care for ESRD. (Directive to Take Action)

43
44 Your Reference Committee heard supportive testimony on Resolution 201. Your Reference
45 Committee heard testimony that our Board of Trustees recently adopted a new policy to have
46 our AMA work with Congress to ensure that any legislation regarding End-Stage Renal
47 Disease (ESRD) does not inappropriately impinge on the patient-physician relationship and is
48 in the best interests of ESRD patients. Your Reference Committee heard further testimony
49 that kidney transplantation is often the best and most cost-effective treatment for patients with
50 ESRD and that the focus of Resolution 201 is on kidney transplantation and not general organ

1 transplantation. Your Reference Committee agrees, and accordingly recommends that
2 Resolution 201 be adopted with amendment.

3
4 (16) RESOLUTION 204 – HOLDING THE PHARMACEUTICAL
5 INDUSTRY ACCOUNTABLE FOR OPIOID-RELATED COSTS

6
7 RECOMMENDATION A:

8
9 Madam Speaker, your Reference Committee recommends that
10 Resolution 204 be amended by addition and deletion as follows:

11
12 RESOLVED, That our American Medical Association advocate
13 that ~~the relevant pharmaceutical industry organizations be held~~
14 ~~financially responsible for the health care and other economic~~
15 ~~costs related to their~~ any monies paid to the states, received as
16 a result of a settlement or judgment, or other financial
17 arrangement or agreement as a result of litigation against
18 pharmaceutical manufacturers, distributors, or other entities
19 alleged to have engaged in unethical and deceptive
20 misbranding, marketing, and advocacy of opioids, be used
21 exclusively for research, education, prevention, and treatment
22 of overdose, opioid use disorder, and pain. (Directive to Take
23 Action)

24
25 RECOMMENDATION B:

26
27 Madam Speaker, your Reference Committee recommends that
28 Resolution be adopted as amended.

29
30 Resolution 204 asks that our American Medical Association advocate that the relevant
31 pharmaceutical industry organizations be held financially responsible for the health care and
32 other economic costs related to their unethical and deceptive misbranding, marketing, and
33 advocacy of opioids. (Directive to Take Action)

34
35 Your Reference Committee heard generally supportive testimony on Resolution 204. At the
36 same time, your Reference Committee heard testimony that our AMA is not a court of law that
37 adjudicates liability. Your Reference Committee appreciates the caution from colleagues in
38 multiple states that our AMA is not well-served by assigning blame. Your Reference
39 Committee heard testimony that if courts render judgments or if settlements are reached that
40 a more appropriate role for our AMA is to provide public health recommendations in support
41 of our patients. Your Reference Committee agrees with testimony in support of a
42 recommendation to focus the resolution on directing any money from the opioid litigation to
43 treatment. Your Reference Committee heard testimony that our AMA has policy to direct
44 settlement funds to public health uses for the National Tobacco Settlement and that this policy
45 should be used as guidance for any opioid-related settlements or judgments. Accordingly,
46 your Reference Committee recommends Resolution 204 be adopted with amendment.

1 (17) RESOLUTION 208 – REPEAL OR MODIFICATION OF THE
2 SUNSHINE ACT

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends that
7 first Resolve of Resolution 208 be amended by deletion:

8
9 ~~RESOLVED, That our American Medical Association adopt as~~
10 ~~policy opposition to the Physician Payments Sunshine Act as it~~
11 ~~currently is written and implemented (New HOD Policy); and be~~
12 ~~it further~~

13
14 RECOMMENDATION B:

15
16 Madam Speaker, your Reference Committee recommends that
17 first Resolve of Resolution 208 be amended by addition and
18 deletion as follows:

19
20 RESOLVED, That our AMA support ~~either repeal of the current~~
21 ~~Sunshine Act or significant modifications to the Sunshine Act,~~
22 ~~such as substantially increasing the monetary threshold for~~
23 ~~reporting, that will decrease the regulatory and paperwork~~
24 ~~burden on physicians, protect physician rights to challenge false~~
25 ~~and misleading reports, and provide a meaningful, accurate~~
26 ~~picture of the physician-industry relationship and “hassle factor”~~
27 ~~and support efforts at administrative simplification for~~
28 ~~physicians, which the Centers for Medicare and Medicaid~~
29 ~~Services and the organized medical community has supported,~~
30 ~~if any portion of the Act is maintained. (New HOD Policy)~~

31
32 RECOMMENDATION C:

33
34 Madam Speaker, your Reference Committee recommends that
35 Resolution 208 be adopted as amended.

36
37 RECOMMENDATION D:

38
39 Madam Speaker, your Reference Committee recommends that
40 the title of Resolution 208 be changed as follows:

41
42 MODIFICATION OF THE SUNSHINE ACT

43
44 Resolution 208 asks that our American Medical Association adopt as policy opposition to the
45 Physician Payments Sunshine Act as it currently is written and implemented (New HOD
46 Policy); and be it further, that our AMA support either repeal of the current Sunshine Act or
47 significant modifications to the Sunshine Act, such as substantially increasing the monetary
48 threshold for reporting, that will decrease the burden and “hassle factor” and support efforts
49 at administrative simplification for physicians, which the Center for Medicare and Medicaid
50 Services and the organized medical community has supported, if any portion of the Act is
51 maintained. (New HOD Policy)

1 Your Reference Committee heard mixed testimony on Resolution 208. Your Reference
2 Committee heard testimony that physicians are frustrated with the implementation of the
3 Sunshine Act known as the Open Payments program. Your Reference Committee further
4 heard testimony that the Open Payments program increases administrative burden and does
5 not adequately protect physician rights to challenge industry reports. However, your
6 Reference Committee also heard testimony that our AMA supports transparency across the
7 entire health care system including physicians' relationships with industry. Further testimony
8 indicated that our AMA is advocating for transparency with drug pricing, pharmacy benefit
9 managers, and data transparency, and that our AMA should not at the same time be
10 supporting less transparency regarding the practice of medicine. Your Reference Committee
11 heard testimony that small contributions or gifts can potentially change physician behavior.
12 Your Reference Committee heard additional testimony that our AMA should continue to
13 advocate for substantial modifications to the Sunshine Act to reduce burden, protect patients,
14 and increase accuracy. Accordingly, your Reference Committee recommends that Resolution
15 208 be adopted as amended.

16

17 (18) RESOLUTION 211 – USE OF FAIR HEALTH

18

19 RECOMMENDATION A:

20

21 Madam Speaker, your Reference Committee recommends that
22 Resolution 211 be amended by addition and deletion as follows:

23

24 RESOLVED, that our American Medical Association advocate
25 that any legislation addressing surprise out of network medical
26 bills use an independent, non-conflicted database of
27 commercial charges-FAIR Health usual and customary data and
28 not all payer database data.

29

30 RECOMMENDATION B:

31

32 Madam Speaker, your Reference Committee recommends that
33 the title of Resolution 211 be changed as follows:

34

35 OUT-OF-NETWORK PAYMENT DATABASE

36

37 Resolution 211 asks that our American Medical Association advocate that any legislation
38 addressing surprise out of network medical bills use FAIR Health usual and customary data
39 and not all payer database data. (Directive to Take Action)

40

41 Your Reference Committee heard positive comments regarding the use of FAIR Health data
42 to help establish out-of-network payment rates. Your Reference Committee also heard
43 concerns about the negative impact of narrowing the scope of current AMA policy by
44 identifying FAIR Health as the only appropriate database for such purposes. Your Reference
45 Committee heard similar concerns about opposing the use of all-payer claims databases
46 (APCDs). Your Reference Committee heard testimony that several states are currently
47 interested in referencing their state APCDs in pending state legislation, and that Washington
48 state enacted legislation this year that will rely on the state APCD as an independent data
49 source. Your Reference Committee heard testimony that adoption of Resolution 211 would
50 compel our AMA to oppose these state-desired initiatives. Your Reference Committee heard
51 testimony that limiting AMA policy on independent data sources for out-of-network

1 benchmarks could be detrimental to our advocacy efforts on surprise billing legislation.
2 Testimony from several witnesses focused on the need to use independent, charge-based
3 data as the basis for out-of-network payments. Your Reference Committee therefore
4 recommends that Resolution 211 be amended by addition and deletion to reflect the concerns
5 that were raised during the hearing.

6
7 (19) RESOLUTION 212 – PHARMACY BENEFIT MANAGERS

8
9 RECOMMENDATION A:

10
11 Madam Speaker, your Reference Committee recommends that
12 Resolution 212 be amended by addition and deletion as follows:

13
14 RESOLVED, That our American Medical Association advocate
15 through all appropriate means to ensure that medications and
16 other treatments used to stabilize palliative and hospice patients
17 for pain, ~~and~~ delirium, and related conditions in the hospital
18 continue to be covered by pharmacy benefit management
19 companies—plans, health insurance companies, hospice
20 programs, and other entities after patients are transitioned out
21 of the hospital. and be it further (Directive to Take Action)

22
23 RECOMMENDATION B:

24
25 Madam Speaker, your Reference Committee recommends that
26 Resolution 212 be amended by addition of a second Resolve
27 as follows:

28
29 RESOLVED, That our AMA advocate to ensure that
30 medications prescribed during hospitalization with ongoing
31 indications for the outpatient and other non-hospital-based care
32 settings continue to be covered by pharmacy benefit
33 management companies, health insurance companies, and
34 other payers after hospital discharge.

35
36 RECOMMENDATION C:

37
38 Madam Speaker, your Reference Committee recommends that
39 Resolution 212 be adopted as amended.

40
41 RECOMMENDATION D:

42
43 Madam Speaker, your Reference Committee recommends that
44 the title of Resolution 212 be changed as follows:

45
46 CONTINUITY OF CARE FOR PATIENTS DISCHARGED
47 FROM A HOSPITAL SETTING

48
49 Resolution 212 asks that our American Medical Association advocate through all appropriate
50 means to ensure that medications used to stabilize palliative and hospice patients for pain

1 and delirium in the hospital continue to be covered by pharmacy benefit plans after patients
2 are transitioned out of the hospital. (Directive to Take Action)

3
4 Your Reference Committee heard positive testimony on Resolution 212. Your Reference
5 Committee heard testimony that our AMA has broad policy supporting comprehensive care
6 for hospice and palliative care, and that Resolution 212 is aligned with recommendations of
7 the AMA Opioid Task Force to ensure comprehensive care for pain for hospice and palliative
8 care. Your Reference Committee heard testimony that our AMA opposes the interference of
9 pharmacy benefit management companies—or any other non-health care entity—in the
10 patient-physician relationship. Your Reference Committee heard further testimony that our
11 AMA should oppose interference not only with pharmaceutical benefits, but also any other
12 treatment recommended by a hospice or palliative care physician.

13
14 Your Reference Committee heard further testimony that the barriers faced by hospice and
15 palliative care patients are not limited to hospice and palliative care. Testimony indicated that
16 the barriers, moreover, are not just imposed by pharmacy benefit management companies.
17 Your Reference Committee notes that the common denominator is that continuity of care for
18 treatments begun in the hospital setting should not be interrupted by health insurance
19 companies or other payers when the patient is discharged. Accordingly, your Reference
20 Committee recommends that Resolution 212 be adopted with amendment.

21
22 (20) RESOLUTION 214 – THE TERM PHYSICIAN
23 RESOLUTION 216 – ELIMINATE THE WORD PROVIDER
24 FROM HEALTHCARE CONTRACTS

25
26 RECOMMENDATION A:

27
28 Madam Speaker, your Reference Committee recommends that
29 the alternate resolution be adopted in lieu of Resolutions 214
30 and 216.

31
32 DEFINITION AND USE OF THE TERM PHYSICIAN

33
34 1. Our AMA affirms that the term physician be limited to those
35 people who have a Doctor of Medicine, Doctor of Osteopathic
36 Medicine, or a recognized equivalent physician degree and who
37 would be eligible for an Accreditation Council for Graduate
38 Medical Education (ACGME) residency.

39 2. Our AMA will, in conjunction with the Federation,
40 aggressively advocate for the definition of physician to be
41 limited as defined above:

42 a. In any federal or state law or regulation including the Social
43 Security Act or any other law or regulation that defines
44 physician;

45 b. To any federal and state legislature or agency including the
46 Department of Health and Human Services, Federal Aviation
47 Administration, the Department of Transportation, or any other
48 federal or state agency that defines physician; and

49 c. To any accrediting body or deeming authority including the
50 Joint Commission, Health Facilities Accreditation Program, or
51 any other potential body or authority that defines physician.

1 3. The AMA urges all physicians to insist on being identified as
2 a physician, to sign only those professional or medical
3 documents identifying them as physicians, and to not let the
4 term physician be used by any other organization or person
5 involved in health care.

6 4. That our AMA ensure that all references to physicians by
7 government, payers, and other health care entities involving
8 contracts, advertising, agreements, published descriptions, and
9 other communications at all times distinguish between
10 physician, as defined above, and non-physicians and to
11 discontinue the use of the term provider.

12 5. AMA policy requires any individual who has direct patient
13 contact and presents to the patient as a doctor, and who is not
14 a physician, as defined above, must specifically and
15 simultaneously declare themselves a non-physician and define
16 the nature of their doctorate degree.

17 6. The AMA will review and revise its own publications as
18 necessary to conform with the House of Delegates' policies on
19 physician identification and physician reference and will refrain
20 from any definition of physicians as providers that is not
21 otherwise covered by existing Journal of the American Medical
22 Association (JAMA) Editorial Governance Plan, which protects
23 the editorial independence of JAMA.

24 7. Our AMA actively supports the Scope of Practice Partnership
25 in the Truth in Advertising campaign. (New HOD Policy)
26

27 RECOMMENDATION B:
28

29 Madam Speaker, your Reference Committee recommends
30 Policies H-405.969, H-405.976, D-405.989, H-330.986, and H-
31 405.968 be rescinded.
32

33 Resolution 214 asks that That our American Medical Association seek the passage of federal
34 regulation and/or legislation that mandates that the term physician be limited to those people
35 trained in accordance with Accreditation Council for Graduate Medical Education guidelines
36 and have an MD, DO or a recognized equivalent physician degree and that the term not be
37 used by any other organization or person involved in healthcare. (Directive to Take Action)
38 Resolution 216 asks that our American Medical Association seek legislation to ensure that all
39 references to physicians in government and insurance contracts, agreements, published
40 descriptions, and printed articles eliminate the word “provider” and substitute the accurate and
41 proper term “physician”. (Directive to Take Action)
42

43 Your Reference Committee heard positive testimony on Resolutions 214 and 216. Your
44 Reference Committee heard testimony that transparency is needed for patients to know who
45 is providing treatment and to be able to evaluate the credential of an individual. Your
46 Reference Committee further heard testimony that our AMA already has multiple policies
47 defining the term physician and the use of the term physician. Your Reference Committee
48 heard testimony that our AMA should consolidate our existing policies and Resolutions 214
49 and 216 into one, comprehensive policy. Your Reference Committee also heard testimony
50 that the consolidated policy should define the term physician to be limited to those people who
51 have an Doctor of Medicine, Doctor of Osteopathic Medicine, or a recognized equivalent

1 physician degree, and who would be eligible for an ACGME residency. Your Reference
2 Committee heard testimony that our AMA will continue to advocate for this definition to be
3 used in any federal or state definition, in front of any federal or state legislative body or agency,
4 and with any accrediting authority. Further testimony also indicated that our AMA will also ask
5 at all times and in all publications including contracts to distinguish between physician, as
6 defined above, and non-physicians and to discontinue the use of the term “provider.” Your
7 Reference Committee heard further testimony that the existing policies should be rescinded
8 because the consolidated alternate resolution includes the relevant aspects of the existing
9 policy. Your Reference Committee believes that having a single reference point in our AMA
10 policy defining the term of physician and use of that term would be beneficial. Accordingly,
11 your Reference Committee recommends that an alternative resolution be adopted in lieu of
12 Resolutions 214 and 216 and existing AMA policy should be rescinded.

13
14 Definition of a Physician H-405.969

15 1. The AMA affirms that a physician is an individual who has received a “Doctor of
16 Medicine” or a “Doctor of Osteopathic Medicine” degree or an equivalent degree
17 following successful completion of a prescribed course of study from a school of
18 medicine or osteopathic medicine. 2. AMA policy requires anyone in a hospital
19 environment who has direct contact with a patient who presents himself or herself to
20 the patient as a “doctor,” and who is not a “physician” according to the AMA definition
21 above, must specifically and simultaneously declare themselves a “non-physician” and
22 define the nature of their doctorate degree. 3. Our AMA actively supports the Scope
23 of Practice Partnership in the Truth in Advertising campaign. (CME Rep. 4-A-94
24 Reaffirmed by Sub. Res. 712, I-94 Reaffirmed and Modified: CME Rep. 2, A-04 Res.
25 846, I-08 Reaffirmed in lieu of Res. 235, A-09 Reaffirmed: Res. 821, I-09 Appended:
26 BOT Rep. 9, I-09 Reaffirmed: BOT Rep. 9, I-11 Reaffirmation A-13 Reaffirmation A-
27 15 Reaffirmed in lieu of: Res. 225, A-17)

28
29 Definition of a Physician H-405.976

30 The AMA urges all physicians to insist on being identified as a physician and to sign
31 only those professional or medical documents identifying them as physicians. The
32 AMA will review and revise its own publications as necessary to conform with the
33 House of Delegates' policies on physician identification and physician reference and
34 will refrain from any definition of physicians as health care providers. The AMA
35 supports seeking immediate modification of the social security laws to change the
36 definition of a physician to conform with AMA policy. The AMA will seek legislation
37 prohibiting the use of the term “physician” as a descriptor other than in the context of
38 a medical doctor (MD) or doctor of osteopathy (DO). (Res. 243, A-91 Reaffirmed BOT
39 Rep. I-93-25 Reaffirmed Sub. Res. 712, I-94 Res. 241, A-97 Reaffirmed in lieu of Res.
40 615, A-05 Reaffirmation I-09 Reaffirmed: Res. 821, I-09 Reaffirmation A-13)

41
42 Definition of a Physician D-405.989

43 1. Our American Medical Association Commissioners to The Joint Commission will be
44 urged to request and continue to work to have The Joint Commission's “Glossary”
45 definition of physician limited to Doctors of Medicine and Osteopathy. 2. Our AMA
46 Commissioners to The Joint Commission will be urged to request The Joint
47 Commission delete any changes made and all references to the Social Security Act
48 definition of physician added to the Elements of Performance with their July 1, 2009
49 change in the “Glossary” definition of physician. 3. Our AMA will advocate with the
50 American Osteopathic Association Health Facilities Accreditation Program, DNV and
51 other potential deeming authorities to maintain a definition of physician as a Doctor of

1 Medicine or Osteopathy. 4. Our AMA will, in conjunction with the Federation,
2 aggressively pursue revision of the Social Security Act and state law definitions of
3 physician to be limited to Doctors of Medicine and Osteopathy. 5. Our AMA will
4 advocate for the Federal Aviation Administration, the Department of Transportation,
5 and Congress to define a “physician” as an individual possessing degree of either a
6 Doctor of Medicine or Doctor of Osteopathic Medicine. (Res. 821, I-09 Appended: Res.
7 256, A-18)

8
9 Physician (“Doctors”) Services Costs as Reported by HHS and Medicare H-330.986
10 Our AMA urges HHS and CMS to, at all times, distinguish between MDs/DOs and non-
11 MDs/DOs, and to discontinue the use of the broad term “provider” when reporting or
12 referring to the cost of physician services. (Res. 71, A-88 Reaffirmed: Sunset Report,
13 I-98 Reaffirmation I-99 Reaffirmation A-02 Reaffirmation I-09)

14
15 Clarification of the Term “Provider” in Advertising, Contracts and Other
16 Communications H-405.968

17 1. Our AMA supports requiring that health care entities, when using the term “provider”
18 in contracts, advertising and other communications, specify the type of provider being
19 referred to by using the provider’s recognized title which details education, training,
20 license status and other recognized qualifications; and supports this concept in state
21 and federal health system reform. 2. Our AMA: (a) considers the generic terms “health
22 care providers” or “providers” as inadequate to describe the extensive education and
23 qualifications of physicians licensed to practice medicine in all its branches; (b) will
24 institute an editorial policy prohibiting the use of the term “provider” in lieu of
25 “physician” or other health professionals for all AMA publications not otherwise
26 covered by the existing JAMA Editorial Governance Plan, which protects editorial
27 independence of the Editor in Chief of JAMA and The JAMA Network journals; and (c)
28 will forward to the editorial board of JAMA the recommendation that the term
29 “physician” be used in lieu of “provider” when referring to MDs and DOs. (Sub. Res.
30 712, I-94 Reaffirmed: Res. 226, I-98 Reaffirmation I-99 Res. 605, A-09 Reaffirmed:
31 CLRPD Rep. 1, A-09 Modified: Speakers Rep., A-15)

32
33 (21) RESOLUTION 217 – MEDICARE VACCINE BILLING

34
35 RECOMMENDATION A:

36
37 Your Reference Committee recommends that Resolution 217
38 be amended by addition as follows:

39
40 RESOLVED, That our American Medical Association advocate
41 that a physician’s office can bill Medicare for all vaccines
42 administered to Medicare beneficiaries and that the patient shall
43 only pay the applicable copay to prevent fragmentation of care.
44 (Directive to Take Action)

45
46 RECOMMENDATION B:

47
48 Your Reference Committee recommends that Resolution 217
49 be adopted as amended.

1 Resolution 217 asks that our American Medical Association advocate that a physician's office
2 can bill Medicare for all vaccines and that the patient shall only pay the applicable copay to
3 prevent fragmentation of care. (Directive to Take Action)
4

5 Your Reference Committee heard supportive testimony on Resolutions 217, which was heard
6 with Resolution 203 at the Reference Committee Hearing. Your Reference Committee further
7 heard substantial support for adoption of Resolution 217. Your Reference Committee agrees
8 that Medicare should reimburse physicians for the cost of vaccines for Medicare beneficiaries.
9 Accordingly, your Reference Committee recommends adopting Resolution 217 with
10 amendment.

11
12 (22) RESOLUTION 218 – PAYMENT FOR MEDICATIONS USED
13 OFF LABEL FOR TREATMENT OF PAIN
14 RESOLUTION 235 – PRESCRIPTION COVERAGE OF THE
15 LIDOCAINE TRANSDERMAL PATCH
16

17 RECOMMENDATION:
18

19 Madam Speaker, your Reference Committee recommends that
20 the alternate resolution be adopted in lieu of Resolutions 218
21 and 235.
22

23 IMPROVED ACCESS AND COVERAGE TO NON-OPIOID
24 MODALITIES TO ADDRESS PAIN
25

26 RESOLVED, That our American Medical Association advocate
27 for increased access and coverage of non-opioid treatment
28 modalities including pharmaceutical pain care options,
29 interventional pain management procedures, restorative
30 therapies, behavioral therapies, physical and occupational
31 therapy, and other evidence-based therapies recommended by
32 the patient's physician; (Directive to Take Action), and be it
33 further
34

35 RESOLVED, That our AMA advocate for non-opioid treatment
36 modalities being placed on the lowest cost-sharing tier for the
37 indication of pain so that patients have increased access to
38 evidence-based pain care as recommended by the HHS
39 Interagency Pain Care Task Force (Directive to Take Action),
40 and be it further
41

42 RESOLVED, That our AMA encourage the manufacturers of
43 pharmaceutical pain care options to seek United States Food
44 and Drug Administration approval for additional indications
45 related to non-opioid pain management therapy. (Directive to
46 Take Action)
47

48 Resolution 218 asks that our American Medical Association petition the Centers for Medicare
49 and Medicaid Services to allow reimbursement for off label use of medications like gabapentin
50 or lidocaine patches at the lowest copayment tier for the indication of pain so that patients can
51 be effectively treated for pain and decrease the number of opioid prescriptions written.

1 (Directive to Take Action) Resolution 235 asks that our American Medical Association
2 encourage the US Food and Drug Administration to consider approving other indications in
3 addition to post-herpetic neuralgia for transdermal lidocaine patches (Directive to Take
4 Action); and be it further, that our AMA urge the Centers for Medicare and Medicaid Services
5 and third-party payers to provide insurance coverage of lidocaine transdermal patches for
6 other indications in addition to post-herpetic neuralgia. (Directive to Take Action)
7

8 Your Reference Committee heard considerable testimony on Resolutions 218 and 235. Your
9 Reference Committee heard testimony that introduced an “omnibus” alternate resolution to
10 try to address the multiple different issues, indications, disease states, procedures, and
11 therapies offered in the original resolutions. Your Reference Committee heard testimony in
12 strong support of the omnibus given its support to increase access and coverage to non-opioid
13 treatment modalities. Your Reference Committee heard testimony that the omnibus provided
14 a strong framework for AMA advocacy in support for an evidence-based framework, much like
15 the framework and recommendations contained in the recent U.S. Department of Health and
16 Human Services “Pain Management Best Practices Inter-Agency Task Force Report” that was
17 released in May 2019.
18

19 Your Reference Committee also heard testimony that Resolution 235 should reflect the fact
20 that manufacturers—and not our AMA—can submit an application to the U.S. Food and Drug
21 Administration to ask for other indications and be broadened to include all pharmaceutical
22 pain options for additional indications related to pain management therapy generally.
23 Accordingly, your Reference Committee recommends adoption of an alternate resolution in
24 lieu of Resolutions 218 and 235.
25

26 (23) RESOLUTION 220 – STUDY OF CONFIDENTIALITY AND
27 PRIVACY PROTECTION IN THE TREATMENT OF
28 SUBSTANCE DISORDERS
29 RESOLUTION 231 – ALIGNMENT OF FEDERAL PRIVACY
30 LAW AND REGULATIONS GOVERNING SUBSTANCE USE
31 DISORDER TREATMENT (42 CFR PART 2) WITH THE
32 HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY
33 ACT
34

35 RECOMMENDATION:
36

37 Madam Speaker, your Reference Committee recommends that
38 the alternate resolution be adopted in lieu of Resolutions 220
39 and 231.
40

41 CONFIDENTIALITY AND PRIVACY PROTECTIONS
42 ENSURING CARE COORINATION AND THE PATIENT-
43 PHYSICIAN RELATIONSHIP
44

45 RESOLVED, That our American Medical Association support
46 amendments to HIPAA and 42 CFR Part 2 that allow for, without
47 penalty, comprehensive care coordination and consultation
48 between health care professionals that permit disclosure
49 between health care professionals of a patient’s medical history
50 to enhance patient safety (New HOD Policy); and

1 RESOLVED, That our AMA oppose amendments to HIPAA and
2 42 CFR Part 2 that would lead to increased access to patients'
3 personal health information by law enforcement, health
4 insurers, data clearinghouses, employers, or other entities
5 outside the patient-physician relationship. (Directive to Take
6 Action)
7

8 Resolution 220 asks that our American Medical Association study whether the confidentiality
9 protections of 42 CFR Part 2 outweigh the potential benefits of coordinating care with HIPAA
10 privacy protections in the treatment of substance related disorders. (Directive to Take Action)
11 Resolution 231 asks that our American Medical Association support the alignment of federal
12 privacy law and regulations (42 CFR Part 2) with the Health Insurance Portability and
13 Accountability Act (HIPAA) for the purposes of treatment, payment and health care
14 operations, while ensuring protections are in place against the use of "Part 2" substance use
15 disorder records in criminal proceedings (New HOD Policy); and be it further; that our AMA
16 support the sharing of substance use disorder patient records as required by the HIPAA
17 Privacy Rule for uses and disclosures of protected health information for treatment, payment
18 and health care operations to improve patient safety and enhance the quality and coordination
19 of care. (New HOD Policy)
20

21 Your Reference Committee heard extensive testimony on Resolutions 220 and 230.
22 Testimony in support of Resolution 220 stated that 42 CFR Part 2 prohibits sharing of
23 information that could identify a patient seeking treatment for a substance use disorder (SUD),
24 help treat a patient with an SUD, or mitigate harm for a patient with an SUD receiving care for
25 another medical condition or acute injury. Your Reference Committee heard testimony that,
26 because of 42 CFR Part 2, treatment records for SUD are separated from a patient's medical
27 record, acting as a life-threatening barrier preventing physicians and other health care
28 professionals from effective care coordination, consultations, and having access to patients'
29 full medical histories, limiting integration, hindering coordination, and resulting in less safe and
30 less effective care. Further testimony demonstrated that there may be an abundance of
31 confusion and misunderstanding on the part of many patients, physicians, and other
32 stakeholders of what is—and is not—allowed to be shared under 42 CFR Part 2.
33

34 Your Reference Committee heard testimony that, when considering the balance between
35 patient privacy and patient confidentiality, the balance tips toward reducing risk and ensuring
36 patient safety. Testimony in support of adopting Resolution 231 also argued that the federal
37 regulations mandating privacy protections contained in 42 CFR Part 2 serve an important
38 purpose but may inadvertently reinforce stigma against patients by reinforcing the belief that
39 SUD is different from other health problems and must be kept siloed. Additional testimony
40 was provided that this stigma may inhibit the delivery of comprehensive integrated care. Your
41 Reference Committee heard testimony that aligning 42 CFR Part 2 with the Health Insurance
42 Portability and Accountability Act (HIPAA) would resolve these problems.
43

44 Your Reference Committee heard testimony supporting that our AMA to have the ability to
45 take action to help resolve the thorny issues presented by alignment of HIPAA and 42 CFR
46 Part 2. Your Reference Committee appreciates that there is a need to provide our AMA with
47 sufficient direction and not simply call on our Board of Trustees to study the issue. Your
48 Reference Committee notes that changes to HIPAA and 42 CFR Part 2 may be coming soon
49 from the Administration, and that "alignment" of moving targets presents unique challenges.
50 Moreover, your Reference Committee does not want to discount the significant concerns
51 raised that removing privacy protections could have immediate and irreversible adverse

1 effects on a patient's employment, housing, parenting, and other socio-economic issues
2 important to help maintain one's recovery. Your Reference Committee strongly supports
3 providing our AMA with the flexibility to advocate for increased patient care coordination for
4 patients with a SUD while protecting patients' personal health information from inappropriate
5 use outside the patient-physician relationship.
6

7 Testimony was presented that, while our AMA supports information sharing and care
8 coordination in the treatment of SUD, our AMA also believes that there need to be guardrails
9 to protect patient confidentiality. Your Reference Committee agrees that simply "aligning Part
10 2 with HIPAA" (which Resolution 231 asks for) or conducting a study (which Resolution 220
11 calls for) are not sufficient solutions to the concerns the sponsors of these resolutions intend
12 to address—particularly when there was no testimony in support of removing patient privacy
13 protections for payment or health care operations.
14

15 To address the numerous and competing issues, your Reference Committee recommends a
16 alternate resolution that will provide our AMA with the direction to actively engage in
17 discussions about revisions to HIPAA and 42 CFR Part 2 that support increased patient care
18 coordination while also protecting patients' personal health information from inappropriate
19 access by law enforcement, health insurers, data clearinghouses, employers, or other entities
20 outside the patient-physician relationship. By focusing on the patient-physician relationship,
21 your Reference Committee believes that the appropriate balance has been met. Accordingly,
22 your Reference Committee recommends an alternate resolution be adopted in lieu of
23 Resolutions 220 and 231.
24

25 (24) RESOLUTION 221 – EXTENDING MEDICAID COVERAGE
26 TO 12-MONTHS POSTPARTUM
27 RESOLUTION 224 – EXTENDING PREGNANCY MEDICAID
28 TO ONE YEAR POSTPARTUM
29

30 RECOMMENDATION:

31
32 Madam Speaker, your Reference Committee recommends that
33 the alternate resolution be adopted in lieu of Resolutions 221
34 and 224.
35

36 EXTENDING MEDICAID COVERAGE FOR ONE YEAR
37 POSTPARTUM
38

39 RESOLVED, That our American Medical Association work with
40 relevant stakeholders to support extension of Medicaid
41 coverage to 12 months postpartum. (Directive to Take Action)
42

43 Resolution 221 asks that our American Medical Association support and actively work toward
44 enactment of state legislation, Section 1115 waiver applications, and federal legislation to
45 extend Medicaid coverage to 12-months postpartum. (Directive to Take Action) Resolution
46 224 asks that our American Medical Association petition the Centers for Medicare and
47 Medicaid Services to extend pregnancy Medicaid to a minimum of one year postpartum.
48 (Directive to Take Action)
49

50 Your Reference Committee heard positive testimony on Resolutions 221 and 224. Your
51 Reference Committee heard testimony that extending Medicaid coverage to 12 months

1 postpartum is an important strategy to reduce maternal mortality rates and address disparities.
2 Your Reference Committee also heard testimony that our AMA has already supported
3 extending Medicaid coverage 12 months postpartum as proposed in the Mothers and
4 Offspring Mortality & Morbidity Awareness (MOMMA) Act. Your Reference Committee
5 received an amendment that offered clarification as to the application of the Resolutions 221
6 and 224 in the form of an alternate resolution. Accordingly, your Reference Committee
7 recommends adopting the alternate resolution in lieu of Resolutions 221 and 224.

8
9 (25) RESOLUTION 228 – TRUTH IN ADVERTISING

10
11 RECOMMENDATION A:

12
13 Madam Speaker, your Reference Committee recommends that
14 the second Resolve of Resolution 228 be amended by deletion
15 as follows:

16
17 RESOLVED, That our AMA oppose any misappropriation of
18 medical specialties' titles and work with state medical societies
19 to advocate for states and administrative agencies overseeing
20 nonphysician providers to authorize only the use of titles and
21 descriptors that align with the nonphysician providers' state
22 issued licenses and ~~national board certification~~. (Directive to
23 Take Action)

24
25 RECOMMENDATION B:

26
27 Madam Speaker, your Reference Committee recommends that
28 Resolution 228 be adopted as amended.

29
30 Resolution 228 asks that that our American Medical Association reaffirm support of the Scope
31 of Practice Partnership's Truth in Advertising Campaign to ensure patients receive accurate
32 information about who is providing their care (AMA Policy H-405.969) (Reaffirm HOD Policy);
33 and be it further, that our AMA oppose any misappropriation of medical specialties' titles and
34 work with state medical societies to advocate for states and administrative agencies
35 overseeing nonphysician providers to authorize only the use of titles and descriptors that align
36 with the nonphysician providers' state issued licenses and national board certification.
37 (Directive to Take Action)

38
39 Your Reference Committee heard positive testimony on Resolution 228. Your Reference
40 Committee heard testimony that there is a need to protect physician specialty titles such as
41 anesthesiologist, dermatologist, and cardiologist, particularly as Advanced Practice
42 Registered Nurses, such as Certified Registered Nurse Anesthetists, are aggressively
43 pushing to use the term "nurse anesthesiologist." Your Reference Committee further heard
44 testimony that our AMA has existing policy on truth in advertising and a robust multi-faceted
45 truth in advertising campaign including model state legislation. Your Reference Committee
46 heard testimony that the second resolve of Resolution 228 should be amended by deleting
47 the term "national board certification." Specifically, concern was raised that AMA policy should
48 not support titles and descriptors of non-physician providers' national board-certifying bodies
49 as to do so could potentially call on our AMA to support terms and descriptors that misalign
50 and even directly contradict our policy and broader advocacy objectives. Accordingly, your
51 Reference Committee recommends that Resolution 228 be adopted as amended.

1 (26) RESOLUTION 232 – COPD NATIONAL ACTION PLAN

2
3 RECOMMENDATION A:

4
5 Madam Speaker, your Reference Committee recommends that
6 the first Resolve of Resolution 232 be amended by deletion as
7 follows:

8
9 Resolved, that our American Medical Association support
10 funding for the National Heart, Lung, and Blood Institute and the
11 CDC, for the purpose of implementing the COPD National
12 Action Plan. ~~the inclusion of \$25 million at NHLBI and an~~
13 ~~additional \$2 million at CDC in the FY2020 Labor Health and~~
14 ~~Human Services and Education Appropriations bill to implement~~
15 ~~the COPD National Action Plan, and be it further,~~

16
17 RECOMMENDATION B:

18
19 Madam Speaker, your Reference Committee recommends that
20 the second Resolve of Resolution 232 be deleted:

21
22 ~~RESOLVED, that our AMA send a letter to House and Senate~~
23 ~~Appropriators convey its support for the COPD National Action~~
24 ~~Plan funding for fiscal year 2020.~~

25
26 RECOMMENDATION C:

27
28 Madam Speaker, your Reference Committee recommends
29 that Resolution 232 be adopted as amended.

30
31 Resolution 232 asks that our American Medical Association support the inclusion of \$25
32 million at NIH's National Heart, Lung, and Blood Institute (NHLBI) and an additional \$2 million
33 at the Centers for Disease Control and Prevention in the FY2020 Labor Health and Human
34 Services and Education Appropriations Bill to implement the Chronic Obstructive Pulmonary
35 Disease (COPD) National Action Plan (Directive to Take Action); and be it further; that our
36 AMA send a letter to House and Senate Appropriators conveying its support for the COPD
37 National Action Plan funding for fiscal year 2020. (Directive to Take Action)

38
39 Your Reference Committee heard largely positive testimony in support of Resolution 232.
40 Your Reference Committee heard testimony that many physicians treat patients with COPD
41 and note the significant burden of this chronic disease. Your Reference Committee further
42 heard testimony that the AMA has committed time and resources to combatting chronic
43 disease and preventing tobacco use, in line with calls to support the COPD National Action
44 Plan. Your Reference Committee heard testimony that our AMA tries to avoid including
45 specific funding level requests in policy to allow flexibility in our advocacy efforts at the local,
46 state, and federal levels. Your Reference Committee also heard testimony that calling for our
47 AMA to send a letter to House and Senate Appropriators is not timely, as the House has
48 already released their FY2020 Appropriations recommendations with a proposed increase of
49 over \$650 million to the NIH, the agency charged with implementation of the COPD National
50 Action Plan in conjunction with the CDC. Accordingly, your Reference Committee
51 recommends that Resolution 232 be adopted as amended.

1 (27) RESOLUTION 233 – GME CAP FLEXIBILITY

2
3 RECOMMENDATION A:

4
5 Madam Speaker, your Reference Committee recommends that
6 Policy D-305.967 be amended by addition and deletion to read
7 as follows:

8
9 The Preservation, Stability and Expansion of Full Funding for
10 Graduate Medical Education D-305.967

11
12 31. Our AMA will advocate to the Centers for Medicare &
13 Medicaid Services ~~for flexibility beyond the current maximum of~~
14 ~~five years for the Medicare graduate medical education cap-~~
15 ~~setting deadline for new residency programs in underserved~~
16 ~~areas and/or economically depressed areas.~~ to adopt the
17 concept of “Cap-Flexibility” and allow new and current Graduate
18 Medical Education teaching institutions to extend their cap-
19 building window for up to an additional five years beyond the
20 current window (for a total of up to ten years), giving priority to
21 new residency programs in underserved areas and/or
22 economically depressed areas.

23
24 RECOMMENDATION B:

25
26 Madam Speaker, your Reference Committee recommends that
27 Policy D-305.967 be adopted as amended in lieu of Resolution
28 233.

29
30 Resolution 233 asks that our American Medical Association advocate for the Centers for
31 Medicare and Medicaid Services (CMS) to adopt the concept of “Cap-Flexibility” and allow
32 new and current Graduate Medical Education teaching institutions to extend their cap-building
33 window for up to an additional five years beyond the current window (for a total of up to ten
34 years), giving priority to primary care residencies (Directive to Take Action); and be it further;
35 that our AMA advocate for CMS to provide funding to hospitals and/or universities prior to the
36 arrival of any residents, removing the clause where “Medicare funding does not begin until the
37 first resident is ‘on-duty’ at the hospital.” (Directive to Take Action)

38
39 Your Reference Committee heard mixed testimony on Resolution 233. Your Reference
40 Committee heard testimony that our AMA has existing policy in support of cap-flexibility. Your
41 Reference Committee further heard testimony that our AMA has been actively advocating for
42 cap-flexibility both with the Centers for Medicare and Medicaid Services (CMS) as well as the
43 U.S. Congress. Your Reference Committee heard testimony that direct GME (DGME)
44 payments are based on a hospital’s submission of a cost report and its residents on duty.
45 Your Reference Committee heard further testimony that removing the residents-on-duty
46 provision would require CMS to develop a new comprehensive formula for DGME payments
47 and may result in less funding for GME. Testimony also indicated that, given that AMA policy
48 on GME is based on the current formula, all existing AMA GME-related policy would need to
49 be reviewed in light of any changes to the funding formula. Accordingly, your Reference
50 Committee recommends amending existing policy on GME in lieu of Resolution 233.

1 (28) RESOLUTION 237 – OPPORTUNITIES IN BLOCKCHAIN
2 FOR HEALTHCARE

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends that
7 the first Resolve of Resolution 237 be amended by addition and
8 deletion to read as follows:

9
10 RESOLVED, That our AMA work with public or private sector
11 standard-setting organizations ~~the Office of the National Health~~
12 ~~Information Technology~~ to create official standards for the
13 development and implementation of blockchain technologies in
14 health_care, and be it further

15
16 RECOMMENDATION B:

17
18 Madam Speaker, your Reference Committee recommends that
19 the Resolution 237 be adopted as amended.

20
21 Resolution 237 asks that our American Medical Association work with the Office of the
22 National Health Information Technology to create official standards for the development and
23 implementation of blockchain technologies in healthcare (Directive to Take Action); and be it
24 further; that our AMA monitor the evolution of blockchain technologies in healthcare and
25 engage in discussion with appropriate stakeholders regarding blockchain development.
26 (Directive to Take Action)

27
28 Your Reference Committee heard positive testimony on Resolution 237. Your Reference
29 Committee heard testimony that blockchain is a distributed database that stores records of all
30 transactions and digital events performed by its participants. Testimony also stated that
31 blockchain technology may help drive transparency, data integrity, and authenticity. Your
32 Reference Committee also heard testimony that in the health care context, many use cases
33 of blockchain exist including medical records, supply chain management, consent
34 management, clinical trials, claims adjudication, precision medicine, and provider directory
35 management. Your Reference Committee further heard testimony raising concerns regarding
36 the first Resolve because the naming of a specific entity may hamper our AMA's ability to
37 advocate in this area. Your Reference Committee also heard testimony that this amended
38 policy would provide greater flexibility for our AMA to work with public or private sector
39 standard-setting organizations to allow for innovation and growth in this emerging technology.
40 Accordingly, your Reference Committee recommends that Resolution 237 be adopted with
41 amendment.

42
43 (29) RESOLUTION 241 – FACILITATION OF RESEARCH WITH
44 MEDICARE CLAIMS DATA

45
46 RECOMMENDATION A:

47
48 Madam Speaker, your Reference Committee recommends that
49 Resolution 241 be amended by addition and deletion as follows:

1 RESOLVED, That our American Medical Association, in an
2 effort to advance the feasibility of population health research to
3 fulfill the promise of value based care, will request that CMS and
4 ~~CMMI~~ eliminate the prohibitions on sharing data outside of any
5 CMS model including Accountable Care Organizations that are
6 the ACO contained in the CMS Data Use Agreement and allow
7 sharing of that data: (1) in the form of de-identified data sets as
8 permitted by ~~HIPAA~~ federal, state, and local privacy laws; and
9 (2) for purposes of research as permitted by ~~HIPAA~~ federal,
10 state, and local privacy laws.

11
12 RECOMMENDATION B:

13
14 Madam Speaker, your Reference Committee recommends that
15 Resolution 241 be adopted as amended.

16
17 Resolution 241 asks that our American Medical Association, in an effort to advance the
18 feasibility of population health research to fulfill the promise of value based care, request that
19 the Centers for Medicare and Medicaid Services (CMS) and CMS's Centers for Medicare and
20 Medicaid Innovation (CMMI) eliminate the prohibitions on sharing data outside of the
21 accountable care organization contained in the CMS Data Use Agreement and allow sharing
22 of that data: (1) in the form of de-identified data sets as permitted by HIPAA; and (2) for
23 purposes of research as permitted by HIPAA. (Directive to Take Action)

24
25 Your Reference Committee heard positive testimony on Resolution 241. Your Reference
26 Committee heard testimony in support of increasing access to valuable data from Accountable
27 Care Organizations for the purposes of globally increasing program transparency and
28 accountability. Your Reference Committee heard testimony that the CMS is using data-use
29 agreements for value-based models that pose a barrier to research. Your Reference
30 Committee heard testimony that value-based models, governmental payers, academics,
31 health care providers, and patients would benefit from efficacy research and improve quality
32 improvement literature. Your Reference Committee further heard testimony that Resolution
33 241 should refer more broadly to CMS considering other Centers within CMS administer
34 value-based programs; should be made broader to cover models outside of Accountable Care
35 Organizations; and should clarify that data should be shared in accordance with all federal,
36 state, and local privacy laws. Accordingly, your Reference Committee recommends that
37 Resolution 241 be adopted as amended.

38
39 (30) RESOLUTION 246 – CALL FOR TRANSPARENCY
40 REGARDING THE ANNOUNCEMENT OF 17,000 CUTS TO
41 MILITARY HEALTH PROVIDERS

42
43 RECOMMENDATION A:

44
45 Madam Speaker, your Reference Committee recommends that
46 Policy D-305.967 be amended by addition and deletion as
47 follows:

48
49 Graduate Medical Education in the Military H-40.995

1 Our AMA: (1) strongly supports and endorses the graduate
2 medical education programs of the military services and
3 recognizes the potential benefit to the military services of
4 recruitment, retention and readiness programs; ~~and~~ (2) is
5 gravely concerned that closures of military medical centers and
6 subsequent reduction of graduate medical education programs
7 conducted therein will not only impede the health care mission
8 of the Department of Defense, but also harm the health care of
9 the nation by increasing the drain on trained specialists
10 available to the civilian sector; (3) urge the U.S. Department of
11 Defense (DOD) to release any assessments or pertinent
12 information used by the DOD to propose any reductions in the
13 overall uniformed medical positions including but not limited to
14 the number of medical provider billet cuts and their distribution
15 amongst specialties and services; (4) advocate to the U.S.
16 Congress to implement legislation mandating a study in the next
17 National Defense Authorization Act to assess the impact of
18 potential cuts on cost and healthcare quality outcomes for
19 military service members, dependents, and retirees before
20 drastic cuts are executed; and (5) oppose any reductions to
21 military GME residency or fellowship positions without
22 dedicated congressional funding for an equal number of civilian
23 residency positions in addition to any other planned increases
24 to civilian GME to avoid further exacerbating the United States'
25 physician shortage. (Directive to Take Action)

26
27 RECOMMENDATION B:

28
29 Madam Speaker, your Reference Committee recommends that
30 Policy H-40.995 be adopted as amended in lieu of Resolution
31 246.
32

33 Resolution 246 asks that our AMA urge the Department of Defense to immediately and
34 publicly release the required assessments that the Military Departments, the Joint Staff, and
35 organizations within the Office of the Secretary of Defense reportedly conducted as submitted
36 in writing by the US Army Surgeon General in Congressional testimony to Senate
37 Appropriations Committee regarding the operational medical requirements needed to support
38 the National Defense Strategy that the Military Departments used in planning to reduce overall
39 uniformed medical positions, as well as provide immediate clarification regarding the
40 proposed cuts including the number of medical provider billet cuts and their distribution
41 amongst specialties and services; and be it further, that if no such Department of Defense
42 assessments exist, are immediately released, or appear inadequate to the AMA to justify the
43 proposed cuts to military billets, that the AMA will urgently lobby the US Congress to
44 implement legislation mandating a study in the next National Defense Authorization Act to
45 assess the impact of potential cuts on cost and healthcare quality outcomes for military service
46 members, dependents, and retirees before drastic cuts are executed; and be it further, that
47 the AMA strongly oppose any reductions to military GME residency or fellowship positions
48 without dedicated congressional funding for parity civilian residency positions in addition to
49 any other planned increases to civilian GME to avoid further exacerbating the United States'
50 physician shortage.

1 Your Reference Committee heard supportive testimony for Resolution 246. Your Reference
2 Committee heard testimony that the U.S. Department of Defense has recently announced
3 plans to decrease the number of military health care provider billets threatening the success
4 and impact of healthcare services for certain service members and their beneficiaries. Your
5 Reference Committee heard further testimony that our AMA has strong existing policy
6 opposing any arbitrary attempt to limit the percentage of resident physicians in military
7 graduate education or training programs. Your Reference Committee heard testimony that
8 our AMA strongly supports and endorses Graduate Medical Education programs of the military
9 services. Your Reference Committee also heard that Resolution 246 brings forth an important
10 issue that needs to be addressed and added to existing policy. Accordingly, your Reference
11 Committee recommends that existing policy be amended in lieu of Resolution 246.

12
13 (31) RESOLUTION 203 – MEDICARE PART B AND PART D
14 DRUG PRICE NEGOTIATION

15
16 RECOMMENDATION:

17
18 Your Reference Committee recommends that Resolution 203
19 be referred.

20
21 Resolution 203 asks that our American Medical Association advocate for Medicare to cover
22 all physician-recommended adult vaccines in both the Medicare Part D and the Medicare Part
23 B programs (Directive to Take Action); and be it further; that our AMA make it a priority to
24 advocate for a mandate on pharmaceutical manufacturers to negotiate drug prices with the
25 Centers for Medicare and Medicaid Services for Medicare Part D and Part B covered drugs
26 (Directive to Take Action); and be it further; that our AMA explore all options with the state
27 and national specialty societies to ensure that physicians have access to reasonable drug
28 prices for the acquisition of Medicare Part B physician-administered drugs and that Medicare
29 reimburse physicians for their actual drug acquisition costs, plus appropriate fees for storage,
30 handling, and administration of the medications, to ensure access to high-quality, cost-
31 effective care in a physician's office. (Directive to Take Action) Resolution 217 asks that our
32 American Medical Association advocate that a physician's office can bill Medicare for all
33 vaccines and that the patient shall only pay the applicable copay to prevent fragmentation of
34 care. (Directive to Take Action)

35
36 Your Reference Committee heard mixed testimony on Resolutions 203. Your Reference
37 Committee heard testimony that our AMA should seek coverage of vaccines under Medicare
38 Part B while others advocated that our AMA seek coverage under both Part B and Part D.
39 Your Reference Committee heard testimony that advocating for coverage under both Part B
40 and Part D could have unintended consequences and referral was recommended for
41 Resolution 203. Accordingly, your Reference Committee recommends referring Resolution
42 203 for study.

43
44 (32) RESOLUTION 207 – DIRECT-TO-CONSUMER GENETIC
45 TESTS

46
47 RECOMMENDATION:

48
49 Madam Speaker, your Reference Committee recommends that
50 Resolution 207 be referred.

1 Resolution 207 asks that our American Medical Association regard research using consumer
2 genome data derived from saliva or cheek swab samples as research on human subjects
3 requiring consents in compliance with the Health and Human Services (HHS) Office for
4 Human Research Protection (OHRP), and recommend an “opt in” option to allow more
5 consumer choice in the consent process (Directive to Take Action); and be it further, that our
6 AMA amend Policy H-315.983, “Patient Privacy and Confidentiality,” by addition to align with
7 current research and privacy infringement findings, as follows: 1. Our AMA affirms the
8 following key principles that should be consistently implemented to evaluate any proposal
9 regarding patient privacy and the confidentiality of medical information: (a) That there exists
10 a basic right of patients to privacy of their medical information and records, and that this right
11 should be explicitly acknowledged; (b) That patients' privacy should be honored unless waived
12 by the patient in a meaningful way or in rare instances when strong countervailing interests in
13 public health or safety justify invasions of patient privacy or breaches of confidentiality, and
14 then only when such invasions or breaches are subject to stringent safeguards enforced by
15 appropriate standards of accountability; (c) That patients' privacy should be honored in the
16 context of gathering and disclosing information for clinical research and quality improvement
17 activities, and that any necessary departures from the preferred practices of obtaining
18 patients' informed consent and of de-identifying all data be strictly controlled; (d) That any
19 information disclosed should be limited to that information, portion of the medical record, or
20 abstract necessary to fulfill the immediate and specific purpose of disclosure; and (e) That the
21 Health Insurance Portability and Accountability Act of 1996 (HIPAA) be the minimal standard
22 for protecting clinician-patient privilege, regardless of where care is received, while working
23 with the Department of Health and Human Services (HHS) to stop the transfer of birthdates
24 and state of residence by genetic testing companies and their affiliates, unless there is explicit
25 user approval, to prevent re-identification of the test user by way of surname inference
26 methods. 2. Our AMA affirms: (a) that physicians and medical students who are patients are
27 entitled to the same right to privacy and confidentiality of personal medical information and
28 medical records as other patients, (b) that when patients exercise their right to keep their
29 personal medical histories confidential, such action should not be regarded as fraudulent or
30 inappropriate concealment, and (c) that physicians and medical students should not be
31 required to report any aspects of their patients' medical history to governmental agencies or
32 other entities, beyond that which would be required by law. 3. Employers and insurers should
33 be barred from unconsented access to identifiable medical information lest knowledge of
34 sensitive facts form the basis of adverse decisions against individuals. (a) Release forms that
35 authorize access should be explicit about to whom access is being granted and for what
36 purpose, and should be as narrowly tailored as possible. (b) Patients, physicians, and medical
37 students should be educated about the consequences of signing overly-broad consent forms.
38 (c) Employers and insurers should adopt explicit and public policies to assure the security and
39 confidentiality of patients' medical information. (d) A patient's ability to join or a physician's
40 participation in an insurance plan should not be contingent on signing a broad and indefinite
41 consent for release and disclosure. 4. Whenever possible, medical records should be de-
42 identified for purposes of use in connection with utilization review, panel credentialing, quality
43 assurance, and peer review. 5. The fundamental values and duties that guide the safekeeping
44 of medical information should remain constant in this era of computerization. Whether they
45 are in computerized or paper form, it is critical that medical information be accurate, secure,
46 and free from unauthorized access and improper use. 6. Our AMA recommends that the
47 confidentiality of data collected by race and ethnicity as part of the medical record, be
48 maintained. 7. Genetic information should be kept confidential and should not be disclosed to
49 third parties without the explicit informed consent of the tested individual. Our AMA regards
50 studies using consumer genome data derived from saliva, cheek swab, or other human tissue
51 samples as research on human subjects requiring consents in compliance with the HHS Office

1 for Human Research Protections (OHRP). An “opt in” option is recommended to allow more
2 consumer choice in the consent process. 8. When breaches of confidentiality are compelled
3 by concerns for public health and safety, those breaches must be as narrow in scope and
4 content as possible, must contain the least identifiable and sensitive information possible, and
5 must be disclosed to the fewest possible to achieve the necessary end. 9. Law enforcement
6 agencies requesting private medical information should be given access to such information
7 only through a court order. This court order for disclosure should be granted only if the law
8 enforcement entity has shown, by clear and convincing evidence, that the information sought
9 is necessary to a legitimate law enforcement inquiry; that the needs of the law enforcement
10 authority cannot be satisfied by non-identifiable health information or by any other information;
11 and that the law enforcement need for the information outweighs the privacy interest of the
12 individual to whom the information pertains. These records should be subject to stringent
13 security measures. 10. Our AMA must guard against the imposition of unduly restrictive
14 barriers to patient records that would impede or prevent access to data needed for medical or
15 public health research or quality improvement and accreditation activities. Whenever possible,
16 de-identified data should be used for these purposes. In those contexts where personal
17 identification is essential for the collation of data, review of identifiable data should not take
18 place without an institutional review board (IRB) approved justification for the retention of 43
19 identifiers and the consent of the patient. In those cases where obtaining patient consent for
20 disclosure is impracticable, our AMA endorses the oversight and accountability provided by
21 an IRB. 11. Marketing and commercial uses of identifiable patients' medical information may
22 violate principles of informed consent and patient confidentiality. Patients divulge information
23 to their physicians only for purposes of diagnosis and treatment. If other uses are to be made
24 of the information, patients must first give their uncoerced permission after being fully informed
25 about the purpose of such disclosures. 12. Our AMA, in collaboration with other professional
26 organizations, patient advocacy groups and the public health community, should continue its
27 advocacy for privacy and confidentiality regulations, including: (a) The establishment of rules
28 allocating liability for disclosure of identifiable patient medical information between physicians
29 and the health plans of which they are a part, and securing appropriate physicians' control
30 over the disposition of information from their patients' medical records. (b) The establishment
31 of rules to prevent disclosure of identifiable patient medical information for commercial and
32 marketing purposes; and (c) The establishment of penalties for negligent or deliberate breach
33 of confidentiality or violation of patient privacy rights. 13. Our AMA will pursue an aggressive
34 agenda to educate patients, the public, physicians and policymakers at all levels of
35 government about concerns and complexities of patient privacy and confidentiality in the
36 variety of contexts mentioned. 14. Disclosure of personally identifiable patient information to
37 public health physicians and departments is appropriate for the purpose of addressing public
38 health emergencies or to comply with laws regarding public health reporting for the purpose
39 of disease surveillance. 15. In the event of the sale or discontinuation of a medical practice,
40 patients should be notified whenever possible and asked for authorization to transfer the
41 medical record to a new physician or care provider. Only de-identified and/or aggregate data
42 should be used for "business decisions," including sales, mergers, and similar business
43 transactions when ownership or control of medical records changes hands. 16. The most
44 appropriate jurisdiction for considering physician breaches of patient confidentiality is the
45 relevant state medical practice act. Knowing and intentional breaches of patient
46 confidentiality, particularly under false pretenses, for malicious harm, or for monetary gain,
47 represents a violation of the professional practice of medicine. 17. Our AMA Board of Trustees
48 will actively monitor and support legislation at the federal level that will afford patients
49 protection against discrimination on the basis of genetic testing. The AMA will work with
50 Congress and HHS to modify the Genetic Information Nondiscrimination Act of 2008 (GINA),
51 which bans genome-based policy and hiring decisions by health insurance companies and

1 employers, by adding Long-Term Care, Life Insurance, and Disability Insurance to the Act to
2 prevent applicant rejection based on their genetic make up. 18. Our AMA supports privacy
3 standards that would require pharmacies to obtain a prior written and signed consent from
4 patients to use their personal data for marketing purposes. a. Our AMA supports privacy
5 standards that would prohibit pharmaceutical companies, biotechnology companies,
6 universities, and all other entities with financial ties to the genetic testing company from
7 sharing identified information with other parties without the consent of the user. An exception
8 would be made when requested by law enforcement authorities or when keeping the
9 information would seriously threaten their health or that of others. If a data security breach
10 occurs with the Direct-To –Consumer genetic company or its collaborators, then the company
11 has the responsibility to inform all users of the breach and the impact of the unprotected
12 private data on those individuals; 19. Our AMA supports privacy standards that require
13 pharmacies and drug store chains to 50 disclose the source of financial support for drug
14 mailings or phone calls. 20. Our AMA supports privacy standards that would prohibit
15 pharmacies from using prescription refill reminders or disease management programs as an
16 opportunity for marketing purposes. 21. Our AMA will draft model state legislation requiring
17 consent of all parties to the recording of a physician-patient conversation (Modify Current HOD
18 Policy); and be it further, that our AMA work with the Department of Health and Human
19 Services or other relevant parties to modify the rules to prevent genetic testing entities from
20 transferring information about the user’s date of birth and state of residence to third parties
21 which may result in the re-identification of the user based on surname inference (Directive to
22 Take Action); and be it further, that our AMA work with Congress and the Department of Health
23 and Human Services to extend the consumer protections of the Genetic Information Non-
24 Discrimination Act (GINA) of 2008 by adding long-term care, disability insurance, and life
25 insurance to the Act, modeled after the laws of other states, such as California. (Directive to
26 Take Action)

27
28 Your Reference Committee heard robust testimony on Resolution 207 largely in support of
29 referral. Your Reference Committee heard testimony that legislative action would be needed
30 to provide consumers of Direct-to-Consumer (DTC) genetic testing with the same type of
31 protections afforded to human research subjects available under the U.S. Department of
32 Health and Human Services (HHS) jurisdiction. Your Reference Committee further heard
33 testimony that the revised HHS Common Rule, which governs human subject research, may
34 not be adequate. Your Reference Committee heard additional testimony that the suggested
35 language concerning releasing information to law enforcement is not consistent with existing
36 AMA Code of Medical Ethics, 4.1.4 Forensic Genetics. Your Reference Committee heard
37 testimony that appreciated the consideration given to privacy and confidentiality, but noted
38 that evaluating the source, quality, and accuracy of genetic information is also an important
39 component to assess and interrogate when developing policy related to DTC genetic tests.
40 Your Reference Committee also heard testimony that strongly encouraged referral for report
41 given the rising use of genetic testing both in the clinical setting and DTC marketplace. Lastly,
42 your Reference Committee heard that there is growing evidence suggesting that de-identified
43 genetic information can become increasingly re-identified through genetic testing databases
44 and data sources. Your Reference Committee heard significant concerns about the Genetic
45 Information Nondiscrimination (GINA) Act of 2008, which bans genome-based policy and
46 hiring decisions by health insurance companies and employers, but does not include
47 protections for Long-Term Care, Life Insurance, and Disability Insurance. Your Reference
48 Committee heard testimony that the inclusion of life insurance provisions in the GINA Act may
49 lead to adverse selection and that this issue is complex, requiring additional study and
50 consideration. Accordingly, your Reference Committee recommends that Resolution 207 be
51 referred.

1 (33) RESOLUTION 219 – MEDICAL MARIJUANA LICENSE
2 SAFETY

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends that
7 Resolution 219 be referred.

8
9 Resolution 219 asks that our American Medical Association draft model state legislation to
10 amend states' prescription drug monitoring programs to include a medical marijuana license
11 registry. (Directive to Take Action)

12
13 Your Reference Committee heard engaging testimony regarding Resolution 219. Your
14 Reference Committee heard testimony that states have moved quickly to embrace medical
15 marijuana for a wide variety of reasons, and that a growing number of states have also
16 supported recreational marijuana despite the known risks of recreational use. Your Reference
17 Committee heard further testimony that a need exists for physicians and other health care
18 professionals to know what—if any—mind-altering substances their patients may be eating,
19 smoking, vaping, inhaling, or ingesting. However, your Reference Committee heard testimony
20 that there exists little guidance regarding appropriate dosing for a variety of marijuana
21 modalities, such as edible products containing CBD, THC, and other products that might have
22 psychoactive components (e.g., gummies, brownies, and chocolates). Further testimony
23 indicated that on the surface, it seems to make a modicum of sense to include medical
24 marijuana in a state prescription drug monitoring program (PDMP). However, your Reference
25 Committee heard testimony identifying multiple potential issues related to distribution,
26 licensing, and access: dispensaries are not operated by licensed health care professionals
27 subject to professional and ethical obligations to safeguard patients' personal health
28 information; the products offered in dispensaries are far from uniform; and it is unclear how a
29 CBD gummy or strain of cannabis would be entered into a PDMP. Your Reference Committee
30 believes these issues are among those that need further study. Accordingly, your Reference
31 Committee recommends referral of Resolution 219.

32
33 (34) RESOLUTION 226 – PHYSICIAN ACCESS TO THEIR
34 MEDICAL AND BILLING RECORDS

35
36 RECOMMENDATION:

37
38 Madam Speaker, your Reference Committee recommends that
39 Resolution 226 be referred.

40
41 Resolution 226 asks that that our American Medical Association advocate that licensed
42 physicians must always have access to all medical and billing records for their patients from
43 and after date of service including after physician termination (Directive to Take Action); and
44 be it further; that our AMA press for legislation or regulation to eliminate contractual language
45 that bars or limits the treating physician's access to the medical and billing records such as
46 treating these records as trade secrets or proprietary. (Directive to Take Action)

47
48 Your Reference Committee heard positive testimony on Resolution 226. Your Reference
49 Committee heard testimony that our AMA has strong policy regarding physician access and
50 management of medical records. Your Reference Committee further heard testimony that our

1 AMA has model state legislation regarding physician employment including a provision that a
2 “physician is entitled to copies of patient charts and any other records relating to the
3 physician’s provision of physician services.” Your Reference Committee also heard testimony
4 that the Council on Legislation is examining the issue of data ownership and stewardship and
5 the rapid advancement in the collection, transferability, and use of health care information.
6 Your Reference Committee heard testimony that our AMA should establish more
7 understanding of health care data within and outside the physician-patient relationship and
8 that the resolves of Resolution 226 touch upon the Council’s work. Accordingly, your
9 Reference Committee recommends that Resolution 226 be referred.

10
11 (35) RESOLUTION 243 – IMPROVING THE QUALITY PAYMENT
12 PROGRAM AND PRESERVING PATIENT ACCESS

13
14 RECOMMENDATION:

15
16 Madam Speaker, your Reference Committee recommends that
17 Resolution 243 be referred for report back at Interim 2019.

18
19 Resolution 243 asks that our American Medical Association strongly advocate for Congress
20 to make participation in the Merit-Based Incentive Payment System and alternative payment
21 models under the Quality Payment Program completely voluntary (Directive to Take Action);
22 and be it further; that our AMA strongly advocate for Congress to eliminate budget neutrality
23 in the Merit-Based Incentive Payment System and to finance incentive payments with
24 supplemental funds that do not come from Medicare Part B payment cuts to physicians and
25 other clinicians (Directive to Take Action); and be it further; that our AMA call on the Centers
26 for Medicare & Medicaid Services (CMS) to provide a transparent, accurate, and complete
27 Quality Payment Program Experience Report on an annual basis so physicians and medical
28 societies can analyze the data to advocate for additional exemptions; flexibilities; and
29 reductions in reporting burdens, administrative hassles, and costs (Directive to Take Action);
30 and be it further; that our AMA advocate that CMS increase the low-volume threshold for the
31 2020 Quality Payment Program and future years of the program for all physicians and
32 continue to offer them the opportunity to opt in or voluntarily report (Directive to Take Action);
33 and be it further; that our AMA reaffirm Policy H-390.838, “MIPS and MACRA Exemption,”
34 and advocate to preserve patient access by exempting small practices (one to 15 clinicians)
35 from required participation in the Merit-Based Incentive Payment System and continue to offer
36 them the opportunity to opt in or voluntarily report (Reaffirm HOD Policy)

37
38 Your Reference Committee heard mixed testimony on Resolution 243. Your Reference
39 Committee heard testimony that many physician practices that serve Medicare beneficiaries
40 cannot sustain additional reductions in their Medicare payments. Your Reference Committee
41 heard testimony that our AMA continues to work closely with CMS to recommend a variety of
42 improvements to the Merit-based Incentive Payment System (MIPS) program. Your
43 Reference Committee also heard testimony that our AMA strongly believes that we should
44 continue working to simplify and improve the MIPS program to make it easier for physicians
45 to avoid a penalty. Your Reference Committee heard testimony that our AMA advocacy efforts
46 are a main reason that CMS developed the policy for the first year of MIPS that allowed any
47 physician who reported on one measure, one time, for one patient avoid a penalty.
48 Furthermore, your Reference Committee heard testimony that at the last interim meeting, our
49 AMA had two similar resolutions asking our AMA to advocate for substantial changes to the
50 MIPS program that were referred for a Board Report due at the Interim Meeting in 2019. Your
51 Reference Committee believes that Resolution 243 should be a part of this forthcoming Board

1 Report as it would be premature for the House of Delegates to weigh in prior to the Board of
2 Trustees' deliberations. Accordingly, your Reference Committee recommends that Resolution
3 243 be referred for study for report back at Interim 2019 with the report that is pending from
4 Resolutions 206-I-18 and 231-I-18.

5
6 (36) RESOLUTION 245 – SENSIBLE APPROPRIATE USE
7 CRITERIA IN MEDICARE
8 RESOLUTION 247 – SENSIBLE APPROPRIATE USE
9 CRITERIA IN MEDICARE

10
11 RECOMMENDATION:

12
13 Madam Speaker, your Reference Committee recommends
14 that Resolutions 245 and 247 be referred.

15
16 Resolution 245 asks that our American Medical Association policy H-320.940, "Medicare's
17 Appropriate Use Criteria Program," be amended by addition as follows: Our AMA will continue
18 to advocate to delay the effective date of the Medicare AUC Program until the Centers for
19 Medicare & Medicaid Services can adequately address technical and workflow challenges
20 with its implementation and any interaction between the Quality Payment Program (QPP) and
21 the use of advanced diagnostic imaging appropriate use criteria, and support regulatory
22 change that resolves technical and workflow challenges and/or removes barriers to modifying
23 or aligning the AUC Program and the QPP. (Modify HOD Policy). Resolution 247 asks that
24 our American Medical Association policy H-320.940, "Medicare's Appropriate Use Criteria
25 Program," be amended by addition as follows: our AMA will continue to advocate to delay the
26 effective date of the Medicare AUC Program until the Centers for Medicare & Medicaid
27 Services can adequately address technical and workflow challenges with its implementation
28 and any interaction between the Quality Payment Program (QPP) and the use of advanced
29 diagnostic imaging appropriate use criteria, and support legislation that resolves technical and
30 workflow challenges and/or removes barriers to modifying or aligning the AUC Program and
31 the QPP. (Modify HOD Policy)

32
33 Your Reference Committee heard mixed testimony on Resolutions 245 and 247. Your
34 Reference Committee heard testimony that the statute regarding appropriate use criteria sets
35 up a rigid system, a complex exchanging of information between ordering and referring
36 providers, and burdensome documentation requirements. Your Reference Committee also
37 heard testimony that appropriate use criteria has been shown to improve quality, reduce
38 unnecessary imaging, and lower costs. Your Reference Committee heard testimony that the
39 Centers for Medicare and Medicaid Services should exempt physicians from the appropriate
40 use criteria requirements when the physician is participating in the QPP. Testimony also
41 indicated that physicians participating in Alternative Payment Models (APM) and MIPS APMs
42 should be exempted because those physicians are already being held accountable for costs
43 and outcomes and are assuming risk. Your Reference Committee heard further testimony that
44 the Resolutions should not be adopted and that existing policy is sufficient. Accordingly, given
45 the disagreement, your Reference Committee recommends that Resolutions 245 and 247 be
46 referred.

1 (37) RESOLUTION 227 – CONTROLLED SUBSTANCE
2 MANAGEMENT

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends that
7 Resolution 227 not be adopted.

8
9 Resolution 227 asks that our American Medical Association work with the Centers for
10 Medicare and Medicaid Services (CMS) and interested physician groups to strongly advocate
11 for a mechanism by which physicians may be compensated for controlled substance
12 management (Directive to Take Action); and be it further; that our AMA strongly encourage
13 CMS and private payers to recognize and establish equitable payment for controlled
14 substance management. (Directive to Take Action)

15
16 Your Reference Committee heard limited testimony on Resolution 227. Your Reference
17 Committee heard supportive testimony for increased payment for conducting activities for
18 controlled substance management. Your Reference Committee also heard testimony that this
19 could include payment, for example, when a physician checks a state's prescription
20 monitoring program (PDMP). Your Reference Committee heard testimony that this example,
21 moreover, is only one of many that could be implicated by the somewhat vague "controlled
22 substance management," which could conceivably include any and all controlled substance
23 discussion with a patient, test result, pill count, practice-related medication adherence, drug
24 utilization review, or refill protocol. Accordingly, while your Reference Committee is
25 sympathetic to the added administrative burdens associated with all of the Evaluation and
26 Management and other work physicians do when a patient receives a controlled substance
27 as part of the treatment care plan, your Reference Committee recommends that Resolution
28 227 not be adopted.

29
30 (38) RESOLUTION 239 – IMPROVING ACCESS TO MEDICAL
31 CARE THROUGH TAX TREATMENT OF PHYSICIANS

32
33 RECOMMENDATION:

34
35 Madam Speaker, your Reference Committee recommends that
36 Resolution 239 not be adopted.

37
38 Resolution 239 asks that our American Medical Association seek legislation and/or regulation
39 that would permit physician practices to utilize 'pass through' tax treatment of practice income
40 in the manner of other small businesses and professionals. (Directive to Take Action)

41
42 Your Reference Committee heard limited but mixed testimony on Resolution 239. Your
43 Reference Committee heard testimony in support of this resolution to provide physicians with
44 the same tax benefits that other small businesses receive through the new tax law regarding
45 so-called "pass through" entities. Your Reference Committee heard testimony against
46 adoption of this resolution because it is based on a misunderstanding of the purpose of the
47 tax law change for pass-through entities, which is to provide relief for small businesses that
48 rely on capital investment to generate their income (rather than their own professional
49 expertise). Your Reference Committee heard that physicians were not singled out for
50 exclusion from this tax benefit; other professionals, such as attorneys, accountants,
51 consultants, financial advisors, and other professionals are treated the same way. Your

1 Reference Committee further considered that the exclusion phases in over specified income
2 levels, so that some physicians whose income is below a certain threshold are still qualified
3 for the deduction. Your Reference Committee also considered that some individual physicians
4 may realize an overall net benefit from the new tax law through other provisions that reduced
5 most individual tax brackets and provide other tax benefits. Your Reference Committee
6 believes that Resolution 239 raises a number of questions regarding complex tax issues that
7 may impact individual physicians in different ways. Accordingly, your Reference Committee
8 recommends that Resolution 239 not be adopted.

9
10 (39) RESOLUTION 206 – CHANGING THE PARADIGM:
11 OPPOSING PRESENT AND OBVIOUS RESTRAINT OF
12 TRADE
13 RESOLUTION 240 – FORMATION OF COLLECTIVE
14 BARGAINING WORKGROUP

15
16 RECOMMENDATION:

17
18 Madam Speaker, your Reference Committee recommends that
19 Policies D-383.981, D-383.982, D-383.983, D-383-985, D-
20 383.988, D-383.990, H-165.833, H-180.975, H-380.987, H-
21 383.988, H-383.990, H-383.992, H-383.993, H-385.946, H-
22 385.973, and H-385.976 be reaffirmed in lieu of Resolutions 206
23 and 240.
24

25 Resolution 206 asks that our American Medical Association seek legislative or regulatory
26 changes to allow physicians to collectively negotiate professional fees, compensation and
27 contract terms without integration. (Directive to Take Action) Resolution 240 asks that that our
28 American Medical Association form a workgroup to outline the legal challenge to federal
29 antitrust statute for physicians (Directive to Take Action); and be it further; that this workgroup
30 engage the state medical associations and other physician groups as deemed appropriate
31 (Directive to Take Action); and be it further; that our AMA report by the 2020 Annual Meeting
32 on the viability of a strategy for the formation of a federal collective bargaining system for all
33 physicians and, to the extent viable, a related organizational plan. (Directive to Take Action)

34
35 Your Reference Committee heard mixed testimony on Resolution 206. Your Reference
36 Committee heard testimony that large health insurers have substantially more bargaining
37 power over physicians that allowing insurers to force bad contract terms and unfair payment
38 rates on physicians. On the other hand, your Reference Committee heard testimony that
39 aggressively pursuing a special antitrust exemption for physicians would stretch our antitrust
40 advocacy agenda. Our AMA has worked hard to earn a reputation for credibility through its
41 aggressive and evidence-based antitrust campaign against various proposed mergers, most
42 recently Anthem-Cigna, Aetna-Humana, and now, CVS-Aetna.

43
44 Testimony also indicated that our AMA already has extensive policy making antitrust reform
45 a high priority for our AMA. For example, that our AMA make passage of legislation in
46 Congress to exempt physicians from antitrust actions in their negotiations with insurance
47 companies a top legislative priority of our AMA and that our AMA continue to aggressively
48 advocate for a level playing field for negotiations between physicians and health insurers by
49 pursuing legislative relief at the federal level and providing support to state medical society
50 efforts to pass legislation are based on the state action doctrine. Our AMA already has
51 developed a sophisticated model bill that any medical association can use that would enable

1 independent physicians to collectively negotiate with health insurers under the state action
2 exemption to federal and state antitrust laws. Through our AMA state Advocacy Resource
3 Center, all interested states and national medical specialty societies have access to antitrust
4 experts and the ability to develop strategies, state roadmaps, and related tools for enacting
5 legislation on the issues raised in Resolution 240. Together with the Advocacy Resource
6 Center, our AMA antitrust advocacy team monitors these issues closely as well. Based on all
7 of the above, your Reference Committee recommends reaffirming policy in lieu of Resolutions
8 206 and 240.

9
10 Employee Associations and Collective Bargaining for Physicians D-383.981

11 Our AMA will study and report back on physician unionization in the United States.
12 (Res. 601, I-14)

13
14 A Level Playing Field in Negotiations Between Health Insurance Companies and
15 Physicians D-383.982

16 Our AMA will make passage of legislation in the US Congress to exempt physicians
17 from antitrust actions in their negotiations with insurance companies a top legislative
18 priority of the AMA, remain vigilant on this issue, continue to regularly provide updates
19 on our AMA Web site and through other AMA communication tools, request sponsors
20 nationally, and allocate appropriate funding and resources necessary to successfully
21 advocate its passage into law. (Res. 202, I-11)

22
23 Collective Bargaining: Antitrust Immunity D-383.983

24 Our AMA will: (1) continue to pursue an antitrust advocacy strategy, in collaboration
25 with the medical specialty stakeholders in the Antitrust Steering Committee, to urge
26 the Department of Justice and Federal Trade Commission to amend the "Statements
27 of Antitrust Enforcement Policy in Health Care" (or tacitly approve expansion of the
28 Statements) and adopt new policy statements regarding market concentration that are
29 consistent with AMA policy; and (2) execute a federal legislative strategy. (BOT Action
30 in response to referred for decision Res. 209, A-07 and Res. 232, A-07 Reaffirmed:
31 Res. 215, A-11)

32
33 Fair Valuation of Physician Services in Third Party Payer Contracting with Hospitals
34 and Health Care Systems D-383.985

35 Our AMA will: (1) continue to advocate for fair payment for physician services
36 regardless of the employment status of physicians on organized medical staffs; (2)
37 develop a new federal antitrust legislative strategy, and reopen a dialogue with the
38 Department of Justice and the Federal Trade Commission concerning more flexible
39 approaches to physician network joint ventures; (3) continue to encourage all
40 physicians who would like to report the unfair business practices of health insurers and
41 other payers to complete the AMA online health plan complaint form; and (4) work to
42 ultimately eliminate the need for cross subsidization practices between third party
43 payers and hospital systems that result in: (a) a decrease in physician market power,
44 (b) a devaluation of physician services, and (c) harm to competition. (BOT Rep. 13, I-
45 06 Reaffirmation A-08 Reaffirmation I-10)

46
47 Collective Bargaining and the Definition of Supervisors D-383.988

48 Our AMA will support legislative efforts by other organizations and entities that would
49 overturn the Supreme Court's ruling in *National Labor Relations Board v. Kentucky*
50 *River Community Care, Inc., et al.* (BOT Action in response to referred for decision
51 Res. 248, A-01 Modified: BOT Rep. 22, A-11)

1
2 AMA's Aggressive Pursuit of Antitrust Reform D-383.990

3 Our AMA will: (1) place a high priority on the level of support provided to AMA's Public
4 and Private Sector Advocacy Units, which are key to successfully addressing the
5 problems physicians face as a result of the current application of federal antitrust laws;
6 (2) through its private and public sector advocacy efforts, continue to aggressively
7 advocate for a level playing field for negotiations between physicians and health
8 insurers by aggressively pursuing legislative relief at the federal level and providing
9 support to state medical society efforts to pass legislation based on the "state action
10 doctrine"; (3) continue to advocate to the Federal Trade Commission and Department
11 of Justice for more flexible and fair treatment of physicians under the antitrust laws
12 and for greater scrutiny of insurers; (4) continue to develop and publish objective
13 evidence of the dominance of health insurers through its comprehensive study,
14 Competition in Health Insurance: Comprehensive Study of US Markets, and other
15 appropriate means; (5) identify consequences of the concentration of market power
16 by health plans to enlist a Senate sponsor for a bill allowing collective negotiation by
17 physicians; and (6) develop practical educational resources to help its member
18 physicians better understand and use the currently available, effective modalities by
19 which physician groups may legally negotiate contracts with insurers and health plans.
20 (Res. 908, I-03 Reaffirmation, A-05 Reaffirmed: BOT Rep. 10, I-05 Reaffirmation A-06
21 Reaffirmation A-08 Reaffirmed: BOT Rep. 09, A-18)

22
23 Amend the Patient Protection and Affordable Care Act (PPACA) H-165.833

24 1. Our AMA continues to advocate to achieve needed reforms of the many defects of
25 the federal Patient Protection and Affordable Care Act (PPACA) law so as to protect
26 the primacy of the physician-patient relationship. These needed changes include but
27 are not limited to: repeal of the Independent Payment Advisory Board (IPAB); study of
28 the Medicare Cost/Quality Index; repeal of the non-physician provider non-
29 discrimination provision; enactment of comprehensive medical liability
30 reform; enactment of long term Medicare physician payment reform including
31 permitting patients to privately contract with physicians not participating in the
32 Medicare program; enactment of antitrust reform to permit independently practicing
33 physicians to collectively negotiate with health insurance companies; and expanding
34 the use of health savings accounts as a means to provide health insurance
35 coverage. 2. Our AMA will vigorously work to change the PPACA to accurately
36 represent our AMA Policy. (Res. 217, A-11 Reaffirmation A-12 Reaffirmed: Res. 239,
37 A-12 Reaffirmed: CMS Rep. 5, I-12 Reaffirmed: CMS Rep. 9, A-14 Reaffirmed in lieu
38 of Res. 215, A-15)

39
40 Insurance Industry Antitrust Exemption H-180.975

41 It is the policy of the AMA to: (1) to continue efforts to have the insurance industry be
42 more responsive to the concerns of physicians, including collective negotiations with
43 physicians and their representatives regarding delivery of medical care; (2) to continue
44 efforts to have the insurance industry be more responsive to the concerns of
45 physicians and their representatives regarding reasonable requests for appropriate
46 information and data; (3) to analyze proposed amendments to the McCarran-Ferguson
47 Act to determine whether they will increase physicians' ability to deal with insurance
48 companies, or increase appropriate scrutiny of insurance industry practices by the
49 courts; and (4) to continue to monitor closely and support appropriate legislation to
50 accomplish the above objectives. (BOT Rep. DD, I-91 Reaffirmed: Res. 213, I-98
51 Reaffirmation A-00 Reaffirmation I-00 Reaffirmation A-01 Reaffirmation I-03

1 Reaffirmed: BOT Rep. 10, I-05 Reaffirmation A-06 Reaffirmation A-08 Reaffirmed:
2 BOT action in response to referred for decision Res. 201, I-12)

3
4 Antitrust Relief as a Priority of the AMA H-380.987

5 Our AMA will continue its aggressive efforts to achieve appropriate negotiations rights
6 and opportunities and necessary antitrust relief for physicians, by whatever means.
7 Achieving this important goal will remain a top priority for the Association. (Sub. Res.
8 223, A-93 Reaffirmed by BOT Rep. 33, A-96 Reaffirmation A-97 Reaffirmation A-00
9 Reaffirmation I-00 Reaffirmation A-04 Reaffirmation A-05 Reaffirmed: BOT Rep. 10, I-
10 05 Reaffirmation A-06 Reaffirmation A-08 Reaffirmation I-10 Reaffirmed: Res. 215, A-
11 11 Reaffirmed: BOT action in response to referred for decision Res. 201, I-12
12 Reaffirmed in lieu of Res. 218, A-15 Reaffirmed: CMS Rep. 05, A-17)

13
14 Physicians' Ability to Negotiate and Undergo Practice Consolidation H-383.988

15 Our AMA will: (1) pursue the elimination of or physician exemption from anti-trust
16 provisions that serve as a barrier to negotiating adequate physician payment; (2) work
17 to establish tools to enable physicians to consolidate in a manner to insure a viable
18 governance structure and equitable distribution of equity, as well as pursuing the
19 elimination of anti-trust provisions that inhibited collective bargaining; and (3) find and
20 improve business models for physicians to improve their ability to maintain a viable
21 economic environment to support community access to high quality comprehensive
22 healthcare. (Res. 229, A-12)

23
24 Antitrust Relief for Physicians Through Federal Legislation H-383.990

25 Our AMA: (1) encourages state medical associations and national medical specialty
26 societies to support federal antitrust reform bills, such as H.R. 1409, as originally
27 introduced in the 112th Congress, and consider sending in letters of support for
28 such antitrust reform legislation to their respective Congressional delegations and
29 select Congressional leaders; (2) supports the intent of antitrust reform bills, such as
30 H.R. 1409, as originally introduced in the 112th Congress, that put access to quality
31 patient medical care and patient rights ahead of health insurer profits; (3) continues to
32 advocate for the principles that support that any health care professional, including a
33 physician or a physician group, which is engaged in negotiations with a health plan
34 regarding the terms of any contract under which the professional provides health care
35 items or services for which benefits are provided shall, in connections with such
36 negotiations, be exempt from federal antitrust laws; (4) continues to advocate for the
37 concepts and limitations incorporated in H.R. 1409, as originally introduced in the
38 112th Congress, including: no new rights for collective cessation of service to patients,
39 no amendments to the National Labor Relations Act; and no application of H.R. 1409,
40 as originally introduced in the 112th Congress, to the Medicare program under Title
41 XVIII, the Medicaid program under Title IX, the SCHIP program under Title XXI of the
42 Social Security Act; or programs related to medical services for members of the
43 uniformed service, veterans, federal employees health benefit program or Indian
44 Health Services; (5) will send a letter of support to Congress of the principles contained
45 in H.R. 1409 as originally introduced in the 112th Congress; and (6) will work with
46 members of Congress to promote antitrust reform in light of Accountable Care
47 Organization (ACO) development. (Res. 212, A-11 Reaffirmed: BOT action in
48 response to referred for decision Res. 201, I-12)

49
50 Antitrust Relief H-383.992

1 Our AMA will: (1) redouble efforts to make physician antitrust relief a top legislative
2 priority, providing the necessary foundation for fair contract negotiations designed to
3 preserve clinical autonomy and patient interest and to redirect medical decision
4 making to patients and physicians; and (2) affirm its commitment to undertake all
5 appropriate efforts to seek legislative and regulatory reform of state and federal law,
6 including federal antitrust law, to enable physicians to negotiate effectively with health
7 insurers. (Sub. Res. 905, I-07 Reaffirmation A-08 Reaffirmed: Res. 215, A-11
8 Reaffirmed: BOT action in response to referred for decision Res. 201, I-12 Reaffirmed
9 in lieu of Res. 218, A-15)

10
11 Negotiations Issue H-383.993

12 Our AMA: (1) will continue its efforts to promote the involvement of physician
13 organizations in health policy decisions by public and private institutions pursuant to
14 health system reform; (2) will continue its efforts to enhance the involvement of
15 physician organizations in the current health system, including the Medicare program
16 and private sector payers and institutions; (3) will continue with its efforts to support
17 and enhance the self regulatory structure of the profession, and will continue to review
18 the development of new self regulatory efforts that may be needed to meet the
19 challenges of the new environment; (4) working through a consortium of appropriate
20 interested organizations (i.e., specialties, groups), may act as the negotiator on behalf
21 of, and with active input from, physicians and physician groups, for reimbursement of
22 physician services, practice-related issues (including quality improvement), utilization
23 review, physician supply and professional liability reform; (5) believes that at the state
24 and local level, physician-directed organizations (i.e. state or county associations) may
25 act as a negotiator on behalf of member physicians after antitrust relief has been
26 obtained; and (6) will continue to pursue enhanced roles for physicians in private
27 sector health plans, including lobbying for appropriate modification of the antitrust laws
28 to facilitate physician negotiation with managed care plans and for legislation requiring
29 managed care plans to allow participating physicians to organize for the purpose of
30 commenting on medical review criteria, and including the development of an AMA
31 team to develop the information and networks of consultants necessary to assist
32 physicians in their interactions with managed care plans.

33 BOT Rep. QQ, I-92 BOT Rep. HHH, A-93 Reaffirmed: BOT Rep. 40, I-93 Reaffirmed:
34 BOT Reps. 25 and 40, I-93 Reaffirmed: Sub. Res. 110, A-94 Reaffirmation I-98
35 Reaffirmation A-00 Reaffirmation I-00 Reaffirmation A-04 Reaffirmation A-05
36 Reaffirmed: BOT Rep. 10, I-05 Consolidated and Renumbered: CMS Rep. 7, I-05
37 Reaffirmation A-06 Reaffirmation A-08 Reaffirmation I-08 Reaffirmation I-10
38 Reaffirmed: Sub. Res. 222, I-10 Reaffirmed: BOT action in response to referred for
39 decision Res. 201, I-12

40
41 Collective Bargaining for Physicians H-385.946

42 The AMA will seek means to remove restrictions for physicians to form collective
43 bargaining units in order to negotiate reasonable payments for medical services and
44 to compete in the current managed care environment; and will include the drafting of
45 appropriate legislation. (Res. 239, A-97 Reaffirmation I-98 Reaffirmation A-01
46 Reaffirmation A-05 Reaffirmation A-06 Reaffirmation A-08 Reaffirmation I-10)

47
48 Collective Negotiations H-385.973

49 It is the policy of the AMA to seek amendments to the National Labor Relations Act
50 and other appropriate federal antitrust laws to allow physicians to negotiate collectively
51 with payers who have market power. (Res. 95, A-90 Reaffirmed by BOT Rep. 33, A-

1 96 Reaffirmation A-97 Reaffirmation I-98 Reaffirmation A-00 Reaffirmation I-00
2 Reaffirmation A-01 Reaffirmation A-04 Reaffirmation A-05 Reaffirmation A-06
3 Reaffirmation A-08 Reaffirmation I-10 Reaffirmed: Res. 215, A-11 Reaffirmed: BOT
4 action in response to referred for decision Res. 201, I-12)

5
6 Physician Collective Bargaining H-385.976

7 Our AMA's present view on the issue of physician collective negotiation is as follows:

8 (1) There is more that physicians can do within existing antitrust laws to enhance their
9 collective bargaining ability, and medical associations can play an active role in that
10 bargaining. Education and instruction of physicians is a critical need. The AMA
11 supports taking a leadership role in this process through an expanded program of
12 assistance to independent and employed physicians. (2) Our AMA supports continued
13 intervention in the courts and meetings with the Justice Department and FTC to
14 enhance their understanding of the unique nature of medical practice and to seek
15 interpretations of the antitrust laws which reflect that unique nature. (3) Our AMA
16 supports continued advocacy for changes in the application of federal labor laws to
17 expand the number of physicians who can bargain collectively. (4) Our AMA vigorously
18 opposes any legislation that would further restrict the freedom of physicians to
19 independently contract with Medicare patients. (5) Our AMA supports obtaining for the
20 profession the ability to fully negotiate with the government about important issues
21 involving reimbursement and patient care. (BOT Rep. P, I-88 Modified: Sunset Report,
22 I-98 Reaffirmation A-00 Reaffirmation I-00 Reaffirmation A-01 Reaffirmation I-03
23 Reaffirmation A-04 Reaffirmed in lieu of Res. 105, A-04 Reaffirmation A-05
24 Reaffirmation A-06 Reaffirmation A-08 Reaffirmed: BOT Rep. 17, A-09 Reaffirmation
25 I-10 Reaffirmed: Sub. Res. 222, I-10 Reaffirmed: Res. 215, A-11 Reaffirmed: BOT
26 action in response to referred for decision Res. 201, I-12)

27
28
29 (40) RESOLUTION 210 – AIR AMBULANCES

30
31 RECOMMENDATION:

32
33 Madam Speaker, your Reference Committee recommends that
34 Policy H-285.904 be reaffirmed in lieu of Resolution 210.

35
36 Resolution 210 asks that that our American Medical Association support federal legislation
37 which would: 1. Establish an expedited independent dispute resolution system to resolve
38 payment disputes between emergency air ambulance providers and health insurers; and 2.
39 Ensure that such independent dispute resolution process would ensure the patient be “held
40 harmless” except for applicable insurance policy in-network cost-sharing requirements. (New
41 HOD Policy)

42
43 Your Reference Committee heard mixed testimony on Resolution 210. Your Reference
44 Committee heard testimony in support of protecting patients from unanticipated out-of-
45 network costs incurred as result of out-of-network air ambulances. Your Reference Committee
46 agrees that air ambulance costs can be financially devastating for patients in the same way
47 as other major medical services, especially when those services are provided out of network.
48 Your Reference Committee heard testimony that our AMA policy (D-130.962—Air Ambulance
49 Regulations and Payments) adopted at the 2018 Interim Meeting that calls for greater price
50 and data transparency for air ambulances. Your Reference Committee also heard testimony
51 that current AMA policy (H-285.904—Out-of-Network Care) on out-of-network services

1 encompasses unanticipated bills from air ambulances, and would protect patients in the
2 manner called for in Resolution 210. Accordingly, your Reference Committee therefore
3 recommends that existing policy be reaffirmed in lieu of adopting Resolution 210.

4
5 Out-of-Network Care H-285.904

6 1. Our AMA adopts the following principles related to unanticipated out-of-network
7 care: A. Patients must not be financially penalized for receiving unanticipated care
8 from an out-of-network provider. B. Insurers must meet appropriate network adequacy
9 standards that include adequate patient access to care, including access to hospital-
10 based physician specialties. State regulators should enforce such standards through
11 active regulation of health insurance company plans. C. Insurers must be transparent
12 and proactive in informing enrollees about all deductibles, copayments and other out-
13 of-pocket costs that enrollees may incur. D. Prior to scheduled procedures, insurers
14 must provide enrollees with reasonable and timely access to in-network physicians. E.
15 Patients who are seeking emergency care should be protected under the “prudent
16 layperson” legal standard as established in state and federal law, without regard to
17 prior authorization or retrospective denial for services after emergency care is
18 rendered. F. Out-of-network payments must not be based on a contrived percentage
19 of the Medicare rate or rates determined by the insurance company. G. Minimum
20 coverage standards for unanticipated out-of-network services should be identified.
21 Minimum coverage standards should pay out-of-network providers at the usual and
22 customary out-of-network charges for services, with the definition of usual and
23 customary based upon a percentile of all out-of-network charges for the particular
24 health care service performed by a provider in the same or similar specialty and
25 provided in the same geographical area as reported by a benchmarking database.
26 Such a benchmarking database must be independently recognized and verifiable,
27 completely transparent, independent of the control of either payers or providers and
28 maintained by a non-profit organization. The non-profit organization shall not be
29 affiliated with an insurer, a municipal cooperative health benefit plan or health
30 management organization. H. Mediation should be permitted in those instances where
31 a physician’s unique background or skills (e.g. the Gould Criteria) are not accounted
32 for within a minimum coverage standard. 2. Our AMA will advocate for the principles
33 delineated in Policy H-285.904 for all health plans, including ERISA plans. (Res. 108,
34 A-17 Reaffirmation: A-18 Appended: Res. 104, A-18 Reaffirmed in lieu of: Res. 225,
35 I-18)

36
37 (41) RESOLUTION 236 – SUPPORT FOR UNIVERSAL BASIC
38 INCOME PILOT STUDIES

39
40 RECOMMENDATION:

41
42 Madam Speaker, your Reference Committee recommends that
43 Policies H-160.909, H-160.896, H-65.963, and D-165.966 be
44 reaffirmed in lieu Resolution 236.

45
46 Resolution 236 asks that That our American Medical Association support federal, state, local,
47 and/or private Universal Basic Income pilot studies in the United States which intend to
48 measure health outcomes and access to care for participants. (New HOD Policy)

49
50 Your Reference Committee heard mixed testimony on Resolution 236. Your Reference
51 Committee heard testimony that our AMA strongly supports protections that seek to alleviate

1 the effects of poverty on health income including Medicaid, Supplemental Nutrition Assistance
2 Program (SNAP), Children's Health Insurance Program (CHIP), and the Special
3 Supplemental Nutrition Program for Women, Infants, and Children (WIC). Your Reference
4 Committee heard testimony that Universal Basic Income pilot programs can be considered
5 contentious policy proposals, particularly when social safety net programs such as Medicaid,
6 SNAP, CHIP, and the WIC may be compromised or replaced during implementation efforts.
7 Your Reference Committee heard further testimony outlining our AMA's comprehensive policy
8 related to addressing health disparities and improving access to care including the
9 establishment of our AMA's Center for Health Equity and subsequent hiring of our AMA's first
10 Chief Health Equity Officer. Your Reference Committee believes that advocacy efforts
11 focused on tackling the asks of this resolution are currently in place in support of our AMA's
12 organizational efforts to address disparities in health outcomes and access to care.
13 Accordingly, your Reference Committee recommends that existing policies H-160.909, H-
14 160.896, H-65.963, and D-165.966 be reaffirmed in lieu of Resolution 236.

15
16 Poverty Screening as a Clinical Tool for Improving Health Outcomes H-160.909

17 Our AMA encourages screening for social and economic risk factors in order to
18 improve care plans and direct patients to appropriate resources. (Res. 404, A-13,
19 Reaffirmed: BOT Rep. 39, A-18)

20
21 Expanding Access to Screening Tools for Social Determinants of Health/Social
22 Determinants of Health in Payment Models H-160.896

23 Our AMA supports payment reform policy proposals that incentivize screening for
24 social determinants of health and referral to community support systems. (BOT Rep.
25 39, A-18)

26
27 Discriminatory Policies that Create Inequities in Health Care H-65.963

28 Our AMA will: (1) speak against policies that are discriminatory and create even
29 greater health disparities in medicine; and (2) be a voice for our most vulnerable
30 populations, including sexual, gender, racial and ethnic minorities, who will suffer the
31 most under such policies, further widening the gaps that exist in health and wellness
32 in our nation. (Res. 001, A-18)

33
34 Giving States New Options to Improve Coverage for the Poor D-165.966

35 Our AMA will (1) advocate that state governments be given the freedom to develop
36 and test different models for improving coverage for patients with low incomes,
37 including combining refundable, advanceable tax credits inversely related to income
38 to purchase health insurance coverage with converting Medicaid from a categorical
39 eligibility program to one that allows for coverage of additional low-income persons
40 based solely on financial need; (2) advocate for changes in federal rules and federal
41 financing to support the ability of states to develop and test such alternatives without
42 incurring new and costly unfunded federal mandates or capping federal funds; and (3)
43 continue to work with interested state medical associations, national medical specialty
44 societies, and other relevant organizations to further develop such state-based options
45 for improving health insurance coverage for low-income persons. (Res. 118, A-04
46 Reaffirmed: CMS Rep. 1, A-05 Modified: CMS Rep. 8, A-08 Reaffirmed: CMS Rep. 9,
47 A-11 Reaffirmed: CMS Rep. 5, I-11 Modified: CCB/CLRPD Rep. 2, A-14;
48 Reaffirmation: A-18)

- 1 Madam Speaker, this concludes the report of Reference Committee B. I would like to thank
- 2 Jenni Bartlotti Telesz, MD; Michael Hoover, MD; Steve Lee, MD; Michael Medlock, MD; Chris
- 3 Pittman, MD; and Stephen Rockower, MD; all those who testified before the Committee; and
- 4 our AMA staff.

Jenni Bartlotti Telesz, MD (Alternate)
American Society of Anesthesiologists

Michael Hoover, MD
Indiana

Steve Y. Lee, MD (Alternate)
American Society of Clinical Oncology

Michael Medlock, MD (Alternate)
Massachusetts

Chris Pittman, MD
American Vein and Lymphatic Society

Stephen Rockower, MD
Maryland

Charles Rothberg, MD
New York
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (A-19)

Report of Reference Committee C

Nicole D. Riddle, MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

2
3 **RECOMMENDED FOR ADOPTION**

- 4
5 1. Board of Trustees Report 25 – All Payer Graduate Medical Education Funding
6 2. Council on Medical Education Report 1 – Council on Medical Education Sunset
7 Review of 2009 House Policies
8 3. Council on Medical Education Report 2 – Update on Maintenance of Certification
9 and Osteopathic Continuous Certification (Resolution 316-A-18)
10 4. Resolution 321 – Physician Health Program Accountability, Consistency, and
11 Excellence in Provision of Service to the Medical Profession
12 5. Resolution 323 – Improving Access to Care in Medically Underserved Areas
13 Through Project ECHO and the Child Psychiatry Access Project Model
14 6. Resolution 324 - Residency and Fellowship Program Director,
15 Assistant/Associate Program Director, and Core Faculty Protected Time and
16 Salary Reimbursement
17

18 **RECOMMENDED FOR ADOPTION AS AMENDED**

- 19
20 7. Council on Medical Education Report 3 – Standardizing the Residency Match
21 System and Timeline (CME Report 6-A-17)
22 8. Council on Medical Education Report 4 – Augmented Intelligence in Medical
23 Education (Resolution 317-A-18)
24 9. Council on Medical Education Report 6 – Study of Medical Student, Resident,
25 and Physician Suicide (Resolution 959-I-18)
26 Resolution 307 – Mental Health Services for Medical Students
27 Resolution 310 – Mental Health Care for Medical Students
28 10. Council on Medical Education/Council on Science and Public Health Report 01 –
29 Protecting Medical Trainees from Hazardous Exposure (Resolution 301-A-18)
30 11. Resolution 302 – The Climate Change Lecture for US Medical Schools
31 12. Resolution 303 – Graduate Medical Education and the Corporate Practice of
32 Medicine
33 13. Resolution 304 – Tracking Outcomes and Supporting Best Practices of Health
34 Care Career Pipeline Programs
35 14. Resolution 313 – Clinical Applications of Pathology and Laboratory Medicine for
36 Medical Students, Residents and Fellows
37 15. Resolution 314 – Evaluation of Changes to Residency and Fellowship
38 Application and Matching Processes
39 16. Resolution 315 – Scholarly Activity by Resident and Fellow Physicians
40 17. Resolution 316 – Medical Student Debt
41 18. Resolution 317 – A Study to Evaluate Barriers to Medical Education for Trainees
42 with Disabilities
43 19. Resolution 318 – Rural Health Physician Workforce Disparities

- 1 20. Resolution 319 – Adding Pipeline Program Participation Questions to Medical
2 School Applications
3 21. Resolution 322 – Support for the Study of the Timing and Causes for Leave of
4 Absence and Withdrawal from United States Medical Schools
5

6 **RECOMMENDED FOR REFERRAL**
7

- 8 22. Resolution 308 – Maintenance of Certification Moratorium
9 23. Resolution 311 – Grandfathering Qualified Applicants Practicing in U.S.
10 Institutions with Restricted Medical Licensure
11

12 **RECOMMENDED FOR NOT ADOPTION**
13

- 14 24. Resolution 301 – American Board of Medical Specialties Advertising
15 25. Resolution 312 – Unmatched Medical Graduates to Address the Shortage of
16 Primary Care Physicians
17

18 Existing policy was reaffirmed in lieu of the following resolutions via the Reaffirmation
19 Consent Calendar:
20

21 *Resolution 305 – Lack of Support for Maintenance of Certification*

22 *Resolution 306 – Interest Rates and Medical Education*

23 *Resolution 309 – Promoting Addiction Medicine During a Time of Crisis*

24 *Resolution 320 – Opioid Education in Medical Schools*

1 (1) BOARD OF TRUSTEES REPORT 25 – ALL PAYER
2 GRADUATE MEDICAL EDUCATION FUNDING
3

4 RECOMMENDATION:
5

6 Madam Speaker, your Reference Committee recommends
7 that the recommendations in Board of Trustees Report 25
8 be adopted and the remainder of the report be filed.
9

10 Board of Trustees Report 25 recommends: 1. That our AMA amend Policy D-305.967,
11 “The Preservation, Stability and Expansion of Full Funding for Graduate Medical
12 Education,” with the addition of a new clause to read as follows, and that the remainder
13 of the report be filed: Our AMA encourages the Secretary of the U.S. Department of
14 Health and Human Services to coordinate with federal agencies that fund GME training
15 to identify and collect information needed to effectively evaluate how hospitals, health
16 systems, and health centers with residency programs are utilizing these financial
17 resources to meet the nation’s health care workforce needs. This includes information on
18 payment amounts by the type of training programs supported, resident training costs and
19 revenue generation, output or outcomes related to health workforce planning (i.e.,
20 percentage of primary care residents that went on to practice in rural or medically
21 underserved areas), and measures related to resident competency and educational
22 quality offered by GME training programs. 2. That our AMA rescind section 33 of Policy
23 D-305.967, which directed the AMA to conduct the study herein.
24

25 Your Reference Committee heard testimony uniformly in favor of the Board of Trustees
26 report, which seeks to encourage government funders to identify and collect the data
27 needed to evaluate how institutions with residency programs are utilizing government
28 financial resources to meet the nation’s health care workforce needs. This is viewed as
29 critical information to determine the true cost of residency programs and ensure
30 sufficient funding for residency education. Therefore, your Reference Committee
31 recommends that Board of Trustees Report 25 be adopted.
32

33 (2) COUNCIL ON MEDICAL EDUCATION REPORT 1 –
34 COUNCIL ON MEDICAL EDUCATION SUNSET REVIEW
35 OF 2009 HOUSE POLICIES
36

37 RECOMMENDATION:
38

39 Madam Speaker, your Reference Committee recommends
40 that the recommendations in Council on Medical Education
41 Report 1 be adopted and the remainder of the report be
42 filed.
43

44 Council on Medical Education Report 1 recommends that the House of Delegates
45 policies listed in the appendix to this report be acted upon in the manner indicated and
46 the remainder of this report be filed.

1 Your Reference Committee heard limited testimony in favor of the report. Therefore,
2 your Reference Committee recommends that Council on Medical Education Report 1 be
3 adopted.

4
5 (3) COUNCIL ON MEDICAL EDUCATION REPORT 2 –
6 UPDATE ON MAINTENANCE OF CERTIFICATION AND
7 OSTEOPATHIC CONTINUOUS CERTIFICATION
8 (RESOLUTION 316-A-18)

9
10 RECOMMENDATION:

11
12 Madam Speaker, your Reference Committee recommends
13 that the recommendations in Council on Medical Education
14 Report 1 be adopted and the remainder of the report be
15 filed.

16
17 Council on Medical Education Report 2 asks: 1. That our American Medical Association
18 (AMA), through its Council on Medical Education, continue to work with the American
19 Board of Medical Specialties (ABMS), ABMS Committee on Continuing Certification
20 (3C), and ABMS Stakeholder Council to pursue opportunities to implement the
21 recommendations of the Continuing Board Certification: Vision for the Future
22 Commission and AMA policies related to continuing board certification. 2. That our AMA,
23 to be consistent with terminology now used by the American Board of Medical
24 Specialties, amend the following policies by addition and deletion to read as follows:
25 Policy H-275.924, Amend the title to read, "~~Maintenance of Continuing Board~~
26 Continuing Board Certification" (AMA Principles on ~~Maintenance of Continuing Board~~
27 Continuing Board Certification), and replace the terms "Maintenance of Certification" and "MOC" with "Continuing Board
28 Certification" and "CBC" throughout the policy, as shown in Appendix H. Policy D-
29 275.954, Amend the title to read, "~~Maintenance of Certification and Osteopathic~~
30 Continuing Board Certification," and replace the terms
31 "Maintenance of Certification" and "MOC" with "Continuing Board Certification" and
32 "CBC" throughout the policy, as shown in Appendix H. 3. That our AMA rescind Policy D-
33 275.954 (37), "Maintenance of Certification and Osteopathic Continuous Certification,"
34 that asks the AMA to "Through its Council on Medical Education, continue to be actively
35 engaged in following the work of the ABMS Continuing Board Certification: Vision for the
36 Future Commission," as this has been accomplished. 4. That our AMA rescind Policy D-
37 275.954 (38), which asks our AMA to "Submit commentary to the American Board of
38 Medical Specialties (ABMS) Continuing Board Certification: Vision for the Future
39 initiative, asking that junior diplomates be given equal opportunity to serve on ABMS and
40 its member boards," as this has been accomplished. 5. That our AMA rescind Policy D-
41 275.954 (39) "Maintenance of Certification and Osteopathic Continuous Certification," as
42 this has been accomplished through this report.

43
44 Your Reference Committee heard testimony in support of the Council's comprehensive
45 annual report to the HOD. During testimony, it was noted that the Council's efforts in
46 working with the American Board of Medical Specialties (ABMS) and its member boards
47 are improving the process for diplomates in many specialties by, for example, offering
48 shorter, more frequent examinations as well as the high-stakes, point-in-time

1 examination to provide a pluralistic approach for all diplomates. The Council on Medical
2 Education continues to be actively engaged in following the recommendations of
3 “Continuing Board Certification: Vision for the Future Commission,” which was
4 established to modernize continuing board certification and engage physicians, the
5 public, and key stakeholders in a collaborative process. The ABMS and ABMS member
6 boards, in collaboration with professional organizations and other stakeholders, will
7 prioritize these recommendations and develop the strategies and infrastructure to
8 implement them. A summary of the Commission’s recommendations is provided in
9 Council on Medical Education Report 2. Therefore, your Reference Committee
10 recommends that the report be adopted.

11
12 (4) RESOLUTION 321 – PHYSICIAN HEALTH PROGRAM
13 ACCOUNTABILITY, CONSISTENCY, AND EXCELLENCE
14 IN PROVISION OF SERVICE TO THE MEDICAL
15 PROFESSION

16
17 RECOMMENDATION:

18
19 Madam Speaker, your Reference Committee recommends
20 that Resolution 321 be adopted.

21
22 Resolution 321 asks: That our AMA amend policy D-405.990, “Educating Physicians
23 About Physician Health Programs,” by addition and deletion to read as follows:
24 Educating Physicians About Physician Health Programs and Advocating for Standards
25 D-405.990 1) Our AMA will work closely with the Federation of State Physician Health
26 Programs (FSPHP) to educate our members as to the availability and services of state
27 physician health programs to continue to create opportunities to help ensure physicians
28 and medical students are fully knowledgeable about the purpose of physician health
29 programs and the relationship that exists between the physician health program and the
30 licensing authority in their state or territory; 2) Our AMA will continue to collaborate with
31 relevant organizations on activities that address physician health and wellness; 3) Our
32 AMA will, in conjunction with the FSPHP, develop state legislative guidelines addressing
33 the design and implementation of physician health programs; ~~and~~ 4) Our AMA will work
34 with FSPHP to develop messaging for all Federation members to consider regarding
35 elimination of stigmatization of mental illness and illness in general in physicians and
36 physicians in training; and 5) Our AMA will continue to work with and support FSPHP
37 efforts already underway to design and implement the physician health program review
38 process, Performance Enhancement and Effectiveness Review (PEER™), to improve
39 accountability, consistency and excellence among its state member PHPs. The AMA will
40 partner with the FSPHP to help advocate for additional national sponsors for this project;
41 6) Our AMA will continue to work with the FSPHP and other appropriate stakeholders on
42 issues of affordability, cost effectiveness, and diversity of treatment options.

43
44 Your Reference Committee reviewed nearly unanimous online and in-person testimony
45 in support of Resolution 321. Testimony noted that the Physician Health Program (PHP)
46 model encourages physicians to proactively seek and receive the confidential health
47 care services they need. The Federation of State Physician Health Programs, with the
48 support of key stakeholder organizations, is developing a Performance Enhancement

1 and Effectiveness Review (PEER™) Program and a Provider Accreditation Program.
2 The PEER program will create and manage an on-site review process of PHPs across
3 the United States and Canada, validate current PHP practices, and identify areas that
4 will benefit from improvements. During testimony it was noted that Resolution 321 is
5 aligned with the AMA's Professional Satisfaction and Practice Sustainability strategic
6 arc, and that the AMA is well positioned to prioritize advocacy efforts that have potential
7 impact on the physician workforce and access to care. Therefore, your Reference
8 Committee recommends that Resolution 321 be adopted.

9
10 (5) RESOLUTION 323 – IMPROVING ACCESS TO CARE IN
11 MEDICALLY UNDERSERVED AREAS THROUGH
12 PROJECT ECHO AND THE CHILD PSYCHIATRY
13 ACCESS PROJECT MODEL

14
15 RECOMMENDATION:

16
17 Madam Speaker, your Reference Committee recommends
18 that Resolution 323 be adopted.

19
20 Resolution 323 asks: 1. That our AMA promote greater awareness and implementation
21 of the Project ECHO (Extension for Community Healthcare Outcomes) and Child
22 Psychiatry Access Project models among academic health centers and community-
23 based primary care physicians; 2. That our AMA work with stakeholders to identify and
24 mitigate barriers to broader implementation of these models in the United States; and 3.
25 That our AMA monitor whether health care payers offer additional payment or incentive
26 payments for physicians who engage in clinical practice improvement activities as a
27 result of their participation in programs such as Project ECHO and the Child Psychiatry
28 Access Project; and if confirmed, promote awareness of these benefits among
29 physicians.

30
31 Your Reference Committee heard testimony uniformly in support of this resolution.
32 Programs such as Project ECHO and the Child Psychiatry Access Project, which
33 promote collaboration between academic health centers and community-based primary
34 care physicians, have made significant impacts. Awareness of such programs should be
35 promoted, and barriers to their broader implementation should be identified and
36 addressed. In addition, payment for participation in these activities should be monitored.
37 Therefore, your Reference Committee recommends that Resolution 323 be adopted.

38
39 (6) RESOLUTION 324 – RESIDENCY AND FELLOWSHIP
40 PROGRAM DIRECTOR, ASSISTANT/ASSOCIATE
41 PROGRAM DIRECTOR, AND CORE FACULTY
42 PROTECTED TIME AND SALARY REIMBURSEMENT

43
44 RECOMMENDATION:

45
46 Madam Speaker, your Reference Committee recommends
47 that Resolution 324 be adopted.

1 Resolution 324 asks: That our American Medical Association work with the Accreditation
2 Council for Graduate Medical Education (ACGME) and other relevant stakeholders to
3 amend the ACGME Common Program Requirements to allow flexibility in the specialty-
4 specific ACGME program requirements enabling specialties to require salary
5 reimbursement or “protected time” for resident and fellow education by “core faculty,”
6 program directors, and assistant/associate program directors. (Directive to Action)

7
8 Your Reference Committee heard strong support for Resolution 324. Testimony noted
9 that this concept is important and that institutions should support faculty for their time
10 spent teaching. It was also noted that other organizations, such as the American College
11 of Physicians, have similar policy. Therefore, your Reference Committee recommends
12 that Resolution 324 be adopted.

13
14 (7) COUNCIL ON MEDICAL EDUCATION REPORT 3 –
15 STANDARDIZING THE RESIDENCY MATCH SYSTEM
16 AND TIMELINE (CME REPORT 6-A-17)

17
18 RECOMMENDATION A:

19
20 Madam Speaker, your Reference Committee recommends
21 that Recommendation 4 in Council on Medical Education
22 Report 3 be amended by addition, to read as follows:

23
24 4. That our AMA encourage the NRMP, the San Francisco
25 Match, the American Urological Association, the Electronic
26 Residency Application Service, and other stakeholders to
27 reduce barriers for medical students, residents, and
28 physicians applying to match into training programs,
29 including barriers to “couples matching,” and to ensure that
30 all applicants have access to robust, informative statistics
31 to assist in decision-making. (Directive to Take Action)

32
33 RECOMMENDATION B:

34
35 Madam Speaker, your Reference Committee recommends
36 that Council on Medical Education Report 3 be amended
37 by the addition of a fifth Recommendation, to read as
38 follows:

39
40 5. That our AMA encourage the NRMP, San Francisco
41 Match, American Urological Association, Electronic
42 Residency Application Service, and other stakeholders to
43 collect and publish data on a) the impact of separate
44 matches on the personal and professional lives of medical
45 students and b) the impact on medical students who are
46 unable to successfully “couples match” with their significant
47 others due to staggered entry into residency, utilization of

1 unlinked match services, or other causes. (Directive to
2 Take Action)

3
4 RECOMMENDATION C:

5
6 Madam Speaker, your Reference Committee recommends
7 that the recommendations in Council on Medical Education
8 Report 3 be adopted as amended and the remainder of the
9 report be filed.

10
11 Council on Medical Education Report 3 asks: 1. That our AMA encourage appropriate
12 stakeholders to explore options to decrease the burden upon medical students who must
13 apply to separate preliminary PGY-1 and categorical PGY-2 positions; 2. That our AMA
14 work with the Accreditation Council for Graduate Medical Education to encourage
15 programs with PGY-2 positions in the National Resident Matching Program (NRMP) to
16 create local PGY-1 positions that will enable coordinated applications and interviews for
17 medical students; 3. That our AMA encourage the NRMP to design a process that will
18 allow competency-based student graduation and off-cycle entry into residency programs;
19 and 4. That our AMA encourage the NRMP, the San Francisco Match, the American
20 Urological Association, the Electronic Residency Application Service, and other
21 stakeholders to reduce barriers for medical students, residents, and physicians applying
22 to match into training programs, and to ensure that all applicants have access to robust,
23 informative statistics to assist in decision-making.

24
25 Your Reference Committee heard testimony applauding the work of the Council on
26 Medical Education concerning this challenging topic, to help ensure a residency
27 matching process that is student-centered and eases the burdens and stresses of this
28 critical career transition. Particular attention, however, was directed towards the issue of
29 “couples matching,” and the need for continued data collection and analysis on this and
30 related concerns, including the impact of separate matches on medical students lives
31 and livelihoods. Accordingly, your Reference Committee proffers the amended language
32 shown above, and recommends that Council on Medical Education Report 3 be adopted
33 as amended.

34
35 (8) COUNCIL ON MEDICAL EDUCATION REPORT 4 –
36 AUGMENTED INTELLIGENCE IN MEDICAL EDUCATION
37 (RESOLUTION 317-A-18)

38
39 RECOMMENDATION A:

40
41 Madam Speaker, your Reference Committee recommends
42 that Council on Medical Education Report 4 be amended
43 by the addition of a new sixth Recommendation, to read as
44 follows:

45
46 6. That our AMA encourage the study of how differences in
47 institutional access to AI may impact disparities in

1 education for students at schools with fewer resources and
2 less access to AI technologies. (Directive to Take Action)

3
4 RECOMMENDATION B:

5
6 Madam Speaker, your Reference Committee recommends
7 that Council on Medical Education Report 4 be amended
8 by the addition of a new eighth Recommendation, to read
9 as follows:

10
11 8. That our AMA encourage the study of how disparities in
12 AI educational resources may impact health care
13 disparities for patients in communities with fewer resources
14 and less access to AI technologies. (Directive to Take
15 Action)

16
17 RECOMMENDATION C:

18
19 Madam Speaker, your Reference Committee recommends
20 that Council on Medical Education Report 4 be amended
21 by the addition of a new eleventh Recommendation, to
22 read as follows:

23
24 11. That our AMA encourage close collaboration with and
25 oversight by practicing physicians in the development of AI
26 applications. (Directive to Take Action)

27
28 RECOMMENDATION D:

29
30 Madam Speaker, your Reference Committee recommends
31 that the recommendations in Council on Medical Education
32 Report 4 (with existing items 6, 7, and 8 of the Report
33 renumbered as 7, 9, and 10) be adopted as amended and
34 the remainder of the report be filed.

35
36 Council on Medical Education Report 4 asks: 1. That our AMA accrediting
37 and licensing bodies to study how AI should be most appropriately addressed in
38 accrediting and licensing standards; 2. That our AMA encourage medical specialty
39 societies and boards to consider production of specialty-specific educational modules
40 related to AI; 3. That our AMA encourage research regarding the effectiveness of AI
41 instruction in medical education on learning and clinical outcomes; 4. That our AMA
42 encourage institutions and programs to be deliberative in the determination of when AI-
43 assisted technologies should be taught, including consideration of established evidence-
44 based treatments, and including consideration regarding what other curricula may need
45 to be eliminated in order to accommodate new training modules; 5. That our AMA
46 encourage stakeholders to provide educational materials to help learners guard against
47 inadvertent dissemination of bias that may be inherent in AI systems; 6. That our AMA
48 encourage enhanced training across the continuum of medical education regarding

1 assessment, understanding, and application of data in the care of patients; 7. That our
2 AMA encourage institutional leaders and academic deans to proactively accelerate the
3 inclusion of nonclinicians, such as data scientists and engineers, onto their faculty
4 rosters in order to assist learners in their understanding and use of AI; and 8. That Policy
5 D-295.328, “Promoting Physician Lifelong Learning,” be reaffirmed.

6
7 Your Reference Committee reviewed testimony uniformly in favor of Council on Medical
8 Education Report 4. This report summarizes existing AMA policy related to AI, provides
9 definitions of related terms, reviews current efforts related to AI in medical education,
10 and provides additional policy to be incorporated by the AMA. While testimony was
11 supportive of the report itself, testimony also called for additional policy related to AI and
12 disparities as well as AI and clinician oversight of its development and implementation.
13 Your Reference Committee agreed, and this testimony was incorporated into three
14 additional recommendations. Therefore, your Reference Committee recommends that
15 Council on Medical Education Report 4 be adopted as amended.

16
17 (9) COUNCIL ON MEDICAL EDUCATION REPORT 6 –
18 STUDY OF MEDICAL STUDENT, RESIDENT, AND
19 PHYSICIAN SUICIDE (RESOLUTION 959-I-18)

20
21 RESOLUTION 307 – MENTAL HEALTH SERVICES FOR
22 MEDICAL STUDENTS

23
24 RESOLUTION 310 – MENTAL HEALTH CARE FOR
25 MEDICAL STUDENTS

26
27 RECOMMENDATION A:

28
29 Madam Speaker, your Reference Committee recommends
30 that Recommendation 1 in Council on Medical Education
31 Report 6 be amended by addition, to read as follows:

- 32
33 1. That our American Medical Association (AMA) explore
34 the viability and cost-effectiveness of regularly
35 collecting National Death Index (NDI) data and
36 confidentially maintaining manner of death information
37 for physicians, residents, and medical students listed
38 as deceased in the AMA Physician Masterfile for long-
39 term studies. (Directive to Take Action)

40
41 RECOMMENDATION B:

42
43 Madam Speaker, your Reference Committee recommends
44 that Recommendation 3 in Council on Medical Education
45 Report 6 be amended by addition and deletion, to read as
46 follows:

- 1 3. That our AMA supports the education of faculty
2 members, residents and medical students in the
3 recognition of the signs and symptoms of burnout and
4 depression and supports access to free, confidential,
5 and immediately available stigma-free ~~behavioral~~
6 mental health and substance use disorder services.
7 (Directive to Take Action)

8

9

RECOMMENDATION C:

10

11

Madam Speaker, your Reference Committee recommends
12 that Recommendation 4 in Council on Medical Education
13 Report 6 be amended by addition, to read as follows:

14

15

4. That our AMA collaborate with other stakeholders to
16 study the incidence of and risk factors for depression
17 and suicide among physicians, residents, and medical
18 students. (Directive to Take Action)

19

20

RECOMMENDATION D:

21

22

Madam Speaker, your Reference Committee recommends
23 that the recommendations in Council on Medical Education
24 Report 6 be adopted as amended in lieu of Resolutions
25 307 and 310 and the remainder of the report be filed.

26

27

Council on Medical Education Report 6 asks: 1. That our AMA explore the viability and
28 cost-effectiveness of regularly collecting National Death Index (NDI) data and
29 maintaining manner of death information for physicians, residents, and medical students
30 listed as deceased in the AMA Physician Masterfile for long-term studies; 2. That our
31 AMA monitor progress by the Association of American Medical Colleges and the
32 Accreditation Council for Graduate Medical Education (ACGME) to collect data on
33 medical student and resident/fellow suicides to identify patterns that could predict such
34 events; 3. That our AMA supports the education of faculty members, residents and
35 medical students in the recognition of the signs and symptoms of burnout and
36 depression and supports access to free, confidential, and immediately available stigma-
37 free behavioral health services; 4. That our AMA collaborate with other stakeholders to
38 study the incidence of suicide among physicians, residents, and medical students; and
39 5. That Policy D-345.984, "Study of Medical Student, Resident, and Physician Suicide,"
40 be rescinded, as having been fulfilled by this report and through requests for action by
41 the Liaison Committee on Medical Education and ACGME.

42

43

Resolution 307 asks: That our AMA recommend that the Association of American
44 Medical Colleges strengthen their recommendations to all medical schools that medical
45 schools provide confidential in-house mental health services at no cost to students,
46 without billing health insurance, and that they set up programs to educate both students
47 and staff about burnout, depression, and suicide.

1 Resolution 310 asks: 1. That our AMA encourage all medical schools to assign a mental
2 health provider to every incoming medical student; 2. That our AMA encourage all
3 medical schools to provide an easy way for medical students to select a different
4 provider at any time; 3. That our AMA encourage all medical schools to require each
5 student's mental health professional or related staff to contact the student once per
6 semester to ask if the student would like to meet with their mental health professional,
7 unless the student already has an appointment to do so or has asked not to be
8 contacted with regards to mental health appointments; and 4. That our AMA encourage
9 all medical schools to provide an easy process for students to initiate treatment with
10 school mental health professionals at no cost to the student or professional from the
11 mental health community at affordable cost to the student, and without undue
12 bureaucratic burden.

13
14 Your Reference Committee reviewed unanimous online and in-person testimony in
15 support of Council on Medical Education Report 6. Testimony noted that this report
16 recognizes the serious matter of medical student, resident, and physician burnout,
17 depression, and suicide, and notes increased rates compared to age and education
18 matched peers in the general population. There was also support for the AMA's plans to
19 conduct a pilot study to evaluate the reliability of the National Death Index as a tool for
20 long-term study of medical student and physician suicide. In addition, it was noted that
21 continued partnerships with organizations such as the ACGME and AAMC to support
22 provider mental health benefits medical students, residents, physicians, and patients.
23 There was also strong support for Resolution 307. However, it was felt that
24 Recommendation 3 in CME Report 6 was very similar and consistent with the intent of
25 Resolution 307. Testimony was also supportive of the intent of Resolution 310. However,
26 the recommendations appeared to be prescriptive and created a potentially intrusive
27 situation in the medical student's life unless the student asks not to be contacted.
28 Furthermore, testimony noted that the recommendations in Resolution 310 were already
29 covered in CME Report 6. Therefore, your Reference Committee recommends that
30 Council on Medical Education Report 6 be adopted in lieu of Resolutions 307 and 310.

31
32 (10) COUNCIL ON MEDICAL EDUCATION / COUNCIL ON
33 SCIENCE AND PUBLIC HEALTH REPORT 1 –
34 PROTECTING MEDICAL TRAINEES FROM
35 HAZARDOUS EXPOSURE (RESOLUTION 301-A-18)

36
37 RECOMMENDATION A:

38
39 Madam Speaker, your Reference Committee recommends
40 that Recommendation 3 of Council on Medical Education /
41 Council on Science and Public Health Report 1 be
42 amended by addition, to read as follows:

43
44 3. That our AMA recommend a) that medical school
45 policies on hazardous exposure include options to limit
46 hazardous agent exposure in a manner that does not
47 impact students' ability to successfully complete their
48 training, and b) that medical school policies on continuity of

1 educational requirements toward degree completion
2 address leaves of absence or temporary reassignments
3 when a pregnant trainee wishes to minimize the risks of
4 hazardous exposures that may affect her the trainee's
5 and/or fetus' personal health status.

6
7 RECOMMENDATION B:

8
9 Madam Speaker, your Reference Committee recommends
10 that the recommendations in Council on Medical
11 Education/Council on Science and Public Health Report 1
12 be adopted as amended and the remainder of the report
13 be filed.

14
15 Council on Medical Education/Council on Science and Public Health Report 1 asks:

16 1. That our American Medical Association (AMA) amend Policy H-295.939, "OSHA
17 Regulations for Students," by addition and deletion, to read as follows: H-295.939,
18 "OSHA Regulations for Students Protecting Medical Trainees from Hazardous
19 Exposure" Our AMA will ~~The AMA, working in conjunction with its Medical School~~
20 ~~Section, to~~ encourages all health care-related educational institutions to apply the
21 existing Occupational Safety and Health Administration (OSHA) Blood Borne Pathogen
22 Standards and OSHA hazardous exposure regulations, including communication
23 requirements, equally to employees, students, and residents/fellows ~~students~~. 2. That our
24 AMA recommend that the Accreditation Council for Graduate Medical Education revise
25 the common program requirements to require education and subsequent demonstration
26 of competence regarding potential exposure to hazardous agents relevant to specific
27 specialties, including but not limited to: appropriate handling of hazardous agents,
28 potential risks of exposure to hazardous agents, situational avoidance of hazardous
29 agents, and appropriate responses when exposure to hazardous material may have
30 occurred in the workplace/training site. 3. That our AMA recommend a) that medical
31 school policies on hazardous exposure include options to limit hazardous agent
32 exposure in a manner that does not impact students' ability to successfully complete
33 their training, and b) that medical school policies on continuity of educational
34 requirements toward degree completion address leaves of absence or temporary
35 reassignments when a pregnant trainee wishes to minimize the risks of hazardous
36 exposures that may affect her personal health status. 4. That our AMA recommend that
37 medical schools and health care settings with medical learners be vigilant in updating
38 educational material and protective measures regarding hazardous agent exposure of its
39 learners and make this information readily available to students, faculty, and staff. 5.
40 That our AMA recommend that medical schools and other sponsors of health
41 professions education programs ensure that their students and trainees meet the same
42 requirements for education regarding hazardous materials and potential exposures as
43 faculty and staff.

44
45 Your Reference Committee reviewed testimony online and in-person in overwhelming
46 support of the report. Therefore, your Reference Committee recommends that Council
47 on Medical Education/Council on Science and Public Health Report 1 be amended and
48 adopted with the addition as shown.

1 (11) RESOLUTION 302 – THE CLIMATE CHANGE LECTURE
2 FOR US MEDICAL SCHOOLS
3

4 RECOMMENDATION:
5

6 Madam Speaker, your Reference Committee recommends
7 that the following alternate resolution be adopted in lieu of
8 Resolution 302.
9

10 CLIMATE CHANGE EDUCATION ACROSS THE
11 MEDICAL EDUCATION CONTINUUM
12

13 RESOLVED, That our American Medical Association
14 (AMA) support teaching on climate change in
15 undergraduate, graduate, and continuing medical
16 education such that trainees and practicing physicians
17 acquire a basic knowledge of the science of climate
18 change, can describe the risks that climate change poses
19 to human health, and counsel patients on how to protect
20 themselves from the health risks posed by climate change
21 (Directive to Take Action); and be it further
22

23 RESOLVED, That our AMA make available a prototype
24 presentation and lecture notes on the intersection of
25 climate change and health for use in undergraduate,
26 graduate, and continuing medical education. (Directive to
27 Take Action); and be it further
28

29 RESOLVED, That our AMA communicate this policy to the
30 appropriate accrediting organizations such as the
31 Commission on Osteopathic College Accreditation and the
32 Liaison Committee on Medical Education (Directive to
33 Take Action).
34

35 Resolution 302 asks: 1. That our AMA recommend that one hour of teaching on climate
36 change, “The Climate Change Lecture,” be required for all medical students before
37 graduation with the M.D. or D.O. degree as a minimum standard, with more than one
38 hour of teaching encouraged for medical schools that so choose; 2. That our AMA
39 recommend that the goals of “The Climate Change Lecture” be for medical students
40 upon graduation to have a basic knowledge of the science of climate change, to be able
41 to describe the risks that climate change poses to human health, and be prepared to
42 advise patients how to protect themselves from the health risks posed by climate
43 change; 3. That our AMA recommend that medical schools be exempted from the
44 requirement of “The Climate Change Lecture” that have already implemented pedagogy
45 on this topic that amounts to an hour or more of required learning on climate change and
46 health for medical students; 4. That our AMA prepare a prototype PowerPoint slide
47 presentation and lecture notes for “The Climate Change Lecture,” which could be used
48 by medical schools, or schools may create their own lecture, video or online course to

1 fulfill the requirements of “The Climate Change Lecture”; 5. That our AMA write to the
2 Commission on Osteopathic College Accreditation (COCA) which is the accrediting
3 organization for schools offering the D.O. degree in the United States; to the Liaison
4 Committee on Medical Education (LCME), which is the accrediting organization for
5 schools offering the M.D. degree in the United States (including for the Uniformed
6 Services University of the Health Sciences); and to the LCME representative from the
7 AMA Medical Student Section, to recommend that “The Climate Change Lecture,” using
8 AMA’s prototype PowerPoint presentation and notes, or other formats, become a
9 requirement for all M.D. and D.O. degrees for United States medical schools beginning
10 with 2021 graduates; and 6. That our AMA delegation to the World Medical Association
11 present a similar resolution to the World Medical Association recommending the concept
12 of the “The Climate Change Lecture” for medical schools worldwide.
13

14 Your Reference Committee heard significant testimony on this resolution. There was
15 support for education on a topic as timely and important as climate change and its
16 impacts on human health, but, as the AMA does not favor curricular mandates (because
17 they are too prescriptive to allow for the autonomy of individual medical schools to
18 innovate on such topics), the resolution was rewritten by the original authors. Testimony
19 on this updated version was generally in support of its revisions, with a request to
20 encompass the continuum of medical education. Your Reference Committee agrees and
21 has incorporated graduate and continuing medical education into the rewritten resolution
22 and changed the title to reflect its expanded scope. Therefore, your Reference
23 Committee recommends that the alternate resolution be adopted in lieu of Resolution
24 302.
25

26 (12) RESOLUTION 303 – GRADUATE MEDICAL EDUCATION
27 AND THE CORPORATE PRACTICE OF MEDICINE
28

29 RECOMMENDATION A:
30

31 Madam Speaker, your Reference Committee recommends
32 that the first Resolve of Resolution 303 be amended by
33 addition and deletion, to read as follows:
34

35 RESOLVED, That our American Medical Association
36 recognize and support that the environment for education
37 of residents and fellows must be free of the conflict of
38 interest created between ~~corporate-owned lay entities'~~ a
39 training site's fiduciary responsibility to shareholders and
40 the educational mission of residency or fellowship training
41 programs (New HOD Policy); and be it further
42

43 RECOMMENDATION B:
44

45 Madam Speaker, your Reference Committee recommends
46 that second Resolve of Resolution 303 be amended by
47 addition and deletion, to read as follows:

1 RESOLVED, That our AMA ~~support~~ encourage that the
2 Accreditation Council for Graduate Medical Education
3 (ACGME) to update its "Principles to Guide the
4 Relationship between Graduate Medical Education,
5 Industry, and Other Funding Sources for Programs and
6 Sponsoring Institutions Accredited by the ACGME" to
7 include corporate-owned lay entity funding sources, ~~require~~
8 ~~that graduate medical education programs must be~~
9 ~~established in compliance with all state laws, including~~
10 ~~prohibitions on the corporate practice of medicine, as a~~
11 ~~condition of accreditation.~~ (New HOD Policy)

12
13 RECOMMENDATION C:

14
15 Madam Speaker, your Reference Committee recommends
16 that Resolution 303 be amended by addition of a new third
17 Resolve, to read as follows:

18
19 RESOLVED, That our AMA study issues, including waiver
20 of due process requirements, created by corporate-owned
21 lay entity control of graduate medical education sites.
22 (Directive to Take Action)

23
24 RECOMMENDATION D:

25
26 Madam Speaker, your Reference Committee recommends
27 that Resolution 303 be adopted as amended.

28
29 Resolution 303 asks: 1. That our AMA recognize and support that the environment for
30 education of residents and fellows must be free of the conflict of interest created
31 between corporate-owned lay entities' fiduciary responsibility to shareholders and the
32 educational mission of residency or fellowship training programs; and 2. That our AMA
33 support that the Accreditation Council for Graduate Medical Education require that
34 graduate medical education programs must be established in compliance with all state
35 laws, including prohibitions on the corporate practice of medicine, as a condition of
36 accreditation.

37
38 Your Reference Committee heard testimony in favor of this item, particularly in light of
39 the need for expanded graduate medical education slots to help meet the growing
40 workforce demands of the nation. As a country of innovation and new ideas, the United
41 States is a natural laboratory for the development of corporate-funded sponsorships in
42 medical education. That said, the unintended consequences of a potentially pernicious
43 influence in medical education and interference in training by corporate interests
44 highlight the need for hypervigilance by the house of medicine. Ensuring high standards
45 in education for our next generation of physicians was indeed one of the founding
46 principles of the AMA in 1847. Towards this end, testimony was shared that this
47 resolution was not worded strongly enough: For example, corporations that administer
48 residency programs may require trainees to waive their contractual rights to due

1 process, which could lead to unfair termination. This issue requires continued attention
2 and study. Accordingly, your Reference Committee proposes the language shown in the
3 new third Resolve. In addition, we agree (as did the majority of testimony) with edits to
4 the original item as proposed by the Council on Medical Education, to include all training
5 sites where there is a fiduciary responsibility to shareholders. In addition, as the Council
6 noted, the ACGME has an existing position statement on the relationship between GME
7 and various funding sources, so your Reference Committee recommended this language
8 be updated to include these newer programs with shareholder interests, and that
9 Resolution 303 be adopted as amended.

10
11 (13) RESOLUTION 304 – TRACKING OUTCOMES AND
12 SUPPORTING BEST PRACTICES OF HEALTH CARE
13 CAREER PIPELINE PROGRAMS

14
15 RECOMMENDATION A:

16
17 Madam Speaker, your Reference Committee recommends
18 that the first Resolve of Resolution 304 be amended by
19 addition, to read as follows:

20
21 1. That our AMA support the publication of a white paper
22 chronicling health care career pipeline programs (also
23 known as pathway programs) across the nation aimed at
24 increasing the number of programs and promoting
25 leadership development of underrepresented minority
26 health care professionals in medicine and the biomedical
27 sciences, with a focus on assisting such programs by
28 identifying best practices and tracking participant
29 outcomes;

30
31 RECOMMENDATION B:

32
33 Madam Speaker, your Reference Committee recommends
34 that Resolution 304 be adopted as amended.

35
36 Resolution 304 asks: 1. That our AMA support the publication of a white paper
37 chronicling health care career pipeline programs across the nation aimed at increasing
38 the number programs and promoting leadership development of underrepresented
39 minority health care professionals in medicine and the biomedical sciences, with a focus
40 on assisting such programs by identifying best practices and tracking participant
41 outcomes; and 2. That our AMA work with various stakeholders, including medical and
42 allied health professional societies, established biomedical science pipeline programs
43 and other appropriate entities, to establish best practices for the sustainability and
44 success of health care career pipeline programs.

45
46 Your Reference Committee reviewed online and in-person testimony in overwhelming
47 support of this resolution. Testimony addressed the contribution that pipeline programs
48 (also known as pathway programs) have made towards increasing diversity among

1 underrepresented groups in medicine such as women and racial and ethnic minorities.
2 Therefore, your Reference Committee recommends that Resolution 304 be adopted as
3 amended.

4
5 (14) RESOLUTION 313 – CLINICAL APPLICATIONS OF
6 PATHOLOGY AND LABORATORY MEDICINE FOR
7 MEDICAL STUDENTS, RESIDENTS AND FELLOWS

8
9 RECOMMENDATION A:

10
11 Madam Speaker, your Reference Committee recommends
12 that Resolution 313 be amended by addition and deletion,
13 to read as follows:

14
15 RESOLVED, That our American Medical Association study
16 current standards practices within medical education
17 regarding the clinical use of pathology and laboratory
18 medicine information to identify potential gaps in training in
19 the principles of decision making and the utilization of
20 quantitative evidence. (Directive to Take Action)

21
22 RECOMMENDATION B:

23
24 Madam Speaker, your Reference Committee recommends
25 that Resolution 313 be adopted as amended.

26
27 Resolution 313 asks: That our AMA study current standards within medical education
28 regarding pathology and laboratory medicine to identify potential gaps in training.

29
30 Your Reference Committee heard mixed testimony on this item, ranging from adoption to
31 not adoption. The Council on Medical Education, for example, testified that this issue is
32 undeniably important but is within the purview of the Liaison Committee on Medical
33 Education and Accreditation Council for Graduate Medical Education, rather than the
34 AMA. Other testimony noted that inappropriate use and interpretation of laboratory and
35 other diagnostic tests can lead to shortfalls in patient safety, harm to patients, and
36 malpractice claims. The need for students and trainees to learn effective stewardship of
37 health care resources was cited as well. This issue goes beyond those in the pathology
38 field to encompass all physicians; indeed, as noted in testimony, approximately three of
39 every four medical decisions derive from lab tests, and the dramatic increase in the
40 number of tests underscore the need for at least minimal training in the medical
41 education continuum and a better understanding of evidence-based medicine across the
42 continuum. Your Reference Committee believes its proposed edits address these
43 concerns and clarify some prior confusion on the resolution's intent, and therefore
44 recommends adoption as amended.

1 (15) RESOLUTION 314 – EVALUATION OF CHANGES TO
2 RESIDENCY AND FELLOWSHIP APPLICATION AND
3 MATCHING PROCESSES
4

5 RECOMMENDATION A:
6

7 Madam Speaker, your Reference Committee recommends
8 that first Resolve of Resolution 314 be amended by
9 addition and deletion, to read as follows:
10

11 RESOLVED, That our American Medical Association
12 ~~support~~ oppose ~~proposed~~ changes to residency and
13 fellowship application requirements ~~only when~~ unless (a)
14 those changes have been evaluated by working groups
15 which have students and residents as representatives; (b)
16 there are data which demonstrates that the proposed
17 application components contribute to an accurate
18 representation of the candidate; (c) there are data
19 available to demonstrate that the new application
20 requirements reduce, or at least do not increase, the
21 impact of ~~implicit~~ bias that affects medical students and
22 residents from underrepresented minority backgrounds;
23 and (d) the costs to medical students and residents are
24 mitigated (New HOD Policy): and be it further
25

26 RECOMMENDATION B:
27

28 Madam Speaker, your Reference Committee recommends
29 that Resolution 314 be amended by deletion of the second
30 Resolve, to read as follows:
31

32 ~~RESOLVED, That our AMA oppose the introduction of new~~
33 ~~and mandatory requirements that fundamentally alter the~~
34 ~~residency and fellowship application process until such~~
35 ~~time as the above conditions are met (New HOD Policy);~~
36 ~~and be it further~~
37

38 RECOMMENDATION C:
39

40 Madam Speaker, your Reference Committee recommends
41 that Resolution 314 be adopted as amended.
42

43 Resolution 314 asks: 1. That our AMA support proposed changes to residency and
44 fellowship application requirements only when (a) those changes have been evaluated
45 by working groups which have students and residents as representatives; (b) there are
46 data which demonstrates that the proposed application components contribute to an
47 accurate representation of the candidate; (c) there are data available to demonstrate that
48 the new application requirements reduce, or at least do not increase, the impact of

1 implicit bias that affects medical students and residents from underrepresented minority
2 backgrounds; and (d) the costs to medical students and residents are mitigated; 2. That
3 our AMA oppose the introduction of new and mandatory requirements that
4 fundamentally alter the residency and fellowship application process until such time as
5 the above conditions are met; and 3. That our AMA continue to work with specialty
6 societies, the Association of American Medical Colleges, the National Resident Matching
7 Program and other relevant stakeholders to improve the application process in an effort
8 to accomplish these requirements.
9

10 Your Reference Committee heard testimony that the test implementation of the
11 standardized video interview (SVI) in emergency medicine residency program
12 applications has raised issues of its validity and lack of fairness to applicants, for
13 example, from underrepresented minority populations or those who speak English as a
14 second language. Medical students should not be subject to additional bias in an already
15 stressful application process. Edits to the first Resolve was proffered, to incorporate the
16 spirit of the second Resolve and remove the word “implicit,” thereby expanding the
17 scope of any bias to be addressed through the proposed policy. Finally, your Reference
18 Committee believes that the second Resolve should be deleted and recommends that
19 Resolution 314 be adopted as amended.
20

21 (16) RESOLUTION 315 – SCHOLARLY ACTIVITY BY
22 RESIDENT AND FELLOW PHYSICIANS
23

24 RECOMMENDATION A:
25

26 Madam Speaker, your Reference Committee recommends
27 that Resolution 315 be amended by addition and deletion
28 of the first Resolve, to read as follows:
29

30 RESOLVED, That our American Medical Association a)
31 define resident and fellow scholarly activity as any
32 rigorous, skill-building experience approved by their
33 program director that involves the discovery, integration,
34 application, or teaching of knowledge, including but not
35 limited to peer-reviewed publications, ~~national~~ leadership
36 positions within health policy organizations, local quality
37 improvement projects, curriculum development, or any
38 activity which would satisfy faculty requirements for
39 scholarly activity, and b) encourage partner organizations
40 to utilize the inclusion of this definition to ensure that
41 residents and fellows are able to fulfill scholarly activity
42 requirements. (New HOD Policy); ~~and be it further~~
43

44 RECOMMENDATION B:
45

46 Madam Speaker, your Reference Committee recommends
47 that second Resolve of Resolution 315 be amended by
48 deletion, to read as follows:

1
2 ~~RESOLVED, That our AMA work with partner~~
3 ~~organizations to ensure that residents and fellows are able~~
4 ~~to fulfill scholarly activity requirements with any rigorous,~~
5 ~~skill-building experience approved by their program~~
6 ~~director that involves the discovery, integration, application,~~
7 ~~or teaching of knowledge, including but not limited to peer-~~
8 ~~reviewed publications, national leadership positions within~~
9 ~~health policy organizations, local quality improvement~~
10 ~~projects, curriculum development, or any activity which~~
11 ~~would satisfy faculty requirements for scholarly activity.~~
12 ~~(Directive to Take Action)~~

13
14 RECOMMENDATION C:

15
16 Madam Speaker, your Reference Committee recommends
17 that Resolution 315 be adopted as amended.

18
19 Resolution 315 asks: 1. That our AMA define resident and fellow scholarly activity as any
20 rigorous, skill-building experience approved by their program director that involves the
21 discovery, integration, application, or teaching of knowledge, including but not limited to
22 peer-reviewed publications, national leadership positions within health policy
23 organizations, local quality improvement projects, curriculum development, or any
24 activity which would satisfy faculty requirements for scholarly activity; and 2. That our
25 AMA work with partner organizations to ensure that residents and fellows are able to
26 fulfill scholarly activity requirements with any rigorous, skill-building experience approved
27 by their program director that involves the discovery, integration, application, or teaching
28 of knowledge, including but not limited to peer-reviewed publications, national leadership
29 positions within health policy organizations, local quality improvement projects,
30 curriculum development, or any activity which would satisfy faculty requirements for
31 scholarly activity.

32
33 Your Reference Committee reviewed testimony online and in-person that was mixed but
34 overwhelmingly supportive of this resolution. Testimony supported developing a broader
35 definition of scholarly activity to allow for expansion of the scope of learning, while
36 acknowledging the range of academic rigor involved in health policy analysis. It was also
37 suggested to examine the intersection of scholarly activity and changes and
38 improvement in medical education, as evidenced by the work of Accelerating Change in
39 Medical Education consortium. The Reference Committee noted that Resolves one and
40 two reiterated the same language; to make the item easier to comprehend, we have
41 merged both Resolves into one to capture the essence and intent of this item. Therefore,
42 your Reference Committee recommends that Resolution 315 be adopted as amended.

1 (17) RESOLUTION 316 – MEDICAL STUDENT DEBT

2
3 RECOMMENDATION A:

4
5 Madam Speaker, your Reference Committee recommends
6 that Resolution 316 be amended by addition and deletion,
7 to read as follows:

8
9 RESOLVED, That our American Medical Association
10 formulate a task force to look at undergraduate medical
11 education training as it relates to specialty career choice,
12 and develop new polices and novel approaches to prevent
13 debt from influencing primary—care specialty and
14 subspecialty choice. (Directive to Take Action)

15
16 RECOMMENDATION B:

17
18 Madam Speaker, your Reference Committee recommends
19 that Resolution 316 be adopted as amended.

20
21 Resolution 316 asks: That our AMA formulate a task force to look at undergraduate
22 medical education training as it relates to specialty choice, and develop new polices and
23 novel approaches to prevent debt from influencing primary care specialty choice.

24
25 Your Reference Committee heard significant testimony that was generally supportive of
26 this resolution. Education debt continues to be a significant burden on medical students,
27 residents, and physicians and influences all aspects of life. In response to testimony
28 about how education debt impacts all fields, not just primary care, the resolution was
29 amended. Therefore, your Reference Committee recommends that Resolution 316 be
30 adopted as amended.

31
32 (18) RESOLUTION 317 – A STUDY TO EVALUATE
33 BARRIERS TO MEDICAL EDUCATION FOR TRAINEES
34 WITH DISABILITIES

35
36 RECOMMENDATION A:

37
38 Madam Speaker, your Reference Committee recommends
39 that Resolution 317 be amended by addition of a new
40 second Resolve, to read as follows:

41
42 RESOLVED, That our AMA work with relevant
43 stakeholders to study available data on medical graduates
44 with disabilities and challenges to employment after
45 training. (Directive to Take Action)

1 RECOMMENDATION B:

2
3 Madam Speaker, your Reference Committee recommends
4 that Resolution 317 be adopted as amended.

5
6 Resolution 317 asks: That our AMA work with relevant stakeholders to study available
7 data on medical trainees with disabilities and consider revision of technical standards for
8 medical education programs.

9
10 Your Reference Committee reviewed strong online and in-person testimony in support of
11 Resolution 317. During testimony it was noted that this request for a study aligns with
12 the Americans with Disabilities Act of 1990 and existing AMA policy. In addition, there
13 was strong support for a study that collects data on medical trainees with disabilities,
14 enumerates the various obstacles the trainees face, describes how a variety of medical
15 schools have overcome those obstacles (best practices), and reviews potential revision
16 of technical standards for medical education. Testimony also recommended that the
17 study include available data on medical graduates with disabilities and challenges to
18 employment after training. Therefore, your Reference Committee recommends that
19 Resolution 317 be adopted as amended.

20
21 (19) RESOLUTION 318 – RURAL HEALTH PHYSICIAN
22 WORKFORCE DISPARITIES

23
24 RECOMMENDATION A:

25
26 Madam Speaker, your Reference Committee recommends
27 that Resolution 318 be amended by addition, to read as
28 follows:

29
30 That our AMA undertake a study of issues regarding rural
31 physician workforce shortages, including federal payment
32 policy issues, and other causes and potential remedies
33 (such as telehealth) to alleviate rural physician workforce
34 shortages.

35
36 RECOMMENDATION B:

37
38 Madam Speaker, your Reference Committee recommends
39 that Resolution 318 be adopted as amended.

40
41 Resolution 318 asks: That our AMA undertake a study of issues regarding rural
42 physician workforce shortages, including federal payment policy issues, and other
43 causes and potential remedies to alleviate rural physician workforce shortages.

44
45 Your Reference Committee reviewed testimony online and in-person in overwhelming
46 support of this issue. AMA has clear policy that looks toward correcting the methodology
47 used by the Centers for Medicare & Medicaid Services (CMS) in determining payment
48 rates, but much of the policy addresses Practice Expense (PE) differences in rent costs.

1 Lacking is the inclusion of the costs necessary for physician recruitment and retention
2 and the effect of these costs on overall practice expense realities. This resolution looks
3 to incorporate these data in a study to evaluate the overall effects that these trends
4 produce, and the possibility that improvements in fee schedules may result, thus
5 assisting in addressing physician shortages. Additionally, the Council on Medical
6 Education has a report in progress related to this issue and will look to include material
7 on this matter in that report. Testimony suggested the addition of “telemedicine and
8 telehealth”; your Reference Committee would proposed use of the broader term
9 “telehealth,” in that telemedicine is encompassed within telehealth. Testimony also
10 addressed the need to alleviate payment to rural physicians without negatively impacting
11 payment to other regions. Therefore, your Reference Committee recommends that
12 Resolution 318 be adopted as amended.

13
14 (20) RESOLUTION 319 – ADDING PIPELINE PROGRAM
15 PARTICIPATION QUESTIONS TO MEDICAL SCHOOL
16 APPLICATIONS

17
18 RECOMMENDATION A:

19
20 Madam Speaker, your Reference Committee recommends
21 that first Resolve of Resolution 319 be amended by
22 addition and deletion, to read as follows:

23
24 RESOLVED, That our AMA ~~collaborate~~ work with the
25 Association of American Medical Colleges (AAMC) and
26 other stakeholders ~~to coalesce the data~~ to create a
27 question for the AAMC electronic medical school
28 application to identify previous pipeline program (also
29 known as pathway program) participation and create a
30 plan to analyze the data in order allow applicants to
31 identify previous pipeline program participation
32 to determine the effectiveness of pipeline programs ~~those~~
33 ~~who are underrepresented in medicine in their decisions to~~
34 ~~pursue careers in medicine.~~ (and be it further)

35
36 RECOMMENDATION B:

37
38 Madam Speaker, your Reference Committee recommends
39 that Resolution 319 be amended by deletion of the second
40 Resolve, to read as follows:

41
42 ~~RESOLVED, That our AMA develop a plan to analyze the~~
43 ~~data once this question is implemented with input from key~~
44 ~~stakeholders, including AAMC, the Accreditation Council~~
45 ~~for Graduate Medical Education, and interested medical~~
46 ~~societies and premed pipeline programs.~~ ~~(Directive to Take~~
47 ~~Action)~~

1 RECOMMENDATION C:

2
3 Madam Speaker, your Reference Committee recommends
4 that Resolution 319 be adopted as amended.

5
6 Resolution 319 asks: 1. That our AMA collaborate with the Association of American
7 Medical Colleges (AAMC) and other stakeholders to coalesce the data to create a
8 question for the AAMC electronic medical school application to allow applicants to
9 identify previous pipeline program participation to determine the effectiveness of pipeline
10 programs those who are underrepresented in medicine in their decisions to pursue
11 careers in medicine; and 2. That our AMA develop a plan to analyze the data once this
12 question is implemented with input from key stakeholders, including AAMC, the
13 Accreditation Council for Graduate Medical Education, and interested medical societies
14 and premed pipeline programs.

15
16 Your Reference Committee reviewed testimony online and in-person in overwhelming
17 support of this resolution. Testimony requested the consideration of the use of pathway
18 programs in addition to pipeline programs due to different uses of the term pipeline
19 regionally. Additionally, testimony requested that the second resolve be struck
20 completely because it presumptively depends on the availability of future data, which
21 would be necessary in order to stand as an independent policy statement. Therefore,
22 your Reference Committee recommends that Resolution 319 be adopted as amended.

23
24 (21) RESOLUTION 322 – SUPPORT FOR THE STUDY OF
25 THE TIMING AND CAUSES FOR LEAVE OF ABSENCE
26 AND WITHDRAWAL FROM UNITED STATES MEDICAL
27 SCHOOLS

28
29 RECOMMENDATION A:

30
31 Madam Speaker, your Reference Committee recommends
32 that Resolution 322 be amended by addition and deletion,
33 to read as follows:

34
35 RESOLVED, That our AMA support the study of factors
36 surrounding leaves of absence and withdrawal from
37 allopathic and osteopathic medical undergraduate and
38 graduate education programs, including the timing of and
39 reasons for these actions, as well as the sociodemographic
40 information of the students involved- (New HOD Policy);
41 and be it further

42
43 RECOMMENDATION B:

44
45 Madam Speaker, your Reference Committee recommends
46 that Resolution 322 be amended by addition of a second
47 Resolve, to read as follows:

1 RESOLVED, that our AMA encourage the Association of
2 American Medical Colleges and the American Association
3 of Colleges of Osteopathic Medicine to support the study of
4 factors surrounding leaves of absence and withdrawal from
5 allopathic and osteopathic medical undergraduate and
6 graduate education programs, including the timing of and
7 reasons for these actions, as well as the sociodemographic
8 information of the students involved (New HOD Policy).

9
10 RECOMMENDATION C:

11
12 Madam Speaker, your Reference Committee recommends
13 that Resolution 322 be adopted as amended.

14
15 RECOMMENDATION D:

16
17 Madam Speaker, your Reference Committee recommends
18 that the title of Resolution 322 be changed, to read as
19 follows:

20
21 SUPPORT FOR THE STUDY OF THE TIMING AND
22 CAUSES FOR LEAVE OF ABSENCE AND
23 WITHDRAWAL FROM UNITED STATES ALLOPATHIC
24 AND OSTEOPATHIC MEDICAL UNDERGRADUATE AND
25 GRADUATE EDUCATION PROGRAMS

26
27 Resolution 322 asks: That our AMA support the study of factors surrounding leaves of
28 absence and withdrawal from allopathic and osteopathic medical education programs,
29 including the timing of and reasons for these actions, as well as the sociodemographic
30 information of the students involved.

31
32 Your Reference Committee reviewed testimony online and in-person in overwhelming
33 support of this resolution. Testimony reflected that many felt this policy could help inform
34 potential medical school applicants, current students and medical school administrators.
35 It was requested that gender be included, and your Reference Committee felt the term
36 sociodemographic was inclusive of gender. Therefore, your Reference Committee
37 recommends that Resolution 322 be adopted as amended.

38
39 (22) RESOLUTION 308 – MAINTENANCE OF
40 CERTIFICATION MORATORIUM

41
42 RECOMMENDATION:

43
44 Madam Speaker, your Reference Committee recommends
45 that Resolution 308 be referred.

46
47 Resolution 308 asks: 1. That our AMA call for an immediate end to the high stakes
48 examination components as well as an end to the Quality Initiative (QI)/Practice

1 Improvement (PI) components of Maintenance of Certification (MOC); 2. That our AMA
2 call for retention of continuing medical education (CME) and professionalism
3 components (how physicians carry out their responsibilities safely and ethically) of MOC
4 only; and 3. That our AMA petition the American Board of Medical Specialties for the
5 restoration of certification status for all diplomates who have lost certification status
6 solely because they have not complied with MOC requirements.

7
8 Your Reference Committee reviewed mixed online and in-person testimony on this
9 resolution. Testimony noted that continuing certification has become another element
10 that contributes to stress and burnout, and that many physicians find elements of
11 Continuous Certification/Maintenance of Certification problematic. However, the Council
12 on Medical Education is currently studying the issues raised in this resolution. In
13 addition, the ABMS has convened a Stakeholders Council to address the
14 recommendations of the recently released report of the “Continuing Board Certification:
15 Vision for the Future Commission” that may address some of these concerns. The AMA
16 also has representation on the ABMS Continuing Certification Committee, which
17 monitors and approves alternative models within the existing components of Continuing
18 Certification and is considering how to integrate the assessment of standards into
19 everyday practice activities. A thorough review and analysis of the issues raised in this
20 item is needed. Therefore, your Reference Committee recommends that Resolution 308
21 be referred with a report back to the House of Delegates at the A-20 meeting.

22
23 (23) RESOLUTION 311 – GRANDFATHERING QUALIFIED
24 APPLICANTS PRACTICING IN U.S. INSTITUTIONS
25 WITH RESTRICTED MEDICAL LICENSURE

26
27 RECOMMENDATION:

28
29 Madam Speaker, your Reference Committee recommends
30 that Resolution 311 be referred.

31
32 Resolution 311 asks: That our AMA work with the Federation of State Medical Boards,
33 the Organized Medical Staff Section and other stakeholders to advocate for state
34 medical boards to support the licensure to practice medicine by physicians who have
35 demonstrated they possess the educational background and technical skills and who are
36 practicing in the U.S. health care system.

37
38 Your Reference Committee heard mixed testimony that was largely in favor of referral,
39 due to the complexity of this issue. Testimony from an international medical graduate
40 academic physician who has trained many residents and fellows in the United States,
41 but who is ineligible to obtain a medical license, reflected the impetus for this item. A
42 physician from Florida testified how that state continues to grapple with the issue of
43 physician immigrants from Cuba and other foreign countries who do not meet state
44 licensure requirements yet seek to find a way in which to put their (often considerable)
45 skills to work in their new country in service to patients and society. This issue merits
46 additional study by the Council on Medical Education, which welcomes the referral, as
47 do the authors of the resolution. Therefore, your Reference Committee recommends that
48 Resolution 311 be referred.

1 (24) RESOLUTION 301 – AMERICAN BOARD OF MEDICAL
2 SPECIALTIES ADVERTISING

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 301 not be adopted.

8
9 Resolution 301 asks: That our AMA oppose the use of any physician fees, dues, etc., for
10 any advertising by the American Board of Medical Specialties or any of their component
11 boards to the general public.

12
13 Your Reference Committee reviewed mixed online and in-person testimony regarding
14 Resolution 301, which noted the existence of public information and advertising
15 campaigns used to inform patients about the value of board certification. Testimony
16 noted that hospitals, insurance companies, malpractice insurers, and others often
17 require board certification for a physician to practice medicine and that physicians are
18 essentially required to maintain active certification and pay yearly fees to their specialty
19 boards. While the AMA maintains robust policy on MOC, including policy related to the
20 cost of development and administration of the MOC components and transparency of
21 finances of the ABMS and its member boards, this policy does not attempt to exert
22 control over ABMS policies and procedures. In addition, this resolution is not consistent
23 with AMA policy that supports informing the public about the value of board certification.
24 Therefore, your Reference Committee recommends that Resolution 301 not be adopted.

25
26 (25) RESOLUTION 312 – UNMATCHED MEDICAL
27 GRADUATES TO ADDRESS THE SHORTAGE OF
28 PRIMARY CARE PHYSICIANS

29
30 RECOMMENDATION:

31
32 Madam Speaker, your Reference Committee recommends
33 that Resolution 312 not be adopted.

34
35 Resolution 312 asks: 1. That our AMA advocate for the state medical boards to accept
36 medical graduates who have passed USMLE Steps 1 and 2 as their criterion for limited
37 license, thus using the existing physician workforce of trained and certified physicians in
38 the primary care field and allowing them to get some credit towards their residency
39 training as is being contemplated in Utah; and 2. That our AMA work with regulatory,
40 licensing, medical, and educational entities dealing with physician workforce issues: the
41 American Board of Medical Specialties, the Association of American Medical Colleges
42 (AAMC), the Association for Hospital Medical Education, Accreditation Council for
43 Graduate Medical Education (ACGME), the Federation of State Medical Boards, and the
44 National Medical Association work together to integrate unmatched physicians in the
45 primary care workforce in order to address the projected physician shortage.

- 1 Your Reference Committee heard, after further consideration, that the sponsors decided
- 2 to withdraw Resolution 312 from consideration. Therefore, Your Reference Committee
- 3 recommends that Resolution 312 not be adopted.

1 Madam Speaker, this concludes the report of Reference Committee C. I would like to
2 thank Ricardo Correa, MD; Albert M. Kwan, MD; George M. Lange, MD; Elizabeth U.
3 Parker, MD; Richard Pieters, Jr, MD; Charles W. Van Way, III, MD; and all those who
4 testified before the committee, as well as our AMA staff, including Catherine Welcher,
5 Fred Lenhoff, Tanya Lopez, and Alejandro Aparicio, MD.

Ricardo Correa, MD (Alternate)
International Medical Graduates

Albert M. Kwan, MD
American Society of General Surgeons

George M. Lange, MD
Wisconsin

Elizabeth U. Parker, MD (Alternate)
Sectional Resident and Fellow

Richard S. Pieters, Jr, MD
Massachusetts

Charles W. Van Way, III, MD
Missouri

Nicole D. Riddle, MD
US and Canadian Academy of
Pathology
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (A-19)

Report of Reference Committee D

Diana Ramos, MD, MPH, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

2
3 **RECOMMENDED FOR ADOPTION**

- 4
5 1. Board of Trustees Report 11 – Policy and Economic Support for Early Child Care
6 2. Board of Trustees Report 16 – Developing Sustainable Solutions for Discharge of
7 Chronically Homeless Patients
8 3. Board of Trustees Report 28 – Opposition to Measures that Criminalize
9 Homelessness
10 4. Council on Science and Public Health Report 3 – Low Nicotine Product Standard
11 5. Council on Science and Public Health Report 4 – Vector-borne Diseases
12 6. Resolution 403 – White House Initiative on Asian Americans and Pacific
13 Islanders
14 7. Resolution 407 – Evaluating Autonomous Vehicles as a Means to Reduce Motor
15 Vehicle Accidents
16 8. Resolution 425 – Distracted Driver Education and Advocacy
17 9. Resolution 427 – Utility of Autonomous Vehicles for Individuals Who are Visually
18 Impaired of Developmentally Disabled
19

20 **RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED**

- 21
22 10. Board of Trustees Report 29 – Improving Safety and Health Code Compliance in
23 School Facilities
24 11. Resolution 401 – Support Pregnancy Intention Screening to Improve the
25 Discussion of Pregnancy Intention, Promote Preventive Reproductive Health
26 Care and Improve Community Health Outcomes by Helping Women Prepare for
27 Healthy Pregnancies and Prevent Unintended Pregnancies
28 12. Resolution 404 – Shade Structures in Public and Private Planning and Zoning
29 Matters
30 13. Resolution 405 – Gun Violence Prevention: Safety Features
31 14. Resolution 406 – Reduction in Consumption of Processed Meats
32 15. Resolution 410 – Addressing Health Disparities Through Education
33 16. Resolution 413 – End the Epidemic of HIV Nationally
34 17. Resolution 415 – Distracted Driving Legislation
35 18. Resolution 416 – Non-medical Exemptions from Immunizations
36 19. Resolution 417 – Improved Health in the United States Prison System Through
37 Hygiene and Health Education Programming for Inmates and Prison Staff
38 20. Resolution 419 – Universal Access for Essential Public Health Services
39 21. Resolution 420 – Coordinating Correctional and Community Healthcare
40 22. Resolution 421 – Contraception for Incarcerated Women
41 23. Resolution 423 – Mandatory Immunizations for Asylum Seekers
42 24. Resolution 426 – Health Care Accreditation of Correctional, Detention and
43 Juvenile Facilities

- 1 25. Resolution 428 – Dangers of Vaping
2 26. Resolution 432 – Decriminalization of Human Immunodeficiency Virus (HIV)
3 Status Non-Disclosure in Virally Suppressed Individuals
4 27. Resolution 433 – Transformation of Rural Community Public Health Systems
5

6 **RECOMMENDED FOR REFERRAL**
7

- 8 28. Resolution 402 – Bullying in the Practice of Medicine
9 29. Resolution 408 – Banning Edible Cannabis Products
10 30. Resolution 411 – AMA to Analyze Benefits / Harms of Legalization of Marijuana
11 31. Resolution 414 – Patient Medical Marijuana Use in Hospitals
12 32. Resolution 424 – Physician Involvement in State Regulation of Motor Vehicle
13 Operation and/or Firearm Use by Individuals with Cognitive Deficits Due to
14 Traumatic Brain Injury
15 33. Resolution 430 – Compassionate Release for Incarcerated Patients
16

17 **RECOMMENDED FOR REFERRAL FOR DECISION**
18

- 19 34. Resolution 418 – Eliminating the Death Toll from Combustible Cigarettes
20

21 **RECOMMENDED FOR NOT ADOPTION**
22

- 23 35. Resolution 409 – Addressing the Vaping Crisis
24 36. Resolution 431 – Eliminating Recommendations to Restrict Dietary Cholesterol
25 and Fat
26

27 **RECOMMENDED FOR REAFFIRMATION IN LIEU OF**
28

- 29 37. Resolution 412 – Regulating Liquid Nicotine and E-Cigarettes
30 38. Resolution 434 – Change in Marijuana Classification to Allow Research

Resolutions handled via the Reaffirmation Consent Calendar:

Resolution 422 – Promoting Nutrition Education Among Healthcare Providers

1 (1) BOARD OF TRUSTEES REPORT 11 – POLICY AND
2 ECONOMIC SUPPORT FOR EARLY CHILD CARE
3

4 Madam Speaker, your Reference Committee recommends
5 that the recommendations in Board of Trustees Report 11
6 be adopted and the remainder of the report be filed.
7

8 Board of Trustees Report 11 asks that our AMA (1) reaffirm Policy H-440.823, which
9 recognizes the public health benefits of paid sick leave and other discretionary paid time off,
10 and supports employer policies that allow employees to accrue paid time off and to use such
11 time to care for themselves or a family member; (2) encourage employers to offer and/or
12 expand paid parental leave policies; (3) encourage state medical associations to work with
13 their state legislatures to establish and promote paid parental leave policies; (4) advocate for
14 improved social and economic support for paid family leave to care for newborns, infants and
15 young; and (5) advocate for federal tax incentives to support early child care and unpaid child
16 care by extended family members
17

18 Your Reference Committee heard testimony that was supportive of the recommendations in
19 Board of Trustees Report 11. The Board was thanked for its consideration of the testimony
20 heard on this report last year and for this revised version. There was strong support for the
21 Board's position that policy supporting paid parental leave for the care of children is good
22 public policy. It was noted that these policies have a positive impact on children's health
23 outcomes. Therefore, your Reference Committee recommends that Board of Trustees Report
24 11 be adopted.
25

26 (2) BOARD OF TRUSTEES REPORT 16 – DEVELOPING
27 SUSTAINABLE SOLUTIONS TO DISCHARGE OF
28 CHRONICALLY HOMELESS PATIENTS
29

30 RECOMMENDATION:
31

32 Madam Speaker, your Reference Committee recommends
33 that the recommendations in Board of Trustees Report 16
34 be adopted and the remainder of the report be filed.
35

36 Board of Trustees Report 16 asks that our AMA: (1) partner with relevant stakeholders to
37 educate physicians about the unique healthcare and social needs of homeless patients and
38 the importance of holistic, cost-effective, evidence-based discharge planning, and physicians'
39 role therein, in addressing these needs; (2) encourage the development of holistic, cost-
40 effective, evidence-based discharge plans for homeless patients who present to the
41 emergency department but are not admitted to the hospital; (3) encourage the collaborative
42 efforts of communities, physicians, hospitals, health systems, insurers, social service
43 organizations, government, and other stakeholders to develop comprehensive homelessness
44 policies and plans that address the healthcare and social needs of homeless patients; (4)
45 reaffirm Policy H-160.903, Eradicating Homelessness, which "supports improving the health
46 outcomes and decreasing the health care costs of treating the chronically homeless through
47 clinically proven, high quality, and cost-effective approaches which recognize the positive
48 impact of stable and affordable housing coupled with social services."; (5) reaffirm Policy H-
49 160.978, The Mentally Ill Homeless, which states that "public policy initiatives directed to the
50 homeless, including the homeless mentally ill population, should...[promote] care that is

1 sensitive to the overriding needs of this population for food, clothing, and residential facilities.”;
2 (6) reaffirm Policy H-160.942, Evidence-Based Principles of Discharge and Discharge
3 Criteria, which "calls on physicians, specialty societies, insurers, and other involved parties to
4 join in developing, promoting, and using evidence-based discharge criteria that are sensitive
5 to the physiological, psychological, social, and functional needs of patients.”; (7) reaffirm
6 Policy H-130.940, Emergency Department Boarding and Crowding, which “supports
7 dissemination of best practices in reducing emergency department boarding and crowding.”;
8 and (8) reaffirm Policy H-270.962, Unfunded Mandates, which “vigorously opposes any
9 unfunded mandates on physicians.”

10
11 Your Reference Committee heard testimony in support of the Board’s recommendations for
12 evidenced-based discharge planning. It was noted that homelessness is an exacerbating
13 factor in emergency department overuse, excess hospitalization, and preventable
14 readmission. Testimony noted the necessity for collaborative partnerships to address
15 homelessness. Therefore, your Reference Committee recommends that Board of Trustees
16 Report 16 be adopted.

17
18 (3) BOARD OF TRUSTEES REPORT 28 – OPPOSITION TO
19 MEASURES THAT CRIMINALIZE HOMELESSNESS

20
21 RECOMMENDATION:

22
23 Madam Speaker, your Reference Committee recommends
24 that the recommendations in Board of Trustees Report 28
25 be adopted and the remainder of the report be filed.

26
27 Board of Trustees Report 28 recommends new policy stating that our AMA: (1) supports laws
28 protecting the civil and human rights of individuals experiencing homelessness; (2) opposes
29 laws and policies that criminalize individuals experiencing homelessness for carrying out life-
30 sustaining activities conducted in public spaces that would otherwise be considered non-
31 criminal activity (i.e., eating, sitting, or sleeping) when there is no alternative private space
32 available; (3) recognizes that stable, affordable housing is essential to the health of
33 individuals, families, and communities, and supports policies that preserve and expand
34 affordable housing across all neighborhoods; and (4) recommends reaffirming Policy H-
35 160.903, “Eradicating Homelessness.”

36
37 Your Reference Committee heard testimony in support of the Board’s recommendations in
38 opposition to criminalizing homelessness. Testimony noted that insufficient income and lack
39 of affordable housing are leading causes of homelessness. Laws criminalizing homelessness
40 have been found to violate international and, in some instances, federal law. Therefore, your
41 Reference Committee recommends Board of Trustees Report 28 be adopted.

1 (4) COUNCIL ON SCIENCE AND PUBLIC HEALTH REPORT
2 3 – LOW NICOTINE PRODUCT STANDARD
3

4 RECOMMENDATION:
5

6 Madam Speaker, your Reference Committee recommends
7 that the recommendations in Council on Science and Public
8 Health Report 3 be adopted and the remainder of the report
9 be filed.

10
11 Council on Science and Public Health Report 3 recommends: (1). That AMA Policy H-495.988,
12 “FDA Regulation of Tobacco Products” be amended by addition to read as follows:
13

14 1. Our AMA: (A) acknowledges that all tobacco products (including but not limited to,
15 cigarettes, smokeless tobacco, chewing tobacco, and hookah/water pipe tobacco) are harmful
16 to health, and that there is no such thing as a safe cigarette; (B) recognizes that currently
17 available evidence from short-term studies points to electronic cigarettes as containing fewer
18 toxicants than combustible cigarettes, but the use of electronic cigarettes is not harmless and
19 increases youth risk of using combustible tobacco cigarettes; (C) encourages long-term
20 studies of vaping (the use of electronic nicotine delivery systems) and recognizes that
21 complete cessation of the use of tobacco and nicotine-related products is the goal; (D) asserts
22 that tobacco is a raw form of the drug nicotine and that tobacco products are delivery devices
23 for an addictive substance; (E) reaffirms its position that the Food and Drug Administration
24 (FDA) does, and should continue to have, authority to regulate tobacco products, including
25 their manufacture, sale, distribution, and marketing; (F) strongly supports the substance of the
26 August 1996 FDA regulations intended to reduce use of tobacco by children and adolescents
27 as sound public health policy and opposes any federal legislative proposal that would weaken
28 the proposed FDA regulations; (G) urges Congress to pass legislation to phase in the
29 production of less hazardous and less toxic tobacco, and to authorize the FDA have broad-
30 based powers to regulate tobacco products; (H) encourages the FDA and other appropriate
31 agencies to conduct or fund research on how tobacco products might be modified to facilitate
32 cessation of use, including elimination of nicotine and elimination of additives (e.g., ammonia)
33 that enhance addictiveness; and (I) strongly opposes legislation which would undermine the
34 FDA’s authority to regulate tobacco products and encourages state medical associations to
35 contact their state delegations to oppose legislation which would undermine the FDA’s
36 authority to regulate tobacco products.
37

38 2. Our AMA: (A) supports the US Food and Drug Administration (FDA) as it takes an important
39 first step in establishing basic regulations of all tobacco products; (B) strongly opposes any
40 FDA rule that exempts any tobacco or nicotine-containing product, including all cigars, from
41 FDA regulation; and (C) will join with physician and public health organizations in submitting
42 comments on FDA proposed rule to regulate all tobacco products.
43

44 3. Our AMA: (A) will continue to monitor the FDA’s progress towards establishing a low
45 nicotine product standard for tobacco products and will submit comments on the proposed
46 rule that are in line with the current scientific evidence and (B) recognizes that rigorous and
47 comprehensive post-market surveillance and product testing to monitor for unintended
48 tobacco use patterns will be critical to the success of a nicotine reduction policy. (Modify
49 Current HOD Policy)

1 2. That American Medical Association Policy H-495.972, “Electronic Cigarettes, Vaping, and
2 Health” be reaffirmed. (Reaffirm HOD Policy)

3
4 The Council on Science and Public Health introduced this report and noted that the AMA
5 submitted extensive comments on this issue to the FDA in July of 2018. The comments were
6 made based on the best available data on a low nicotine product standard. It was noted that
7 the AMA specifically called for this standard to apply to all tobacco and nicotine products, not
8 just combustible cigarettes. Some questions were raised in testimony regarding varying levels
9 of addiction to nicotine among individuals and across populations, and how those most
10 susceptible would be addressed. Your Reference Committee believes that the Council got
11 this right. Federal law prohibits the FDA from taking the nicotine level to zero. Committing the
12 AMA to continue to monitor the FDA’s progress as well as the evidence base on this issue is
13 appropriate. Therefore, your Reference Committee recommends that Council on Science and
14 Public Health Report 3 be adopted.

15
16 (5) COUNCIL ON SCIENCE AND PUBLIC HEALTH REPORT
17 4 – VECTOR-BORNE DISEASES

18
19 RECOMMENDATION:

20
21 Madam Speaker, your Reference Committee recommends
22 that the recommendation in Council on Science and Public
23 Health Report 4 be adopted and the remainder of the report
24 be filed.

25
26 Council on Science and Public Health Report 4 recommends:

27
28 1. That Policy H-440.820, “Vector-Borne Diseases,” be amended by addition and deletion to
29 read as follows:

30
31 H-440.820 Vector-Borne Diseases

32 Due to the increasing threat and limited capacity to respond to vector-borne diseases, Our
33 our AMA supports and will advocate for local, state and national research, education, reporting
34 and tracking on vector-borne diseases.

35
36 (1) Improved surveillance for vector-borne diseases to better understand the geographic
37 distribution of infectious vectors and where people are at risk;

38 (2) The development and funding of comprehensive and coordinated vector-borne disease
39 prevention and control programs at the state and local level;

40 (3) Investments that strengthen our nation’s public health infrastructure and the public health
41 workforce;

42 (4) Education and training for health care professionals and the public about the risk of vector-
43 borne diseases and prevention efforts as well as the dissemination of available information;

44 (5) Research to develop new vaccines, diagnostics, and treatments for existing and emerging
45 vector-borne diseases, including Lyme disease;

46 (6) Research to identify novel methods for controlling vectors and vector-borne diseases; and
47 (7) Increased and sustained funding to address the growing burden of vector-borne diseases
48 in the United States. (Modify Current HOD Policy)

1 2. That Policy H-135.438, “Global Climate Change and Human Health” and Policy, D-440.940,
2 “Global Tracking System of Zoonotic Diseases,” be reaffirmed. (Reaffirm HOD Policy)

3
4 The Council was thanked for its thorough and thoughtful report on the issue of vector-borne
5 diseases. Overall, testimony was very supportive of this report. Several amendments were
6 suggested, including putting the language referring to the local, state, and federal levels of
7 government taking action back into the policy. Your Reference Committee believes that
8 leaving it broad is the best approach, thereby ensuring it applies to all jurisdictions. There was
9 also a recommendation to add the One Health Initiative into the recommendations. The
10 Reference Committee felt that inserting the name of a specific coalition was unnecessary
11 noting that we have existing policy on collaborations with veterinary medicine (H-440.871).
12 Therefore, your Reference Committee recommends adoption.

13
14 (6) RESOLUTION 403 – WHITE HOUSE INITIATIVE ON
15 ASIAN AMERICANS AND PACIFIC ISLANDERS

16
17 RECOMMENDATION:

18
19 Madam Speaker, your Reference Committee recommends
20 that Resolution 403 be adopted.

21
22 Resolution 403 asks that our AMA: (1) advocate for restoration of webpages on the Asian
23 American and Pacific Islander (AAPI) initiative (similar to those from prior administrations) that
24 specifically address disaggregation of health outcomes related to AAPI data; (2) support the
25 disaggregation of data regarding AAPIs in order to reveal the AAPI ethnic subgroup disparities
26 that exist in health outcomes; (3) support the disaggregation of data regarding AAPIs in order
27 to reveal the AAPI ethnic subgroup disparities that exist in representation in medicine,
28 including but not limited to leadership positions in academic medicine; and (4) report back at
29 the 2020 Annual Meeting on the issue of disaggregation of data regarding AAPIs (and other
30 ethnic subgroups) with regards to the ethnic subgroup disparities that exist in health outcomes
31 and representation in medicine, including leadership positions in academic medicine.

32
33 Your Reference Committee heard strong support on the issue of disaggregation of data
34 regarding Asian American and Pacific Islanders. It was noted that while there is existing AMA
35 policy on this issue, these requests are more specific and necessary to address disparities in
36 these populations. Therefore, your Reference Committee recommends that Resolution 403
37 be adopted.

38
39 (7) RESOLUTION 407 – EVALUATING AUTONOMOUS
40 VEHICLES AS A MEANS TO REDUCE MOTOR VEHICLE
41 ACCIDENTS

42
43 RECOMMENDATION:

44
45 Madam Speaker, your Reference Committee recommends
46 that Resolution 407 be adopted.

47
48 Resolution 407 asks that our AMA monitor the development of autonomous vehicles, with
49 particular focus on the technology’s impact on motor vehicle related injury and death and
50 promote driver, pedestrian, and general street and traffic safety as key priorities in the
51 development of autonomous vehicles.

1 Your Reference Committee heard testimony in support of Resolution 407. It was noted that
2 autonomous vehicle technology is being developed and applied rapidly. Testimony
3 acknowledged the potential for fully autonomous vehicles to save lives and the need for
4 monitoring to ensure safety is a priority in development. Therefore, your Reference Committee
5 recommends that Resolution 407 be adopted.

6
7 (8) RESOLUTION 425 – DISTRACTED DRIVER EDUCATION
8 AND ADVOCACY

9
10 RECOMMENDATION:

11
12 Madam Speaker, your Reference Committee recommends
13 that Resolution 425 be adopted.

14
15 Resolution 425 asks that our AMA make it a priority to create a national education and
16 advocacy campaign on distracted driving in collaboration with the Centers for Disease Control
17 and Prevention and other interested stakeholders; and explore developing an advertising
18 campaign on distracted driving with report back to the House of Delegates at the 2019 Interim
19 Meeting.

20
21 Your Reference Committee heard limited, but unanimous testimony in support of Resolution
22 425. The positive impact of distracted driving efforts was noted in testimony, using as an
23 example hands-free legislation in Georgia that reduced motor vehicle collision mortality by 4
24 percent. While one individual suggested targeting education toward middle school and high
25 school students as they begin driver education, your Reference Committee felt that the
26 specifics of the educational programming should be addressed in collaboration with
27 stakeholders. Therefore, your Reference Committee recommends that Resolution 425 be
28 adopted.

29
30 (9) RESOLUTION 427 – UTILITY OF AUTONOMOUS
31 VEHICLES FOR INDIVIDUALS WHO ARE VISUALLY
32 IMPAIRED OR DEVELOPMENTALLY DISABLED

33
34 RECOMMENDATION:

35
36 Madam Speaker, your Reference Committee recommends
37 that Resolution 427 be adopted.

38
39 Resolution 427 asks that our AMA work with the National Transportation Safety Board to
40 support physician input on research into the capability of autonomous or “self-driving” vehicles
41 to enable individuals who are visually impaired or developmentally disabled to benefit from
42 autonomous vehicle technology.

43
44 Your Reference Committee heard testimony in support of Resolution 427. Testimony
45 acknowledged the potential of fully autonomous vehicles to expand mobility of those who
46 cannot be mobile. It was noted that transportation is a significant barrier for employment
47 among the developmentally disabled and autonomous vehicle technology could expand
48 employment opportunities for this population. It was suggested that the elderly be added to
49 this resolution as well, but your Reference Committee felt that this was outside the scope of

1 this resolution. Therefore, your Reference Committee recommends that Resolution 427 be
2 adopted.

3
4 (10) BOARD OF TRUSTEES REPORT 29 – IMPROVING
5 SAFETY AND HEALTH CODE COMPLIANCE IN
6 SCHOOL FACILITIES

7
8 RECOMMENDATION A:

9
10 Madam Speaker, your Reference Committee recommends
11 that the first recommendations in Board of Trustees Report
12 29 be amended by addition to read as follows:

13
14 1. That our AMA adopt the following new policy:

15
16 “Environmental Health and Safety in Schools”

17 Our AMA: (1) supports the adoption of standards in schools
18 that limit harmful substances from school facility
19 environments, ensure safe drinking water, and indoor air
20 quality, and promote childhood environmental health and
21 safety in an equitable manner, (2) encourages the
22 establishment of a system of governmental oversight,
23 charged with ensuring the regular inspection of schools and
24 identifying shortcomings that might, if left untreated,
25 negatively impact the health of those learning and working
26 in school buildings; (3) supports policies that increase
27 funding for such remediations to take place, especially in
28 vulnerable, resource-limited neighborhoods; and (4)
29 supports continued data collection and reporting on the
30 negative health effects of substandard conditions in
31 schools. (New HOD Policy)

32
33 RECOMMENDATION B:

34
35 Madam Speaker, your Reference Committee recommends
36 that the first recommendations in Board of Trustees Report
37 29 be adopted as amended and the remainder of the report
38 be filed.

39
40 1. Board of Trustees Report 29 recommends that our AMA adopt the following new policy:

41
42 “Environmental Health and Safety in Schools”

43 Our AMA supports the adoption of standards in schools that limit harmful substances
44 from school facility environments, ensure safe drinking water, and indoor air quality, and
45 promote childhood environmental health and safety in an equitable manner.

46
47 2. That the following policies be reaffirmed: H-135.428, “Safe Drinking Water,” and H-135.998,
48 “AMA Position on Air Pollution.”

1 Your Reference Committee heard testimony in support of the Board's recommendation on
2 school compliance with health and safety codes. It was noted that while there are number of
3 recommendations available to guide the implementation of programs to promote and protect
4 children's health, few states have adopted these guidelines into law. Schools in lower income
5 districts may be particularly vulnerable to environmental health hazards, which can contribute
6 to health inequities. An amendment was proposed supporting the enforcement and
7 implementation of these guidelines. Your Reference Committee agrees and therefore,
8 recommends that Board of Trustees Report 29 be adopted as amended.

9
10 (11) RESOLUTION 401 – SUPPORT PREGNANCY
11 INTENTION SCREENINGS TO IMPROVE THE
12 DISCUSSION OF PREGNANCY INTENTION, PROMOTE
13 PREVENTIVE REPRODUCTIVE HEALTH CARE AND
14 IMPROVE COMMUNITY HEALTH OUTCOMES BY
15 HELPING WOMEN PREPARE FOR HEALTHY
16 PREGNANCIES AND PREVENT UNINTENDED
17 PREGNANCIES

18
19 RECOMMENDATION A:

20
21 Madam Speaker, your Reference Committee recommends
22 that Resolution 401 be amended by addition and deletion to
23 read as follows:

24
25 RESOLVED, That our American Medical Association
26 support the use of pregnancy intention screening, ~~such as~~
27 ~~One Key Question[®], PATH, or the Centers for Disease~~
28 ~~Control and Prevention (CDC) reproductive life planning,~~
29 and contraceptive screening in appropriate women and men
30 as part of routine well-care and recommend it be built in
31 electronic health records so that providers can document
32 intention screening and services provided based on a
33 woman's response appropriately documented in the
34 medical record. (New HOD Policy)

35
36 RECOMMENDATION B:

37
38 Madam Speaker, your Reference Committee recommends
39 that Resolution 401 be adopted as amended.

40
41 RECOMMENDATION C:

42
43 Madam Speaker, your Reference Committee recommends
44 that the title of Resolution 401 be changed to read as
45 follows:

46
47 SUPPORT PREGNANCY INTENTION SCREENING

1 Resolution 401 asks that our AMA support the use of pregnancy intention screening, such as
2 One Key Question®, PATH, or the Centers for Disease Control and Prevention (CDC)
3 reproductive life planning, as part of routine well care and recommend it be built in electronic
4 health records so that providers can document intention screening and services provided
5 based on a woman's response.
6

7 Your Reference Committee heard testimony in support of this resolution. The importance of
8 reducing unmet contraceptive need and increasing preconception care were noted. Testimony
9 questioned whether specific tools should be recommended. It was also suggested that
10 language related to documentation be streamlined to eliminate language around electronic
11 health records. Therefore, Your Reference Committee recommends that Resolution 401 be
12 adopted as amended.
13

14 (12) RESOLUTION 404 – SHADE STRUCTURES IN PUBLIC
15 AND PRIVATE PLANNING AND ZONING MATTERS
16

17 RECOMMENDATION A:
18

19 Madam Speaker, your Reference Committee recommends
20 that Resolution 404 be amended by addition to read as
21 follows:
22

23 That our AMA support sun shade structures (such as trees,
24 awnings, gazebos and other structures providing shade) in
25 the planning of public and private spaces, as well as in
26 zoning matters and variances in recognition of the critical
27 important of sun protection as a public health measure.
28

29 RECOMMENDATION B:
30

31 Madam Speaker, your Reference Committee recommends
32 that Resolution 404 be adopted as amended.
33

34 Resolution 404 asks that our AMA support sun shade structures (such as awnings, gazebos
35 and other structures providing shade) in the planning of public and private spaces, as well as
36 in zoning matters and variances in recognition of the critical importance of sun protection as
37 a public health measure.
38

39 Your Reference Committee heard testimony in support of Resolution 404. Skin cancer is a
40 growing medical concern, and sun shade structures should be considered in public space
41 planning. In addition, sun shade structures may provide other benefits, such as increasing
42 use of public spaces and encouraging physical activity. An amendment to add the word trees
43 was suggested. Therefore, your Reference Committee recommends that Resolution 404 be
44 adopted as amended.

1 (13) RESOLUTION 405 –GUN VIOLENCE PREVENTION:
2 SAFETY FEATURES

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 405 be amended by addition and deletion to
8 read as follows:

9
10 RESOLVED, That our American Medical Association
11 advocate for firearm ~~gun~~ safety features, including but not
12 limited to mechanical or smart technology, to reduce
13 accidental discharge of a firearm or misappropriation of the
14 weapon by a non-registered user; and support legislation
15 and regulation to standardize the use of these firearm ~~gun~~
16 safety features on weapons sold for non-military and non-
17 peace officer use within the U.S.; with the aim of
18 establishing manufacturer liability for the absence of safety
19 features on newly manufactured firearms ~~guns~~. (Directive to
20 Take Action)

21
22 RECOMMENDATION B:

23
24 Madam Speaker, your Reference Committee recommends
25 that Resolution 405 be adopted as amended.

26
27 RECOMMENDATION C:

28
29 Madam Speaker, your Reference Committee recommends
30 that the title of Resolution 405 be changed.

31
32 FIREARM VIOLENCE PREVENTION: SAFETY FEATURES

33
34 Resolution 405 asks that our AMA advocate for gun safety features, including but not limited
35 to mechanical or smart technology, to reduce accidental discharge of a firearm or
36 misappropriation of the weapon by a non-registered user; and support legislation and
37 regulation to standardize the use of these gun safety features on weapons sold for non-military
38 and non-peace officer use within the U.S.; with the aim of establishing manufacturer liability
39 for the absence of safety features on newly manufactured guns.

40
41 Your Reference Committee heard testimony that was mostly supportive of Resolution 405. It
42 was noted in testimony that 37 percent of unintended firearm deaths could have been
43 prevented through smart firearm technology. It was also noted that existing law has had a
44 chilling effect on the sale of smart firearms in the United States. Your Reference Committee
45 noted that what we are referring to in the resolution is firearms rather than guns and amended
46 the language accordingly.

1 (14) RESOLUTION 406 – REDUCTION IN CONSUMPTION OF
2 PROCESSED MEATS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 406 be amended by addition and deletion to
8 read as follows:

9
10 That our AMA support: (1) reduction of processed meat
11 consumption, especially for patients diagnosed or at risk for
12 ~~coronary artery~~ cardiovascular disease, type 2 diabetes,
13 and ~~colorectal~~ cancer (2) initiatives to reduce processed
14 meats consumed in public schools, hospitals, food markets
15 and restaurants while promoting healthy alternatives such
16 as a whole foods and plant-based nutrition; (3) public
17 awareness of the risks of processed meat consumption,
18 ~~including research that better defines the health risks~~
19 ~~imposed by different methods of meat processing~~; and (4)
20 programs for health care professionals on the risks of
21 processed meat consumption and the benefits of healthy
22 alternatives.

23
24 RECOMMENDATION B:

25
26 Madam Speaker, your Reference Committee recommends
27 that Resolution 406 be adopted as amended.

28
29 Resolution 406 asks that our AMA support: (1) reduction of processed meat consumption,
30 especially for patients diagnosed or at risk for coronary artery disease, type 2 diabetes and
31 colorectal cancer; (2) initiatives to reduce processed meats consumed in public schools,
32 hospitals, food markets and restaurants while promoting healthy alternatives such as a
33 whole foods and plant-based nutrition; (3) awareness of the risks of processed meat
34 consumption, including research that better defines the health risks imposed by different
35 methods of meat processing; and (4) programs for health care professionals on the risks of
36 processed meat consumption and the benefits of healthy alternatives.

37
38 Your Reference Committee heard testimony in support of Resolution 406. Testimony noted
39 that consumption of processed meat is a serious health concern for patients, referencing
40 recent studies linking consumption of processed meats to increased cancer risks. It was noted
41 alternatives such as whole foods and plant-based nutrition should be offered in public schools,
42 hospitals, food markets, and restaurants. It was also noted that more education for children
43 and adults on the health risks of processed meat consumption is needed. Your Reference
44 Committee recommends that Resolution 406 be adopted as amended.

1 (15) RESOLUTION 410 – REDUCING HEALTH DISPARITIES
2 THROUGH EDUCATION

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends that
7 second Resolve of Resolution 410 be amended by addition and
8 deletion to read as follows:

9
10 RESOLVED, That our AMA work with Centers for Disease
11 Control and Prevention and other stakeholders to promote HHS
12 and DOE to establish a meaningful health curriculum (including
13 nutrition) for grades kindergarten through 12 which is required
14 for high school graduation (Directive to Take Action); and be it
15 further

16
17 RECOMMENDATION B:

18
19 Madam Speaker, your Reference Committee recommends
20 that third Resolve of Resolution 410 be deleted.

21
22 ~~RESOLVED, That our AMA work nationally toward the same~~
23 ~~goals and strategies to reduce health disparities. (Directive to~~
24 ~~Take Action)~~

25
26 RECOMMENDATION C:

27
28 Madam Speaker, your Reference Committee recommends
29 that Resolution 410 be adopted as amended.

30
31 RECOMMENDATION D:

32
33 Madam Speaker, your Reference Committee recommends
34 that Policy H-60.917 be reaffirmed.

35
36 Resolution 410 asks that our AMA: (1) work with the Health and Human Services Department
37 (HHS) and Department of Education (DOE) to raise awareness about the health benefits of
38 education; (2) work with HHS and DOE to establish a meaningful health curriculum (including
39 nutrition) for grades kindergarten through 12 which is required for high school graduation; and
40 (3) work nationally toward the same goals and strategies to reduce health disparities.

41
42 Your Reference Committee heard testimony that was mostly supportive of the intent of this
43 resolution. It was noted that the CDC already has a meaningful health curriculum that outlines
44 the eight components of coordinated school health. Rather than develop a new curriculum,
45 the AMA should promote the existing one. There was confusion around the focus of this
46 resolution, with some supporting early child education and authors indicating their intent was
47 actually to focus on health professional education. Your Reference Committee believes that
48 AMA policy already addresses early childhood education. Therefore, your Reference
49 Committee recommends that Resolution 410 be adopted as amended and existing policy be
50 reaffirmed.

1 Policy recommended for reaffirmation:

2
3 Policy H-60.917, "Disparities in Public Education as a Crisis in Public Health and Civil
4 Rights"

5 Our AMA: (1) considers continued educational disparities based on ethnicity, race and
6 economic status a detriment to the health of the nation; (2) will issue a call to action to
7 all educational private and public stakeholders to come together to organize and
8 examine, and using any and all available scientific evidence, to propose strategies,
9 regulation and/or legislation to further the access of all children to a quality
10 public education, including early childhood education, as one of the great unmet
11 health and civil rights challenges of the 21st century; and (3) acknowledges the role
12 of early childhood brain development in persistent educational and health disparities
13 and encourage public and private stakeholders to work to strengthen and expand
14 programs to support optimal early childhood brain development and school readiness.

15
16 (16) RESOLUTION 413 – END THE EPIDEMIC OF HIV
17 NATIONALLY

18
19 RECOMMENDATION A:

20
21 Madam Speaker, your Reference Committee recommends
22 that Resolution 413 be amended by addition and deletion to
23 read as follows:

24
25 RESOLVED, That our American Medical Association
26 supports and will strongly advocate for the funding of plans
27 to end the HIV epidemic that focus on: (1) diagnosing
28 individuals with HIV infection as early as possible, (2)
29 treating HIV infection to achieve sustained viral
30 suppression, (3) preventing at-risk individuals from
31 acquiring HIV infection, including through the use of pre-
32 exposure prophylaxis; and (4) rapidly detecting and
33 responding to emerging clusters of HIV infection to prevent
34 transmission. ~~advocate that the federal budget include~~
35 ~~provisions to End the HIV epidemic and that such a plan be~~
36 ~~structured after New York State's EtE 2020 or other similar~~
37 ~~state programs.~~ (Directive to Take Action)

38
39 RECOMMENDATION B:

40
41 Madam Speaker, your Reference Committee recommends
42 that Resolution 413 be adopted as amended.

43
44 Resolution 413 asks that our AMA advocate that the federal budget include provisions to End
45 the HIV epidemic and that such a plan be structured after New York State's EtE 2020 or other
46 similar state programs

47
48 Your Reference Committee heard testimony in strong support of plans to end the HIV
49 epidemic nationally. Testimony noted that there is already a national plan in place, "Ending
50 the HIV Epidemic: A Plan for America" for which the President's Fiscal Year 2020 Budget
51 proposed \$291 million to work towards ending the HIV epidemic in America by 2030. Your

1 Reference Committee felt that rather than naming specific plans in our policy, it would be best
2 to outline the goals of the plan for which the AMA, the federation of medicine, and physicians
3 should support. It was also noted that the AMA should advocate for funding to implement the
4 plan. Your Reference Committee also acknowledges that funding should not be limited to
5 federal funding, but broadly applicable to all levels of government. Therefore, your Reference
6 Committee recommends that Resolution 413 be adopted as amended.

7
8 (17) RESOLUTION 415 – DISTRACTED DRIVER
9 LEGISLATION

10
11 RECOMMENDATION A:

12
13 Madam Speaker, your Reference Committee recommends
14 that Resolution 415 be amended by deletion to read as
15 follows:

16
17 That our AMA actively lobby for federal legislation to: ~~(1)~~
18 decrease distracted driving injuries and fatalities by banning
19 the use of electronic communication such as texting, taking
20 photos or video and posting on social media while operating
21 a motor vehicle and ~~(2) require automobile manufacturers to~~
22 ~~integrate hands-free technology into new automobiles.~~

23
24 RECOMMENDATION B:

25
26 Madam Speaker, your Reference Committee recommends
27 that Resolution 415 be adopted as amended.

28
29 Resolution 415 asks that our AMA actively lobby for federal legislation to: (1) decrease
30 distracted driving injuries and fatalities by banning the use of electronic communication such
31 as texting, taking photos or video and posting on social media while operating a motor vehicle
32 and (2) require automobile manufacturers to integrate hands-free technology into new
33 automobiles.

34
35 Your Reference Committee heard testimony about the number of fatalities and injuries caused
36 by distracted drivers in the United States. While testimony supported efforts to curb distracted
37 driving, it was noted the federal legislation proposed in this resolution runs contrary to Section
38 8 of the U.S. Constitution; laws on distracted driving are therefore in the purview of the states.
39 Your Reference Committee also noted that the research indicates that hands-free technology
40 while driving still poses a risk to drivers. Therefore, your Reference Committee recommends
41 that Resolution 415 be adopted as amended.

1 (18) RESOLUTION 416 – NON-MEDICAL EXEMPTIONS
2 FROM IMMUNIZATIONS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 416 be amended by addition and deletion to
8 read as follows:

9
10 RESOLVED, That our American Medical Association
11 actively advocate for ~~federal—legislation, regulations,~~
12 programs, and policies that incentivizes states to eliminate
13 non-medical exemptions ~~to~~ from mandated pediatric
14 immunizations. (Directive to Take Action)

15
16 RECOMMENDATION B:

17
18 Madam Speaker, your Reference Committee recommends
19 that Resolution 416 be adopted as amended.

20
21 Resolution 416 asks that our AMA actively advocate for federal legislation that incentivizes
22 states to eliminate non-medical exemptions to mandated pediatric immunizations.

23
24 Your Reference Committee heard unanimous support for this resolution, which is consistent
25 with existing AMA policy. An amendment was offered by the U.S. Public Health Service,
26 suggesting that this not be limited to federal legislation. It was suggested that programs such
27 as, but not limited to the Center for Medicare and Medicaid Innovation and Head Start could
28 also incentivize states to eliminate non-medical exemptions from immunizations. Your
29 Reference Committee believes that the AMA should be broadly supporting these incentives
30 and not limiting them to only federal jurisdictions. Therefore, your Reference Committee
31 recommends that Resolution 416 be adopted as amended.

32
33 (19) RESOLUTION 417 – IMPROVED HEALTH IN THE
34 UNITED STATES PRISON SYSTEM THROUGH
35 HYGIENE AND HEALTH EDUCATION PROGRAMMING
36 FOR INMATES AND PRISON STAFF

37
38 RECOMMENDATION A:

39
40 Madam Speaker, your Reference Committee recommends
41 that Resolution 417 be amended by addition and deletion to
42 read as follows:

43
44 RESOLVED, that our AMA collaborate with state medical
45 societies and federal regulators to emphasize the
46 importance of hygiene and health literacy information
47 sessions for both inmates and staff in ~~state and local prison~~
48 systems—correctional facilities.

1 RECOMMENDATION B:

2

3 Madam Speaker, your Reference Committee recommends
4 that Resolution 417 be adopted as amended.

5

6 RECOMMENDATION C:

7

8 Madam Speaker, your Reference Committee recommends
9 that the title of Resolution 417 be changed to read as
10 follows:

11

12

13

14

15

16 IMPROVED HEALTH IN CORRECTIONAL FACILITIES
17 THROUGH HYGIENE AND HEALTH EDUCATIONAL
18 PROGRAMMING FOR INMATES AND STAFF

19

20 Resolution 417 asks that our AMA collaborate with state medical societies to emphasize the
21 importance of hygiene and health literacy information sessions for both inmates and staff in
22 state and local prison systems.

23

24

25 Your Reference Committee heard testimony in support of this resolution. It was suggested
26 that your Reference Committee consider the updated term “correctional facilities”, and that
27 federal regulators be included. Therefore, your Reference Committee recommends that
28 Resolution 417 be adopted as amended.

29

30

31 (20) RESOLUTION 419 – UNIVERSAL ACCESS FOR
32 ESSENTIAL PUBLIC HEALTH SERVICES

33

34

35 RECOMMENDATION:

36

37

38 Madam Speaker, your Reference Committee recommends
39 that the following alternate resolution be adopted in lieu of
40 Resolution 419.

41

42

43

44

45 UNIVERSAL ACCESS FOR ESSENTIAL PUBLIC HEALTH
46 SERVICES

47

48

49 RESOLVED that our AMA: (1) supports updating the 10
50 Essential Public Health Services to bring them in line with
current and future public health practice; (2) encourages
state, local, tribal, and territorial public health departments
to pursue accreditation through the Public Health
Accreditation Board (PHAB); (3) will work with the National
Association of City and County Health Officials (NACCHO),
the Association of State and Territorial Health Officials
(ASTHO), the Big Cities Health Coalition, the Centers for
Disease Control and Prevention (CDC), and other related
entities that are working to assess and assure appropriate
funding levels, service capacity, and adequate infrastructure
of the nation’s public health system; and (4) Reaffirms
existing Policy H-440.912.

1 Resolution 419 asks that our AMA study the options and/or make recommendations regarding
2 the establishment of: (1) a list of all essential public health services that should be provided in
3 every jurisdiction in the United States; (2) a federal data system that can capture the amount
4 of federal, state, and local public health capabilities and spending that occurs in every
5 jurisdiction to assure that their populations have universal access to all essential public health
6 services; and (3) a federal data system that can capture actionable evidence-based outcomes
7 data from public health activities in every jurisdiction. Resolution 419 also asks the AMA to
8 prepare and publicize annual reports on current efforts and progress to achieve universal
9 access to all essential public health services.

10
11 Your Reference Committee heard testimony in support of the intent of this resolution. The
12 Council on Science and Public Health offered an amendment, noting that work is ongoing to
13 address this issue by a number of public health organizations and that the AMA should work
14 collaboratively with public health organizations on this effort. The current list of Essential
15 Public Health Services were developed in 1994. The Public Health Accreditation Board
16 recently announced that it will partner with the de Beaumont Foundation on a project aimed
17 at updating the 10 Essential Public Health Services national framework. The Essential Public
18 Health Services provide the basis for the standards and measures by which governmental
19 public health departments' performance is evaluated through the Public Health Accreditation
20 Board. Since the list of essential public health services exists and is being updated and these
21 services are the basis of accreditation standards, your Reference Committee agreed that the
22 AMA's efforts should be focused on working with public health organizations to assess and
23 assure appropriate funding, service capacity, and an adequate public health infrastructure for
24 the nation.

25
26 Policy recommended for reaffirmation:

27
28 Policy H-440.912, "Federal Block Grants and Public Health"

29 (1) Our AMA should collaborate with national public health organizations to explore
30 ways in which public health and clinical medicine can become better integrated; such
31 efforts may include the development of a common core of knowledge for public health
32 and medical professionals, as well as educational vehicles to disseminate this
33 information. (2) Our AMA urges Congress and responsible federal agencies to: (a)
34 establish set-asides or stable funding to states and localities for essential public health
35 programs and services, (b) provide for flexibility in funding but ensure that states and
36 localities are held accountable for the appropriate use of the funds; and (c) involve
37 national medical and public health organizations in deliberations on proposed changes
38 in funding of public health programs. (3) Our AMA will work with and through state and
39 county medical societies to: (a) improve understanding of public health, including the
40 distinction between publicly funded medical care and public health; (b) determine the
41 roles and responsibilities of private physicians in public health, particularly in the
42 delivery of personal medical care to underserved populations; (c) advocate for
43 essential public health programs and services; (d) monitor legislative proposals that
44 affect the nation's public health system; (e) monitor the growing influence of managed
45 care organizations and other third party payers and assess the roles and
46 responsibilities of these organizations for providing preventive services in
47 communities; and (f) effectively communicate with practicing physicians and the
48 general public about important public health issues. (4) Our AMA urges state and
49 county medical societies to: (a) establish more collegial relationships with public health
50 agencies and increase interactions between private practice and public health
51 physicians to develop mutual support of public health and clinical medicine; and (b)

1 monitor and, to the extent possible, participate in state deliberations to ensure that
2 block grant funds are used appropriately for health-related programs.
3 (5) Our AMA urges physicians and medical societies to establish community
4 partnerships comprised of concerned citizens, community groups, managed care
5 organizations, hospitals, and public health agencies to: (a) assess the health status of
6 their communities and determine the scope and quality of population- and personal-
7 based health services in their respective regions; and (b) develop performance
8 objectives that reflect the public health needs of their states and communities.
9 Our AMA: (a) supports the continuation of the Preventive Health and Health Services Block
10 Grant, or the securing of adequate alternative funding, in order to assure preservation
11 of many critical public health programs for chronic disease prevention and health
12 promotion in California and nationwide, and to maintain training of the public health
13 physician workforce; and (b) will communicate support of the continuation of the
14 Preventive Health and Health Services Block Grant, or the securing of adequate
15 alternative funding, to the US Congress.

16
17 (21) RESOLUTION 420 – COORDINATING COMMUNITY AND
18 CORRECTIONAL HEALTH CARE

19
20 RECOMMENDATION A:

21
22 Madam Speaker, your Reference Committee recommends
23 that the first Resolve of Resolution 420 be amended by
24 addition and deletion to read as follows:

25
26 RESOLVED, That our American Medical Association
27 support linkage of those incarcerated to community clinics
28 upon release in order to accelerate access to primary
29 comprehensive health care, including mental health and
30 substance abuse disorder services, and improve health
31 outcomes among this vulnerable patient population, as well
32 as adequate funding (New HOD Policy);

33
34 RECOMMENDATION B:

35
36 Madam Speaker, your Reference Committee recommends
37 that Resolution 420 be adopted as amended.

38
39 Resolution 420 asks that our AMA support (1) linkage of those incarcerated to community
40 clinics upon release in order to accelerate access to primary care and improve health
41 outcomes among this vulnerable patient population, as well as adequate funding and (2) the
42 collaboration of correctional health workers and community health care providers for those
43 transitioning from a correctional institution to the community.

44
45 Your Reference Committee heard supportive testimony on this resolution. It was noted that
46 this should be more comprehensive beyond primary care and should include mental health
47 and substance abuse services. Your Reference Committee recommends that Resolution 420
48 be adopted as amended.

1 (22) RESOLUTION 421 – CONTRACEPTION FOR
2 INCARCERATED WOMEN

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 422 be adopted as amended by addition and
8 deletion to read as follows:

9
10 That our AMA support an incarceration incarcerated
11 person's' right prior to release to (1) accessible,
12 comprehensive, ~~to~~ evidence-based contraception
13 counseling education, (2) access to all reversible
14 contraceptive methods, and (3) autonomy over
15 contraceptive the decision-making prior to release process
16 without coercion.

17
18 RECOMMENDATION B:

19
20 Madam Speaker, your Reference Committee recommends
21 that Resolution 421 be adopted as amended.

22
23 Resolution 421 asks that our AMA support incarcerated persons' access to evidence-based
24 contraception counseling, access to all contraceptive methods and autonomy over
25 contraceptive decision-making prior to release.

26
27 Your Reference Committee heard strong support for Resolution 421. Testimony noted that
28 access to evidence-based contraception and education is limited for incarcerated women.
29 American College of Obstetricians and Gynecologists (ACOG) noted the original language
30 could include irreversible procedures such as sterilization and recommended the resolution
31 as amended. Widespread testimony supported the amended resolution. Therefore, your
32 Reference Committee recommends adoption of Resolution 421 as amended.

33
34 (23) RESOLUTION 423 – MANDATORY IMMUNIZATION FOR
35 ASYLUM SEEKERS

36
37 RECOMMENDATION A:

38
39 Madam Speaker, your Reference Committee recommends
40 that Resolution 423 be amended by addition to read as
41 follows:

42
43 That our AMA call for asylum seekers to receive all
44 medically-appropriate care, including vaccinations in a
45 patient centered, language and culturally appropriate way
46 upon presentation for asylum regardless of country of origin.

1 RECOMMENDATION B:
2

3 Madam Speaker, your Reference Committee recommends
4 that Resolution 423 be adopted as amended.

5 RECOMMENDATION C:
6

7 Madam Speaker, your Reference Committee recommends
8 that the title of Resolution 423 be changed to read as
9 follows:

10
11 MEDICALLY APPROPRIATE CARE FOR ASYLUM
12 SEEKERS
13

14 Resolution 423 asks that our AMA Call for asylum seekers to receive all medically-appropriate
15 vaccinations upon presentation for asylum regardless of country of origin.
16

17 Your Reference Committee heard supportive testimony for this resolution. Testimony was
18 heard requesting that the scope of the resolution be expanded to include all medically-
19 appropriate care, to reflect the diverse health needs of asylum seekers. Testimony asked that
20 'mandatory' be replaced in the title to reflect this expanded scope. It was also noted that
21 language and cultural barriers should be considered in the delivery of care to asylum seekers.
22 Therefore, your Reference Committee recommends that Resolution 423 be adopted as
23 amended.
24

25 (24) RESOLUTION 426 – HEALTH CARE ACCREDITATION
26 OF CORRECTIONAL, DETENTION AND JUVENILE
27 FACILITIES
28

29 RECOMMENDATION A:
30

31 Madam Speaker, your Reference Committee recommends
32 that the first Resolve of Resolution 426 be amended by
33 deletion to read as follows:
34

35 RESOLVED, That our AMA work with an accrediting
36 organization, such as National Commission on Correctional
37 Health Care (NCCHC), ~~American Correctional Association~~
38 ~~(ACA) and others with accreditation expertise,~~ in developing
39 a strategy to accredit all correctional, detention and juvenile
40 facilities;
41

42 RECOMMENDATION B:
43

44 Madam Speaker, your Reference Committee recommends
45 that the second Resolve of Resolution 426 be amended by
46 addition and deletion to read as follows:
47

48 RESOLVED, That our AMA advocate that all correctional,
49 detention and juvenile facilities be accredited by ~~a national~~
50 ~~accrediting organization, such as the NCCHC or ACA,~~ no

1 later than 2025; and support funding for correctional
2 facilities to assist in this effort.

3
4 RECOMMENDATION C:

5
6 Madam Speaker, your Reference Committee recommends
7 that the Resolution 426 be adopted as amended.

8
9 Resolution 426 asks that our AMA work with an accrediting organization, such as National
10 Commission on Correctional Health Care (NCCHC), American Correctional Association
11 (ACA) and others with accreditation expertise, in developing a strategy to accredit all
12 correctional, detention and juvenile facilities and advocate that all correctional, detention and
13 juvenile facilities be accredited by a national accrediting organization, such as the NCCHC or
14 ACA, no later than 2025.

15
16 Your Reference Committee heard testimony in support of Resolution 426. It was suggested
17 that 90% of correctional facilities in the United States have no oversight even though
18 accreditation is considered important in demonstrating adequate health care provisions. The
19 National Commission of Correctional Health Care (NCCHC) testified that other organizations
20 suggested in the resolution were not accredited based solely on health care, and that this
21 distinction was important. Additional testimony noted the importance of securing funds to
22 support the work outlined in this resolution. Therefore, your Reference Committee
23 recommends that Resolution 426 be adopted as amended.

24
25 (25) RESOLUTION 428 – DANGERS OF VAPING

26
27 RECOMMENDATION A:

28
29 Madam Speaker, your Reference Committee recommends that
30 Policy H-495.989 be amended by addition and deletion to read
31 as follows:

32
33 Tobacco Product Labeling H-495.989

34
35 Our AMA: (1) supports requiring more explicit and effective
36 health warnings, such as graphic warning labels, regarding the
37 use of tobacco (and alcohol) products (including but not limited
38 to, cigarettes, smokeless tobacco, chewing tobacco, and
39 hookah/water pipe tobacco, and ingredients
40 of tobacco products sold in the United States); (2) encourages
41 the Food and Drug Administration, as required under Federal
42 law, to revise its rules to require color graphic warning labels on
43 all cigarette packages depicting the negative health
44 consequences of smoking; (3) supports legislation or
45 regulations that require (a) tobacco companies to accurately
46 label their products, including electronic nicotine delivery
47 systems (ENDS), indicating nicotine content in easily
48 understandable and meaningful terms that have plausible
49 biological significance; (b) picture-based warning labels
50 on tobacco products produced in, sold in, or exported from the
51 United States; (c) an increase in the size of warning labels to

1 include the statement that smoking is ADDICTIVE and may
2 result in DEATH; and (d) all advertisements for cigarettes and
3 each pack of cigarettes to carry a legible, boxed warning such
4 as: "Warning: Cigarette Smoking causes CANCER OF THE
5 MOUTH, LARYNX, AND LUNG, is a major cause of HEART
6 DISEASE AND EMPHYSEMA, is ADDICTIVE, and may result
7 in DEATH. Infants and children living with smokers have an
8 increased risk of respiratory infections and cancer;" ~~and~~(4)
9 urges the Congress to require that: (a) warning labels on
10 cigarette packs should appear on the front and the back and
11 occupy twenty-five percent of the total surface area on each
12 side and be set out in black-and-white block; (b) in the case of
13 cigarette advertisements, warning labels of cigarette packs
14 should be moved to the top of the ad and should be enlarged to
15 twenty-five percent of total ad space; and (c) warning labels
16 following these specifications should be included on cigarette
17 packs of U.S. companies being distributed for sale in foreign
18 markets; and (4) supports requiring warning labels on all ENDS
19 products.

20
21 RECOMMENDATION B:

22
23 Madam Speaker, your Reference Committee recommends that
24 Policy H-495.989 be adopted as amended in lieu of Resolution
25 428.

26
27 Resolution 428 asks that our American Medical Association amend existing policy H-495.986,
28 "Sales and Distribution of Tobacco Products and Electronic Nicotine Delivery Systems
29 (ENDS) and E cigarettes," by addition to read as follows:

30
31 Our AMA: (1) recognizes the use of e-cigarettes and vaping as an urgent public health
32 epidemic and will actively work with the Food and Drug Administration and other
33 relevant stakeholders to counteract the marketing and use of addictive e-cigarette and
34 vaping devices, including but not limited to bans and strict restrictions on marketing to
35 minors under the age of 21 and requirements to include warning labels on all electronic
36 nicotine delivery systems (ENDS);(2) encourages the passage of laws, ordinances
37 and regulations that would set the minimum age for purchasing tobacco products,
38 including electronic nicotine delivery systems (ENDS) and e-cigarettes, at 21 years
39 and require warning labels on all ENDS, and urges strict enforcement of laws
40 prohibiting the sale of tobacco products to minors; (3) supports the development of
41 model legislation regarding enforcement of laws restricting children's access to
42 tobacco, including but not limited to attention to the following issues: (a) provision for
43 licensure to sell tobacco and for the revocation thereof; (b) appropriate civil or criminal
44 penalties (e.g., fines, prison terms, license revocation) to deter violation of laws
45 restricting children's access to and possession of tobacco; (c) requirements for
46 merchants to post notices warning minors against attempting to purchase tobacco and
47 to obtain proof of age for would-be purchasers; (d) measures to facilitate enforcement;
48 (e) banning out-of-package cigarette sales ("loosies"); and (f) requiring tobacco
49 purchasers and vendors to be of legal smoking age; and (g) requirements for warning
50 labels on all ENDS; (4) requests that states adequately fund the enforcement of the
51 laws related to tobacco sales to minors; (5) opposes the use of vending machines to

1 distribute tobacco products and supports ordinances and legislation to ban the use of
2 vending machines for distribution of tobacco products; (6) seeks a ban on the
3 production, distribution, and sale of candy products that depict or resemble tobacco
4 products; (7) opposes the distribution of free tobacco products by any means and
5 supports the enactment of legislation prohibiting the disbursement of samples of
6 tobacco and tobacco products by mail; (8) (a) publicly commends (and so urges local
7 medical societies) pharmacies and pharmacy owners who have chosen not to sell
8 tobacco products, and asks its members to encourage patients to seek out and
9 patronize pharmacies that do not sell tobacco products; (b) encourages other
10 pharmacists and pharmacy owners individually and through their professional
11 associations to remove such products from their stores; (c) urges the American
12 Pharmacists Association, the National Association of Retail Druggists, and other
13 pharmaceutical associations to adopt a position calling for their members to remove
14 tobacco products from their stores; and (d) encourages state medical associations to
15 develop lists of pharmacies that have voluntarily banned the sale of tobacco for
16 distribution to their members; and (9) opposes the sale of tobacco at any facility where
17 health services are provided; and (10) supports that the sale of tobacco products be
18 restricted to tobacco specialty stores. (Modify Current HOD Policy)
19

20 Your Reference Committee heard testimony that was mostly supportive of the intent of this
21 resolution. Your Reference Committee felt that the best place for this language was in the
22 AMA's existing policy on tobacco product labeling rather than the policy on sales and
23 distribution. Therefore, your Reference Committee recommends amending existing policy in
24 lieu of Resolution 428.
25

26 (26) RESOLUTION 432 – DECRIMINALIZATION OF HUMAN
27 IMMUNODEFICIENCY VIRUS (HIV) STATUS NON-
28 DISCLOSURE IN VIRALLY SUPPRESSED INDIVIDUALS
29

30 RECOMMENDATION A:

31
32 Madam Speaker, your Reference Committee recommends
33 that Resolution 432 be amended by addition and deletion to
34 read as follows:
35

36 RESOLVED, That our American Medical Association
37 ~~support repealing~~ advocate for repeal of legislation that
38 criminalizes non-disclosure of Human Immunodeficiency
39 Virus (HIV) status for people living with HIV ~~who have an~~
40 ~~undetectable viral load~~. (New HOD Policy)
41

42 RECOMMENDATION B:

43
44 Madam Speaker, your Reference Committee recommends
45 that Resolution 432 be adopted as amended.
46

47 RECOMMENDATION C:

48
49 Madam Speaker, your Reference Committee recommends
50 that the title of Resolution 432 be changed to read as
51 follows:

1 DECRIMINALIZATION OF HUMAN IMMUNODEFICIENCY
2 VIRUS (HIV) STATUS NON-DISCLOSURE
3

4 Resolution 432 asks that our AMA support repealing legislation that criminalizes non-
5 disclosure of Human Immunodeficiency Virus (HIV) status for people living with HIV who have
6 an undetectable viral load.
7

8 Your Reference Committee heard testimony that was mostly supportive of the intent of this
9 resolution. Generally, it was felt that criminalization laws are outdated and do not reflect the
10 current science of HIV transmission or the fact that HIV is a chronic, but manageable medical
11 condition. There was some discussion that focused on the need to reduce stigma outside of
12 decriminalization, but others noted that stigma and decriminalization were linked. Your
13 Reference Committee considered the fact that non-disclosure of other infectious diseases are
14 not criminalized and supported the language removing reference to the language an
15 “undetectable viral load.” Therefore, your Reference Committee recommends that Resolution
16 432 be adopted as amended.
17

18 (27) RESOLUTION 433 – TRANSFORMATION OF RURAL
19 COMMUNITY PUBLIC HEALTH SYSTEMS
20

21 RECOMMENDATION A:
22

23 Madam Speaker, your Reference Committee recommends
24 that Resolution 433 be amended by addition and deletion to
25 read as follows:
26

27 RESOLVED, That our American Medical Association work
28 with other entities and organizations interested in public
29 health to:

30 -Identify and disseminate concrete examples of
31 administrative leadership and funding structures that
32 support and optimize local, community-based rural public
33 health

34 -Develop an actionable advocacy plan to positively impact
35 local, community-based rural public health including but not
36 limited to the development of rural public health networks,
37 training of current and future rural physicians in core public
38 health techniques and novel funding mechanisms to support
39 public health initiatives that are led and managed by local
40 public health authorities

41 - ~~Periodically~~ Study efforts to optimize rural public health.
42 (Directive to Take Action)
43

44 RECOMMENDATION B:
45

46 Madam Speaker, your Reference Committee recommends
47 that Resolution 433 be adopted as amended.
48

49 Resolution 433 asks that our AMA work with other entities and organizations interested in
50 public health to: (1) identify and disseminate concrete examples of administrative leadership

1 and funding structures that support and optimize local, community-based rural public health
2 and (2) develop an actionable advocacy plan to positively impact local, community-based rural
3 public health including but not limited to the development of rural public health networks,
4 training of current and future rural physicians in core public health techniques and novel
5 funding mechanisms to support public health initiatives that are led and managed by local
6 public health authorities. Resolution 433 also asks the AMA to periodically study efforts to
7 optimize rural public health.

8
9 Your Reference Committee heard testimony largely in support of this resolution. The Council
10 on Science and Public Health supported a study, but suggested starting with one study rather
11 than periodic studies; this friendly amendment was acknowledged by the author. Your
12 Reference Committee recommends that Resolution 433 be adopted as amended.

13
14 (28) RESOLUTION 402 – BULLYING IN THE PRACTICE OF
15 MEDICINE

16
17 RECOMMENDATION:

18
19 Madam Speaker, your Reference Committee recommends that
20 Resolution 402 be referred.

21
22 Resolution 402 asks that our AMA help establish a clear definition of professional bullying,
23 establish prevalence and impact of professional bullying, and establish guidelines for
24 prevention of professional bullying with a report back at the 2020 Annual Meeting.

25
26 Your Reference Committee heard testimony that was in support of Resolution 402. This
27 resolution is calling for a study on the issue of professional bullying; specifically, requests to
28 define professional bullying, how it may appear within the field of medicine, and potential
29 strategies to prevent it. Therefore, your Reference Committee recommends that Resolution
30 402 be referred for study.

31
32 (29) RESOLUTION 408 – BANNING EDIBLE CANNABIS
33 PRODUCTS

34
35 RECOMMENDATION:

36
37 Madam Speaker, your Reference Committee recommends
38 that Resolution 408 be referred.

39
40 Resolution 408 asks that our AMA adopt policy supporting a total ban on recreational edible
41 cannabis products and support or cause to be introduced legislation to ban all recreational
42 edible cannabis products.

43
44 Your Reference Committee heard mixed testimony on this resolution. It is clear that edible
45 cannabis products are a growing industry in the states that have legalized the sale of
46 recreational cannabis. Products in forms that appeal to children have led to unintentional
47 ingestion. A number of questions were raised regarding appropriate terminology and the
48 application of this ban to cannabidiol products. Given these questions, your Reference
49 Committee believes referral for study is warranted.

1 (30) RESOLUTION 411 – AMA TO ANALYZE BENEFITS /
2 HARMS OF LEGALIZATION OF MARIJUANA

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 411 be referred.

8
9 Resolution 411 asks that our AMA review pertinent data from those states that have legalized
10 marijuana.

11
12 Your Reference Committee heard testimony indicating that a lot has happened in the states
13 since the Council on Science and Public Health’s last report on this topic in 2017. There was
14 tremendous support for a review of the data from states that have legalized cannabis.
15 Therefore, your Reference Committee recommends referral of Resolution 411.

16
17 (31) RESOLUTION 414 – PATIENT MARIJUANA USE IN
18 HOSPITALS

19
20 RECOMMENDATION:

21
22 Madam Speaker, your Reference Committee recommends
23 that Resolution 414 be referred.

24
25 Resolution 414 asks that our AMA offer guidance to medical staffs regarding patient use of
26 non-US Food and Drug Administration approved medical marijuana and cannabinoids on
27 hospital property, including product use, storage in patient rooms, nursing areas and/or
28 pharmacy, with report back to the House of Delegates at the 2019 Interim Meeting.

29
30 Your Reference Committee heard conflicting testimony on Resolution 414. It was noted that
31 the AMA does not support the legalization of cannabis for medical purposes through the
32 legislative, referendum, or ballot measure process. Some members testified that guidance
33 from the AMA on this issue would be helpful. Others testified that the AMA should leave this
34 alone, have the hospital associations address this issue, or refer further study. Your Reference
35 Committee agrees that referral is appropriate.

36
37 (32) RESOLUTION 424 – PHYSICIAN INVOLVEMENT IN
38 STATE REGULATIONS OF MOTOR VEHICLE
39 OPERATION AND/OR FIREARM USE BY INDIVIDUALS
40 WITH COGNITIVE DEFICITS DUE TO TRAUMATIC
41 BRAIN INJURY

42
43 RECOMMENDATION:

44
45 Madam Speaker, your Reference Committee recommends
46 that Resolution 424 be referred.

47
48 Resolution 424 asks that our AMA reaffirm current AMA policy, H 145.999, “Gun Regulation,”
49 stating it supports stricter enforcement of current federal and state gun legislation and

1 advocate for physician-led committees in each state to give further recommendations to the
2 state regarding driving and/or gun use by individuals who are cognitively impaired and/or a
3 danger to themselves or others.

4
5 Your Reference Committee heard mixed testimony on this resolution and numerous calls for
6 referral. The resolution covers the issues of traumatic brain injury, cognitive decline, firearm
7 use, and driving. Some noted that the issues of firearm use and driving motor vehicles should
8 be considered separately and others noted the complexity around traumatic brain injuries and
9 cognitive decline. Your Reference Committee believes that a study on this issue would be
10 beneficial to offer guidance to physicians.

11
12 (33) RESOLUTION 430 – COMPASSIONATE RELEASE FOR
13 INCARCERATED PATIENTS

14
15 RECOMMENDATION:

16
17 Madam Speaker, your Reference Committee recommends
18 that Resolution 430 be referred.

19
20 Resolution 430 asks that our AMA: (1) support policies that facilitate compassionate release
21 on the basis of serious medical conditions and advanced age; (2) collaborate with appropriate
22 stakeholders to draft model legislation that establishes clear, evidence-based eligibility criteria
23 for timely compassionate release; and (3) promote transparent reporting of compassionate
24 release statistics, including numbers and demographics of applicants, approvals, denials, and
25 revocations, and justifications for decisions.

26
27 Your Reference Committee heard testimony in support of the resolution. However, testimony
28 also called for additional study to better understand the points raised and guide the AMA's
29 course of action. Therefore, your Reference Committee recommends that Resolution 430 be
30 referred.

31
32 (34) RESOLUTION 418 – ELIMINATING THE DEATH TOLL
33 FROM COMBUSTIBLE CIGARETTES

34
35 RECOMMENDATION:

36
37 Madam Speaker, your Reference Committee recommends
38 that Resolution 418 be referred for decision.

39
40 Resolution 418 asks that our AMA study and report on the conditions under which our country
41 could successfully eliminate the manufacture, distribution, and sale of combustible cigarettes
42 and other combustible tobacco products at the earliest feasible date.

43
44 Your Reference Committee heard testimony in support of the concept of this resolution. Some
45 members encouraged the Council on Science and Public Health to imagine that this could
46 happen, while others cautioned that this is “pie in the sky.” It was suggested that this not be
47 limited to combustible cigarettes given the epidemic of e-cigarette use among youth. The
48 Council on Science and Public Health noted that the Family Smoking Prevention and Tobacco
49 Control Act prohibits banning certain classes of tobacco products and noted Native American
50 tribes, as sovereign nations and self-governing entities, are able to engage in a variety of on-

1 reservation and off-reservation commercial tobacco activities. Given these concerns, your
2 Reference Committee recommends referral for decision.

3
4 (35) RESOLUTION 409 – ADDRESSING THE VAPING CRISIS

5
6 RECOMMENDATION:

7
8 Madam Speaker, your Reference Committee recommends
9 that Resolution 409 not be adopted.

10
11 Resolution 409 asks that our AMA advocate to the Food and Drug Administration that vaping
12 devices should be available only by prescription for smokers who are trying to quit smoking.

13
14 Your Reference Committee heard testimony on the magnitude of the vaping crisis in the
15 United States and use of vaping devices for smoking cessation. Testimony from the Food and
16 Drug Administration noted that the Family Smoking and Tobacco Control Act prohibits making
17 tobacco products, including vaping devices, available by prescription only. Furthermore, there
18 is no evidence to support the use of vaping devices for the purposes of tobacco cessation.
19 For these reasons, your Reference Committee recommends that Resolution 409 not be
20 adopted.

21
22 (36) RESOLUTION 431 – ELIMINATING
23 RECOMMENDATIONS TO RESTRICT DIETARY
24 CHOLESTEROL AND FAT

25
26 RECOMMENDATION:

27
28 Madam Speaker, your Reference Committee recommends
29 that Resolution 431 not be adopted.

30
31 Resolution 431 asks that American Medical Association amend Policy H-150.944, “Combating
32 Obesity and Health Disparities,” by addition and deletion to read as follows:

33
34 H-150.944 Combating Obesity and Health Disparities

35 Our AMA supports efforts to: (1) reduce health disparities by basing food assistance
36 programs on the health needs of their constituents; (2) provide vegetables, fruits,
37 legumes, grains, vegetarian foods, and healthful dairy and nondairy beverages in
38 school lunches and food assistance programs; and (3) ensure that federal subsidies
39 encourage the consumption of ~~foods and beverages low in fat, added sugars, and~~
40 ~~cholesterol,~~ healthful foods and beverages. (Modify Current HOD Policy)

41
42 Your Reference Committee heard testimony that opposed removing dietary cholesterol and
43 fat restriction language from current AMA policy. Cardiovascular disease, specifically the 2019
44 ACC/AHA Guidelines on the Primary Prevention of Cardiovascular Disease, was addressed
45 by several speakers in support of the AMA’s existing policy. Therefore, your Reference
46 Committee recommends that Resolution 431 not be adopted.

1 (37) RESOLUTION 412 – REGULATING LIQUID NICOTINE
2 AND E-CIGARETTES

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that Policy H-495.988 be reaffirmed in lieu of Resolution
8 412.

9
10 Resolution 412 asks that our AMA seek legislation or regulations that limit higher
11 concentration nicotine salts (greater than 10mg) in nicotine vaping pods and restrict bulk sale
12 of vaping products and associated paraphernalia.

13
14 Your Reference Committee heard mixed testimony on this resolution. Your Reference
15 Committee discussed the perspectives and noted that AMA policy encourages the FDA and
16 other appropriate agencies to conduct or fund research on how tobacco products might be
17 modified to facilitate cessation of use, including elimination of nicotine and elimination of
18 additives that enhance addictiveness. Based on this policy, the AMA has called on the FDA
19 to create a non-addictive nicotine level standard for all tobacco products – including electronic
20 nicotine delivery systems (ENDS), “heat not burn products,” and any other tobacco products
21 containing nicotine for recreational use. That level would likely be well below the 10 mg called
22 for in this resolution as the nicotine level for combustible tobacco products is 0.4 mg/g.
23 Therefore, your Reference Committee recommends that Policy H-495.988 be reaffirmed in
24 lieu of Resolution 412.

25
26 Policy recommended for reaffirmation:

27
28 Policy H-495.988, “FDA Regulation of Tobacco Products”

29 1. Our AMA: (A) acknowledges that all tobacco products (including but not limited to,
30 cigarettes, smokeless tobacco, chewing tobacco, and hookah/water pipe tobacco) are
31 harmful to health, and that there is no such thing as a safe cigarette; (B) recognizes
32 that currently available evidence from short-term studies points to electronic cigarettes
33 as containing fewer toxicants than combustible cigarettes, but the use of electronic
34 cigarettes is not harmless and increases youth risk of using combustible tobacco
35 cigarettes; (C) encourages long-term studies of vaping (the use of electronic nicotine
36 delivery systems) and recognizes that complete cessation of the use of tobacco and
37 nicotine-related products is the goal; (D) asserts that tobacco is a raw form of the drug
38 nicotine and that tobacco products are delivery devices for an addictive substance; (E)
39 reaffirms its position that the Food and Drug Administration (FDA) does, and should
40 continue to have, authority to regulate tobacco products, including their manufacture,
41 sale, distribution, and marketing; (F) strongly supports the substance of the August
42 1996 FDA regulations intended to reduce use of tobacco by children and adolescents
43 as sound public health policy and opposes any federal legislative proposal that would
44 weaken the proposed FDA regulations; (G) urges Congress to pass legislation to
45 phase in the production of less hazardous and less toxic tobacco, and to authorize the
46 FDA have broad-based powers to regulate tobacco products; (H) encourages the FDA
47 and other appropriate agencies to conduct or fund research on how tobacco products
48 might be modified to facilitate cessation of use, including elimination of nicotine and
49 elimination of additives (e.g., ammonia) that enhance addictiveness; and (I) strongly

1 opposes legislation which would undermine the FDA's authority to regulate tobacco
2 products and encourages state medical associations to contact their state delegations
3 to oppose legislation which would undermine the FDA's authority to regulate tobacco
4 products. 2. Our AMA: (A) supports the US Food and Drug Administration (FDA) as it
5 takes an important first step in establishing basic regulations of all tobacco products;
6 (B) strongly opposes any FDA rule that exempts any tobacco or nicotine-containing
7 product, including all cigars, from FDA regulation; and (C) will join with physician and
8 public health organizations in submitting comments on FDA proposed rule to regulate
9 all tobacco products.

10
11 (38) RESOLUTION 434 – CHANGE IN MARIJUANA
12 CLASSIFICATION TO ALLOW RESEARCH

13
14 RECOMMENDATION:

15
16 Madam Speaker, your Reference Committee recommends
17 that Policy H-95.952 be reaffirmed in lieu of Resolution 434.

18
19 Resolution 434 asks that our AMA petition the US Food and Drug Administration / US Drug
20 Enforcement Administration to change the schedule classification of marijuana so that it can
21 be subjected to appropriate research.

22
23 Your Reference Committee heard testimony supportive of advancing research on cannabis.
24 Some called for rescheduling cannabis to Schedule II, while others noted that the AMA's
25 existing policy gets this right and that moving cannabis to Schedule II is not possible without
26 an amendment to the Controlled Substances Act. The Council on Legislation testified that the
27 AMA has been working with members of Congress and the administration on legislation to
28 eliminate the barriers to researching cannabis and cannabidiol, which stipulates leaving
29 cannabis in Schedule I. Your Reference Committee agrees that the AMA's existing policy gets
30 this right and therefore recommends reaffirming H-95.952 in lieu of Resolution 434.

31
32 Policy recommended for reaffirmation:

33
34 Policy H-95.952, "Cannabis and Cannabinoid Research"

35 1. Our AMA calls for further adequate and well-controlled studies of marijuana and
36 related cannabinoids in patients who have serious conditions for which preclinical,
37 anecdotal, or controlled evidence suggests possible efficacy and the application of
38 such results to the understanding and treatment of disease. 2. Our AMA urges that
39 marijuana's status as a federal schedule I controlled substance be reviewed with the
40 goal of facilitating the conduct of clinical research and development of cannabinoid-
41 based medicines, and alternate delivery methods. This should not be viewed as an
42 endorsement of state-based medical cannabis programs, the legalization of
43 marijuana, or that scientific evidence on the therapeutic use of cannabis meets the
44 current standards for a prescription drug product. 3. Our AMA urges the National
45 Institutes of Health (NIH), the Drug Enforcement Administration (DEA), and the Food
46 and Drug Administration (FDA) to develop a special schedule and implement
47 administrative procedures to facilitate grant applications and the conduct of well-
48 designed clinical research involving cannabis and its potential medical utility. This
49 effort should include: a) disseminating specific information for researchers on the
50 development of safeguards for cannabis clinical research protocols and the
51 development of a model informed consent form for institutional review board

1 evaluation; b) sufficient funding to support such clinical research and access for
2 qualified investigators to adequate supplies of cannabis for
3 clinical research purposes; c) confirming that cannabis of various and consistent
4 strengths and/or placebo will be supplied by the National Institute on Drug Abuse to
5 investigators registered with the DEA who are conducting bona fide
6 clinical research studies that receive FDA approval, regardless of whether or not the
7 NIH is the primary source of grant support. 4. Our AMA supports research to determine
8 the consequences of long-term cannabis use, especially among youth, adolescents,
9 pregnant women, and women who are breastfeeding. 5. Our AMA urges legislatures
10 to delay initiating the legalization of cannabis for recreational use until
11 further research is completed on the public health, medical, economic, and social
12 consequences of its use.

Madam Speaker, this concludes the report of Reference Committee D. I would like to thank the members of the committee: Robert Dannenhoffer, MD, James D. Felsen, MD, MPH, Vito Imbasciani, MD, PhD, Shilpen A. Patel, MD, Rohan Rastogi, MPH, Kevin E. Taubman, MD; our AMA staff: Andrea Garcia, Rebecca Benson, Andrea Houlihan, and Amber Ryan; and all those who testified before the Committee.

Robert Dannenhoffer, MD
Oregon

James D. Felsen, MD, MPH
West Virginia

Vito Imbasciani, PhD, MD
California

Shilpen A. Patel, MD
American Society for Radiation
Oncology

Rohan Rastogi, MPH (Alternate)
Massachusetts

Kevin E. Taubman, MD
Oklahoma

Diana E. Ramos, MD, MPH
American College of Obstetricians and
Gynecologists
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (A-19)

Report of Reference Committee E

Leslie H. Secrest, MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:
2

3 **RECOMMENDED FOR ADOPTION**

- 4
5 1. Resolution 502 – Destigmatizing the Language of Addiction
6 2. Resolution 511 – Mandating Critical Congenital Heart Defect Screening in
7 Newborns
8 3. Resolution 519 – Childcare Availability for Persons Receiving Substance Use
9 Disorder Treatment
10 4. Resolution 524 – Availability of Naloxone Boxes
11 5. Resolution 528 – Developing Diagnostic Criteria and Evidence-Based Treatment
12 Options for Problematic Pornography Viewing
13 6. Resolution 532 – Dispelling Myths of Bystander Opioid Overdose
14

15 **RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED**

- 16
17 7. Council on Science and Public Health Report 1 – CSAPH Sunset Review of 2009
18 House of Delegates Policies
19 8. Resolution 501 – USP 800
20 9. Resolution 503 – Addressing Healthcare Needs of Children of Incarcerated
21 Parents
22 Resolution 531 – Support for Children of Incarcerated Parents
23 10. Resolution 504 – Screening, Intervention, and Treatment for Adverse Childhood
24 Experiences
25 Resolution 526 – Trauma-Informed Care Resources and Settings
26 11. Resolution 508 – Benzodiazepine and Opioid Warning
27 12. Resolution 510 – The Intracranial Hemorrhage Anticoagulation Reversal (ICHAR)
28 Initiative
29 13. Resolution 512 – Fertility Preservation in Pediatric and Reproductive Aged
30 Cancer Patients
31 14. Resolution 513 – Determining Why Infertility Rates Differ Between Military and
32 Civilian Women
33 15. Resolution 514 – Opioid Addiction
34 16. Resolution 515 – Reversing Opioid Epidemic
35 17. Resolution 516 – Alcohol Consumption and Health
36 18. Resolution 517 – Compounding
37 19. Resolution 520 – Substance Use During Pregnancy
38 20. Resolution 522 – Improved Deferral Periods for Blood Donors
39 21. Resolution 525 – Support for Rooming-in of Neonatal Abstinence Syndrome
40 Patients with Their Parents
41 22. Resolution 527 – Increasing the Availability of Bleeding Control Supplies
42 23. Resolution 529 – Adverse Impacts of Delaying the Implementation of Public
43 Health Regulations

1 **RECOMMENDED FOR REFERRAL**

2

- 3 24. Resolution 518 – Chemical variability in pharmaceutical products

4

5 **RECOMMENDED FOR REFERRAL FOR DECISION**

6

- 7 25. Resolution 507 – Removing Ethylene Oxide as a Medical Sterilant from
8 Healthcare

9

10 **RECOMMENDED FOR NOT ADOPTION**

11

- 12 26. Resolution 530 – Implementing Naloxone Training into the Basic Life Support
13 Certification Program

14

15 **RECOMMENDED FOR REAFFIRMATION IN LIEU OF**

16

- 17 27. Resolution 505 – Glyphosate Studies

Resolutions handled via the Reaffirmation Consent Calendar:

Resolution 506 – Clarify Advertising and Contents of Herbal Remedies and Dietary
Supplements

Resolution 509 – Addressing Depression to Prevent Suicide Epidemic

Resolution 523 – Availability and Use of Low Starting Opioid Doses

Resolution 521 – Put Over-the-Counter Inhaled Epinephrine Behind Pharmacy Counter

1 (1) RESOLUTION 502 – DESTIGMATIZING THE LANGUAGE
2 OF ADDICTION

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends that
7 Resolution 502 be adopted.

8
9 Resolution 502 asks that our American Medical Association (AMA) use clinically accurate,
10 non-stigmatizing terminology (substance use disorder, substance misuse, recovery,
11 negative/positive urine screen) in all future resolutions, reports, and educational materials
12 regarding substance use and addiction and discourage the use of stigmatizing terms including
13 substance abuse, alcoholism, clean and dirty and that our AMA and relevant stakeholders
14 create educational materials on the importance of appropriate use of clinically accurate, non-
15 stigmatizing terminology and encourage use among all physicians and U.S. healthcare
16 facilities.

17
18 Your Reference Committee heard testimony unanimously in favor of this resolution.
19 Testimony noted that much of the terminology typically used around persons with substance
20 use disorder is not clinically accurate and not in line with terminology used with other medical
21 disorders. Words such as “abuse, junkie, dirty/clean tests,” and other commonly used terms
22 convey stigma that can negatively affect physician’s attitudes, interfere with good patient care
23 and negatively affect patient outcomes. Multiple parties testified that organizations and
24 government entities such as the International Classification of Diseases (ICD), the Substance
25 Abuse and Mental Health Services Administration (SAMHSA), and the National Institutes of
26 Health (NIH), are either changing their own language accordingly or being challenged to do
27 so. There was compelling testimony from the US Surgeon General that physicians should be
28 “wrapping our arms around” people who have substance use disorder instead of stigmatizing
29 them. The testimony reflects that the ask of this resolution to replace stigmatizing terms
30 regarding substance use disorder and persons with substance use disorder with non-
31 stigmatizing terminology in AMA materials going forward is reasonable and in line with current
32 AMA policy/efforts as well as actions and statements from other high level and authoritative
33 bodies. Therefore, your Reference Committee recommends that Resolution 502 be adopted.

34
35 (2) RESOLUTION 511 – MANDATING CRITICAL CONGENITAL
36 HEART DEFECT SCREENING IN NEWBORNS

37
38 RECOMMENDATION:

39
40 Madam Speaker, your Reference Committee recommends that
41 Resolution 511 be adopted.

42
43 Resolution 511 asks that our American Medical Association support screening for critical
44 congenital heart defects for newborns following delivery prior to hospital discharge.

45
46 Your Reference Committee heard strong support for this resolution. Testimony noted that
47 Critical Congenital Heart Defect (CCHD) Screening is an important element of uniform
48 newborn screening, and that it has already been adopted by all 50 states. Therefore, your
49 Reference Committee recommends that Resolution 511 be adopted.

1 (3) RESOLUTION 519 – CHILDCARE AVAILABILITY FOR
2 PERSONS RECEIVING SUBSTANCE USE DISORDER
3 TREATMENT
4

5 RECOMMENDATION:
6

7 Madam Speaker, your Reference Committee recommends that
8 Resolution 519 be adopted.
9

10 Resolution 519 asks that our American Medical Association support the implementation of
11 childcare resources in existing substance use treatment facilities and acknowledge childcare
12 infrastructure and support as a major priority in the development of new substance use
13 programs.
14

15 Your Reference Committee heard testimony strongly in favor of this resolution. Evidence
16 about the need for childcare services in addiction treatment primarily for women with children
17 was noted. Testimony was heard that lack of childcare is a significant barrier to treatment and
18 one among multiple barriers for women who have substance use disorder. Testimony
19 supported the AMA calling for increasing capacity for childcare in addiction treatment settings
20 and including childcare in the development of new treatment programs to help reduce barriers
21 to treatment and to reduce incidents of young children and infants being separated from
22 parents. Therefore, your Reference Committee recommends that Resolution 519 be adopted.
23

24 (4) RESOLUTION 524 – AVAILABILITY OF NALOXONE BOXES
25

26 RECOMMENDATION A:
27

28 Madam Speaker, your Reference Committee recommends that
29 resolution 524 be adopted.
30

31 Resolution 524 asks that our American Medical Association (AMA) support the legal access
32 to and use of naloxone in all public spaces regardless of whether the individual holds a
33 prescription and that our AMA amend policy H-95.932, “Increasing Availability of Naloxone,”
34 by addition and deletion as follows:

35 1. Our AMA supports legislative, regulatory, and national advocacy efforts to increase
36 access to affordable naloxone, including but not limited to collaborative practice
37 agreements with pharmacists and standing orders for pharmacies and, where
38 permitted by law, community-based organizations, law enforcement agencies,
39 correctional settings, schools, and other locations that do not restrict the route of
40 administration for naloxone delivery. 2. Our AMA supports efforts that enable law
41 enforcement agencies to carry and administer naloxone. 3. Our AMA encourages
42 physicians to co-prescribe naloxone to patients at risk of overdose and, where
43 permitted by law, to the friends and family members of such patients. 4. Our AMA
44 encourages private and public payers to include all forms of naloxone on their
45 preferred drug lists and formularies with minimal or no cost sharing. 5. Our AMA
46 supports liability protections for physicians and other health care professionals and
47 others who are authorized to prescribe, dispense and/or administer naloxone pursuant
48 to state law. 6. Our AMA supports efforts to encourage individuals who are authorized
49 to administer naloxone to receive appropriate education to enable them to do so
50 effectively. 7. Our AMA encourages manufacturers or other qualified sponsors to
51 pursue the application process for over the counter approval of naloxone with the Food

1 and Drug Administration. 8. Our AMA ~~urges the Food and Drug Administration to study~~
2 ~~the practicality and utility of~~ supports the widespread implementation of easily
3 accessible Naloxone rescue stations (public availability of Naloxone through wall-
4 mounted display/storage units that also include instructions) throughout the country
5 following distribution and legislative edicts similar to those for Automated External
6 Defibrillators.
7

8 Your Reference Committee heard unanimously supportive testimony for this Resolution,
9 including support from the U.S. Surgeon General. Your Reference Committee notes the
10 logistical issues associated with publicly available naloxone boxes. These issues include the
11 need for the FDA to regulate this practice and approve over-the-counter (OTC) availability of
12 a naloxone product that would be suitable for placement in a public setting and amenable to
13 untrained bystander use; a requirement for stability testing, expiration dating, and product
14 replacement; and the need to place the product for maximum effectiveness. Despite these
15 logistical issues, your Reference Committee understands the urgent need for the
16 implementation of this type of program, encourages the evaluation of the feasibility of
17 implementing this type of approach, and urges manufacturers and FDA to expedite the
18 availability of OTC naloxone so this ask can be accomplished. Therefore, your Reference
19 Committee recommends adoption of Resolution 524.
20

21 (5) RESOLUTION 528 – DEVELOPING DIAGNOSTIC
22 CRITERIA AND EVIDENCE-BASED TREATMENT
23 OPTIONS FOR PROBLEMATIC PORNOGRAPHY
24 VIEWING
25

26 RECOMMENDATION:
27

28 Madam Speaker, your Reference Committee
29 recommends that resolution 528 be adopted.
30

31 Resolution 528 asks that our American Medical Association support research on problematic
32 pornography use, including its physiological and environmental drivers, appropriate diagnostic
33 criteria, effective treatment options, and relationships to erectile dysfunction and domestic
34 violence.
35

36 Your Reference Committee heard largely supportive testimony for this resolution. It was noted
37 that current evidence was not conclusive to support diagnostic criteria, and that additional
38 study may be needed to determine what link, if any, there might be between problematic
39 pornography use and health conditions or domestic violence. Testimony noted that obsessive
40 and compulsive pornography viewing may be defined as problematic, which may also be
41 analogous to other conditions such as video games or gambling. Additional testimony offered
42 that other sexually explicit material use may be considered less problematic, such as use for
43 sample collection in fertility clinics. Therefore, your Reference Committee recommends that
44 Resolution 528 be adopted.

1 (6) RESOLUTION 532 – DISPELLING THE MYTHS OF
2 BYSTANDER OPIOID OVERDOSE

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends that
7 Resolution 532 be adopted.

8
9 Resolution 532 asks that our American Medical Association (AMA) work with appropriate
10 stakeholders to develop and disseminate educational materials aimed at dispelling the fear of
11 bystander overdose via inhalation or dermal contact with fentanyl or other synthetic
12 derivatives and that our AMA work with appropriate stakeholders to identify those professions,
13 such as first responders, most impacted by opioid overdose deaths in order to provide
14 targeted education to dispel the myth of bystander overdose via inhalation or dermal contact
15 with fentanyl or other synthetic derivatives.

16
17 Your Reference Committee heard largely supportive testimony related to this resolution.
18 Testimony from the authors strongly noted no verified evidence of any bystander opioid
19 overdoses. Isolated concerns were raised about the enhanced risks of contact with carfentanil
20 and other fentanyl analogs and the intense potency of these substances. However, no
21 evidence was presented that showed a high level of risk of meaningful exposure to these
22 analogs by first responders during the normal course of their duties and while taking normal,
23 appropriate precautions. Several parties noted the anxiety that inaccurate media articles
24 promote and that are not supported by any verifiable incidences. Although there is
25 acknowledgement of the potency of carfentanil and other fentanyl analogs, the committee and
26 testimony support the resolution to support first responders intervening in possible overdose
27 and other situations without undue fear of harm. Guidelines from the American Academy of
28 Clinical Toxicology and the American College of Medical Toxicology address potential
29 dangers of dermal and respiratory contact with fentanyl and its analogs to prevent
30 occupational exposure for emergency responders including the use of nitrile gloves and other
31 evidence-based precautions. Therefore, your Reference Committee recommends that
32 Resolution 532 be adopted.

1 (7) COUNCIL ON SCIENCE AND PUBLIC HEALTH REPORT 1 –
2 CSAPH SUNSET REVIEW OF 2009 HOUSE OF
3 DELEGATES POLICIES

4
5 RECOMMENDATION A:

6
7 Madam Speaker, your Reference Committee recommends that
8 the recommendation in Council on Science and Public Health
9 Report 1 be amended by addition to read as follows:

10
11 That the House of Delegates policies listed in the Appendix to
12 this report be acted upon in the manner indicated, with the
13 exception of Policy H-440.927 clause number 4, which should
14 be retained, and the remainder of the report be filed.

15
16 RECOMMENDATION B:

17
18 Madam Speaker, your Reference Committee recommends that
19 Council on Science and Public Health Report be adopted as
20 amended.

21
22 Council on Science and Public Health Report 1 presents the Council's recommendations on
23 the disposition of the House policies and directives from 2009 that were assigned to it. The
24 report recommends that House of Delegates policies that are listed in the Appendix to the
25 report be acted upon in the manner indicated and the remainder of the Report be filed.

26
27 The Council on Science and Public Health introduced its Sunset report, and testimony noted
28 that clause four of Policy H-440.927, "Tuberculosis," should be retained because controlling
29 tuberculosis globally is still important. Your Reference Committee agrees and therefore
30 recommends adoption as amended.

31
32 (8) RESOLUTION 501 – USP 800

33
34 RECOMMENDATION A:

35
36 Madam Speaker, your Reference Committee recommends that
37 the first Resolve of Resolution 501 be amended by deletion to
38 read as follows:

39
40 ~~RESOLVED, That our American Medical Association (AMA)~~
41 ~~adopt as policy that physicians and other health care providers~~
42 ~~administering medications (defined as the mixing or~~
43 ~~reconstituting of a drug according to manufacturers'~~
44 ~~recommendations for a single patient for immediate use) not be~~
45 ~~subject to the USP 800 compounding guidance (New HOD~~
46 ~~Policy); and be it further~~

1 RECOMMENDATION B:

2
3 Madam Speaker, your Reference Committee recommends that
4 the second Resolve of Resolution 501 be amended by deletion
5 to read as follows:

6
7 ~~RESOLVED, That our AMA support development of specialty~~
8 ~~specific white papers/best practices and systems for both safe~~
9 ~~medication administration practices and ongoing monitoring of~~
10 ~~potential complications from the administration of medications~~
11 ~~deemed suitable for exemptions from the National Institute for~~
12 ~~Occupational Safety and Health, United States Pharmacopeia,~~
13 ~~and other regulatory bodies when used in an office setting under~~
14 ~~the direction of a licensed physician (New HOD Policy); and be~~
15 ~~it further~~

16
17 RECOMMENDATION C:

18
19 Madam Speaker, your Reference Committee recommends that
20 the third Resolve of Resolution 501 be amended by addition and
21 deletion to read as follows:

22
23 RESOLVED, That our AMA continue its compounding working
24 group, consisting of national specialty organizations, state
25 medical societies, relevant agencies, and other appropriate
26 stakeholders to advocate for such exemptions appropriate
27 application of standards and to monitor policy impacting
28 physicians. (Directive to Take Action)

29
30 RECOMMENDATION D:

31
32 Madam Speaker, your Reference Committee recommends that
33 Resolution 501 be adopted as amended.

34
35 Resolution 501 asks that our American Medical Association (AMA) adopt as policy that
36 physicians and other health care providers administering medications (defined as the mixing
37 or reconstituting of a drug according to manufacturers' recommendations for a single patient
38 for immediate use) not be subject to the USP 800 compounding guidance, that our AMA
39 support development of specialty specific white papers/best practices and systems for both
40 safe medication administration practices and ongoing monitoring of potential complications
41 from the administration of medications deemed suitable for exemptions from the National
42 Institutes for Occupational Safety and Health, United States Pharmacopeia, and other
43 regulatory bodies when used in an office setting under the direction of a licensed physician,
44 and that our AMA continue its working group, consisting of national specialty organizations,
45 state medical societies and other stakeholders to advocate for such exemptions.

46
47 Your Reference Committee heard passionate testimony on this issue. Several people noted
48 the unintended consequences of the regulations outlined in <800>, yet others noted that the
49 drugs included in <800> are indeed hazardous to those handling them, warranting safety
50 standards for employees. USP offered testimony to clarify some of the points of the Resolution
51 stating that Resolves one and two are already being addressed by existing efforts in

1 collaboration with the AMA and appropriate stakeholders. The five-year chapter review
2 process is presently complete and there is no administrative mechanism for editing this
3 chapter at this time. USP also noted that the principles of <800> are broadly relevant to
4 hazardous drug handling activities across all facility types, and that they encourage the
5 widespread adoption and use of <800> across all healthcare settings. They further specified
6 that General Chapter <800> is compendially applicable – as opposed to informational – only
7 to the extent to which USP General Chapters <795> and <797>, which are limited to non-
8 sterile and sterile compounding respectively, apply. USP continued to note that State and
9 other regulators may make their own determinations regarding the applicability and
10 enforceability of <800> to entities within their jurisdiction, but that continued engagement with
11 the AMA and appropriate stakeholders to develop resources and tools designed to protect
12 patients and health care workers from potential harm of hazardous materials is a priority.
13 Therefore, your Reference Committee recommends that Resolution 501 be adopted as
14 amended.

15
16 (9) RESOLUTION 503 – ADDRESSING HEALTHCARE NEEDS
17 OF CHILDREN OF INCARCERATED PARENTS

18
19 RESOLUTION 531 – SUPPORT FOR CHILDREN OF
20 INCARCERATED PARENTS

21
22 RECOMMENDATION:

23
24 Madam Speaker, your Reference Committee recommends that
25 the following alternate Resolution 503 be adopted in lieu of
26 Resolutions 503 and 531:

27
28 CHILDREN OF INCARCERATED PARENTS

29
30 RESOLVED, That our American Medical Association support
31 comprehensive evidence-based care, legislation, and initiatives
32 that address the specific healthcare needs of children with
33 incarcerated parents and promote earlier intervention for those
34 children who as at risk. (New HOD Policy)

35
36 Resolution 503 asks that our American Medical Association support comprehensive and
37 evidence-based care that addresses the specific healthcare needs of children with
38 incarcerated parents and promote earlier intervention for those children who are at risk.

39
40 Resolution 531 asks that our American Medical Association support legislation and initiatives
41 that provide resources and support for children of incarcerated parents.

42
43 Your Reference Committee heard testimony unanimously in support of both of these closely
44 related resolutions. Therefore, your Reference Committee recommends that an alternate
45 Resolution, which is a combination of the asks of the similar and original Resolutions 503 and
46 531, be adopted in lieu of them.

1 (10) RESOLUTION 504 – SCREENING, INTERVENTION, AND
2 TREATMENT FOR ADVERSE CHILDHOOD EXPERIENCES

3
4 RESOLUTION 526 – TRAUMA-INFORMED CARE
5 RESOURCES AND SETTINGS

6
7 RECOMMENDATION:

8
9 Madam Speaker, your Reference Committee recommends that
10 the following alternate Resolution 504 be adopted in lieu of
11 Resolutions 504 and 526:

12
13 ADVERSE CHILDHOOD EXPERIENCES AND TRAUMA-
14 INFORMED CARE

15
16 RESOLVED, That our American Medical Association supports:

- 17 1. evidence-based primary prevention strategies for Adverse
18 Childhood Experiences (ACEs);
- 19 2. evidence-based trauma-informed care in all medical
20 settings that focuses on the prevention of poor health and
21 life outcomes after ACEs or other trauma occurs;
- 22 3. efforts for data collection, research and evaluation of cost-
23 effective ACEs screening tools without additional burden for
24 physicians;
- 25 4. efforts to educate physicians about the facilitators, barriers
26 and best practices for providers implementing ACEs
27 screening and trauma-informed care approaches into a
28 clinical setting; and
- 29 5. funding for schools, behavioral and mental health services,
30 professional groups, community and government agencies
31 to support patients with ACEs or trauma;
32 (New HOD Policy)

33
34 Resolution 504 asks that our American Medical Association (AMA) support efforts for data
35 collection, research and evaluation of Adverse Childhood Experiences (ACEs), cost-effective
36 ACE screening tools without additional burden for physicians, and effective interventions,
37 treatments and support services necessary for a positive screening practice in pediatric and
38 adult populations, that our AMA support efforts to educate physicians about the facilitators,
39 barriers and best practices for providers implementing ACE screening and trauma-informed
40 care approaches into a clinical setting, and that our AMA support additional funding sources
41 for schools, behavioral and mental health services, professional groups, community and
42 government agencies to support children and adults with ACEs.

43
44 Resolution 526 asks that our American Medical Association (AMA) recognize trauma-
45 informed care as a practice that recognizes the widespread impact of trauma on patients,
46 identifies the signs and symptoms of trauma, and treats patients by fully integrating knowledge
47 about trauma into policies, procedures, and practices and seeking to avoid re-traumatization
48 and that our AMA support trauma-informed care in all settings, including but not limited to
49 clinics, hospitals, and schools, by directing physicians and medical students to evidenced-
50 based resources.

1 Your Reference Committee heard overwhelmingly supportive testimony for both Resolution
2 504 and Resolution 526. Many commenters noted the relationship between ACEs and trauma
3 informed care. Many also commented that trauma is both physical and emotional and can
4 occur throughout the lifespan of a patient. Physician testimony noted a need for clarification
5 of the term “trauma-informed care.” Your Reference Committee notes the phrase is an
6 accepted term referring to the organizational structure and treatment framework involving the
7 understanding, recognizing, and responding to the effects of all types of trauma, including
8 physical, psychological and emotional safety. Because of the closely related ideas in these
9 resolutions, your Reference Committee recommends that an alternate Resolution that
10 combines concepts into a comprehensive policy be adopted in lieu of Resolution 504 and
11 Resolution 526.

12
13 (11) RESOLUTION 508 – BENZODIAZEPINE AND OPIOID
14 WARNING

15
16 RECOMMENDATION A:

17
18 Madam Speaker, your Reference Committee recommends that
19 the first Resolve of Resolution 508 be amended by addition and
20 deletion to read as follows:

21
22 RESOLVED, That our American Medical Association (AMA)
23 raise the awareness of ~~its members~~ physicians and patients
24 regarding ~~of~~ the increased use of illicit benzodiazepine
25 sedative/opioid combinations leading to addiction and overdose
26 death (Directive to Take Action); and be it further

27
28 RECOMMENDATION B:

29
30 Madam Speaker, your Reference Committee recommends that
31 the second Resolve of Resolution 508 be amended by addition
32 and deletion to read as follows:

33
34 RESOLVED, That our AMA warn ~~members~~ physicians and
35 patients about the risks associated with concomitant use of
36 benzodiazepines and opioids ~~this public health problem.~~

37
38 RECOMMENDATION C:

39
40 Madam Speaker, your Reference Committee recommends that
41 Resolution 508 be adopted as amended.

42
43 RECOMMENDATION D:

44
45 Madam Speaker, your Reference Committee recommends that
46 the title of Resolution 508 be changed to read as follows:

47
48 CONCOMITANT USE OF BENZODIAZEPINES AND OPIOIDS

49
50 Resolution 508 asks that our American Medical Association (AMA) raise the awareness of its
51 members of the increased use of illicit sedative/opioid combinations leading to addiction and

1 overdose death and that our AMA warn members and patients about this public health
2 problem.

3
4 Your Reference Committee heard testimony largely in favor of this resolution as amended.
5 Evidence from authoritative sources was brought up in testimony and illustrated the significant
6 risks of concurrent benzodiazepine and opioid use. These risks include dramatic increase in
7 the risk of opioid related overdose, dependence, and other adverse events. Research and
8 reports from the National Institute on Drug Abuse and the Substance Abuse and Mental Health
9 Services Administration confirming these dangers and increases in benzodiazepine-related
10 emergency visits was discussed and considered. The FDA black box warnings on
11 benzodiazepine medications was noted in considering this Resolution. Evidence was
12 discussed that overall, benzodiazepine prescribing as well as concomitant benzodiazepine
13 and opioid use has been increasing. Testimony noted that increased risks apply in legitimately
14 prescribed combinations of these drugs as well. Increased physician and public awareness
15 on the risks of benzodiazepine and opioid combining is warranted in the interest of public
16 health. Therefore, your Reference Committee recommends that Resolution 508 be adopted
17 as amended.

18
19 (12) RESOLUTION 510 – THE INTRACRANIAL HEMORRHAGE
20 ANTICOAGULATION REVERSAL (ICHAR) INITIATIVE

21
22 RECOMMENDATION A:

23
24 Madam Speaker, your Reference Committee recommends that
25 Resolution 510 be amended by addition and deletion to read as
26 follows:

27
28 RESOLVED, That our American Medical Association support
29 initiatives to improve education, and reduce ~~the~~ barriers,
30 (including lack of resources) for ~~to~~ the use of anticoagulation
31 reversal agents, in emergency settings to reduce the
32 occurrence, disability, and death associated with hemorrhagic
33 stroke and other life-threatening conditions ~~clinical indications~~.
34 (New HOD Policy)

35
36 RECOMMENDATION: B

37
38 Madam Speaker, your Reference Committee recommends that
39 Resolution 510 be adopted as amended.

40
41 Resolution 510 asks that our American Medical Association support initiatives to improve and
42 reduce the barriers to the use of anticoagulation reversal agents in emergency settings to
43 reduce the occurrence, disability, and death associated with hemorrhagic stroke and other
44 life-threatening clinical indications.

45
46 Your Reference Committee heard largely supportive testimony for this resolution, including
47 studies and guidelines supporting the use anticoagulant reversal agents in the emergency
48 setting. There was commentary pertaining to the lack of resources being a prohibitive factor
49 to using anticoagulation reversal agents, and not just lack of education. Therefore, your
50 Reference Committee recommends that Resolution 510 be adopted as amended.

1 (13) RESOLUTION 512 – FERTILITY PRESERVATION IN
2 PEDIATRIC AND REPRODUCTIVE AGED CANCER
3 PATIENTS
4

5 RECOMMENDATION A:
6

7 Madam Speaker, your Reference Committee recommends that
8 the first Resolve of Resolution 512 be amended by addition and
9 deletion to read as follows:
10

11 RESOLVED, That our American Medical Association (AMA)
12 encourage supports as best practice the disclosure to cancer
13 and other patients on of risks to fertility when gonadotoxic
14 gonadotoxicity due to cancer treatment is used. ~~a possibility~~
15 (New HOD Policy)
16

17 RECOMMENDATION B:
18

19 Madam Speaker, your Reference Committee recommends that
20 the second Resolve of Resolution 512 be amended by addition
21 and deletion to read as follows:
22

23 RESOLVED, That our AMA support ongoing education for
24 providers who counsel patients ~~that~~ who may benefit from
25 fertility preservation. (New HOD Policy)
26

27 RECOMMENDATION C:
28

29 Madam Speaker, your Reference Committee recommends that
30 the Resolution 512 be adopted as amended.
31

32 RECOMMENDATION D:
33

34 Madam Speaker, your Reference Committee recommends that
35 the title of Resolution 512 be changed to read as follows:
36

37 DISCLOSURE OF RISK TO FERTILITY WITH
38 GONADOTOXIC TREATMENT
39

40 Resolution 512 asks that our American Medical Association (AMA) encourage disclosure to
41 cancer patients on risks to fertility when gonadotoxicity due to cancer treatment is a possibility
42 and that our AMA support education for providers who counsel patients that may benefit from
43 fertility preservation.
44

45 Your Reference Committee heard testimony in strong support of this resolution. It was noted
46 that existing guidelines support fertility counseling for at risk patients in advance of treatment,
47 including for cancer patients. It was also noted that this principle may be applicable for other
48 indications such as transplantation and the use of non-oncologic systemic agents that pose a
49 risk of gonadotoxicity. A change in title was proposed to broaden the resolution to apply to
50 additional conditions beyond cancer, and to ensure no overemphasis for certain age groups.
51 Amendments were proposed to emphasize that disclosure is best practice and that education

1 should be ongoing, along with broadening to patients with other conditions. Testimony from
2 NIH and USPHS supported amendments. Therefore, your Reference Committee
3 recommends that Resolution 512 be adopted as amended with a change in title, to support
4 disclosure of risks to fertility for all at risk patients.

5
6 (14) RESOLUTION 513 – DETERMINING WHY INFERTILITY
7 RATES DIFFER BETWEEN MILITARY AND CIVILIAN
8 WOMEN

9
10 RECOMMENDATION A:

11
12 Madam Speaker, your Reference Committee recommends that
13 Resolution 513 be amended by addition and deletion to read as
14 follows:

15
16 RESOLVED, That our American Medical Association ~~advocate~~
17 for support additional research to better understand whether
18 higher rates of infertility in servicewomen may be linked to
19 military service, and which approaches might reduce the burden
20 of infertility among service women. (Directive to Take Action)

21
22 RECOMMENDATION B:

23
24 Madam Speaker, your Reference Committee recommends that
25 Resolution 513 be adopted as amended.

26
27 Resolution 513 asks that our American Medical Association advocate for additional research
28 to better understand whether higher rates of infertility in service women may be linked to
29 military service and which approaches might reduce the burden of infertility among service
30 women.

31
32 Your Reference Committee heard testimony in strong support of this resolution. Testimony
33 noted that a recent report documented higher rates of infertility among service women in a
34 small study. Investigators who are actively researching this topic note the need for continued
35 and additional work to understand the issue. An amendment was proposed to “support”
36 instead of “advocate” for the research as clarification, given the role of the military and
37 Congress in funding the research. Therefore, your Reference Committee recommends that
38 Resolution 513 be adopted as amended.

1 (15) RESOLUTION 514 – OPIOID ADDICTION

2
3 RECOMMENDATION A:

4
5 Madam Speaker, your Reference Committee recommends that
6 Policy H-420.962 be reaffirmed in lieu of the first Resolve of
7 Resolution 514.

8
9 RECOMMENDATION B:

10
11 Madam Speaker, your Reference Committee recommends that
12 the second Resolve of Resolution 514 be amended by addition
13 and deletion to read as follows:

14
15 RESOLVED, That our AMA ~~advocate that women who use~~
16 ~~opioids prior to caesarian section are offered~~ support a
17 stepwise, multi-modalities approach to analgesia management
18 (which may include nonpharmacologic and pharmacologic
19 therapies including opioids) using a shared decision-making
20 approach to minimize pain and control pain and improve
21 function after caesarean birth ~~the procedure~~ with the goal of
22 transitioning to other methods of pain control for long term.
23 (Directive to Take Action)

24
25 RECOMMENDATION C:

26
27 Madam Speaker, your Reference Committee recommends that
28 the third Resolve of Resolution 514 be amended by addition and
29 deletion to read as follows:

30
31 RESOLVED, That our AMA work with hospitals and relevant
32 stakeholders constituent organizations to assure that the
33 support the adoption of enhanced recovery after surgery
34 protocol for caesarian section ~~is widely adopted~~ to optimize
35 recovery and improve function while decreasing use of opioid
36 medications for pain, ~~especially given the impact of such use in~~
37 ~~breast-feeding mothers and their infants.~~ (Directive to Take
38 Action)

39
40 RECOMMENDATION D:

41
42 Madam Speaker, your Reference Committee recommends that
43 Resolution 514 be amended by the addition of the following new
44 Resolve:

45
46 RESOLVED, that our AMA support counseling of women who
47 are prescribed opioid analgesics following caesarean birth
48 about the risk of central nervous system depression in the
49 woman and the breastfed infant. (Directive to Take Action)

1 RECOMMENDATION E:

2
3 Madam Speaker, your Reference Committee recommends that
4 Resolution 514 be adopted as amended.

5
6 RECOMMENDATION F:

7
8 Madam Speaker, your Reference Committee recommends that
9 the title of Resolution 514 be changed to read as follows:

10
11 PAIN MANAGEMENT FOLLOWING CAESAREAN BIRTH

12
13 Resolution 514 asks that our American Medical Association (AMA) work with constituent
14 organizations to assure that women of child-bearing age who are using opioids and are
15 accessing the health care system undergo evaluation for pregnancy and, if pregnancy, be
16 offered prenatal care, that our AMA advocate that women who use opioids prior to caesarian
17 section are offered multi-modalities to control pain and improve function after the procedure
18 with the goal of transitioning to other methods of pain control for long term, and that our AMA
19 work with hospitals and relevant constituent organizations to assure that the enhanced
20 recovery after surgery protocol for caesarian section is widely adopted to optimize recovery
21 and improve function while decreasing use of opioid medications for pain, especially given the
22 impact of such use in breast-feeding mothers and their infants.

23
24 Your Reference Committee heard testimony largely in favor of this resolution. Several
25 amendments were offered to clarify the language of the Resolution. Your Reference
26 Committee agrees with proffered amendments and, therefore, recommends that Resolution
27 514 be adopted as amended with a change in title.

28
29 Policy recommended for reaffirmation:

30
31 H-420.962, "Perinatal Addiction - Issues in Care and Prevention"

32
33 Our AMA: (1) adopts the following statement: Transplacental drug transfer should not
34 be subject to criminal sanctions or civil liability; (2) encourages the federal government
35 to expand the proportion of funds allocated to drug treatment, prevention, and
36 education. In particular, support is crucial for establishing and making broadly
37 available specialized treatment programs for drug-addicted pregnant and
38 breastfeeding women wherever possible; (3) urges the federal government to fund
39 additional research to further knowledge about and effective treatment programs for
40 drug-addicted pregnant and breastfeeding women, encourages also the support of
41 research that provides long-term follow-up data on the developmental consequences
42 of perinatal drug exposure, and identifies appropriate methodologies for early
43 intervention with perinatally exposed children; (4) reaffirms the following statement:
44 Pregnant and breastfeeding patients with substance use disorders should be provided
45 with physician-led, team-based care that is evidence-based and offers the ancillary
46 and supportive services that are necessary to support rehabilitation; and (5) through
47 its communication vehicles, encourages all physicians to increase their knowledge
48 regarding the effects of drug and alcohol use during pregnancy and breastfeeding and
49 to routinely inquire about alcohol and drug use in the course of providing prenatal care.

1 (16) RESOLUTION 515 – REVERSING OPIOID EPIDEMIC

2
3 RECOMMENDATION A:

4
5 Madam Speaker, your Reference Committee recommends that
6 Resolution 515 be amended by addition and deletion to read as
7 follows:

8
9 RESOLVED, That our American Medical Association include
10 educational materials for physicians regarding sex-based
11 differences in their resources related to the opioid epidemic
12 program, Reversing the Opioid Epidemic, educational materials
13 for physicians regarding sex-based differences. These sex-
14 based differences include in the perception of pain, including
15 the impact of co-morbid conditions, sex-based differences in
16 response to opioids, and risks for opioid use disorder addiction,
17 and issues with accessing, and outcomes of addiction treatment
18 programs among women.

19
20 RECOMMENDATION B:

21
22 Madam Speaker, your Reference Committee recommends that
23 Resolution 515 be adopted as amended.

24
25 RECOMMENDATION C:

26
27 Madam Speaker, your Reference Committee recommends that
28 the title of Resolution 515 be changed to read as follows:

29
30 EDUCATION ON SEX-BASED RESPONSE TO OPIOIDS

31
32 Resolution 515 asks that our American Medical Association include in their program,
33 Reversing the Opioid Epidemic, education materials for physicians regarding sex-based
34 differences in perception of pain, including the impact of co-morbid conditions, sex-based
35 differences in response to opioids and risks for opioid addiction, and issues with accessing
36 and outcomes of addiction programs among women.

37
38 Your Reference Committee heard testimony in favor of adopting this resolution based on
39 evidence of sex-based differences in women's response to opioids, issues of co-morbid
40 conditions, and risk for opioid use disorder. Testimony and evidence presented related to sex-
41 based responses to pain, co-morbid conditions, and that interventions for women should be
42 based on the current sex-based research. Incongruency of the resolution and the title was
43 noted and testimony was heard supporting changing the title of the resolution. Therefore, your
44 Reference Committee recommends that Resolution 515 be adopted as amended with a
45 change in title.

1 (17) RESOLUTION 516 – ALCOHOL CONSUMPTION AND
2 HEALTH

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends that
7 the first Resolve of Resolution 516 be amended by addition and
8 deletion to read as follows:

9
10 RESOLVED, That our American Medical Association (AMA)
11 recognize that alcohol consumption at any level, not just as well
12 as heavy alcohol abuse use or addictive alcohol use, as is a
13 modifiable risk factor for cancer (New HOD Policy)

14
15 RECOMMENDATION B:

16
17 Madam Speaker, your Reference Committee recommends that
18 Resolution 516 be adopted as amended.

19
20 Resolution 516 asks that our American Medical Association (AMA) recognize alcohol
21 consumption as well as alcohol abuse as a modifiable risk factor for cancer, that our AMA
22 support research and educational efforts about the connection between alcohol consumption
23 and several types of cancer, and that our AMA amend policy H-425.993, "Health Promotion
24 and Disease Prevention," by addition and deletion to read as follows:

25 "... (4) actively supports appropriate scientific, educational and legislative activities that
26 have as their goals: (a) prevention of smoking and its associated health hazards; (b)
27 avoidance of alcohol consumption, abuse, particularly that which leads to illness,
28 cancer, and accidental injury and death; (c) reduction of death and injury from
29 vehicular and other accidents; and (d) encouragement of healthful lifestyles and
30 personal living habits..."

31
32 Your Reference Committee heard testimony largely in support of this resolution. The
33 connection between alcohol as a modifiable risk factor and cancer is well established, a public
34 health need exists to communicate this risk to patients, but this is not covered by existing AMA
35 policy. Therefore, your Reference Committee recommends that Resolution 516 be adopted
36 as amended.

1 (18) RESOLUTION 517 – COMPOUNDING

2
3 RECOMMENDATION A:

4
5 Madam Speaker, your Reference Committee recommends that
6 the second Resolve of Resolution 517 be amended by deletion
7 to read as follows:

8
9 ~~RESOLVED, That our AMA oppose any state medical board~~
10 ~~action to delegate authority or oversight of physicians preparing~~
11 ~~medications in physicians' offices to another regulatory body~~
12 ~~(e.g., state pharmacy board) (Directive to Take Action); and be~~
13 ~~it further~~

14
15 RECOMMENDATION B:

16
17 Madam Speaker, your Reference Committee recommends that
18 the third Resolve of Resolution 517 be amended by addition to
19 read as follows:

20
21 RESOLVED, That our AMA work with medical specialty
22 societies to preserve a physician's ability to prepare
23 medications in physicians' offices, and to be able to do so
24 without being subject to unreasonable and burdensome
25 equipment and process requirements by engaging with state
26 policymakers (including but not limited to state legislatures,
27 state medical boards, and state pharmacy boards) as well as
28 accreditors.

29
30 RECOMMENDATION C:

31
32 Madam Speaker, your Reference Committee recommends that
33 Resolution 517 be adopted as amended.

34
35 Resolution 517 asks that our American Medical Association (AMA) provide a 50-state analysis
36 of state law requirements governing in-office preparation of medications in physicians' offices,
37 including which states have adopted USP Chapter 797 and how compounding is defined by
38 state law, that our AMA oppose any state medical board action to delegate authority or
39 oversight of physicians preparing medications in physicians' offices to another regulatory body
40 (e.g., state pharmacy board), and that our AMA work with medical specialty societies to
41 preserve a physician's ability to prepare medications in physicians' offices and be able to do
42 so without being subject to unreasonable and burdensome equipment and process
43 requirements.

44
45 Your Reference Committee heard mixed testimony on this resolution. Testimony noted that
46 there is a need to better understand state law governing compounding which is addressed by
47 Resolve one. Additional testimony noted that there might be a risk that physician ability to
48 prepare medication may be impacted due to such legislation and additional understanding is
49 necessary. USP provided strong testimony highlighting its ongoing collaboration with the
50 AMA, dermatology associations, and physicians in the revision of <797> which was published
51 on June 1, 2019 and reflects the advancements in science and practice as well as the input

1 from patients, health care practitioners, policymakers, academicians, and industry to ensure
2 and maintain patient safety and access to quality of medicine. Your Reference Committee
3 believes that the intent of Resolve two is unclear as it assumes that medical boards proactively
4 delegate authority on this issue as opposed to pharmacy boards assuming it. Therefore, your
5 Reference Committee recommends that Resolution 517 be adopted as amended.

6
7 (19) RESOLUTION 520 – SUBSTANCE USE DURING
8 PREGNANCY

9
10 RECOMMENDATION A:

11
12 Madam Speaker, your Reference Committee recommends that
13 Resolution 520 be amended by addition and deletion to read as
14 follows:

15
16 Our AMA will: (1) oppose any efforts to imply that the diagnosis
17 of substance abuse disorder during pregnancy represents child
18 abuse; ~~and~~ (2) support legislative and other appropriate efforts
19 for the expansion and improved access to evidence-based
20 treatment for substance use disorders during pregnancy.; ~~and~~
21 (3) oppose the removal of infants from their mothers solely
22 based on a single positive prenatal drug screen without
23 appropriate –an evaluation from a social worker. –and (4)
24 advocate for appropriate medical evaluation, which takes into
25 account the patient’s treatment status and current impairment
26 when substance use is suspected, prior to removal of the child.
27 (Modify Current HOD Policy)

28
29 RECOMMENDATION B:

30
31 Madam Speaker, your Reference Committee recommends that
32 Resolution 520 be adopted as amended.

33
34 RECOMMENDATION C:

35
36 Madam Speaker, your Reference Committee recommends that
37 Policy H-95.985 be reaffirmed.

38
39 Resolution 520 asks that our American Medical Association amend policy H-420.950,
40 “Substance Use Disorders During Pregnancy,” by addition as follows:

41 Our AMA will: (1) oppose any efforts to imply that the diagnosis of substance abuse
42 disorder during pregnancy represents child abuse; and (2) support legislative and
43 other appropriate efforts for the expansion and improved access to evidence-based
44 treatment for substance use disorders during pregnancy.; and (3) oppose the removal
45 of infants from their mothers solely based on a single positive prenatal drug screen
46 without an evaluation from a social worker.

47
48 Your Reference Committee heard testimony largely in favor of this amendment to AMA policy.
49 Testimony noted that substance use disorder should be seen primarily as a disease and that
50 the focus should be on proper assessment and treatment for the patient and not on criminality.
51 Also noted was the idea that a single drug test does not provide conclusive evidence of

1 substance use disorder or child abuse or neglect; this concept is addressed in current policy.
2 Therefore, your Reference Committee recommends that Resolution 520 should be adopted
3 as amended and Policy H-95.985 reaffirmed.
4 Policy recommended for reaffirmation:

5
6 H-95.985, "Drug Testing"
7

8 Our AMA believes that physicians should be familiar with the strengths and limitations
9 of drug testing techniques and programs:

- 10 1. Due to the limited specificity of the inexpensive and widely available non-
11 instrumented devices such as point-of-care drug testing devices, acceptable
12 clinical drug testing programs should include the ability to access highly specific,
13 analytically acceptable confirmation techniques, which definitively establish the
14 identities and quantities of drugs, in order to further analyze results from
15 presumptive testing methodologies. Physicians should consider the value of data
16 from non-confirmed preliminary test results, and should not make major clinical
17 decisions without using confirmatory methods to provide assurance about the
18 accuracy of the clinical data.
- 19 2. Results from drug testing programs can yield accurate evidence of prior exposure
20 to drugs. Drug testing does not provide any information about pattern of use of
21 drugs, dose of drugs taken, physical dependence on drugs, the presence or
22 absence of a substance use disorder, or about mental or physical impairments that
23 may result from drug use, nor does it provide valid or reliable information about
24 harm or potential risk of harm to children or, by itself, provide indication or proof of
25 child abuse, or neglect or proof of inadequate parenting.
- 26 3. Before implementing a drug testing program, physicians should: (a) understand
27 the objectives and questions they want to answer with testing; (b) understand the
28 advantages and limitations of the testing technology; (c) be aware of and educated
29 about the drugs chosen for inclusion in the drug test; and (d) ensure that the cost
30 of testing aligns with the expected benefits for their patients. Physicians also
31 should be satisfied that the selection of drugs (analytes) and subjects to be tested
32 as well as the screening and confirmatory techniques that are used meet the stated
33 objectives.
- 34 4. Since physicians often are called upon to interpret results, they should be familiar
35 with the disposition characteristics of the drugs to be tested before interpreting any
36 results. If interpretation of any given result is outside of the expertise of the
37 physician, assistance from appropriate experts such as a certified medical review
38 officer should be pursued.

1 (20) RESOLUTION 522 – IMPROVED DEFERRAL PERIODS FOR
2 BLOOD DONORS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends that
7 Resolution 522 be amended by addition and deletion to read as
8 follows:

9
10 Our AMA: (1) supports the use of rational, scientifically-based
11 blood and tissue donation deferral periods that are fairly and
12 consistently applied to donors according to their individual risk;
13 (2) opposes all policies on deferral of blood and tissue
14 donations that are not based on evidence the scientific
15 literature; and (3) supports a blood donation deferral period for
16 men who have sex with men those determined to be at risk for
17 transmission of HIV that is representative of current HIV testing
18 technology. (Modify Current HOD Policy)

19
20 RECOMMENDATION B:

21
22 Madam Speaker, your Reference Committee recommends that
23 Resolution 522 be adopted as amended.

24
25 Resolution 522 asks that our American Medical Association amend AMA policy H-50.973,
26 “Blood Donor Deferral Criteria,” by addition and deletion to read as follows:

27 Our AMA: (1) supports the use of rational, scientifically-based blood and tissue
28 donation deferral periods that are fairly and consistently applied to donors according
29 to their individual risk; (2) opposes all policies on deferral of blood and tissue donations
30 that are not based on the scientific literature; and (3) supports a blood donation deferral
31 period for men who have sex with men that is representative of current HIV testing
32 technology; and (4) supports research into individual risk assessment criteria for blood
33 donation.

34
35 Your Reference Committee heard unanimously supportive testimony for this Resolution with
36 several requests for amending language that singles out men who have sex men and asks for
37 it to be replaced with language that does not single out one group but focuses instead on
38 individual risk factors. Testimony from the GLMA and others supported this change in
39 language. Several commenters noted that the current evidence-base does not support the
40 current deferral period. Others noted that the current deferral period relies on categories rather
41 than assessing an individual’s risk for HIV infection and potential transmission. The committee
42 also recommended the use of evidence that includes, but is not limited to, only scientific
43 literature when assessing blood and tissue donation policies. Therefore, your Reference
44 Committee recommends that Resolution 522 be adopted as amended.

1 (21) RESOLUTION 525 – SUPPORT FOR ROOMING-IN OF
2 NEONATAL ABSTINENCE SYNDROME PATIENTS WITH
3 THEIR PARENTS
4

5 RECOMMENDATION A:
6

7 Madam Speaker, your Reference Committee recommends that
8 the first Resolved of Resolution 525 be amended by addition
9 and deletion to read as follows:
10

11 RESOLVED, That our American Medical Association (AMA)
12 supports keeping patients with neonatal abstinence syndrome
13 with their parents or legal guardians in the hospital throughout
14 their treatment, as the patient's health and safety permits, and
15 as supported by validated risk stratification tools for ~~through the~~
16 ~~implementation of~~ rooming-in programs. (New HOD Policy)
17

18 RECOMMENDATION B:
19

20 Madam Speaker, your Reference Committee recommends that
21 Resolution 525 be adopted as amended.
22

23 Resolution 525 asks that our American Medical Association (AMA) support keeping patients
24 with neonatal abstinence syndrome with their parents or legal guardians in the hospital
25 throughout their treatment, as the patient's health and safety permits, through the
26 implementation of rooming-in programs and that our AMA support the education of physicians
27 about rooming-in patients with neonatal abstinence syndrome.
28

29 Your Reference Committee heard testimony largely in support of the intent of this Resolution.
30 However, several commenters noted that some of the language in the original Resolution was
31 too prescriptive, and others noted that tools are available and should be utilized in the
32 management of patients with NAS. Therefore, your Reference Committee agrees that risk
33 stratification tools can be useful for physicians when managing patients with NAS and
34 recommends that Resolution 525 be adopted as amended.

1 (22) RESOLUTION 527 – INCREASING THE AVAILABILITY
2 OF BLEEDING CONTROL SUPPLIES

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee
7 recommends that Resolution 527 be adopted as amended
8 to read as follows:

9
10 RESOLVED, That American Medical Association Policy
11 H-130.935, “Support for Hemorrhage Control Training,” be
12 amended by addition to read as follows:

13
14 H-130.935, “Support for Hemorrhage Control Training”

- 15 (1) Our AMA encourages state medical and specialty
16 societies to promote the training of both lay public and
17 professional responders in essential techniques of
18 bleeding control.
19 (2) Our AMA encourages, through state medical and
20 specialty societies, the inclusion of hemorrhage
21 control kits (including pressure bandages, hemostatic
22 dressings, tourniquets and gloves) for all first
23 responders.
24 (3) Our AMA supports the increased availability of
25 bleeding control supplies with adequate and relevant
26 training in schools, places of employment, and public
27 buildings.

28
29 RECOMMENDATION B:

30 Madam Speaker, your Reference Committee
31 recommends that Resolution 527 be adopted as
32 amended.

33
34 Resolution 527 asks that our American Medical Association Policy H-130.935, “Support for
35 Hemorrhage Control Training,” be amended by addition to read as follows:

36 H-130.935 Support for Hemorrhage Control Training

- 37 (4) Our AMA encourages state medical and specialty societies to promote the training
38 of both lay public and professional responders in essential techniques of bleeding
39 control.
40 (5) Our AMA encourages, through state medical and specialty societies, the inclusion
41 of hemorrhage control kits (including pressure bandages, hemostatic dressings,
42 tourniquets and gloves) for all first responders.
43 (6) Our AMA supports the increased availability of bleeding control supplies in
44 schools, places of employment, and public buildings.

45
46 Your Reference Committee heard overwhelming supportive testimony for the Resolution.
47 Commenters noted the significant need for relevant civilian preparedness to address bleeding
48 incidences, the “Stop the Bleed” campaign, and the need for adequate education on effective
49 tourniquet usage citing the phrase “turn it til it hurts.” The original resolution did not specify
50 the need for adequate education on tourniquet usage. Therefore, your Reference Committee
51 recommends that Resolution 527 be adopted as amended.

1
2 (23) RESOLUTION 529 – ADVERSE IMPACTS OF DELAYING
3 THE IMPLEMENTATION OF PUBLIC HEALTH
4 REGULATIONS

5
6 RECOMMENDATION A:

7
8 Madam Speaker, your Reference Committee recommends that
9 the first Resolve of Resolution 529 be amended by deletion to
10 read as follows:

11
12 ~~RESOLVED, That our American Medical Association (AMA)~~
13 ~~urge the Environmental Protection Agency and other federal~~
14 ~~regulatory agencies to enforce pesticide regulations,~~
15 ~~particularly of restricted use pesticides, that safeguard human~~
16 ~~and environmental health, especially in vulnerable populations~~
17 ~~including but not limited to agricultural workers, immigrant~~
18 ~~migrant workers, and children (Directive to Take Action); and be~~
19 ~~it further~~

20
21 RECOMMENDATION B:

22
23 Madam Speaker, your Reference Committee recommends that
24 the second Resolve of Resolution 529 be amended by addition
25 and deletion to read as follows:

26
27 RESOLVED, That our AMA ~~analyze~~ monitor and evaluate
28 ~~ongoing~~ regulation delays that impact public health, and
29 advocate as deemed appropriate to decrease regulatory delays.
30 (Directive to Take Action)

31
32 RECOMMENDATION C:

33
34 Madam Speaker, your Reference Committee recommends that
35 Resolution 529 be adopted as amended.

36
37 Resolution 529 asks that our American Medical Association (AMA) urge the Environmental
38 Protection Agency and other federal regulatory agencies to enforce pesticide regulations,
39 particularly of restricted use pesticides, that safeguard human and environmental health,
40 especially in vulnerable populations including but not limited to agricultural workers, immigrant
41 migrant workers, and children and that our AMA analyze ongoing regulation delays that impact
42 public health, as deemed appropriate.

43
44 Testimony was largely supportive of this resolution and noted that delays in enforcement of
45 environmental and health regulations could have an adverse effect on public health,
46 particularly for vulnerable populations. Testimony proposed an amendment to strike Resolve
47 1, which was considered much broader, and not reflective of the title of the amendment. In
48 addition, testimony expressed concern over the focus on analysis, and it was pointed out that
49 other groups are already analyzing the impact of these delays. Therefore, your Reference
50 Committee recommends that Resolution 529 be adopted as amended.

1 (24) RESOLUTION 518 – CHEMICAL VARIABILITY IN
2 PHARMACEUTICAL PRODUCTS

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends that
7 Resolution 518 be referred for report back at the 2020 Annual
8 Meeting.

9
10 Resolution 518 asks that our American Medical Association (AMA) do a study and report back
11 by the 2019 Interim Meeting regarding the pharmaceutical variability, both in active
12 pharmaceutical ingredient and dissolution, the impact on patient care and make
13 recommendations for action from their report findings, that our AMA advocate for legislation
14 requiring independent testing and verification of the chemical content of batches of
15 pharmaceuticals, and that our AMA advocate for the logging of batches at the patient level,
16 so the batches can be traced and connected to patient outcomes or adverse events.

17
18 Your Reference Committee heard testimony largely in support of this Resolution. Several
19 commenters noted confusion about some of the concepts detailed in the Resolution. The U.S.
20 Public Health Service provided some clarification on concepts presented and the Council on
21 Science and Public Health noted that there are several issues related to pharmacovigilance,
22 track and trace, and testing and verification of pharmaceuticals that could benefit from further
23 study. Your Reference Committee agrees with the Council and, therefore, recommends that
24 Resolution 518 be referred.

25
26 (25) RESOLUTION 507 – REMOVING ETHYLENE OXIDE AS A
27 MEDICAL STERILANT FROM HEALTHCARE

28
29 RECOMMENDATION:

30
31 Madam Speaker, your Reference Committee recommends
32 that Resolution 507 be referred for decision.

33
34 Resolution 507 asks that our American Medical Association (AMA) adopt as policy and urge,
35 as appropriate, the prevention of ethylene oxide emissions and substitution of ethylene oxide
36 with less toxic sterilization alternatives that are currently available, including hydrogen
37 peroxide, steam, and other safer alternatives, which do not release carcinogens into the
38 workplace or community air and allow no residual exposures to the patient and that our AMA
39 adopt as policy and urge that when health care facilities are evaluating surgical and medical
40 devices that require sterilization, in addition to effectiveness of the device for best patient
41 outcomes, that facilities also be required to prioritize the modes of sterilization for the highest
42 degree of worker and environmental safety.

43
44 Mixed testimony was offered for this resolution. It was noted that ethylene oxide is toxic and
45 a group 1 carcinogen and that exposures should be minimized. Incidence of excessive
46 ethylene oxide emissions in an IL sterilization facility are being investigated at the state and
47 federal level; the facility has been shut down during the investigation. Conversely, CA passed
48 a legislation limiting the use of ethylene oxide due to similar public health concerns, but this
49 led to unintended consequences including surgical supply shortage and compromised patient
50 care. The FDA noted in testimony that they are taking a comprehensive approach on this
51 issue and are actively working with sterilization experts, medical device manufacturers, and

1 other government agencies to advance innovative ways to sterilize medical devices. Given
2 these concerns and conflicting outcomes, your Reference Committee recommends that
3 Resolution 507 be referred for decision.

4
5 (26) RESOLUTION 530 – IMPLEMENTING NALOXONE
6 TRAINING INTO THE BASIC LIFE SUPPORT (BLS)
7 CERTIFICATION PROGRAM

8
9 RECOMMENDATION:

10
11 Madam Speaker, your Reference Committee recommends that
12 Resolution 530 not be adopted.

13
14 Resolution 530 asks that our American Medical Association collaborate with the Occupational
15 Safety and Health Administration and state medical societies to include naloxone rescue kits
16 in first aid equipment.

17
18 Your Reference Committee heard testimony supportive of the concepts noted in this
19 Resolution, but also heard calls for clarification of the ask of the Resolution since the title and
20 text are incongruent. To include naloxone training in BLS, the American Heart Association
21 would need to change their training and certification requirements; currently, many free
22 naloxone training programs exist. It was also noted that logistic issues are associated with the
23 inclusion of naloxone in first-aid kits due to storage and stability issues related to heat and
24 light exposure. Additionally, the need for the FDA to regulate this practice and approve over-
25 the-counter availability of a naloxone product that would be suitable for placement in a public
26 setting or first-aid kit should be addressed. Your Reference Committee commends the intent
27 of this resolution and welcomes future Resolutions with clarified language on this topic.
28 Therefore, your Reference Committee recommends that Resolution 530 not be adopted.

29
30 (27) RESOLUTION 505 – GLYPHOSATE STUDIES

31
32 RECOMMENDATION:

33
34 Madam Speaker, your Reference Committee recommends that
35 Policies H-135.942 and D-135.997 be reaffirmed in lieu of
36 Resolution 505.

37
38 Resolution 505 asks that our American Medical Association advocate for a reduction in the
39 use of glyphosate-based pesticides (the primary chemical in the herbicide branded Roundup),
40 encourage the evaluation of alternatives, and support additional research to determine the
41 long term effects and association between glyphosate and disease.

42
43 Your reference committee heard mixed testimony on this controversial topic. It was noted that
44 the scientific literature on the topic has failed to show a consistent connection between
45 agricultural use of glyphosate and cancer, but that some studies have supported the
46 connection resulting in recent multi-billion-dollar liability awards. The issue is emotionally-
47 charged with media suggesting corporate interference in some of the numerous large-scale
48 studies showing no adverse health effects. Existing AMA policy supports research and
49 evidence-based policies that protect the environment and public health, and this certainly
50 applies directly to this issue. Policy H-135.942 supports the assessment of adverse effects of
51 chemicals, and D-135.997 advocates for funding for research into the environmental

1 contributors to disease. Your Reference Committee felt that Resolution 505 overstates what
2 we can confidently conclude about glyphosate in a way that will certainly be construed
3 politically. We therefore recommend reaffirmation of H-135.942 and D-135.997 in lieu of this
4 resolution.

5
6 Policies recommended for reaffirmation:

7
8 H-135.942, "Modern Chemicals Policies"

9
10 Our AMA supports: (1) the restructuring of the Toxic Substances Control Act to serve
11 as a vehicle to help federal and state agencies to assess efficiently the human and
12 environmental health hazards of industrial chemicals and reduce the use of those of
13 greatest concern; and (2) the Strategic Approach to International Chemicals (SAICM)
14 process leading to the sound management of chemicals throughout their life-cycle so
15 that, by 2020, chemicals are used and produced in ways that minimize adverse effects
16 on human health and the environment.

17
18 D-135.997, "Research into the Environmental Contributors to Disease"

19
20 Our AMA will (1) advocate for greater public and private funding for research into the
21 environmental causes of disease, and urge the National Academy of Sciences to
22 undertake an authoritative analysis of environmental causes of disease; (2) ask the
23 steering committee of the Medicine and Public Health Initiative Coalition to consider
24 environmental contributors to disease as a priority public health issue; and (3) lobby
25 Congress to support ongoing initiatives that include reproductive health outcomes and
26 development particularly in minority populations in Environmental Protection Agency
27 Environmental Justice policies.

- 1 Madam Speaker, this concludes the report of Reference Committee E. I would like to thank
- 2 William Bowman, MD, Wayne C. Hardwick, MD, Shane Hopkins, MD, Shawn C. Jones, MD,
- 3 Nancy L. Mueller, MD, Raymond Wynn, MD, and all those who testified before the Committee
- 4 as well as our AMA staff.

William Bowman, MD
North Carolina Medical Society

Shawn C. Jones, MD, FACS (Alternate)
Kentucky Medical Association

Wayne C. Hardwick, MD
Nevada State Medical Association

Nancy L. Mueller, MD, FAAN
Medical Society of New Jersey

L. Shane Hopkins, MD (Alternate)
American Society for Radiation
Oncology

Raymond B. Wynn, MD
American College of Radiology

Leslie H. Secrest, MD
Texas Medical Association
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (A-19)

Report of Reference Committee F

Greg Tarasidis, MD, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:

2
3 **RECOMMENDED FOR ADOPTION**

- 4
5 1. Board of Trustees Report 4 – AMA 2020 Dues
6
7 2. Board of Trustees Report 10 – Conduct at AMA Meetings and Events
8
9 3. Board of Trustees Report 12 – Data Used to Apportion Delegates
10
11 4. Board of Trustees Report 24 – Discounted/Waived CPT Fees as an AMA
12 Member Benefit and for Membership Promotion
13
14 5. Board of Trustees Report 27 – Advancing Gender Equity in Medicine
15
16 6. Report of the House of Delegates Committee on the Compensation of the
17 Officers
18
19 7. Resolution 602 – Expectations for Behavior at House of Delegates Meetings
20
21 8. Resolution 605 – State Societies and the AMA Litigation Center
22
23 9. Resolution 607 – Re-establishment of National Guideline Clearinghouse
24
25 10. Resolution 609 – Update to AMA Policy H-525.998, “Women in Organized
26 Medicine”
27
28 11. Resolution 610 – Mitigating Gender Bias in Medical Research
29
30 12. Resolution 616 – TIME’S UP Healthcare

31
32 **RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED**

- 33
34 13. Resolution 603 – Creation of an AMA Election Reform Committee
35 Resolution 611 – Election Reform
36
37 14. Resolution 606 – Investigation into Residents, Fellows, and Physician Unions
38
39 15. Resolution 614 – Racial and Ethnic Identity Demographic Collection by the AMA
40
41 16. Resolution 617 – Disabled Physician Advocacy

1 17. Resolution 618 – Stakeholder Input to Reports of the House of Delegates
2

3 **RECOMMENDED FOR REFERRAL**
4

5 18. Resolution 608 – Financial Protections for Doctors in Training
6

7 19. Resolution 612 – Request to AMA for Training in Health Policy and Health Law
8

9 20. Resolution 613 – Language Proficiency Data of Physicians in AMA Masterfile
10

11 21. Resolution 615 – Implementing AMA Climate Change Principles Through JAMA
12 Paper Consumption Reduction and Green Healthcare Leadership
13

14 **RECOMMENDED FOR NOT ADOPTION**
15

16 22. Resolution 601 – AMA Policy Statement with Editorials
17

18 23. Resolution 604 – Engage and Collaborate with the Joint Commission
19

20 **RECOMMENDED FOR FILING**
21

22 24. Board of Trustees Report 1 – Annual Report

1 (1) BOARD OF TRUSTEES REPORT 4 - AMA 2020 DUES

2
3 RECOMMENDATION:

4
5 Madam Speaker, your Reference Committee recommends
6 that the recommendation in Board of Trustees Report 4 be
7 adopted and the remainder of the Report be filed.

8
9 Board of Trustees Report 4 recommends no changes to our AMA membership dues levels
10 for 2020. The Report further notes that our AMA last raised its dues in 1994.

11
12

Regular Members	\$420
Physicians in Their Second Year of Practice	\$315
Physicians in Military Service	\$280
Physicians in Their First Year of Practice	\$210
Semi-Retired Physicians	\$210
Fully Retired Physicians	\$84
Physicians in Residency Training	\$45
Medical Students	\$20

19
20

21 Your Reference Committee heard limited testimony seeking clarity on the dues pricing
22 structure. The Board of Trustees explained that membership pilot programs are currently
23 being tested and posted on the website, which may result in discrepancies.

24
25 Your Reference Committee wishes to highlight the continued stability in the cost of an
26 AMA membership. This year marks the 25th year since the last increase in dues occurred.

27
28
29 (2) BOARD OF TRUSTEES REPORT 10 - CONDUCT AT
30 AMA MEETINGS AND EVENTS

31
32 RECOMMENDATION:

33
34 Madam Speaker, your Reference Committee recommends
35 that the recommendations in Board of Trustees Report 10
36 be adopted and the remainder of the Report be filed.

37
38 Board of Trustees Report 10 summarizes the evaluation and joint recommendations
39 provided by the external consultants called for in Policy D-140.954, "Harassment Issues
40 Within the AMA," and recommends the following revisions to the procedures implementing
41 the anti-harassment policy with respect to conduct during meetings of the House of
42 Delegates, councils, sections, and all other AMA entities:

- 43
44 1. That Policy D-140.954, "Harassment Issues Within the AMA," be rescinded as having
45 been fulfilled by the report. (Rescind HOD Policy)
46
47 2. That Policy H-140.837, "Anti-Harassment Policy," be renamed "Policy on Conduct at
48 AMA Meetings and Events" and further amended by insertion and deletion as follows
49 (Modify Current HOD Policy):

1 **Anti-Harassment Policy Applicable to AMA Entities**
2 **Policy on Conduct at AMA Meetings and Events**
3

4 It is the **policy** of the American Medical Association that all attendees of AMA hosted
5 meetings, events and other activities are expected to exhibit respectful, professional,
6 and collegial behavior during such meetings, events and activities, including but not
7 limited to dinners, receptions and social gatherings held in conjunction with such AMA
8 hosted meetings, events and other activities. Attendees should exercise consideration
9 and respect in their speech and actions, including while making formal presentations
10 to other attendees, and should be mindful of their surroundings and fellow participants.

11
12 ~~a~~Any type of harassment of any attendee of an AMA staff, fellow delegates or others
13 ~~by members of the House of Delegates or hosted meeting, event and other attendees~~
14 ~~at or in connection with HOD meetings, or otherwise activity,~~ including but not limited
15 to dinners, receptions and social gatherings held in conjunction with ~~HOD meetings,~~
16 an AMA hosted meeting, event or activity, is prohibited conduct and is not tolerated.
17 The AMA is committed to a zero tolerance for harassing conduct at all locations where
18 ~~AMA delegates and staff are conducting AMA business~~ is conducted. This zero
19 tolerance **policy** also applies to meetings of all AMA sections, councils, committees,
20 task forces, and other leadership entities (each, an “AMA Entity”), as well as other
21 AMA-sponsored events. The purpose of the policy is to protect participants in AMA-
22 sponsored events from harm.

23
24 **Definition**
25

26 Harassment consists of unwelcome conduct whether verbal, physical or visual that
27 denigrates or shows hostility or aversion toward an individual because of his/her race,
28 color, religion, sex, sexual orientation, gender identity, national origin, age, disability,
29 marital status, citizenship or ~~otherwise protected group status,~~ and that: (1) has the
30 purpose or effect of creating an intimidating, hostile or offensive environment; (2) has
31 the purpose or effect of unreasonably interfering with an individual’s participation in
32 meetings or proceedings of the HOD or any AMA Entity; or (3) otherwise adversely
33 affects an individual’s participation in such meetings or proceedings or, in the case of
34 AMA staff, such individual’s employment opportunities or tangible job benefits.
35

36 Harassing conduct includes, but is not limited to: epithets, slurs or negative
37 stereotyping; threatening, intimidating or hostile acts; denigrating jokes; and written,
38 electronic, or graphic material that denigrates or shows hostility or aversion toward an
39 individual or group and that is placed on walls or elsewhere on the AMA’s premises or
40 at the site of any AMA meeting or circulated in connection with any AMA meeting.
41

42 **Sexual Harassment**
43

44 Sexual harassment also constitutes discrimination, and is unlawful and is absolutely
45 prohibited. For the purposes of this **policy**, sexual harassment includes:

- 46
47 - making unwelcome sexual advances or requests for sexual favors or other verbal,
48 physical, or visual conduct of a sexual nature; and

- 1 - creating an intimidating, hostile or offensive environment or otherwise unreasonably
2 interfering with an individual's participation in meetings or proceedings of the HOD
3 or any AMA Entity or, in the case of AMA staff, such individual's work performance,
4 by instances of such conduct.
5

6 Sexual harassment may include such conduct as explicit sexual propositions, sexual
7 innuendo, suggestive comments or gestures, descriptive comments about an
8 individual's physical appearance, electronic stalking or lewd messages, displays of
9 foul or obscene printed or visual material, and any unwelcome physical contact.

10
11 Retaliation against anyone who has reported harassment, submits a complaint,
12 reports an incident witnessed, or participates in any way in the investigation of a
13 harassment claim is forbidden. Each complaint of harassment or retaliation will be
14 promptly and thoroughly investigated. To the fullest extent possible, the AMA will keep
15 complaints and the terms of their resolution confidential.
16

17 **Operational Guidelines**

18
19 The AMA shall, through the Office of General Counsel, implement and maintain
20 mechanisms for reporting, investigation, and enforcement of the Policy on Conduct at
21 AMA Meetings and Events in accordance with the following:
22

23 1. *Conduct Liaison and Committee on Conduct at AMA Meetings and Events (CCAM)*
24

25 The Office of General Counsel will appoint a "Conduct Liaison" for all AMA House
26 of Delegates meetings and all other AMA hosted meetings or activities (such as
27 meetings of AMA councils, sections, the RVS Update Committee (RUC), CPT
28 Editorial Panel, or JAMA Editorial Boards), with responsibility for receiving reports
29 of alleged policy violations, conducting investigations, and initiating both
30 immediate and longer-term consequences for such violations. The Conduct
31 Liaison appointed for any meeting will have the appropriate training and
32 experience to serve in this capacity, and may be a third party or an in-house AMA
33 resource with assigned responsibility for this role. The Conduct Liaison will be (i)
34 on-site at all House of Delegates meetings and other large, national AMA meetings
35 and (ii) on call for smaller meetings and activities. Appointments of the Conduct
36 Liaison for each meeting shall ensure appropriate independence and neutrality,
37 and avoid even the appearance of conflict of interest, in investigation of alleged
38 policy violations and in decisions on consequences for policy violations.
39

40 The AMA shall establish and maintain a Committee on Conduct at AMA Meetings
41 and Events (CCAM), to be comprised of 5-7 AMA members who are nominated by
42 the Office of General Counsel (or through a nomination process facilitated by the
43 Office of General Counsel) and approved by the Board of Trustees. The CCAM
44 should include one member of the Council on Ethical and Judicial Affairs (CEJA).
45 The remaining members may be appointed from AMA membership generally, with
46 emphasis on maximizing the diversity of membership. Appointments to the CCAM
47 shall ensure appropriate independence and neutrality, and avoid even the
48 appearance of conflict of interest, in decisions on consequences for policy
49 violations. Appointments to the CCAM should be multi-year, with staggered terms.

1 2. Reporting Violations of the Policy
2

3 Any persons who believe they have experienced or witnessed conduct in violation
4 of Policy H-140.837, "Policy on Conduct at AMA Meetings and Events," during any
5 AMA House of Delegates meeting or other activities associated with the AMA
6 (such as meetings of AMA councils, sections, the RVS Update Committee (RUC),
7 CPT Editorial Panel or JAMA Editorial Boards) should promptly notify the (i)
8 Conduct Liaison appointed for such meeting, and/or (ii) the AMA Office of General
9 Counsel and/or (iii) the presiding officer(s) of such meeting or activity.

10 Alternatively, violations may be reported using an AMA reporting hotline (telephone
11 and online) maintained by a third party on behalf of the AMA. The AMA reporting
12 hotline will provide an option to report anonymously, in which case the name of the
13 reporting party will be kept confidential by the vendor and not be released to the
14 AMA. The vendor will advise the AMA of any complaint it receives so that the
15 Conduct Liaison may investigate.

16 These reporting mechanisms will be publicized to ensure awareness.

17
18
19
20 3. Investigations
21

22 All reported violations of Policy H-140.837, "Policy on Conduct at AMA Meetings
23 and Events," pursuant to Section 2 above (irrespective of the reporting mechanism
24 used) will be investigated by the Conduct Liaison. Each reported violation will be
25 promptly and thoroughly investigated. Whenever possible, the Conduct Liaison
26 should conduct incident investigations on-site during the event. This allows for
27 immediate action at the event to protect the safety of event participants. When this
28 is not possible, the Conduct Liaison may continue to investigate incidents following
29 the event to provide recommendations for action to the CCAM. Investigations
30 should consist of structured interviews with the person reporting the incident (the
31 reporter), the person targeted (if they are not the reporter), any witnesses that the
32 reporter or target identify, and the alleged violator.

33
34 Based on this investigation, the Conduct Liaison will determine whether a violation
35 of the Policy on Conduct at AMA Meetings and Events has occurred.

36
37 All reported violations of the Policy on Conduct at AMA Meetings and Events, and
38 the outcomes of investigations by the Conduct Liaison, will also be promptly
39 transmitted to the AMA's Office of General Counsel (i.e. irrespective of whether
40 the Conduct Liaison determines that a violation has occurred).

41
42 4. Disciplinary Action
43

44 If the Conduct Liaison determines that a violation of the Policy on Conduct at AMA
45 Meetings and Events has occurred, the Conduct Liaison may take immediate
46 action to protect the safety of event participants, which may include having the
47 violator removed from the AMA meeting, event or activity, without warning or
48 refund.

1 Additionally, if the Conduct Liaison determines that a violation of the Policy on
2 Conduct at AMA Meetings and Events has occurred, the Conduct Liaison shall
3 report any such violation to the CCAM, together with recommendations as to
4 whether additional commensurate disciplinary and/or corrective actions (beyond
5 those taken on-site at the meeting, event or activity, if any) are appropriate.
6

7 The CCAM will review all incident reports, perform further investigation (if needed)
8 and recommend to the Office of General Counsel any additional commensurate
9 disciplinary and/or corrective action, which may include but is not limited to the
10 following:

- 11
- 12 ▪ Prohibiting the violator from attending future AMA events or activities;
- 13 ▪ Removing the violator from leadership or other roles in AMA activities;
- 14 ▪ Prohibiting the violator from assuming a leadership or other role in future AMA
15 activities;
- 16 ▪ Notifying the violator's employer and/or sponsoring organization of the actions
17 taken by AMA;
- 18 ▪ Referral to the Council on Ethical and Judicial Affairs (CEJA) for further review
19 and action;
- 20 ▪ Referral to law enforcement.
- 21

22 The CCAM may, but is not required to, confer with the presiding officer(s) of
23 applicable events activities in making its recommendations as to disciplinary and/or
24 corrective actions. Consequence for policy violations will be commensurate with
25 the nature of the violation(s).
26

27 5. Confidentiality

28

29 All proceedings of the CCAM should be kept as confidential as practicable.
30 Reports, investigations, and disciplinary actions under Policy on Conduct at AMA
31 Meetings and Events will be kept confidential to the fullest extent possible,
32 consistent with usual business practices.
33

34 6. Assent to Policy

35

36 As a condition of attending and participating in any meeting of the House of
37 Delegates, or any council, section, or other AMA entities, such as the RVS Update
38 Committee (RUC), CPT Editorial Panel and JAMA Editorial Boards, or other AMA
39 hosted meeting or activity, each attendee will be required to acknowledge and
40 accept (i) AMA policies concerning conduct at AMA HOD meetings, including the
41 Policy on Conduct at AMA Meetings and Events and (ii) applicable adjudication
42 and disciplinary processes for violations of such policies (including those
43 implemented pursuant to these Operational Guidelines), and all attendees are
44 expected to conduct themselves in accordance with these policies.
45

46 Additionally, individuals elected or appointed to a leadership role in the AMA or its
47 affiliates will be required to acknowledge and accept the Policy on Conduct at AMA
48 Meetings and Events and these Operational Guidelines.

1 ~~1. Reporting a complaint of harassment~~

2
3 Any persons who believe they have experienced or witnessed conduct in violation
4 of Anti-Harassment Policy H-140.837 during any AMA House of Delegates
5 meeting or associated functions should promptly notify the Speaker or Vice
6 Speaker of the House or the AMA Office of General Counsel.

7
8 Any persons who believe they have experienced or witnessed conduct in other
9 activities associated with the AMA (such as meetings of AMA councils, sections,
10 the RVS Update Committee (RUC), or CPT Editorial Panel) in violation of Anti-
11 Harassment Policy H-140.837 should promptly notify the presiding officer(s) of
12 such AMA-associated meeting or activity or either the Chair of the Board or the
13 AMA Office of General Counsel.

14
15 Anyone who prefers to register a complaint to an external vendor may do so using
16 an AMA compliance hotline (telephone and online) maintained on behalf of the
17 AMA. The name of the reporting party will be kept confidential by the vendor and
18 not be released to the AMA. The vendor will advise the AMA of any complaint it
19 receives so that the AMA may investigate.

20
21 ~~2. Investigations~~

22
23 Investigations of harassment complaints will be conducted by AMA Human
24 Resources. Each complaint of harassment or retaliation shall be promptly and
25 thoroughly investigated. Generally, AMA Human Resources will (a) use
26 reasonable efforts to minimize contact between the accuser and the accused
27 during the pendency of an investigation and (b) provide the accused an opportunity
28 to respond to allegations. Based on its investigation, AMA Human Resources will
29 make a determination as to whether a violation of Anti-Harassment Policy H-
30 140.837 has occurred.

31
32 ~~3. Disciplinary Action~~

33
34 If AMA Human Resources shall determine that a violation of Anti-Harassment
35 Policy H-140.837 has occurred, AMA Human Resources shall
36 (i) notify the Speaker and Vice Speaker of the House or the presiding officer(s) of
37 such other AMA-associated meeting or activity in which such violation occurred,
38 as applicable, of such determination, (ii) refer the matter to the Council on Ethical
39 and Judicial Affairs (CEJA) for disciplinary and/or corrective action, which may
40 include but is not limited to expulsion from the relevant AMA-associated meetings
41 or activities, and (iii) provide CEJA with appropriate training.

42
43 If a Delegate or Alternate Delegate is determined to have violated Anti-Harassment
44 Policy H-140.837, CEJA shall determine disciplinary and/or corrective action in
45 consultation with the Speaker and Vice Speaker of the House.

46
47 If a member of an AMA council, section, the RVS Update Committee (RUC), or
48 CPT Editorial Panel is determined to have violated Anti-Harassment Policy H-
49 140.837, CEJA shall determine disciplinary and/or corrective action in consultation
50 with the presiding officer(s) of such activities.

1 ~~If a nonmember or non-AMA party is the accused, AMA Human Resources shall~~
2 ~~refer the matter to appropriate AMA management, and when appropriate, may~~
3 ~~suggest that the complainant contact legal authorities.~~

4
5 ~~4. Confidentiality~~

6
7 ~~To the fullest extent possible, the AMA will keep complaints, investigations and~~
8 ~~resolutions confidential, consistent with usual business practice.~~

9
10 Your Reference Committee heard overwhelming support for Board of Trustees Report 10,
11 including accolades for culminating a two-year process with a progressive plan to ensure
12 our AMA is a safe environment for everyone. Concerns were expressed in testimony to
13 the Reference Committee regarding due process, and asked that the Board of Trustees
14 address this issue in the near future. However, the preponderance of testimony was
15 supportive of immediate implementation of Board of Trustees Report 10.

16
17
18 (3) BOARD OF TRUSTEES REPORT 12 - DATA USED TO
19 APPORTION DELEGATES

20
21 RECOMMENDATION:

22
23 Madam Speaker, your Reference Committee recommends
24 that the recommendations in Board of Trustees Report 12
25 be adopted and the remainder of the Report be filed.

26
27 Board of Trustees Report 12 is presented in response to Policy G-600.016, "Data Used to
28 Apportion Delegates" and includes an amendment to the current policy, which serves to
29 clarify mid-year reporting of membership counts as follows:

30
31 A. That Policy G-600.016, "Data Used to Apportion Delegates," be amended to read as
32 follows:

- 33
34 1. Our AMA shall issue an annual, mid-year report on or around June 30 to inform
35 each state medical society and each national medical specialty society that is in
36 the process of its 5-year review and state medical society of its current AMA
37 membership count-status report. (New HOD Policy)
38
39 2. "Pending members" will be added to the number of active AMA members in the
40 December 31 count for the purposes of AMA delegate allocations to ~~national~~
41 ~~medical specialty and state medical societies for the following year~~ and this total
42 will be used to determine the number of national medical specialty delegates to
43 maintain parity. (New HOD Policy)
44
45 3. ~~Our AMA Physician Engagement department will develop a mechanism to prevent~~
46 ~~a second counting of those previous "pending members" at the end of the following~~
47 ~~year until their membership has been renewed.~~ (Directive to Take Action)
48
49 4. Our AMA will track "pending members" from a given year who are counted towards
50 delegate allocation for the following year and these members will not be counted

1 again for delegate allocation unless they renew their membership before the end
2 of the following year. (New HOD Policy)
3

- 4 5. Our AMA Board of Trustees will issue a report to the House of Delegates at the
5 2022 Annual Meeting on the impact of Policy G-600.016 and recommendations
6 regarding continuation of this policy. (Directive to Take Action)
7

8 B. That the Council on Constitution and Bylaws prepare a report for the 2019 Interim
9 Meeting that will allow the implementation of Policy G-600.016, as amended herein.

10
11 Your Reference Committee heard only supportive testimony favoring adoption of Board of
12 Trustees Report 12.

- 13
14
15 (4) BOARD OF TRUSTEES REPORT 24 - DISCOUNTED /
16 WAIVED CPT FEES AS AN AMA MEMBER BENEFIT
17 AND FOR MEMBERSHIP PROMOTION

18
19 RECOMMENDATION:

20
21 Madam Speaker, your Reference Committee recommends
22 that the recommendation in Board of Trustees Report 24 be
23 adopted and the remainder of the Report be filed.
24

25 Board of Trustees Report 24 is presented in response to Resolution 607-A-18, which
26 called upon our AMA to investigate mechanisms by which AMA members may receive a
27 discount or waiver on CPT-related fees, including fees associated with using CPT codes
28 within electronic medical billing systems.
29

30 Through the analysis that led to this report, an opportunity was identified to improve AMA
31 member benefits for direct licensees with 25 or fewer users by increasing their discount to
32 30 percent. This change will go into effect for the 2020 CPT data file. The increased
33 discount will enable the AMA to continue to support its mission, while having a positive
34 impact on AMA members in small practices. This is also consistent with other AMA
35 Membership discount programs. Consequently, the Board of Trustees recommends that
36 Resolution 607-A-18 not be adopted and that the remainder of the report be filed.
37

38 Your Reference Committee received no testimony in response to Board of Trustees
39 Report 24. Your Reference Committee agrees with the recommendations in the report.
40

- 41
42 (5) BOARD OF TRUSTEES REPORT 27 - ADVANCING
43 GENDER EQUITY IN MEDICINE

44
45 RECOMMENDATION:

46
47 Madam Speaker, your Reference Committee recommends
48 that the recommendations in Board of Trustees Report 27
49 be adopted and the remainder of the Report be filed.

1 Board of Trustees Report 27 is presented in response to Policy D-65.989, "Advancing
2 Gender Equity in Medicine," which directs our AMA to draft and disseminate a report
3 detailing its positions and recommendations for gender equity in medicine, including
4 clarifying principles for state and specialty societies, academic medical centers, and other
5 entities that employ physicians.

6
7 In this report, the Board of Trustees recognizes gender inequity in medicine as a complex,
8 pervasive issue that requires a multilayered approach. Accordingly, the Board
9 recommends that the following be adopted and that the remainder of the report be filed:

10
11 a. That our American Medical Association adopt the following language as policy,
12 "Principles for Advancing Gender Equity in Medicine":

13
14 Our AMA:

- 15
16 1. declares it is opposed to any exploitation and discrimination in the workplace
17 based on personal characteristics (i.e., gender);
- 18
19 2. affirms the concept of equal rights for all physicians and that the concept of equality
20 of rights under the law shall not be denied or abridged by the U.S. Government or
21 by any state on account of gender;
- 22
23 3. endorses the principle of equal opportunity of employment and practice in the
24 medical field;
- 25
26 4. affirms its commitment to the full involvement of women in leadership roles
27 throughout the Federation, and encourages all components of the Federation to
28 vigorously continue their efforts to recruit women members into organized
29 medicine;
- 30
31 5. acknowledges that mentorship and sponsorship are integral components of one's
32 career advancement, and encourages physicians to engage in such activities;
- 33
34 6. declares that compensation should be equitable and based on demonstrated
35 competencies/expertise and not based on personal characteristics;
- 36
37 7. recognizes the importance of part-time work options, job sharing, flexible
38 scheduling, re-entry, and contract negotiations as options for physicians to support
39 work-life balance;
- 40
41 8. affirms that transparency in pay scale and promotion criteria is necessary to
42 promote gender equity, and as such academic medical centers, medical schools,
43 hospitals, group practices and other physician employers should conduct periodic
44 reviews of compensation and promotion rates by gender and evaluate protocols
45 for advancement to determine whether the criteria are discriminatory; and
- 46
47 9. affirms that medical schools, institutions and professional associations should
48 provide training on leadership development, contract and salary negotiations and
49 career advancement strategies that include an analysis of the influence of gender
50 in these skill areas. (New HOD Policy)

- 1 b. That our AMA rescind the following policies, as they have been incorporated into the
2 "Principles for Advancing Gender Equity in Medicine":
3
- 4 a. D-200.981, "Gender Disparities in Physician Income and Advancement,"
5 b. H-525.992, "Women in Medicine," and
6 c. H-65.968, "Equal Opportunity" (Rescind HOD Policy)
7
- 8 c. That our AMA rescind AMA Policy D-65.989 (1), "Advancing Gender Equity in
9 Medicine," as this report has fulfilled the request for information on positions and
10 recommendations regarding gender equity in medicine, including the development of
11 clarifying principles. (Rescind HOD Policy)
12
- 13 d. That our AMA encourage state and specialty societies, academic medical centers,
14 medical schools, hospitals, group practices and other physician employers to adopt
15 the AMA Principles for Advancing Gender Equity in Medicine. (Directive to Take
16 Action)
17
- 18 e. That our AMA encourage academic medical centers, medical schools, hospitals, group
19 practices, and other physician employers to: (a) adopt policies that prohibit
20 harassment, discrimination and retaliation; (b) provide anti-harassment training; and
21 (c) prescribe disciplinary and/or corrective action should violation of such policies
22 occur. (Directive to Take Action)
23
- 24 f. That our AMA modify Policy D-65.989, "Advancing Gender Equity in Medicine," and
25 continue to: (a) advocate for institutional, departmental and practice policies that
26 promote transparency in defining the criteria for initial and subsequent physician
27 compensation; (b) advocate for pay structures based on objective, gender-neutral
28 objective criteria; (c) encourage a specified approach, sufficient to identify gender
29 disparity, to oversight of compensation models, metrics, and actual total compensation
30 for all employed physicians; and (d) advocate for training to identify and mitigate
31 implicit bias in compensation determination for those in positions to determine salary
32 and bonuses, with a focus on how subtle differences in the further evaluation of
33 physicians of different genders may impede compensation and career advancement.
34 (Modify HOD Policy)
35
- 36 g. That our AMA amend AMA Policy G-600.035, "The Demographics of the House of
37 Delegates," to read as follows:
38
- 39 a. A report on the demographics of our AMA House of Delegates will be issued
40 annually and include information regarding age, gender, race/ethnicity, education,
41 life stage, present employment, and self-designated specialty.
42
- 43 b. As one means of encouraging greater awareness and responsiveness to diversity,
44 our AMA will prepare and distribute a state-by-state demographic analysis of the
45 House of Delegates, with comparisons to the physician population and to our AMA
46 physician membership every other year.
47
- 48 c. Future reports on the demographic characteristics of the House of Delegates
49 should, whenever possible, will identify and include information on successful

1 initiatives and best practices to promote diversity ~~within, particularly by age,~~ state
2 and specialty society delegations. (Modify Current HOD Policy)
3

4 Your Reference Committee heard overwhelming testimony in favor of this report. Limited
5 testimony was received on language used in the Principles for Advancing Gender Equity
6 in Medicine. It was raised that the term “gender nonconforming members” should be
7 included in the fourth principle. Your Reference Committee wishes to note that this study
8 specifically addressed disparities between female and male physicians. Additionally, it
9 was suggested that “gender” should replace “personal characteristics” in the sixth
10 principle. Your Reference Committee highlights the fact that evaluating compensation can
11 include factors that are indirectly related to gender. Your Reference Committee commends
12 the Board of Trustees for the development of these principles to help advance equity for
13 women physicians and physicians-in-training.
14

15
16 (6) REPORT OF THE HOUSE OF DELEGATES COMMITTEE
17 ON THE COMPENSATION OF THE OFFICERS
18

19 RECOMMENDATION:
20

21 Madam Speaker, your Reference Committee recommends
22 that the recommendations in the Report of the House of
23 Delegates Committee on the Compensation of the Officers
24 be adopted and the remainder of the Report be filed.
25

26 The Report of the House of Delegates Committee on the Compensation of the Officers
27 reminds the House that at the 2018 Interim Meeting a stipend was approved for the
28 President and his/her family when they lose their employer’s health insurance.
29

30 In this report, the Compensation Committee recommends amending the definition of
31 eligibility so that President(s) who already have health insurance coverage through
32 Medicare when elected will not be eligible for the stipend for themselves or family
33 members.
34

35 Additionally, this report of the Compensation Committee recommends amending the
36 eligibility definition so that if a President becomes Medicare eligible while in office, the
37 President will be expected to enroll in Medicare and the stipend will continue to cover
38 family members who are not Medicare eligible; the amount of the stipend will be adjusted
39 accordingly; and the stipend would be reported as taxable income to the President(s).

40 Your Reference Committee received no testimony in response to the Report of the House
41 of Delegates Committee on the Compensation of the Officers.
42

43 Your Reference Committee extends its appreciation to the members of the House of
44 Delegates Committee on the Compensation of the Officers for this follow-up report and
45 solution that addresses specific concerns about insurance coverage impacting a President
46 who becomes Medicare eligible while in office.

1 (7) RESOLUTION 602 - EXPECTATIONS FOR BEHAVIOR
2 AT HOUSE OF DELEGATES MEETINGS
3

4 RECOMMENDATION:
5

6 Madam Speaker, your Reference Committee recommends
7 that Resolution 602 be adopted.
8

9 Resolution 602 calls upon our AMA to require every AMA HOD delegate and alternate
10 delegate, as a condition to receiving their credentials for any AMA HOD meeting, to
11 acknowledge and accept during our AMA HOD meeting registration process AMA policies
12 concerning conduct at AMA HOD meetings, and applicable adjudication and disciplinary
13 processes for violations of such policies.
14

15 Additionally, Resolution 602 directs that any AMA HOD delegate or alternate delegate
16 who knowingly fails to acknowledge and accept during our AMA HOD meeting registration
17 process AMA policies concerning conduct at AMA HOD meetings, and applicable
18 adjudication and disciplinary processes for violations of such policies shall not be
19 credentialed as a delegate or alternate delegate at that meeting.
20

21 Beyond your Speakers' introduction of Resolution 602, your Reference Committee
22 received no on-site testimony and only a supportive online comment. Your Reference
23 Committee appreciates the efforts of our AMA speakers for codifying standards of
24 acceptable behavior within our House of Delegates.
25

26
27 (8) RESOLUTION 605 - STATE SOCIETIES AND THE AMA
28 LITIGATION CENTER
29

30 RECOMMENDATION:
31

32 Madam Speaker, your Reference Committee recommends
33 that Resolution 605 be adopted.
34

35 Resolution 605 directs that when seeking a state medical society's support of an amicus
36 brief on a legal matter, especially one pertaining to an issue in that state, the AMA
37 Litigation Center consider the state medical society's point of view in developing the
38 argument, and maintain full disclosure during the drafting of an amicus brief or any change
39 in strategy.
40

41 Your Reference Committee heard limited testimony outlining an occurrence in which a
42 state did not feel that our AMA was considerate of its position. Background information
43 provided to your Reference Committee indicated that our AMA makes a strong attempt to
44 be as collaborative as possible with the members of the Federation while maintaining a
45 broad representative voice.

1 (9) RESOLUTION 607 - RE-ESTABLISHMENT OF
2 NATIONAL GUIDELINE CLEARINGHOUSE
3

4 RECOMMENDATION:
5

6 Madam Speaker, your Reference Committee recommends
7 that Resolution 607 be adopted.
8

9 Resolution 607 calls upon our AMA reaffirm Policy H-410.965, "Clinical Practice
10 Guidelines, Performance Measures, and Outcomes Research Activities."
11

12 Additionally, Resolution 607 calls upon our AMA to research possible and existing
13 alternatives for the functions of the National Guidelines Clearinghouse with a report back
14 to the House of Delegates.
15

16 Your Reference Committee heard overwhelming support in identifying options for
17 organizations that can make clinical practice guidelines available to physicians that will
18 support patient safety and improve health outcomes. In particular, it was noted that our
19 AMA should provide guidance regarding potential conflicts of interest.
20

21
22 (10) RESOLUTION 609 - UPDATE TO AMA POLICY
23 H-525.998, "WOMEN IN ORGANIZED MEDICINE"
24

25 RECOMMENDATION:
26

27 Madam Speaker, your Reference Committee recommends
28 that Resolution 609 be adopted.
29

30 Resolution 609 calls upon our AMA to amend Policy H-525.998, "Women in Organized
31 Medicine," by deletion to read as follows:
32

33 Our AMA:
34

- 35 (1) reaffirms its policy advocating equal opportunities and opposing sex discrimination
36 in the medical profession;
37
38 (2) supports the concept of increased tax benefits for working parents;
39
40 (3) (a) supports the concept of proper child care for families of working parents;
41 (b) reaffirms its position on child care facilities in or near medical centers and
42 hospitals; (c) encourages business and industry to establish employee child care
43 centers on or near their premises when possible; and (d) encourages local medical
44 societies to survey physicians to determine the interest in clearinghouse activities
45 and in child care services during medical society meetings; and
46 (4) reaffirms its policy supporting flexibly scheduled residencies and encourages
47 increased availability of such programs; ~~and~~
48
49 ~~(5) supports that the AMA Guidelines for Establishing Sexual Harassment Prevention~~
50 ~~and Grievance Procedures be updated by the AMA Women Physicians Congress;~~

1 ~~and forwarded to the House of Delegates for approval, and include not only~~
2 ~~resources for training programs but also private practice settings. To facilitate wide~~
3 ~~distribution and easy access, the Guidelines will be placed on the AMA Web site.~~
4

5 Your Reference Committee heard limited testimony indicating the purpose of this
6 resolution is to align with ongoing efforts of our AMA to address harassment. Harassment
7 awareness continues to be on the forefront of our AMA's priorities and there is a more
8 detailed process in place, which renders this stricken language obsolete.
9

10
11 (11) RESOLUTION 610 - MITIGATING GENDER BIAS IN
12 MEDICAL RESEARCH

13
14 RECOMMENDATION:

15
16 Madam Speaker, your Reference Committee recommends
17 that Resolution 610 be adopted.
18

19 Resolution 610 calls upon our AMA to advocate for the establishment of best practices
20 that remove any gender bias from the review and adjudication of grant applications and
21 submissions for publication in peer-reviewed journals, including removing names and
22 gender identity from the applications or submissions during the review process.
23

24 Your Reference Committee heard overwhelming support in favor of establishing best
25 practices to remove gender bias from the review and adjudication of grant applications
26 and submissions for publication in peer-reviewed journals. The resolution called for
27 removal of names and gender identity from such applications and submissions; however,
28 there was limited testimony regarding the validity of complete removal versus minimizing
29 identifying information. Further testimony identified best practices allowing for complete
30 de-identification
31

32
33 (12) RESOLUTION 616 - TIME'S UP HEALTHCARE

34
35 RECOMMENDATION:

36
37 Madam Speaker, your Reference Committee recommends
38 that Resolution 616 be adopted.
39

40 Resolution 616 calls upon our AMA to evaluate the TIME'S UP Healthcare program and
41 consider participation as a TIME'S UP partner in support of our mutual objectives to
42 eliminate harassment and discrimination in medicine with a report back at the 2019 Interim
43 Meeting.
44

45 Your Reference Committee heard supportive testimony encouraging safe and welcoming
46 professional environments for women physicians and physicians-in-training. A relationship
47 with TIME'S UP Healthcare might advance our AMA's efforts to support women in
48 medicine. As with any relationship, consideration needs to be given to preserving the
49 reputation of our AMA. Your Reference Committee heard testimony regarding referral for
50 decision, but felt the resolution accomplished the intent of our AMA Board of Trustees

1 evaluating the progress in deciding whether to join. Therefore, your Reference Committee
2 recommends adoption so that the requested evaluation of TIME'S UP Healthcare can be
3 conducted and a potential relationship be considered.

4
5
6 (13) RESOLUTION 603 - CREATION OF AN AMA ELECTION
7 REFORM COMMITTEE
8 RESOLUTION 611 - ELECTION REFORM

9
10 RECOMMENDATION:

11
12 Madam Speaker, your Reference Committee recommends
13 that Alternative Resolution 603 be adopted in lieu of
14 Resolutions 603 and 611.

15
16 RESOLVED, That our AMA create a Speaker-appointed
17 task force for the purpose of recommending improvements
18 to the current AMA House of Delegates election process
19 with a broad purview to evaluate all aspects. The task force
20 shall present an initial status report at the 2019 Interim
21 Meeting.

22
23 Resolution 603 calls upon our AMA to appoint a House of Delegates Election Reform
24 Committee to develop recommendations with which to expedite and streamline the current
25 election and voting process for AMA officers and council positions, and to report back to
26 the House of Delegates at the 2019 Interim Meeting.

27
28 Options that should be considered by the Election Reform Committee, include:

- 29
30
- 31 • the creation of an interactive election web page;
 - 32 • candidate video submissions submitted in advance for HOD members to view;
 - 33 • eliminate all speeches and concession speeches during HOD deliberations, with the
34 exception of the President-Elect, Speaker, and Board of Trustee positions;
 - 35 • move elections earlier in the meeting to Sunday or Monday;
 - 36 • conduct voting from HOD seats; and
 - 37 • reduce and control the cost of campaigns.

38
39 Resolution 611 calls upon our AMA to create a Speaker-appointed task force to re-
40 examine election rules and logistics, including social media, emails, mailers, receptions,
41 and parties; the ability of candidates from smaller delegations to compete; electronic
42 balloting; and timing within the meeting. The task force shall report back at the 2019
43 Interim Meeting recommendations regarding election processes and procedures to
44 accommodate improvements, which allow delegates to focus their efforts and time on
45 policy-making.

46
47 Additionally, Resolution 611 calls upon the Speaker-appointed task force to consider
addressing the following ideas:

- 1 a. elections being held on the Sunday morning of the Annual and Interim meetings of the
- 2 House of Delegates;
- 3 b. coordination of a large format interview session on Saturday by the Speakers to allow
- 4 interview of candidates by all interested delegations simultaneously;
- 5 c. separating the logistical election process based on the office (e.g., larger interview
- 6 session for council candidates, more granular process for other offices);
- 7 d. an easily accessible system allowing voting members to either opt in or opt out of
- 8 receiving AMA approved forms of election materials from candidates with respect to
- 9 email and physical mail;
- 10 e. electronic balloting potentially using delegates' personal devices as an option for initial
- 11 elections and runoffs to facilitate timely results and minimal interruptions to the
- 12 business;
- 13 f. seeking process and logistics suggestions and feedback from HOD caucus leaders,
- 14 non-HOD physicians (potentially more objective and less influenced by current politics
- 15 in the HOD), and other constituent groups with a stake in the election process; and
- 16 g. address the propriety and/or recommended limits of the practice of delegates being
- 17 directed on how to vote by other than their sponsoring society (e.g., vote trading, block
- 18 voting, etc.).
- 19

20 Your Reference Committee heard overwhelming support in favor of appointing a
21 committee to look at the current AMA House of Delegates election process. As noted by
22 testimony, the original resolutions proffered were proscriptive. It is believed that a
23 Speaker-appointed task force, comprised of AMA House of Delegates members, will
24 address the ideas outlined in Resolutions 603 and 611. Furthermore, your Reference
25 Committee believes that an initial status report at the 2019 Interim Meeting will include a
26 project timeline established by the task force.

27
28

29 (14) RESOLUTION 606 - INVESTIGATION INTO RESIDENTS,
30 FELLOWS, AND PHYSICIAN UNIONS

31
32

RECOMMENDATION A:

33
34

Madam Speaker, your Reference Committee recommends
35 that Resolution 606 be amended by addition and deletion to
36 read as follows:

37
38

RESOLVED, That our American Medical Association ~~to~~
39 study the feasibility of a national house staff union to
40 represent all interns, residents and fellows risks and benefits
41 of collective bargaining for physicians and physicians-in-
42 training in today's health care environment. (Directive to
43 Take Action)

44
45

RECOMMENDATION B:

46
47

Madam Speaker, your Reference Committee recommends
48 that Resolution 606 adopted as amended.

1 Resolution 606 calls upon our AMA to study the feasibility of a national house-staff union
2 to represent all interns, residents, and fellows.

3
4 Your Reference Committee heard testimony indicating that our AMA cannot legally create
5 a union but that an attempt to support unionization was made in 1999 and carried out for
6 three years resulting in a large financial loss to our AMA; however, your Reference
7 Committee heard additional testimony that the changed environment of medicine merits a
8 renewed and expanded examination of whether there is a role for our AMA.

9
10
11 (15) RESOLUTION 614 - RACIAL AND ETHNIC IDENTITY
12 DEMOGRAPHIC COLLECTION BY THE AMA

13
14 RECOMMENDATION A:

15
16 Madam Speaker, your Reference Committee recommends
17 that Resolution 614 be amended by addition and deletion to
18 read as follows:

19
20 RESOLVED, That our American Medical Association
21 develop a plan with input from the Minority Affairs Section
22 and the Chief Health Equity Officer to ~~consistently include~~
23 improve consistency and reliability in the collection of racial
24 and ethnic minority demographic information for physicians
25 and medical students. (Directive to Take Action)

26
27 RECOMMENDATION B:

28
29 Madam Speaker, your Reference Committee recommends
30 that Resolution 614 be adopted as amended.

31
32 Resolution 614 calls upon our AMA to develop a plan, with input from the Minority Affairs
33 Section and the Chief Health Equity Officer, to consistently include racial and ethnic
34 minority demographic information for physicians and medical students.

35
36 Your Reference Committee heard overwhelmingly supportive testimony in favor of this
37 resolution and believes that the amended language allows the opportunity to expand
38 outdated racial and ethnic categories; thereby, improving accuracy and supporting
39 workforce diversity.

40
41
42 (16) RESOLUTION 617 - DISABLED PHYSICIAN ADVOCACY

43
44 RECOMMENDATION A:

45
46 Madam Speaker, your Reference Committee recommends
47 that Resolution 617 be amended by addition and deletion to
48 read as follows:

1 RESOLVED, That our American Medical Association study
2 and report back on eliminating stigmatization and enhancing
3 inclusion of ~~disabled physicians~~ physicians with disabilities
4 including but not limited to:

5
6 1) Enhancing representation of ~~disabled physicians~~
7 physicians with disabilities within the AMA.

8
9 2) Examining support groups, education, legal
10 resources and any other means to increase the
11 inclusion of physicians with disabilities in the AMA;
12 and be it further

13
14 RESOLVED, That our AMA identify medical, professional
15 and social rehabilitation, education, vocational training and
16 rehabilitation, aid, counseling, placement services and other
17 services which will enable ~~disabled physicians~~ physicians
18 with disabilities to develop their capabilities and skills to the
19 maximum and will hasten the processes of their social and
20 professional integration or reintegration-; and be it further

21
22 RESOLVED, That our AMA support physicians and
23 physicians-in-training education programs about legal rights
24 related to accommodation and freedom from discrimination
25 for physicians, patients, and employees with disabilities.

26
27 RECOMMENDATION B:
28 Madam Speaker, your Reference Committee recommends
29 that Resolution 617 be adopted as amended.

30
31 RECOMMENDATION C:
32 Madam Speaker, your Reference Committee recommends
33 that the title of Resolution 617 be changed to read as
34 follows:

35
36 ADVOCACY FOR PHYSICIANS WITH DISABILITIES

37
38 Resolution 617 calls upon our AMA to study and report back on eliminating stigmatization
39 and enhancing inclusion of disabled physicians, including but not limited to: (1) enhancing
40 representation of disabled physicians within the AMA; and (2) examining support groups,
41 education, legal resources, and any other means to increase the inclusion of physicians
42 with disabilities in the AMA.

43
44 Additionally, Resolution 617 calls upon our AMA to identify medical, professional and
45 social rehabilitation, education, vocational training and rehabilitation, aid, counseling,
46 placement services, and other services that will enable disabled physicians to develop
47 their capabilities and skills to the maximum and will hasten the processes of their social
48 and professional integration or reintegration.

1 Your Reference Committee heard supportive testimony; however, there was testimony on
2 using person-first language. Accordingly, your Reference Committee recommends
3 “disabled physicians” be replaced with “physicians with disabilities.”
4
5

6 (17) RESOLUTION 618 - STAKEHOLDER INPUT TO
7 REPORTS OF THE HOUSE OF DELEGATES
8

9 RECOMMENDATION A:

10
11 Madam Speaker, your Reference Committee recommends
12 that Resolution 618 be amended by addition and deletion to
13 read as follows:
14

15 RESOLVED, That our American Medical Association ~~study~~
16 ~~and propose a process for interested stakeholders~~
17 ~~represented in the House of Delegates to view~~ provide an
18 online list of AMA Council and Board reports under
19 development, including a staff contact and a mechanism for
20 providing stakeholder input on draft reports, and report
21 ~~back at the 2019 Interim Meeting.~~
22

23 RECOMMENDATION B:

24
25 Madam Speaker, your Reference Committee recommends
26 that Resolution 618 be adopted as amended.
27

28 Resolution 618 calls upon our AMA to study and report back at the 2019 Interim Meeting
29 on a proposed process for interested stakeholders represented in the House of Delegates
30 to view an online list of AMA Council and Board reports under development, including a
31 mechanism for on draft reports.
32

33 Your Reference Committee heard opposition to Resolution 618 as written because it
34 would place a burden on our AMA Councils and Board of Trustees, as well as could result
35 in delayed reports. Additionally, some reports to be published cannot be placed in the
36 public domain prior to publication. Therefore, your Reference Committee believes the
37 proffered amendment achieves the desired transparency.
38
39

40 (18) RESOLUTION 608 - FINANCIAL PROTECTIONS FOR
41 DOCTORS IN TRAINING
42

43 RECOMMENDATION:

44
45 Madam Speaker, your Reference Committee recommends
46 that Resolution 608 be referred.
47

48 Resolution 608 calls upon our AMA to support retirement plans for all residents and
49 fellows, which includes retirement plan matching to further secure the financial stability of
50 physicians and increase financial literacy during training.

1 Additionally, Resolution 608 calls upon our AMA to support that all programs provide
2 financial advising to resident and fellows.

3
4 Your Reference Committee heard limited testimony in support of retirement plans for
5 residents and fellows. However, it was noted that additional financial protections such as
6 adjustment of salaries for cost of living; eliminating interest accrual during training; credit
7 bureau reporting practices; and partnering with preferred lenders for bridge loans are
8 needed. Limited testimony indicated that nuances, such as GME funding, may impact the
9 delivery of a retirement plan and should be studied.

10
11 Your Reference Committee heard further testimony acknowledging that physicians-in-
12 training need more robust financial counseling. Factors such as significant medical student
13 debt, delayed start in professional life, and decreased financial literacy may have an
14 impact on retirement planning. Although your Reference Committee heard positive
15 testimony in support of the second Resolve, it believes that an examination of factors
16 related to financial protections is also warranted.

17
18
19 (19) RESOLUTION 612 - REQUEST TO AMA FOR TRAINING
20 IN HEALTH POLICY AND HEALTH LAW

21
22 RECOMMENDATION:

23
24 Madam Speaker, your Reference Committee recommends
25 that Resolution 612 be referred.

26
27 Resolution 612 calls upon our AMA to offer its members training in health policy and health
28 law, and develop a fellowship in health policy and health law.

29
30 Your Reference Committee heard mixed testimony. It was noted that understanding and
31 developing health policy and health law is an important skill for physicians to acquire.
32 Testimony supported our AMA sharing resources and opportunities to serve its members,
33 yet there was uncertainty over whether our AMA should implement a fellowship program.

34
35 Our AMA Board of Trustees is currently writing a report on this topic to be presented at
36 the 2019 Interim Meeting and referral of this item will allow for consideration of a fellowship
37 program.

38
39
40 (20) RESOLUTION 613 - LANGUAGE PROFICIENCY DATA
41 OF PHYSICIANS IN AMA MASTERFILE

42
43 RECOMMENDATION:

44
45 Madam Speaker, your Reference Committee recommends
46 that Resolution 613 be referred.

47
48 Resolution 613 calls upon our AMA to initiate collection of self-reported physician
49 language proficiency data in the Masterfile by asking physicians with the validated

1 six-point adapted ILR-scale to indicate their level of proficiency for each language besides
2 English in the healthcare settings.

3
4 Your Reference Committee heard testimony in support of the spirit of this resolution, but
5 concern was raised as to the challenges of implementation. There was additional
6 testimony indicating that there are other sources recording this data; however, proficiency
7 measures are not always captured. Therefore, your Reference Committee recommends
8 referral to allow our Board of Trustees to examine this complex issue and provide
9 recommendations.

10
11
12 (21) RESOLUTION 615 - IMPLEMENTING AMA CLIMATE
13 CHANGE PRINCIPLES THROUGH JAMA PAPER
14 CONSUMPTION REDUCTION AND GREEN
15 HEALTHCARE LEADERSHIP

16
17 RECOMMENDATION:

18
19 Madam Speaker, your Reference Committee recommends
20 that Resolution 615 be referred.

21
22 Resolution 615 calls upon our AMA to change existing automatic paper JAMA
23 subscriptions to opt-in paper subscriptions by the year 2020, while preserving the option
24 to receive paper JAMA, to support broader climate change efforts.

25
26 Your Reference Committee heard extensive testimony acknowledging this is a complex
27 issue that could result in unintended financial consequences. Testimony further reflected
28 that the driver for publishing has shifted from print advertising to institutional digital site
29 licensing; however, the move to digital does not translate into an equal shift in advertising
30 revenue because digital ads are valued less by media managers and generate a fraction
31 of print revenue. For these reasons, your Reference Committee believes that a study is
32 needed to ensure our AMA to preserve the editorial independence and integrity of its
33 publishing operations.

34
35
36 (22) RESOLUTION 601 - AMA POLICY STATEMENT WITH
37 EDITORIALS

38
39 RECOMMENDATION:

40
41 Madam Speaker, your Reference Committee recommends
42 that Resolution 601 not be adopted.

43
44 Resolution 601 calls upon our AMA to include a policy statement after all editorials in which
45 policy has been established to clarify our position.

46
47 Your Reference Committee heard testimony indicating that by longstanding academic
48 tradition and AMA operational policy, oversight and authority for all intellectual content
49 published within the journals is exclusively assigned to the Editor-in-Chief of JAMA and is

1 explicitly safeguarded by numerous policies and procedures. The published content is
2 directly attributed to the authors of the material.

3
4 Your Reference Committee notes that there is a statement on our AMA web site and at
5 the bottom of every print issue on the second page of the mast head that says, "*JAMA*
6 *does not hold itself responsible for statements made by any contributor. All articles*
7 *published, including opinion articles, represent the views of the authors and do not reflect*
8 *the policy of JAMA, the American Medical Association, or the institution with which the*
9 *author is affiliated unless otherwise indicated.*"

10
11 Your Reference Committee heard further testimony indicating that viewpoints, editorials,
12 and commentaries in JAMA often address topics at odds with AMA policy and has led the
13 way toward broader thinking.

14
15
16 (23) RESOLUTION 604 - ENGAGE AND COLLABORATE
17 WITH THE JOINT COMMISSION

18
19 RECOMMENDATION:

20
21 Madam Speaker, your Reference Committee recommends
22 that Resolution 604 be not adopted.

23
24 Resolution 604 calls upon our AMA to study and report back on the impact, influence, and
25 conflict of interest related to unrestricted grants from pharmaceutical and medical device
26 manufacturers on the development of Joint Commission accreditation standards
27 (especially those that relate to medical prescribing, procedures, and clinical care by
28 licensed physicians).

29
30 Your Reference Committee heard extensive testimony in opposition to this resolution. The
31 Chair of The Joint Commission noted that the Commission does not now nor since its
32 inception has it ever accepted money from pharmaceutical or device manufacturers for
33 the development of its standards.

34
35 (24) BOARD OF TRUSTEES REPORT 1 - ANNUAL REPORT

36
37 RECOMMENDATION:

38
39 Madam Speaker, your Reference Committee recommends
40 that Board of Trustees Report 1 be filed.

41
42 Board of Trustees Report 1 introduces our AMA's 2017 and 2018 Consolidated Financial
43 Statements and an Independent Auditor's report, which are included in a separate
44 document titled, "2018 Annual Report" that was made available with the Handbook
45 materials.

46
47 Your Reference Committee received no testimony in response to the Board of Trustees
48 Report 1. On behalf of our AMA membership, your Reference Committee extends
49 appreciation to the Board of Trustees for executing sound fiscal responsibility throughout
50 this past year, which resulted in the continuation of an ongoing trend of positive operating

1 results. Additionally, the number of AMA dues paying members increased in 2018 by 3.4
2 percent, achieving eight years of consecutive growth in membership.

3
4 Madam Speaker, this concludes the report of Reference Committee F. I would like to thank
5 Michael D. Chafty, MD, JD, Melissa J. Garretson, MD, Jerry L. Halverson, MD, Candace
6 E. Keller, MD, MPH, A. Lee Morgan, MD, Ann R. Stroink, MD, and all those who testified
7 before the Committee.

Michael D. Chafty, MD, JD
Michigan

Candace E. Keller, MD, MPH
American Society of Anesthesiologists

Melissa J. Garretson, MD (Alternate)
American Academy of Pediatrics

A. Lee Morgan, MD
Colorado

Jerry L. Halverson, MD
American Psychiatric Association

Ann R. Stroink, MD
Congress of Neurological Surgeons

Greg Tarasidis, MD
South Carolina
Chair

AMERICAN MEDICAL ASSOCIATION HOUSE OF DELEGATES (A-19)

Report of Reference Committee G

Rodney Trytko, MD, MPH, MBA, Chair

1 Your Reference Committee recommends the following consent calendar for acceptance:
2

3 **RECOMMENDED FOR ADOPTION**

4

- 5 1. Board of Trustees Report 31 – Non-Payment and Audit Takebacks by CMS
- 6 2. Board of Trustees Report 32 – Impact of High Capital Costs of Hospital EHRs on
7 the Medical Staff
- 8 3. Council on Medical Service Report 1 – Council on Medical Service Sunset
9 Review of 2009 AMA House Policies
- 10 4. Council on Medical Service Report 8 – Group Purchasing Organizations and
11 Pharmacy Benefit Manager Safe Harbor
- 12 5. Council on Medical Service Report 10 – Alternative Payment Models and
13 Vulnerable Populations
- 14 6. Resolution 704 – Prior Authorization Reform
- 15 7. Resolution 710 – Council for Affordable Quality Healthcare Attestation
16

17 **RECOMMENDED FOR ADOPTION AS AMENDED OR SUBSTITUTED**

18

- 19 8. Board of Trustees Report 13 – Employed Physician Bill of Rights and Basic
20 Practice Professional Standards
- 21 9. Board of Trustees Report 15 – Physician Burnout and Wellness Challenges;
22 Physician and Physician Assistant Safety Net; Identification and Reduction of
23 Physician Demoralization
- 24 10. Council on Medical Service Report 7 – Hospital Consolidation
- 25 11. Council on Medical Service Report 9 – Health Plan Payment of Patient Cost-
26 Sharing
- 27 12. Council on Medical Service Report 11 – Corporate Investors
- 28 13. Resolution 702 – Peer Support Groups for Second Victims
- 29 14. Resolution 706 – Hospital Falls and “Never Events” – A Need for More in Depth
30 Study
- 31 15. Resolution 708 – Access to Psychiatric Treatment in Long-Term Care
- 32 16. Resolution 711 – Impact on the Medical Staff of the Success or Failure in
33 Generating Savings of Hospital Integrated System ACOs
- 34 17. Resolution 712 – Promotion of Early Recognition and Treatment of Sepsis by
35 Out-of-Hospital Healthcare Providers to Save Lives
- 36 18. Resolution 714 – Medicare Advantage Step Therapy
- 37 19. Resolution 717 – Military Physician Reintegration into Civilian Practice
38

39 **RECOMMENDED FOR REFERRAL**

40

- 41 20. Resolution 703 – Preservation of the Patient-Physician Relationship

1 **RECOMMENDED FOR REFERRAL FOR DECISION**

2

- 3 21. Resolution 719 – Interference with Practice of Medicine by the Nuclear
4 Regulatory Commission

5

6 **RECOMMENDED FOR NOT ADOPTION**

7

- 8 22. Resolution 705 – Physician Requirements for Comprehensive Stroke Center
9 Designation

10

11 **RECOMMENDED FOR REAFFIRMATION IN LIEU OF**

12

- 13 23. Resolution 709 – Promoting Accountability in Prior Authorization
14 24. Resolution 713 – Selective Application of Prior Authorization
15 25. Resolution 718 – Economic Discrimination in the Hospital Practice Setting

Existing policy was reaffirmed in lieu of the following resolutions via the Reaffirmation Consent Calendar:

- Resolution 701 – Coding for Prior Authorization Obstacles
- Resolution 707 – Cost of Unpaid Patient Deductibles on Physician Staff Time
- Resolution 715 – Managing Patient-Physician Relations Within Medicare Advantage Plans
- Resolution 716 – Health Plan Claim Auditing Programs

16

1 (1) BOARD OF TRUSTEES REPORT 31 - NON-PAYMENT
2 AND AUDIT TAKEBACKS BY CMS
3

4 RECOMMENDATION:
5

6 Madam Speaker, your Reference Committee recommends
7 that recommendations in Board of Trustees Report 31 be
8 adopted and the remainder of the report be filed.
9

10
11 Board of Trustees Report 31 recommends that our AMA advocate to oppose claim
12 nonpayment, extrapolation of overpayments, and bundled payment denials based on
13 minor wording or clinically insignificant documentation inconsistencies.
14

15 Testimony was limited but supportive of Board of Trustees Report 31. A member of the
16 Board of Trustees introduced the report, explaining that although the AMA has extensive
17 policy opposing claim nonpayment for inadvertent, unintentional, or clerical
18 documentation errors, the Board believes that AMA policy could be more specific in
19 addressing minor wording errors or clinically insignificant inconsistencies. Because
20 testimony was supportive, your Reference Committee recommends that the
21 recommendations in Board of Trustees Report 31 be adopted and the remainder of the
22 report be filed.
23

24 (2) BOARD OF TRUSTEES REPORT 32 - IMPACT OF HIGH
25 CAPITAL COSTS OF HOSPITAL EHR'S ON THE
26 MEDICAL STAFF
27

28 RECOMMENDATION:
29

30 Madam Speaker, your Reference Committee recommends
31 that recommendations in Board of Trustees Report 32 be
32 adopted and the remainder of the report be filed.
33

34 Board of Trustees Report 32 recommends that our AMA rescind Policy D-225.974.
35

36 A member of the Board of Trustees introduced the report. Testimony overall was
37 supportive of the report. Your Reference Committee thanks the Board of Trustees for its
38 thoughtful and thorough report. Moreover, your Reference Committee highlights that the
39 Board's report was well-researched and based on all available evidence. Accordingly,
40 your Reference Committee recommends that Board of Trustees Report 32 be adopted.

1 (3) COUNCIL ON MEDICAL SERVICE REPORT 1 -
2 COUNCIL ON MEDICAL SERVICE SUNSET REVIEW OF
3 2009 AMA HOUSE POLICIES
4

5 RECOMMENDATION:
6

7 Madam Speaker, your Reference Committee recommends
8 that the recommendation in Council on Medical Service
9 Report 1 be adopted and the remainder of the report be
10 filed.
11

12 Council on Medical Service Report 1 contains recommendations to retain or rescind
13 2009 AMA socioeconomic policies.
14

15 Testimony on Council on Medical Service 1 was provided by a member of the Council on
16 Medical Service who introduced the report which is the result of the Council's review of
17 81 assigned socioeconomic policies. Because there was no additional testimony, your
18 Reference Committee recommends that the recommendations in Council on Medical
19 Service Report 1 be adopted and the remainder of the report be filed.
20

21 (4) COUNCIL ON MEDICAL SERVICE REPORT 8 - GROUP
22 PURCHASING ORGANIZATIONS AND PHARMACY
23 BENEFIT MANAGER SAFE HARBOR
24

25 RECOMMENDATION:
26

27 Madam Speaker, your Reference Committee recommends
28 that the recommendations in Council on Medical Service
29 Report 8 be adopted and the remainder of the report be
30 filed.
31

32 Council on Medical Service Report 8 recommends that our AMA reaffirm Policies H-
33 125.986, H-110.992, and H-100.956; renew efforts urging the federal government to
34 support greater public transparency and accountability efforts involving the contracting
35 mechanisms and funding structures subject to the Group Purchasing Organization and
36 PBMs anti-kickback safe harbor, including the potential impact on drug pricing and drug
37 shortages; and support efforts to update and modernize the fraud and abuse laws and
38 regulations to address changes in the health care delivery and payment systems
39 including the potential impact on drug pricing and drug shortages.
40

41 Testimony on Council on Medical Service Report 8 was unanimously supportive. A
42 member of the Council on Medical Service introduced the report. The Council stated
43 that, although the Council agrees with the sentiment that the GPO safe harbor is flawed,
44 the Council finds little empirical evidence exists to definitively assess the impact of the
45 GPO safe harbor. Moreover, a limited economic model found that, while removal of the
46 safe harbor decreased providers' nominal purchasing price, their total purchasing costs
47 are the same when the safe harbor was present. This means that repeal of the safe
48 harbor would not affect any party's profits or costs.

1 Additionally, the Council member testified that the Council has numerous concerns
2 should the safe harbor be repealed including that GPOs and PBMs could simply shift
3 fees into other forms, such as rebates or other fees, rather than lose their revenue
4 streams. The Council believes that repeal of the GPO safe harbor could create
5 widespread disruption of the supply chain and administrative challenges for not only
6 hospitals—including physician-owned hospitals—but also clinics, ambulatory surgery
7 centers, and other provider arrangements. As such, physician-owned practice settings
8 could be adversely impacted if the viability of the GPO business model is compromised.
9 Overall, the Council found that, whatever the defects in their funding structure, GPOs
10 serve a function in enabling cost savings and efficiencies in procurement to facilitate
11 patient care. Testimony echoed this statement saying that GPOs can help level the field
12 among smaller sites and practices.

13
14 An amendment was offered to state that the GPO safe harbor should not apply to PBMs.
15 However, as the Council on Legislation highlighted, our AMA is already advocating that
16 the Office of the Inspector General (OIG) needs to either eliminate the application of the
17 GPO regulatory safe harbor to PBMs or clarify its application only to administrative fees
18 and define what services are covered. Our AMA's comments stated that PBMs may be
19 able to avail themselves to existing regulatory safe harbors including the GPO safe
20 harbor, the personal services and management contracts safe harbor, managed care
21 safe harbor, and the proposed certain PBM services safe harbor. Our AMA requested
22 that OIG clarify what PBM fees and services apply to both the proposed and existing
23 safe harbors. Otherwise, our AMA is concerned that the lack of clarity may provide
24 further opportunity for exploitation. Taking into account this recent comment letter and
25 advocacy, the Reference Committee does not recognize the need for the proposed
26 amendment.

27
28 Moreover, specifically regarding PBMs, testimony highlighted CMS Report 5-A-19, which
29 is before the House of Delegates at this meeting in Reference Committee A. CMS
30 Report 5-A-19 recommends supporting the active regulation of PBMs under state
31 departments of insurance, supporting efforts to ensure that PBMs are subject to federal
32 laws that prevent discrimination against patients, and supporting improved transparency
33 in PBM operations including a list of disclosures.

34
35 Your Reference Committee thanks the Council on Medical Service for its thorough report
36 of a complex and nuanced issue. Accordingly, your Reference Committee recommends
37 that the report be adopted and the remainder of the report be filed.

38
39 (5) COUNCIL ON MEDICAL SERVICE REPORT 10 -
40 ALTERNATIVE PAYMENT MODELS AND VULNERABLE
41 POPULATIONS

42
43 RECOMMENDATION:

44
45 Madam Speaker, your Reference Committee recommends
46 that the recommendations in Council on Medical Service
47 Report 10 be adopted and the remainder of the report be
48 filed.

1 Council on Medical Service Report 10 recommends that our AMA reaffirm Policies H-
2 385.913, H-385.908, H-350.974, D-35.985, D-350.995, H-440.828, H-450.924, H-
3 280.945, and H-160.896; support APMs that link quality measures and payments to
4 outcomes specific to vulnerable and high-risk populations; encourage the development
5 and implementation of APMs that provide services to improve the health of vulnerable
6 and high-risk populations; and continue to advocate for appropriate risk adjustment of
7 performance results based on clinical and social determinants of health.

8
9 Testimony on Council on Medical Service Report 10 was mixed. A member of the
10 Council introduced the report stating that the report builds upon the AMA's current policy
11 on value-based payment and social determinants of health. In its report, the Council
12 offers a set of recommendations that it hopes mitigates negative outcomes, penalties,
13 and events for both vulnerable populations and the physicians serving them. In doing so,
14 the Council recommended ways in which the health care system can do more to address
15 non-medical factors that often go undetected and untreated among vulnerable
16 populations within the context of a changing payment and delivery system.

17
18 The Reference Committee believes that the Council produced a strong report that
19 furthers the health of vulnerable populations and incentivizes physicians to care for
20 them. There was testimony that the report should have included practice costs.
21 However, your Reference Committee believes that this mention is outside of the scope
22 of this report and represents an area of significant and ongoing AMA study and
23 advocacy efforts. Additionally, while there were concerns that the report did not
24 specifically address what risk adjustment methods may be most appropriate to care for
25 vulnerable populations, your Reference Committee highlights that the Council on
26 Medical Service is producing a report specifically on risk adjustment improvements for
27 Interim 2019. Your Reference Committee believes it is imperative to start advocating for
28 the recommendations in Council on Medical Service Report 10 immediately and
29 continue to build upon this work following the Council's upcoming report at Interim and
30 beyond. Your Reference Committee believes the intersection of APMs and vulnerable
31 populations deserves significant attention and believes that the Council's report
32 represents a first step in the right direction. Accordingly, your Reference Committee
33 recommends that Council on Medical Service Report 10 be adopted.

34
35 (6) RESOLUTION 704 - PRIOR AUTHORIZATION REFORM

36
37 RECOMMENDATION:

38
39 Madam Speaker, your Reference Committee recommends
40 that Resolution 704 be adopted.

41
42 Resolution 704 asks that our AMA explore emerging technologies to automate the prior
43 authorization process for medical services and evaluate their efficiency and scalability,
44 while advocating for reduction in the overall volume of prior authorization requirements
45 to ensure timely access to medically necessary care for patients and reduce practice
46 administrative burdens.

47
48 Your Reference Committee agrees with the uniformly supportive testimony for
49 Resolution 704. Of note, the Council on Medical Services testified on the importance of
50 the evaluation of the efficacy and appropriateness of emerging technological resources

1 designed to automate the prior authorization process, while also maintaining the AMA's
2 efforts to reduce the overall volume of prior authorizations. Your Reference Committee
3 notes that the AMA's Prior Authorization and Utilization Management Reform Principles,
4 released in 2017, specifically call for the utilization of technology to standardize prior
5 authorization and reduce its patient and physician burdens. Your Reference Committee
6 believes that this resolution represents an appropriate extension of existing AMA efforts
7 and policy and recommends that Resolution 704 be adopted.

8
9 (7) RESOLUTION 710 - COUNCIL FOR AFFORDABLE
10 QUALITY HEALTHCARE ATTESTATION

11
12 RECOMMENDATION:

13
14 Madam Speaker, your Reference Committee recommends
15 that Resolution 710 be adopted.

16
17 RESOLVED, That our American Medical Association work
18 with the Council for Affordable Quality Healthcare (CAQH)
19 and any other relevant organizations to reduce the
20 frequency of required CAQH reporting to twelve months or
21 longer unless the physician has a change in relevant
22 information to be updated. (Directive to Take Action)

23
24 Resolution 710 asks that our AMA work with the Council for Affordable Quality
25 Healthcare (CAQH) and any other relevant organizations to reduce the frequency of
26 required CAQH reporting to twelve months or longer unless the physician has a change
27 in relevant information to be updated.

28
29 Testimony was limited but supportive of Resolution 710. Your Reference Committee
30 concurs with testimony describing CAQH attestation requirements as an administrative
31 burden for physicians. Accordingly, your Reference Committee recommends that
32 Resolution 710 be adopted.

33
34 (8) BOARD OF TRUSTEES REPORT 13 - EMPLOYED
35 PHYSICIAN BILL OF RIGHTS AND BASIC PRACTICE
36 PROFESSIONAL STANDARDS

37
38 RECOMMENDATION A:

39
40 Madam Speaker, your Reference Committee recommends
41 that Recommendation 2 of Board of Trustees Report 13 be
42 amended by addition to read as follows:

43
44 2. That our AMA amend policy H-225.955, Protection of
45 Medical Staff Members' Personal Proprietary Financial
46 Information:

47 "(1)(a) Physicians should be required to disclose relevant
48 personal financial information to the hospital/health system
49 only if they are serving or being considered to serve as a
50 member of the governing body, as a corporate officer, or

1 as an employee/contractor of the hospital/health system;
2 and such information should be used only so that other
3 individuals understand what conflicts may exist when
4 issues are discussed and when recusal from voting or
5 discussion on an issue may be appropriate.” (Modify
6 Current HOD Policy)
7

8 RECOMMENDATION B:
9

10 Madam Speaker, your Reference Committee recommends
11 that the recommendations in Board of Trustees Report 13
12 be adopted as amended and the remainder of the report
13 be filed.
14

15 Board of Trustees Report 13 recommends that our AMA reaffirm Policies H-225.950, H-
16 225.997, H-225.942, H-225.955, H-300.982, and H-383.998; amend Policies H-225.955
17 and H-225.950; and advocate that employed physicians should be provided sufficient
18 administrative and clinical support to ensure that they can appropriately care for their
19 patients.
20

21 A member of the Board of Trustees introduced the report stating that the Board’s
22 analysis found that most of the concepts set forth in the referred resolutions are already
23 addressed in AMA policy, and the Board recommends reaffirmation of these policies. In
24 some cases, the proposed policies in the resolutions were inconsistent with existing
25 policy. Finally, the Board’s analysis identified two themes in Resolutions 701 and 702-A-
26 18 not addressed by existing policy—academic freedom for employed physicians and
27 appropriate levels of administrative and clinical support—and recommends adoption of
28 new policy in these areas.
29

30 Testimony on the report was unanimously supportive. There was one amendment
31 presented asking that physicians only need to disclose *relevant* financial information.
32 Your Reference Committee agrees and accepts this amendment. Accordingly, your
33 Reference Committee recommends that Board of Trustees Report 13 be adopted as
34 amended.

1 (9) BOARD OF TRUSTEES REPORT 15 - PHYSICIAN
2 BURNOUT AND WELLNESS CHALLENGES; PHYSICIAN
3 AND PHYSICIAN ASSISTANT SAFETY NET;
4 IDENTIFICATION AND REDUCTION OF PHYSICIAN
5 DEMORALIZATION
6

7 RECOMMENDATION A:
8

9 Madam Speaker, your Reference Committee recommends
10 that Recommendation 3 of Board of Trustees Report 15 be
11 amended by addition to read as follows:
12

13 3. That our AMA amend existing Policy D-310.968,
14 "Physician and Medical Student Burnout," to add the
15 following directives (Modify Current HOD Policy):

16 1. Our AMA recognizes that burnout, defined as emotional
17 exhaustion, depersonalization, and a reduced sense of
18 personal accomplishment or effectiveness, is a problem
19 among residents, fellows, and medical students.

20 2. Our AMA will work with other interested groups to
21 regularly inform the appropriate designated institutional
22 officials, program directors, resident physicians, and
23 attending faculty about resident, fellow, and medical
24 student burnout (including recognition, treatment, and
25 prevention of burnout) through appropriate media outlets.

26 3. Our AMA will encourage partnerships and collaborations
27 with accrediting bodies (e.g., the Accreditation Council for
28 Graduate Medical Education and the Liaison Committee
29 on Medical Education) and other major medical
30 organizations to address the recognition, treatment, and
31 prevention of burnout among residents, fellows, and
32 medical students and faculty.

33 4. Our AMA will encourage further studies and disseminate
34 the results of studies on physician and medical student
35 burnout to the medical education and physician
36 community.

37 5. Our AMA will continue to monitor this issue and track its
38 progress, including publication of peer-reviewed research
39 and changes in accreditation requirements.

40 6. Our AMA encourages the utilization of mindfulness
41 education as an effective intervention to address the
42 problem of medical student and physician burnout.

43 7. Our AMA will encourage medical staffs and/or
44 organizational leadership to anonymously survey
45 physicians to identify local factors that may lead to
46 physician demoralization.

1 8. Our AMA will continue to offer burnout assessment
2 resources and develop guidance to help organizations and
3 medical staffs implement organizational strategies that will
4 help reduce the sources of physician demoralization and
5 promote overall medical staff well-being.

6 9. Our AMA will continue to (1) address the institutional
7 causes of physician demoralization and burnout, such as
8 the burden of documentation requirements, inefficient work
9 flows, and regulatory oversight; and (2) develop and
10 promote mechanisms by which physicians in all practices
11 settings can reduce the risk and effects of demoralization
12 and burnout, including implementing targeted practice
13 transformation interventions, validated assessment tools,
14 and promoting a culture of well-being.

15
16 RECOMMENDATION B:

17
18 Madam Speaker, your Reference Committee recommends
19 that the recommendations on Board of Trustees Report 15
20 be adopted as amended and the remainder of the report
21 be filed.

22
23 Board of Trustees Report 15 recommends that our AMA reaffirm Policies H-170.986, H-
24 405.957, H-405.961, D-405.990, H-95.955, and H-295.858; amend policy H-405.961 to
25 encourage state medical societies to collaborate with state medical boards to develop
26 strategies to destigmatize physician burnout and encourage physicians to participate in
27 the state's physician health program without fear of loss of license or employment; and
28 amend Policy D-310.968 to encourage medical staffs and/or organizational leadership to
29 anonymously survey physicians to identify factors that may lead to physician
30 demoralization; continue to offer burnout assessment resources and develop guidance
31 to help organizations and medical staffs implement organizational strategies that will
32 help reduce the sources of physician demoralization and promote overall medical staff
33 well-being; and continue to address the institutional causes of physician demoralization
34 and burnout, and develop and promote mechanisms by which physicians in all practice
35 settings can reduce the risk and effects of demoralization and burnout, including
36 implementing targeted practice transformation interventions, validated assessment tools
37 and promoting a culture of well-being.

38
39 Testimony strongly supported Board of Trustees Report 15. A member of the Board of
40 Trustees introduced the report, affirming that the AMA fully supports programs to assist
41 physicians in early identification and management of stress and prevention of burnout
42 and demoralization, which is evidenced by the AMA's ongoing development of targeted
43 policies and tools and its recognition of professional satisfaction and practice
44 sustainability as one of its three strategic pillars. Additional testimony was appreciative of
45 the AMA's ongoing work to address physician burnout and demoralization. Your
46 Reference Committee agrees with a minor amendment to Recommendation 3.7, and
47 recommends that the recommendations in Board of Trustees Report 15 be adopted as
48 amended and the remainder of the report be filed.

1 (10) COUNCIL ON MEDICAL SERVICE REPORT 7 -
2 HOSPITAL CONSOLIDATION
3

4 RECOMMENDATION A:
5

6 Madam Speaker, your Reference Committee recommends
7 that Recommendation 3 in Council on Medical Service
8 Report 7 be amended by addition and deletion to read as
9 follows:

10
11 3. That our AMA ~~encourage~~ work with interested state
12 medical associations to monitor hospital markets and
13 review the impact of horizontal and vertical health system
14 integration on patients, physicians and hospital prices.
15 (New HOD Policy)
16

17 RECOMMENDATION B:
18

19 Madam Speaker, your Reference Committee recommends
20 that the recommendations in Council on Medical Service
21 Report 7 be adopted as amended and the remainder of the
22 report be filed.
23

24 Council on Medical Service Report 7 recommends that our AMA affirm that: (a) health
25 care entity mergers should be examined individually, considering case-specific variables
26 of market power and patient needs; (b) our AMA strongly supports and encourages
27 competition in all health care markets; (c) our AMA supports rigorous review and scrutiny
28 of proposed mergers to determine their effects on patients and providers; and (d)
29 antitrust relief for physicians remains a top AMA priority. The report also recommends
30 that our AMA continue to support actions that promote competition and choice, including:
31 (a) eliminating state CON laws; (b) repealing the ban on physician-owned hospitals; (c)
32 reducing administrative burdens that make it difficult for physician practices to compete;
33 and (d) achieving meaningful price transparency.
34

35 There was supportive testimony on Council on Medical Service Report 7. A member of
36 the Council on Medical Service introduced the report, noting that our AMA's own
37 research has found that most hospital markets are highly concentrated, and that this
38 concentration is largely due to consolidation. The Council member explained that
39 addressing hospital mergers with the same vigor that our AMA has addressed major
40 health insurance mergers would place an undue burden on the association's resources
41 and could alienate some AMA members. Additional testimony affirmed that the
42 consolidation trend is worrisome but that it would be difficult for our AMA to address
43 these mergers. Your Reference Committee agrees with an amendment to
44 Recommendation 3 asking our AMA to work with interested state medical associations
45 to monitor hospital markets and review the impact of health system integration.
46 Accordingly, your Reference Committee recommends that the recommendations in
47 Council on Medical Service Report 7 be adopted and the remainder of the report be
48 filed.

1 (11) COUNCIL ON MEDICAL SERVICE REPORT 9 - HEALTH
2 PLAN PAYMENT OF PATIENT COST-SHARING
3

4 RECOMMENDATION A:
5

6 Madam Speaker, your Reference Committee recommends
7 that the recommendations in Council on Medical Service
8 Report 9 be amended by addition of a new
9 Recommendation to read as follows:

10
11 7. That our AMA advocate for the inclusion of health
12 insurance contract provisions that permit network
13 physicians to collect patient cost-sharing financial
14 obligations (eg, deductibles, co-payments, and co-
15 insurance) at the time of service. (Directive to Take Action)
16

17 RECOMMENDATION B:
18

19 Madam Speaker, your Reference Committee recommends
20 that the recommendations in Council on Medical Service
21 Report 9 be amended by addition of a new
22 Recommendation to read as follows:
23

24 8. That our AMA support health plan and insurer programs
25 that collect patient co-payments and deductibles only if
26 such programs allow physicians to opt out, are transparent
27 about all program specifics, and do not penalize physicians
28 who elect not to participate. (New HOD Policy)
29

30 RECOMMENDATION C:
31

32 Madam Speaker, your Reference Committee recommends
33 that the recommendations in Council on Medical Service
34 Report 9 be amended by addition of a new
35 Recommendation to read as follows:
36

37 9. That our AMA monitor programs wherein health plans
38 and insurers bear the responsibility of collecting patient co-
39 payments and deductibles. (New HOD Policy)
40

41 RECOMMENDATION D:
42

43 Madam Speaker, your Reference Committee recommends
44 that the recommendations in Council on Medical Service
45 Report 9 be adopted as amended and the remainder of the
46 report be filed.
47

48 Council on Medical Service Report 9 recommends that our AMA reaffirm Policies H-
49 165.985, H-165.838, H-165.849, and H-165.828; amend Policy D-190.974 to prioritize
50 efforts to determine patient financial responsibility at the point of care, especially for

1 patients in high-deductibles plans; and support the development of IT systems to enable
2 physicians and patients to better understand financial obligations and to encourage
3 states and others to monitor the growth of high deductible health plans and other forms
4 of cost-sharing to assess their impacts on access to care, health outcomes, medical
5 debt, and physician practice sustainability.

6
7 Testimony on Council on Medical Service Report 9 was generally supportive. A member
8 of the Council introduced the report. The Council noted that it has concerns over asking
9 insurance companies to get further entrenched in the health care system and patient
10 care by taking over collection of co-payments and deductibles. Additionally, the Council
11 does not believe that it is feasible that insurers will agree to assume the financial risk of
12 taking over patient payments for physicians, which could end up as insurer bad debt.
13 And, if insurers do assume this risk, the Council doubts the insurer's motives. Inevitably,
14 the Council believes that the insurer will profit off of this arrangement, and, when a
15 patient does not pay the insurer, the Council doubts that insurers will pay physicians
16 their contracted rate. Moreover, the Council is concerned that, if patients do not pay the
17 insurer, they may lose coverage, which is neither helpful for physician practices nor is it
18 in the best interest of the patient.

19
20 Your Reference Committee offers several new recommendations to address testimony
21 that stated that the Council did not call for sufficient action in its report. First, your
22 Reference Committee recommends advocating for the inclusion of health insurance
23 contract provisions that permit physicians to collect patient cost-sharing financial
24 obligations (eg, deductibles, co-payments, and co-insurance) at the time of service. Your
25 Reference Committee believes that it is imperative that all physicians, other than those
26 prohibited by EMTALA, should be legally permitted to collect patient financial obligations
27 at the point of care. Your Reference Committee highlights that report recommendations
28 4 and 5 are also directly aimed at simplifying and expediting patient collections at the
29 point of care.

30
31 Moreover, your Reference Committee offers a new recommendation consistent with our
32 AMA's long-standing policy on freedom of choice to support health plan and insurer
33 programs that collect patient co-payments and deductibles only if the program allows
34 physicians to opt-out, is transparent about all program specifics, and does not penalize
35 physicians who elect not to participate. Your Reference Committee believes that our
36 AMA must support physicians who choose to utilize insurer programs and subsequently
37 be paid directly by the insurer rather than the patient. However, your Reference
38 Committee recognizes the need for safe-guarding such insurer policies, particularly to
39 protect physicians who wish not to participate in such arrangements and to ensure that
40 they are not penalized for their non-participation.

41
42 Finally, your Reference Committee recommends a new recommendation calling on our
43 AMA to monitor programs wherein health plans and insurers bear the responsibility of
44 collecting patient co-payments and deductibles. Your committee recognizes the benefits
45 and downsides of participating in such arrangements and calls on the AMA to monitor
46 these programs and how they affect physician practices, including practice sustainability.

47
48 Your Reference Committee believes its recommended amendments represent a
49 politically viable solution to the issue of insurers collecting co-payments and deductibles
50 and also offers a balanced approach recognizing varying physician preferences on how

1 to collect, or be paid, patient financial obligations. Accordingly, your Reference
2 Committee recommends that the recommendations of Council on Medical Service
3 Report 9 be adopted as amended and the remainder of the report be filed.

4
5 (12) COUNCIL ON MEDICAL SERVICE REPORT 11 -
6 CORPORATE INVESTORS

7
8 RECOMMENDATION A:

9
10 Madam Speaker, your Reference Committee recommends
11 that Council on Medical Service Report 11 be amended by
12 addition of a new recommendation to read as follows:

13
14 9. That our AMA support consideration of options for
15 gathering information on the impact of private equity and
16 corporate investors on the practice of medicine. (New HOD
17 Policy)

18
19 RECOMMENDATION B:

20
21 Madam Speaker, your Reference Committee recommends
22 that the recommendations in Council on Medical Service
23 Report 11 be adopted as amended and the remainder of
24 the report be filed.

25
26 Council on Medical Service Report 11 recommends that our AMA adopt a series of
27 guidelines that should be considered by physicians contemplating corporate investor
28 partnerships. Additionally, the report recommends supporting improved transparency
29 regarding corporate investment in physician practices, and encourages further study by
30 affected national medical specialty societies.

31
32 Testimony was supportive of Council on Medical Service 11. A member of the Council
33 on Medical Service introduced the report, explaining that growing numbers of physicians
34 are employed by corporations, although the extent of corporate investment in physician
35 practices is not known. The Council member highlighted longstanding AMA policy on the
36 corporate practice of medicine and also policy affirming that physicians are free to
37 choose their mode of practice and enter into contractual arrangements as they see fit.
38 Additional testimony described the challenges of obtaining data on corporate investment
39 in physician practices which is frequently not disclosed. Your Reference Committee
40 heard testimony asking our AMA to solicit feedback on corporate investors, and supports
41 the addition of a new recommendation asking our AMA to support consideration of
42 options for gathering information on this important and rapidly evolving issue. Your
43 Reference Committee also notes that our AMA will continue to monitor corporate
44 investment in physician practices and its impact on patients and physicians. Your
45 Reference Committee recommends that the recommendations in Council on Medical
46 Service Report 11 be adopted as amended and the remainder of the report be filed.

1 (13) RESOLUTION 702 - PEER SUPPORT GROUPS FOR
2 SECOND VICTIMS

3
4 RECOMMENDATION A:

5
6 Madam Speaker, your Reference Committee recommends
7 that the first Resolve of Resolution 702 be amended by
8 addition to read as follows:

9
10 RESOLVED, That our American Medical Association
11 encourage institutional, local, and state physician wellness
12 programs to consider developing voluntary, confidential,
13 and non-discoverable peer support groups to address the
14 “second victim phenomenon” (Directive to Take Action);
15 and be it further

16
17 RECOMMENDATION B:

18
19 Madam Speaker, your Reference Committee recommends
20 that the second Resolve of Resolution 702 be amended by
21 addition and deletion to read as follows:

22
23 RESOLVED, That our AMA work with other interested
24 organizations to encourage that any future surveys of
25 physician burnout should incorporate questions about the
26 prevalence and potential impact of the “second victim
27 phenomenon” ~~develop a survey of all physicians in the~~
28 ~~United States to quantitate the effects of stress and~~
29 ~~burnout on them, and its potential impact on our physician~~
30 ~~workforce.~~ (Directive to Take Action)

31
32 RECOMMENDATION C:

33
34 Madam Speaker, your Reference Committee recommends
35 that Resolution 702 be adopted as amended.

36
37 Resolution 702 asks that our AMA encourage institutional, local, and state physician
38 wellness programs to consider developing peer support groups to address the “second
39 victim phenomenon”; and work with other interested organizations to develop a survey of
40 all physicians in the United States to quantitate the effects of stress and burnout on
41 them, and its potential impact on our physician workforce.

42
43 Testimony was generally supportive of Resolution 702. Several speakers noted the
44 value of peer support groups centered around “second victim” experiences. One speaker
45 expressed concerns regarding legal issues that could impact peer support groups,
46 although others stated that these legal issues, such as discoverability, had not been
47 problematic. Testimony on the second Resolve clause questioned whether physician
48 surveys on this issue are needed, and an amended version was offered. Your Reference
49 Committee incorporated amendments to the first and second Resolve clauses and
50 recommends that Resolution 702 be adopted as amended.

1 (14) RESOLUTION 706 - HOSPITAL FALLS AND "NEVER
2 EVENTS" - A NEED FOR MORE IN DEPTH STUDY
3

4 RECOMMENDATION:
5

6 Madam Speaker, your Reference Committee recommends
7 that the following alternate resolution be adopted in lieu of
8 Resolution 706:
9

10 RESOLVED, That our American Medical Association work
11 with interested state medical associations and national
12 medical specialty societies to support research regarding
13 the feasibility and impact of removing patient falls with
14 injury from Medicare's list of "never events." (New HOD
15 Policy)
16

17 Resolution 706 asks that our AMA study the merits of recommending that "Patient death
18 or serious injury associated with a fall while being cared for in a health care setting" be
19 removed from the list of "Never Events" for which a hospital may face an adverse
20 payment decision by third-party payors or an adverse accreditation decision by The Joint
21 Commission; and study the merits of recommending that a pay-for-performance
22 measure be added which would reward health care organizations for taking steps
23 resulting in patients' improved ability to participate in self-care, improved functional
24 status, and improved mobility for seniors who have been admitted to a facility for a
25 condition resulting in a temporary need for bed rest.
26

27 Testimony was generally supportive of Resolution 706. Testimony was also supportive
28 of alternate language offered by a member of the Council on Medical Service that asks
29 the AMA to work with interested state medical associations and national medical
30 specialty societies to support research regarding the feasibility and impact of removing
31 patient falls with injury from Medicare's list of "never events." Your Reference Committee
32 supports this language and recommends that the alternate resolution be adopted in lieu
33 of Resolution 706.
34

35 (15) RESOLUTION 708 - ACCESS TO PSYCHIATRIC
36 TREATMENT IN LONG-TERM CARE
37

38 RECOMMENDATION A:
39

40 Madam Speaker, your Reference Committee recommends
41 that the first Resolve in Resolution 708 be amended by
42 deletion to read as follows:
43

44 ~~RESOLVED, That our American Medical Association ask~~
45 ~~the Centers for Medicare and Medicaid Services (CMS) to~~
46 ~~acknowledge that psychotropic medications can be an~~
47 ~~appropriate long-term care treatment for patients with~~
48 ~~chronic mental illness (Directive to Take Action)~~

1 RECOMMENDATION B:

2
3 Madam Speaker, your Reference Committee recommends
4 that the second Resolve in Resolution 708 be amended by
5 addition and deletion to read as follows:
6

7 RESOLVED, That our AMA ask CMS to discontinue the
8 use of antipsychotic ~~psychotropic~~ medication as a factor
9 contributing to the Nursing Home Compare rankings,
10 unless the data utilized is limited to medically inappropriate
11 administration of these medications (Directive to Take
12 Action); and be it further
13

14 RECOMMENDATION C:

15
16 Madam Speaker, your Reference Committee recommends
17 that the third Resolve in Resolution 708 be amended by
18 deletion to read as follows:
19

20 ~~RESOLVED, That our AMA ask the CMS to acknowledge~~
21 ~~that antipsychotic medication can be an appropriate~~
22 ~~treatment for dementia-related psychosis if non-~~
23 ~~pharmacologic approaches have failed (Directive to Take~~
24 ~~Action)~~
25

26 RECOMMENDATION D:

27
28 Madam Speaker, your Reference Committee recommends
29 that the fourth Resolve in Resolution 708 be amended by
30 deletion to read as follows:
31

32 ~~RESOLVED, That our AMA ask CMS to refrain from~~
33 ~~issuing citations or imposing financial penalties for the~~
34 ~~medically necessary and appropriate use of antipsychotic~~
35 ~~medication for the treatment of dementia-related~~
36 ~~psychosis. (Directive to Take Action)~~
37

38 RECOMMENDATION E:

39
40 Madam Speaker, your Reference Committee recommends
41 that Resolution 708 be adopted as amended and Policy D-
42 120.951 be reaffirmed.
43

44 Resolution 708 asks that our AMA ask the Centers for Medicare and Medicaid Services
45 (CMS) to acknowledge that psychotropic medications can be an appropriate long-term
46 care treatment for patients with chronic mental illness; ask CMS to discontinue the use
47 of psychotropic medication as a factor contributing to the Nursing Home Compare
48 rankings, unless the data utilized is limited to medically inappropriate administration of
49 these medications; ask the CMS to acknowledge that antipsychotic medication can be
50 an appropriate treatment for dementia-related psychosis if non-pharmacologic

1 approaches have failed; and ask CMS to refrain from issuing citations or imposing
 2 financial penalties for the medically necessary and appropriate use of antipsychotic
 3 medication for the treatment of dementia-related psychosis.

4
 5 Testimony on Resolution 708 was unanimously supportive. A member of the Council on
 6 Medical Service called for an amendment to adopt the second Resolve and reaffirm
 7 Policy D-120.951 in lieu of the other Resolve clauses. In its testimony, the Council noted
 8 that Policy D-120.951 not only addresses the first, third, and fourth Resolve clauses but
 9 also is nearly identical language. However, the Council supports adoption of the second
 10 Resolve and recognizes our AMA's lack of policy on the use of antipsychotic medication
 11 as a factor in Nursing Home Compare rankings. Testimony noted that current CMS
 12 policies on the use of antipsychotic medications may cause patient harm and urged AMA
 13 action on this issue. Your Reference Committee agrees and therefore recommends that
 14 Resolution 708 be adopted as amended and Policy D-120.951 be reaffirmed.

15
 16 Appropriate Use of Antipsychotic Medications in Nursing Home Patients D-
 17 120.951

18 Our AMA will meet with the Centers for Medicare & Medicaid Services (CMS) for
 19 a determination that acknowledges that antipsychotics can be an appropriate
 20 treatment for dementia-related psychosis if non-pharmacologic approaches have
 21 failed and will ask CMS to cease and desist in issuing citations or financial
 22 penalties for medically necessary and appropriate use of antipsychotics for the
 23 treatment of dementia-related psychosis. (Res. 523, A-12)

24
 25 (16) RESOLUTION 711 - IMPACT ON THE MEDICAL STAFF
 26 OF THE SUCCESS OR FAILURE IN GENERATING
 27 SAVINGS OF HOSPITAL INTEGRATED SYSTEM ACOS

28
 29 RECOMMENDATION:

30
 31 Madam Speaker, your Reference Committee recommends
 32 that the following alternate Resolution be adopted in lieu of
 33 Resolution 711:

34
 35 EFFECTS OF HOSPITAL INTEGRATED SYSTEM
 36 ACCOUNTABLE CARE ORGANIZATIONS

37
 38 RESOLVED, That our American Medical Association
 39 encourage studies into the effect of hospital integrated
 40 system Accountable Care Organizations' (ACOs) ability to
 41 generate savings and the effect of these ACOs on medical
 42 staffs and potential consolidation of medical practices.
 43 (New HOD Policy)

44
 45 Resolution 711 asks that our AMA study the effect of hospital integrated system ACOs'
 46 failure to generate savings on downsizing of the medical staff and further consolidation
 47 of medical practices and the root causes for failure to generate savings in hospital
 48 integrated ACOs, as compared to physician-owned ACOs, and report back at the 2019
 49 Interim Meeting.

1 There was generally supportive testimony on Resolution 711. The Council on Medical
2 Service called for adoption of an alternate resolution to support studies into how to
3 improve ACO performance and physician satisfaction with ACOs. In its testimony, the
4 Council stated that it believes that the request of Resolution 711 is not best directed at
5 our AMA but rather that the request is more appropriate for ACO organizations or the
6 American Hospital Association. In particular, the Council noted that, though well-
7 intentioned, our AMA simply does not have the necessary data to complete this study.
8 Your Reference Committee agrees and therefore recommends an alternate resolution
9 encouraging other organizations to study hospital integrated system ACOs.

10
11 (17) RESOLUTION 712 - PROMOTION OF EARLY
12 RECOGNITION AND TREATMENT OF SEPSIS BY OUT-
13 OF-HOSPITAL HEALTHCARE PROVIDERS TO SAVE
14 LIVES

15
16 RECOMMENDATION:

17
18 Madam Speaker, your Reference Committee recommends
19 that the following alternate resolution be adopted in lieu of
20 Resolution 712:

21
22 RESOLVED, That our American Medical Association work
23 with interested national medical specialty societies to
24 promote the importance of early detection and treatment of
25 sepsis by physicians. (New AMA Policy)

26
27 Resolution 712 asks that our AMA collaborate with interested medical organizations
28 such as the Centers for Disease Control and Prevention and the Society of Critical Care
29 Medicine to promote the importance of early detection and expedited intervention of
30 sepsis by healthcare providers who work in out-of-hospital settings to improve patient
31 outcomes and save lives.

32
33 There was limited but supportive testimony on Resolution 712. An amended version of
34 Resolution 712 was offered by the resolution's sponsor to address concerns regarding
35 early antibiotic use among emergency medical technicians. Your Reference Committee
36 crafted an simpler alternate resolution which achieves the intent of Resolution 712 and is
37 inclusive of physicians in all settings. Accordingly, your Reference Committee
38 recommends that the alternate resolution be adopted in lieu of Resolution 712.

39
40 (18) RESOLUTION 714 - MEDICARE ADVANTAGE STEP
41 THERAPY

42
43 RECOMMENDATION:

44
45 Madam Speaker, your Reference Committee recommends
46 that the following alternate resolution be adopted in lieu of
47 Resolution 714.

48
49 RESOLVED, That our AMA believes that step therapy
50 programs create barriers to patient care and encourages

1 health plans to instead focus utilization management
2 protocol on review of statistical outliers; and be it further
3

4 RESOLVED, That our AMA advocate that the Medicare
5 Advantage step therapy protocol, if not repealed, should
6 feature the following patient protections:

- 7 1. Enable the treating physician, rather than another
8 entity such as the insurance company, to determine
9 if a patient “fails” a treatment;
- 10 2. Exempt patients from the step therapy protocol
11 when the physician believes the required step
12 therapy treatments would be ineffective, harmful, or
13 otherwise against the patients’ best interests;
- 14 3. Permit a physician to override the step therapy
15 process when patients are stable on a prescribed
16 medication;
- 17 4. Permit a physician to override the step therapy if
18 the physician expects the treatment to be
19 ineffective based on the known relevant medical
20 characteristics of the patient and the known
21 characteristics of the drug regimen; if patient
22 comorbidities will cause, or will likely cause, an
23 adverse reaction or physical harm to the patient; or
24 is not in the best interest of the patient, based on
25 medical necessity;
- 26 5. Include an exemption from step therapy for
27 emergency care;
- 28 6. Require health insurance plans to process step
29 therapy approval and override request processes
30 electronically;
- 31 7. Not require a person changing health insurance
32 plans to repeat step therapy that was completed
33 under a prior plan; and
- 34 8. Consider a patient with recurrence of the same
35 systematic disease or condition to be considered
36 an established patient and therefore not subject to
37 duplicative step therapy policies for that disease or
38 condition.

39
40 Resolution 714 asks that our AMA our AMA work with the Centers for Medicare and
41 Medicaid Services (CMS) to immediately publish guidance to plans that lays out, at
42 minimum, the patient safeguards proposed/finalized in the Modernizing Part D and
43 Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses
44 proposed rule so that beneficiaries have some protections in 2019, and asks that CMS
45 does not respond to stakeholder input and publish guidance according to these and
46 other principles, our AMA support and actively work to advance Congressional action to
47 provide patients safeguards in the 2019 plan year.

48
49 Your Reference Committee agreed with the significant testimony in support of
50 Resolution 714. In order to adequately protect patients from the problematic aspects of

1 step therapy, your Reference Committee believes that the AMA needs to further weigh in
2 on this issue. As highlighted in testimony from the Council on Legislation, the AMA has
3 been extremely active in attempting to prevent the expansion of step therapy to
4 Medicare Part B drugs. Unfortunately, as noted by several commenters, these efforts
5 have failed to prevent implementation of this problematic program, making further action
6 at this time appropriate. The Committee notes that it received an alternate resolution
7 submitted by the Council on Legislation, which called for the AMA to adopt policy
8 consistent with both the current AMA compendium and ongoing federal and state
9 legislative bills and regulatory developments. Although the Council's language was
10 useful, we believe it fell short of adequately calling for direct action while also failing to
11 adequately address the recurrence of a systematic disease event. As a result, the
12 Committee crafted and recommends adoption of the alternate resolution in lieu of
13 Resolution 714.

14
15 (19) RESOLUTION 717 - MILITARY PHYSICIAN
16 REINTEGRATION INTO CIVILIAN PRACTICE

17
18 RECOMMENDATION:

19
20 Madam Speaker, your Reference Committee recommends
21 that the following alternate resolution be adopted in lieu of
22 Resolution 717:

23
24 REENTRY INTO PHYSICIAN PRACTICE

25
26 RESOLVED, That our American Medical Association
27 encourage hospitals to establish alternative processes to
28 evaluate competence, for the purpose of credentialing, of
29 physicians who do not meet the traditional minimum
30 volume requirements needed to obtain and maintain
31 credentials and privileges; and be it further

32
33 RESOLVED, That our AMA encourage The Joint
34 Commission and other accrediting organizations to support
35 alternative processes to evaluate competence, for the
36 purpose of credentialing, of physicians who do not meet
37 the traditional minimum volume requirements needed to
38 obtain and maintain credentials and privileges.

39
40 Resolution 717 asks that our AMA develop recommendations to inform local
41 credentialing bodies of pathways to facilitate the process of military veteran physicians
42 and surgeons to return to civilian practice without compromising patient care.

43
44 Testimony on Resolution 717 was mixed. An alternate resolution was offered to broaden
45 the resolution to include all physicians attempting to reenter the physician workforce.
46 This alternate received overwhelming supportive testimony and highlights that all
47 physicians who, for whatever reason, stepped away from medicine for a period of time
48 need assistance transitioning back to practice. Your Reference Committee
49 wholeheartedly agrees and therefore recommends adoption of the alternate resolution.

1 (20) RESOLUTION 703 - PRESERVATION OF THE PATIENT-
2 PHYSICIAN RELATIONSHIP

3
4 RECOMMENDATION:

5
6 Madam Speaker, your Reference Committee recommends
7 that Resolution 703 be referred.

8
9 Resolution 703 asks that our AMA, in an effort to improve professional satisfaction
10 among physicians while also enhancing patient care, conduct a study to identify
11 perceived barriers to optimal patient-physician communication from the perspective of
12 both the patient and the physician, as well as identify healthcare work environment
13 factors that impact a physician's ability to deliver high quality patient care, including but
14 not limited to: (1) the use versus non-use of electronic devices during the clinical
15 encounter; and (2) the presence or absence of a scribe during the patient-physician
16 encounter, and report back at the 2020 Interim Meeting.

17
18 Testimony on Resolution 703 was supportive of the study called for in Resolution 703.
19 Your Reference Committee received an alternative resolution from the author to study,
20 from the perspective of both the patient and physician, the adequacy of the time allotted
21 to or spent in direct patient-physician contact, with a goal of establishing a minimum time
22 required for a clinical encounter that is effective and satisfactory to both parties. As such,
23 your Reference Committee recommends that Resolution 703 be referred for study and
24 requests that the proposed alternative resolution be considered with the referral.

25
26 (21) RESOLUTION 719 - INTERFERENCE WITH PRACTICE
27 OF MEDICINE BY THE NUCLEAR REGULATORY
28 COMMISSION

29
30 RECOMMENDATION:

31
32 Madam Speaker, your Reference Committee recommends
33 that Resolution 719 be referred for decision.

34
35 Resolution 719 asks that our AMA advocate for a follow-up review by the Institute of
36 Medicine of the Nuclear Regulatory Commission's medical use program, specifically
37 evaluating effects of the Nuclear Regulatory Commission's regulatory policy in the last
38 25 years on the current state of nuclear medicine in the U.S. and patients' access to
39 care.

40
41 Testimony was supportive of Resolution 719. An additional Resolve clause offered very
42 specific instructions to the AMA to oppose a proposed rule open for comment until July
43 3, 2019. Given the complexity and timeliness of the issues raised in Resolution 719 and
44 the proposed amendment, your Reference Committee recommends that the item be
45 referred for decision.

1 (22) RESOLUTION 705 - PHYSICIAN REQUIREMENTS FOR
2 COMPREHENSIVE STROKE CENTER DESIGNATION
3

4 RECOMMENDATION:
5

6 Madam Speaker, your Reference Committee recommends
7 that Resolution 705 be not adopted.
8

9 Resolution 705 asks that our AMA advocate for changing the following two provisions
10 from The Joint Commission Stroke Center Requirements: (1) Stroke procedurists should
11 not be required to perform 15 mechanical thrombectomies per year to qualify for taking
12 endovascular call at designated stroke hospitals; and (2) Stroke procedurists should be
13 able to take call at more than one hospital at a time.
14

15 There was considerable and mixed testimony on Resolution 705. Your Reference
16 Committee heard varying testimony on the use of volume requirements, the levels of
17 stroke center designation, and patient care and safety. Importantly, your Reference
18 Committee heard testimony from relevant specialty societies that this resolution is highly
19 specific and complex, and best dealt with by the relevant specialty societies not our
20 AMA. Your Reference Committee strongly agrees and therefore recommends that
21 Resolution 705 not be adopted.
22

23 (23) RESOLUTION 709 - PROMOTING ACCOUNTABILITY IN
24 PRIOR AUTHORIZATION
25

26 RECOMMENDATION:
27

28 Madam Speaker, your Reference Committee recommends
29 that Policies H-285.987 and H-285.939 be reaffirmed in
30 lieu of Resolution 709.
31

32 Resolution 709 asks that our AMA amend Policy H-320.968 to advocate that any
33 physician who recommends a denial as to the medical necessity of services on behalf of
34 a utilization review entity or health plan be of the same specialty and have expertise to
35 treat the medical condition or disease as the practitioner who provided the services
36 under review; and that our AMA and its Council on Judicial and Ethical Affairs study the
37 ethical and medicolegal responsibilities of physicians who participate in the prior
38 authorization process on behalf of utilization review entities or health plans, particularly
39 with regard to determinations of medical necessity, and report back to the HOD at the
40 2020 Annual Meeting with guidance for physicians who provide utilization review
41 services.
42

43 Your Reference Committee heard a significant amount of testimony for Resolution 709
44 recognizing the importance of health plan decision-makers having the appropriate level
45 of education and experience when making prior authorization denials. Of note, the
46 Committee recognizes the importance of the amendment seeking to explicitly require all
47 denials to be made by a physician, and when possible, that the physician be of the same
48 specialty and have expertise in the condition under review. Your Reference Committee
49 agrees with this sentiment and the largely supportive testimony received on the
50 resolution. However, as invoked by the Council on Legislation's testimony, we believe

1 that current policy and ongoing AMA advocacy initiatives already accomplish this
2 Resolution's intent.

3
4 The AMA has been extremely active in advocating to reduce physician and patient
5 harms caused by prior authorization. This work includes the development of physician
6 surveys on negative impacts of prior authorization, an AMA Grassroots website
7 (www.fixpriorauth.org) enabling physicians to provide testimonials to be used in AMA
8 advocacy, the development and promotion of state legislative efforts, and collaboration
9 amongst the healthcare industry to improve prior authorization processes. Amongst the
10 most common aspects of these efforts has been the need to ensure that health plans
11 utilize properly trained physician experts when denying care. For example, the Prior
12 Authorization and Utilization Management Reform Principles explicitly call for any
13 physician making a decision on a prior authorization appeal to be of the same specialty,
14 and subspecialty whenever possible, as the prescribing/ordering physician. Additionally,
15 as highlighted in testimony, the Council on Legislation has model legislation requiring an
16 adverse decision on a prior authorization to be made by a physician with a current and
17 valid non-restricted license to practice medicine and must be board certified in the same
18 specialty as the health care provider who typically manages the denied medical
19 condition.

20
21 In addition to these active advocacy efforts, the AMA has relevant and overlapping policy
22 and ethical opinions on the issues raised in Resolution 709. Policy H-285.987
23 establishes detailed guidelines for physicians to follow when serving as medical
24 directors/decision-makers for managed care plans, with requirements that they be
25 licensed and credentialed in the same state as network physicians over whose care they
26 are making decisions. Policy H-285.939 calls on the AMA to undertake federal and state
27 legislative and regulatory measures necessary to hold health plan medical directors
28 liable for medical decisions regarding contractually covered medical services.
29 Additionally, this resolution is extensively addressed by the AMA Code of Medical Ethics
30 Policy 10.1.1 "Ethical Obligations of Medical Directors," which explicitly details the ethical
31 considerations that physicians must take into account when making benefit
32 determinations on behalf of health plans.

33
34 As a result of these policies and the ongoing initiatives, your Reference Committee
35 recommends that H-285.987 and H-285.939 be reaffirmed in lieu of Resolution 709.

36
37 Guidelines for Qualifications of Managed Care Medical Directors H-285.987

38 The AMA has adopted the following "Guidelines for Qualifications of Medical
39 Directors of Managed Care Organizations:"

40 To the greatest extent possible, physicians who are employed as medical
41 directors of managed care organizations shall:

- 42 (1) hold an unlimited current license to practice medicine in one of the states
43 served by the managed care organization, and where that Medical Director will
44 be making clinical decisions or be involved in peer review that Medical Director
45 should have a current license in each applicable state;
46 (2) meet credentialing requirements equivalent to those met by plan providers;
47 (3) be familiar with local medical practices and standards in the plan's service
48 area;

- 1 (4) be knowledgeable concerning the applicable accreditation or "program
2 approval" standards for preferred provider organizations and health maintenance
3 organizations;
4 (5) possess good interpersonal and communications skills;
5 (6) demonstrate knowledge of risk management standards;
6 (7) be experienced in and capable of overseeing the commonly used processes
7 and techniques of peer review, quality assurance, and utilization management;
8 (8) demonstrate knowledge of due process procedures for resolving issues
9 between the participating physicians and the health plan administration, including
10 those related to medical decision-making and utilization review;
11 (9) be able to establish fair and effective grievance resolution mechanisms for
12 enrollees;
13 (10) be able to review, advise, and take action on questionable hospital
14 admissions, medically unnecessary days, and all other medical care cost issues;
15 and
16 (11) be willing to interact with physicians on denied authorizations.
17 The AMA strongly encourages managed care organizations and payer groups to
18 utilize these guidelines in their recruitment and retention of medical directors.
19

20 Managed Care Medical Director Liability H-285.939

21 AMA policy is that utilization review decisions to deny payment for medically
22 necessary care constitute the practice of medicine. (1) Our AMA seeks to include
23 in federal and state patient protection legislation a provision subjecting medical
24 directors of managed care organizations to state medical licensing requirements,
25 state medical board review, and disciplinary actions; (2) that medical directors of
26 insurance entities be held accountable and liable for medical decisions regarding
27 contractually covered medical services; and (3) that our AMA continue to
28 undertake federal and state legislative and regulatory measures necessary to
29 bring about this accountability.
30

31 (24) RESOLUTION 713 - SELECTIVE APPLICATION OF
32 PRIOR AUTHORIZATION

33
34 RECOMMENDATION:

35
36 Madam Speaker, your Reference Committee recommends
37 that Policy H-320.939 be reaffirmed in lieu of Resolution
38 713.
39

40 Resolution 713 asks that our AMA support policies such that prior authorization
41 requirements will not be applied to items or services ordered by physicians and other
42 health care practitioners: (i) whose prescribing or ordering practices align with an
43 evidence-based guideline established or approved by a national professional medical
44 association; or (ii) who meet quality (eg gold standard) criteria; or (iii) whose orders or
45 prescriptions are routinely approved; or (iv) who adhere to a high quality clinical care
46 pathway; or (v) who participate in an alternative payment model or care delivery model
47 that aims to improve health care quality.
48

49 Testimony on Resolution 713 was significantly supportive of pursuing ways of
50 eliminating prior authorization requirements for physicians whose conduct does not

1 warrant their application, a belief with which your Reference Committee agrees. The
2 committee notes that both the resolution and the author's testimony referred to the
3 Consensus Statement on Improving the Prior Authorization Process as a particularly
4 relevant resource in the development of Resolution 713. This resource, which was
5 spearheaded and co-authored by the AMA, specifically calls for the selective application
6 of prior authorization and calls for programmatic exemptions for physicians in risk-based
7 contracts. Your Reference Committee notes that the creation of this resource was
8 directly spurred by advocacy efforts coordinated with the release of the AMA Prior
9 Authorization and Utilization Management Reform Principles.

10
11 Policy H-320.939 establishes that the AMA will continue its widespread prior
12 authorization (PA) advocacy and outreach, including promotion and/or adoption of the
13 Prior Authorization and Utilization Management Reform Principles. As highlighted in
14 testimony from the Council on Medical Service, these principles call for health plans to
15 restrict prior authorization programs to physicians whose prescribing patterns routinely
16 deviate from protocol (Principle 19), call for gold-carding exemptions and non-application
17 to physicians using clinical decision support systems or pathways (Principle 20), and
18 does not apply to physicians in risk-based contracts (Principle 21).

19
20 Because these Principles already address the concepts, your Reference Committee
21 recommends reaffirmation of H-320.939 in lieu of Resolution 713.

22
23 Prior Authorization and Utilization Management Reform H-320.939

24 1. Our AMA will continue its widespread prior authorization (PA) advocacy and
25 outreach, including promotion and/or adoption of the Prior Authorization and
26 Utilization Management Reform Principles, AMA model legislation, Prior
27 Authorization Physician Survey and other PA research, and the AMA Prior
28 Authorization Toolkit, which is aimed at reducing PA administrative burdens and
29 improving patient access to care.

30 2. Our AMA will oppose health plan determinations on physician appeals based
31 solely on medical coding and advocate for such decisions to be based on the
32 direct review of a physician of the same medical specialty/subspecialty as the
33 prescribing/ordering physician.

34 3. Our AMA supports efforts to track and quantify the impact of health plans' prior
35 authorization and utilization management processes on patient access to
36 necessary care and patient clinical outcomes, including the extent to which these
37 processes contribute to patient harm.

38
39 (25) RESOLUTION 718 - ECONOMIC DISCRIMINATION IN
40 THE HOSPITAL PRACTICE SETTING

41
42 RECOMMENDATION:

43
44 Madam Speaker, your Reference Committee recommends
45 that Policies H-180.963, H-230.971, H-230.975, and H-
46 230.976 be reaffirmed in lieu of Resolution 718.

47
48 Resolution 718 asks that our AMA actively oppose policies that limit a physician's
49 access to hospital services based upon the number of referrals made, the number of
50 procedures performed, the use of any and all hospital services or employment affiliation.

1 Testimony on Resolution 718 was limited to the resolution's author. Your Reference
2 Committee takes issue with use of the term "referrals," and believes that the intent of the
3 resolution is addressed by existing AMA policy. Accordingly, your Reference Committee
4 recommends that Policies H-180.963, H-230.971, H-230.975, and H-230.976 be
5 reaffirmed in lieu of Resolution 718.

6
7 H-180.963 Volume Discrimination Against Physicians

8 The AMA recommends that volume indicators should be applied only to those
9 treatments where outcomes have been shown by valid statistical methods to be
10 significantly influenced by frequency of performance; and affirms that volume
11 indicators should not be used as the sole criteria for credentialing and
12 reimbursement and that, when volume indicators are used, allowances should be
13 made for physicians starting practice. (Res. 101, A-96; Reaffirmed: CMS Rep. 8,
14 A-06; Reaffirmed: BOT Rep. 3, A-09; Reaffirmed: Res. 703, A-18)

15
16 H-230.971 Economic Credentialing

17 Our AMA will work with The Joint Commission to assure, through the survey
18 process, that any criteria used in the credentialing process are directly related to
19 the quality of patient care. (BOT Rep. 15, I-93; Reaffirmed: CLRPD Rep. 1, A-05;
20 Modified: CMS Rep. 1, A-15)

21
22 H-230.975 Economic Credentialing

23 The AMA (1) adopts the following definition of economic credentialing: economic
24 credentialing is defined as the use of economic criteria unrelated to quality of
25 care or professional competency in determining an individual's qualifications for
26 initial or continuing hospital medical staff membership or privileges; (2) strongly
27 opposes the practice of economic credentialing; (3) believes that physicians
28 should continue to work with their hospital boards and administrators to develop
29 appropriate educational uses of physician hospital utilization and related financial
30 data and that any such data collected be reviewed by professional peers and
31 shared with the individual physicians from whom it was collected; (4) believes
32 that physicians should attempt to assure provision in their hospital medical staff
33 bylaws of an appropriate role for the medical staff in decisions to grant or
34 maintain exclusive contracts or to close medical staff departments; (5) will
35 communicate its policy and concerns on economic credentialing on a continuing
36 basis to the American Hospital Association, Federation of American Health
37 Systems, and other appropriate organizations; (6) encourages state medical
38 societies to review their respective state statutes with regard to economic
39 credentialing and, as appropriate, to seek modifications therein; (7) will explore
40 the development of draft model legislation that would acknowledge the role of the
41 medical staff in the hospital medical staff credentialing process and assure
42 various elements of medical staff self-governance; and (8) will study and address
43 the issues posed by the use of economic credentialing in other health care
44 settings and delivery systems. (CMS Rep. B, I-91; Reaffirmed by BOT Rep. 14,
45 A-98; Reaffirmation A-07; Reaffirmed: CMS Rep. 01, A-17)

46
47 H-230.976 Economic Credentialing

48 The AMA opposes the use of economic criteria not related to quality to determine
49 an individual physician's qualifications for the granting or renewal of medical staff
50 membership or privileges. (Res. 2, A-91; Reaffirmed: CME Rep. 8, I-93;

1 Reaffirmed by BOT Rep. 14, A-98; Reaffirmation A-07; Reaffirmed: CMS Rep.
2 01, A-17)
3

- 1 Madam Speaker, this concludes the report of Reference Committee G. I would like to
- 2 thank Michael Bishop, MD, Jayne Courts, MD, Sterling Ransone Jr., MD, Stephen
- 3 Tharp, MD, Brett Youngerman, MD, and all those who testified before the Committee.

Michael Bishop, MD
American College of Emergency
Physicians

Sterling Ransone Jr., MD (Alternate)
Virginia

Jayne Courts, MD (Alternate)
Michigan

Stephen Tharp, MD
Indiana

Brett Youngerman, MD
New York

Rodney Trytko, MD, MPH, MBA
Washington
Chair